

***Bioelectromagnetic
Medicine***



edited by
Paul J. Rosch
Marko S. Markov

**Also available as a printed book
see title verso for ISBN details**

Bioelectromagnetic Medicine

Bioelectromagnetic Medicine

edited by

Paul J. Rosch, M.D.

*The American Institute of Stress
Yonkers
and New York Medical College
Valhalla, New York, U.S.A.*

Marko S. Markov, Ph.D.

*Research International
Buffalo, New York, U.S.A.*



MARCEL DEKKER, INC.
NEW YORK • BASEL

Although great care has been taken to provide accurate and current information, neither the author(s) nor the publisher, nor anyone else associated with this publication, shall be liable for any loss, damage, or liability directly or indirectly caused or alleged to be caused by this book. The material contained herein is not intended to provide specific advice or recommendations for any specific situation.

Trademark notice: Product or corporate names may be trademarks or registered trademarks and are used only for identification and explanation without intent to infringe.

Library of Congress Cataloging-in-Publication Data

A catalog record for this book is available from the Library of Congress.

ISBN 0-203-02165-7 Master e-book ISBN

ISBN: 0-8247-4700-3 (Print Edition)

Headquarters

Marcel Dekker, Inc., 270 Madison Avenue, New York, NY 10016, U.S.A.
tel: 212-696-9000; fax: 212-685-4540

This edition published in the Taylor & Francis e-Library, 2005.

“To purchase your own copy of this or any of Taylor & Francis or Routledge’s collection of thousands of eBooks please go to www.eBookstore.tandf.co.uk.”

Distribution and Customer Service

Marcel Dekker, Inc., Cimarron Road, Monticello, New York 12701, U.S.A.
tel: 800-228-1160; fax: 845-796-1772

Eastern Hemisphere Distribution

Marcel Dekker AG, Hutgasse 4, Postfach 812, CH-4001 Basel, Switzerland
tel: 41-61-260-6300; fax: 41-61-260-6333

World Wide Web

<http://www.dekker.com>

The publisher offers discounts on this book when ordered in bulk quantities. For more information, write to Special Sales/Professional Marketing at the headquarters address above.

Copyright © 2004 by Marcel Dekker, Inc. All Rights Reserved.

Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage and retrieval system, without permission in writing from the publisher.

Preface

A BRIEF HISTORICAL PERSPECTIVE

According to *The Yellow Emperor's Canon of Internal Medicine*, our oldest extant medical text, magnetic stones (lodestones) applied to acupuncture points were used to relieve pain and other complaints 40 centuries ago. The *Vedas*, religious scriptures of the Hindus also believed to be several thousand years old, similarly allude to the therapeutic powers of *ashmana* and *siktavati* (instruments of stone). The Greeks referred to these as *lapus-vivas* (live-stones) and Hippocrates purportedly used them to cure sterility. Egyptian physicians ascribed a variety of benefits to magnetic stones, as did early Buddhists. Tibetan monks still place bar magnets on the skull to improve the concentration and learning ability of novitiates in accordance with an age-old protocol.

In the early 1500s, the Swiss physician and alchemist Paracelsus became convinced that magnetism could restore the body's vitality and used magnets to promote healing and treat epilepsy, diarrhea, and certain types of hemorrhage. Lodestones were ground up to make powders that could be applied as magnetic salves or ingested to provide energy and stop bleeding. Such practices became very popular but were debunked in 1600 by William Gilbert in *De Magnete*. By the middle 1700s, more powerful, carbon-steel magnets had become available in Europe and there was heightened interest in their curative powers. Franz Anton Mesmer quickly became famous for his miraculous cures of everything from deafness to paralysis. In his 1775 report *On the Medicinal Uses of the Magnet*, he vividly described how he had restored health to a patient with uncontrollable seizures and numerous other nervous system complaints by feeding her iron filings and applying specially shaped magnets over affected organs. He later claimed that the healing force actually resided in his own "animal magnetism" (*magnetisomum animale*). This was hailed as a new force analogous to Newton's gravity, and people from all over Europe waited in long lines to be treated in his Paris salon. French physicians considered him a fraud and convinced Louis XVI to establish an unbiased commission consisting of Benjamin Franklin, Antoine Lavoisier, and Dr. J.I. Guillotin to investigate Mesmer's claims. They observed blindfolded patients who were exposed to very strong magnets and asked to describe their responses when fake objects were unknowingly substituted. The commission concluded in 1784 that magnetic healing was entirely due to the belief of the patient (placebo effect) and the power of suggestion (hypnosis). We still refer to hypnotism as "mesmerism."

Although Mesmer was thoroughly discredited, magnet therapy flourished in the United States and permanent magnet sales soared after the Civil War, particularly in the newly industrialized Western farm belts. Magnets, magnetic salves, and liniments were dispensed by traveling magnetic healers and were readily available at food and grain stores. By the turn of the century, mail-order catalogs offered magnetic soles for boots (profitable at 18 cents a pair) as well as magnetic rings, belts, caps, girdles, and other apparel

that purportedly could cure anything from menstrual cramps to baldness and impotence. The king of magnetic healers was Dr. C.J.Thacher, whose Chicago's Magnetic Company in the 1920s promised "health without the use of medicine." His mail-order pamphlet explained that the energy responsible for life comes from the magnetic force of the sun, which is conducted through the rich iron content of the blood. Disease resulted when stressful lifestyles and environmental factors interfered with these healing forces. However, "magnetism properly applied will cure every curable disease no matter what the cause." The most efficient way to expedite this alleged ability of iron in the blood to transmit healing magnetic energy was to wear magnetic clothing, and almost every conceivable garment was available. A complete costume, which promised "full and complete protection of all the vital organs of the body," contained 700 magnets!

It is not clear when electricity was first used to treat illness but electric catfish native to the Nile are portrayed in Egyptian murals several thousand years old that suggest medical applications. The Roman physician Scribonius Largus used a live torpedo fish to treat a patient with gout and wrote in 46 A.D. that headaches and other pains could be cured by standing in shallow water near these electric fish. The powerful South American electric eel was introduced to Europe in 1750, and people flocked to be treated with its "natural electricity." Around the same time, the invention of the Leyden jar had dramatically demonstrated the ability of a stored electrical charge to produce muscle contractions and shocks. The publication of Mary Shelley's *Frankenstein* in 1818 stimulated interest in electricity as the source of life. Since Galvani had shown that limbs or other body parts would jump when electrical shocks were administered to animal and human cadavers, it was believed that electricity could bring the dead to life. Various "reanimation" chairs and devices were constructed, some of which may possibly have acted as pacemakers or defibrillators in the rare cases that responded. An induction coil with sponge-tipped electrodes was used in 1853 to successfully treat abnormal heart rhythms and angina. Over the next few decades, as batteries were progressively improved and electricity from generating stations became available, all sorts of "medical coils" were developed with diverse curative claims.

By the early 1900s, electrotherapeutics was viewed as a legitimate medical specialty much like the growing fields of radiology and radium therapy, and medical textbooks devoted chapters to the use of magnetism and electricity. Devices were devised to diagnose and treat anemia, hysteria, convulsions, insomnia, migraine, neuralgia, arthritis, fatigue, and all types of pain. Some were based on the proposition that each organ or individual was "tuned" to a specific electromagnetic wavelength whose application could energize or rejuvenate them. The most popular were the dynamiser and oscilloclast devised by Albert Abrams, a physician who was described by the American Medical Association in 1925 as the "dean of twentieth century charlatans." The dynamizer was said to be so sensitive it could not only diagnose a disease from a drop of blood, photograph, or handwriting sample but also pinpoint its location in the body. The oscilloclast was then simply set to the vibratory rate of the disease to be treated and the treatment was likened to shattering a wineglass with sound vibrations. A decade later, Wilhelm Reich claimed he had discovered a universal cosmic and biological energy called orgone that permeated the universe. He constructed an orgone accumulator box he claimed could collect and accumulate orgone obtained from the atmosphere. Sitting in the accumulator would not only restore and promote health and vitality but was an effective treatment for cancer. The FDA sued and convicted him for fraud, and the court ordered his books and research burned and his equipment destroyed. Although Abrams died in prison in 1957, he still has fervent followers who believe in his theories and devices, judging from various Web sites. Other contraptions made similar extravagant but worthless claims, so it is not surprising that all bioelectromagnetic approaches came to be regarded as fraudulent. A more detailed discussion of the above is available elsewhere (1).

Unfortunately, this dismissed included legitimate research, and it is not unlikely that in some instances the baby was thrown out with the bathwater. One example may be the work of Harold Saxton Burr, whose theory of “L fields” of life showed great potential for the diagnosis of cancer and the treatment of various disorders. His research results using the comparatively crude devices available over a half century ago are now being intensively reinvestigated and confirmed with more sophisticated technology. In recent years, magnetic resonance imaging (MRI) and positive emission tomography (PET scanning) have emerged as superior diagnostic aids. Cardiac pacemakers, defibrillators, and other implantable electromedical devices have saved countless lives and eased the suffering of patients with Parkinson’s disease and other debilitating disorders. The FDA has also approved specific electromagnetic devices to promote the healing of bone fractures that have failed to unite despite other interventions; this procedure has proven successful and safe in hundreds of thousands of patients over the past few decades. More recently, electromagnetic therapies for the treatment of urinary incontinence, sports injuries, and liver and kidney tumors have also been approved. Other approaches, for the treatment of osteoarthritis, pain, tinnitus, and other indications, have satisfied criteria for efficacy and safety that have led to their approval in European and other countries and that may allow them to be available in the United States under the “globalization” and “harmonization” provisions of the 1997 FDA Modernization Act.

WHY AND HOW THIS BOOK WAS WRITTEN

Permanent magnet and electromagnetic therapies are now riding the crest of a tidal wave of interest in “alternative” and “complementary” medicine. Unfortunately, charlatans, entrepreneurs, and misguided zealots with worthless devices and unfounded claims still abound. It is essential to distinguish these from authentic approaches and products. As a result, in this book we have tried to separate the wheat from the chaff by restricting contributions to evidence-based medicine supported by references in peer-reviewed publications and to provide the reader with tools and skills for evaluating the legitimacy of devices and claims. In addition to a lengthy history of quackery and fraud, another criticism that has hampered wider acceptance of bioelectromagnetic approaches is the inability to identify the mechanisms of action responsible for any benefits. We have therefore attempted to identify concepts and theories that attempt to explain the mechanisms responsible for mediating the diverse benefits of bioelectromagnetic therapies and, in some instances, how they may relate to ancient concepts of subtle energies in the body that are also found in nature. How weak environmental electromagnetic energies as well as those generated internally can produce nonthermal biological effects is not clear since the absence of detectable heat exchange would appear to violate the laws of thermodynamics.

In addition, our current concept of how communication takes place in the body is at a chemical/molecular level as we visualize small peptide and other messengers fitting into specific receptor sites on cell walls much like keys opening certain locks. Such physical structural matching that could occur only on a random-collision basis cannot explain the myriad instantaneous and automatic reactions such as those that occur in “fight or flight” responses to severe stress. As will be seen, there is an emerging paradigm of cellular communication at a physical/atomic level that may provide some answers and also provide insights into widely acknowledged but poorly understood phenomena such as the placebo effect, the power of prayer and a firm faith, telepathic communication, the benefits of acupuncture, homeopathy, therapeutic touch, various bodywork and massage therapies, and Kirlian and other low-level imaging procedures.

Another issue that has caused wariness about bioelectromagnetic therapies are safety concerns about possible increased risk of certain malignancies and birth defects resulting from proximity to high power lines, cell phones, microwave ovens, and electric blankets. It is not surprising that electromagnetic fields,

like many other therapies, can be two-edged swords. For example, all the modalities we use to treat cancer, including radiation, chemotherapy, and hormonal interventions, can also cause cancer. Such effects may depend on dosage, duration of exposure, and genetic and other influences. It is not likely that any clear conclusion about adverse electromagnetic effects can be reached until more information has been obtained from long-term studies that focus on these factors. For this reason, we have refrained from participating in this debate other than to devote a chapter on the importance of dosimetry and to emphasize that no such adverse effects have been observed or seem likely in the therapies presented in this book. Indeed, those that have been proposed and implemented by Demetrio Sodi Pallares and Björn Nordenström and confirmed by others have shown stunning success in treating various malignancies. Many of the chapters in this book are based on presentations at the annual International Congress on Stress over the past decade or so, and additional information on these events can be obtained at www.stress.org.

We have also attempted in this book to trace the origin and development of various therapies, such as TENS and vagal nerve stimulation by pioneers in the field such as Norman Shealy, Donlin Long, and Jacob Zabara. Kirk Jeffrey has contributed a similar chapter on the evolution of cardiac pacemakers. We have made a concerted effort to include prominent scientists whose research may not be well known in the United States. When initially approached to serve as editor of this book, I explained that this was not my field of expertise and asked Marko Markov, a distinguished physicist, to serve as coeditor. He is also much more familiar with relevant advances in Eastern Europe and Russia, and I am grateful for his careful review of all chapters and for those he has attracted from these countries as well as his own contributions. I am also indebted to Russell Dekker for expediting this work so that the material would be current and important late-breaking advances could be included, such as radiofrequency coblation nucleoplasty for disc disease. I would also like to thank all the authors for their cooperation in responding so promptly to urgent requests for revisions necessary to adhere to this very accelerated publication schedule.

The above is a brief summary of why this book is needed and how it was assembled. I believe it is particularly appropriate to conclude with the following quotation.

In the decade to come, it is safe to predict, bioelectromagnetics will assume a therapeutic importance equal to, or greater than, that of pharmacology and surgery today. With proper interdisciplinary effort, significant inroads can be made in controlling the ravages of cancer, some forms of heart disease, arthritis, hormonal disorders, and neurological scourges such as Alzheimer's disease, spinal cord injury, and multiple sclerosis. This prediction is not pie-in-the-sky. Pilot studies and biological mechanisms already described in primordial terms, form a rational basis for such a statement. —
J. Andrew L. Bassett, 1992

Andy Bassett was one of the early advocates of the use of electromagnetic fields for uniting fractures that refused to heal. Unfortunately, he died before he could see that his prophecy would come true well ahead of schedule. In many respects, this book is a tribute to him and other pioneers such as Bob Becker, Abe Liboff, Björn Nordenström, and Ross Adey who recognized the vast potential of bioelectromagnetic medicine and have helped to put it on a solid scientific footing. I am particularly delighted that we were able to obtain contributions from most of these trailblazers.

Paul J. Rosch, M.D., F.A.C.P.

REFERENCES

1. Lawrence R, Rosch PJ, Plowden J. Magnet Therapy. Rocklin, CA: Prima Press, 1998.

Contents

<i>Preface</i>	iv
Paul J.Rosch	
<i>Contributors</i>	xv
I. INTRODUCTION	
1. Potential Therapeutic Applications of Nonthermal Electromagnetic Fields: Ensemble Organization of Cells in Tissue as a Factor in Biological Field Sensing <i>W.Ross Adey</i>	1
2. Signal Shapes in Electromagnetic Therapies: A Primer <i>A.R.Liboff</i>	16
3. Magnetic Field Generation and Dosimetry <i>Stefan Engström</i>	36
4. Image-Guided Electromagnetic Therapy <i>Frank S.Prato</i>	47
II. THE EVOLUTION OF BIOELECTROMAGNETIC THERAPIES	
5. The Theology of Electricity: Electricity, Alchemy, and the Unconscious <i>Dennis Stillings</i>	56
6. Recent Developments in Bioelectromagnetic Medicine <i>James L.Oschman</i>	71
7. Evolution of Electrotherapy: From TENS to Cyberpharmacology <i>C.Norman Shealy, Saul Liss and Bernard S.Liss</i>	87

8. Origin and Evolution of Vagal Nerve Stimulation: Implications for Understanding Brain Electrodynamics, Neuroendocrine Function, and Clinical Applications 109
Jacob Zabara
9. Chronic Therapeutic Brain Stimulation: History, Current Clinical Indications, and Future Prospects 126
Alon Y.Mogilner, Alim-Louis Benabid and Ali R.Rezai

III. MECHANISMS OF ACTION AND THEORETICAL CONSIDERATIONS

10. Quantum Holography: A Basis for the Interface Between Mind and Matter 145
Edgar Mitchell
11. Subtle Energies and Their Roles in Bioelectromagnetic Phenomena 151
William A.Tiller
12. Electromagnetism Versus Bioelectromagnetism 184
William A.Tiller
13. A Fundamental Basis for the Effects of EMFs in Biology and Medicine: The Interface Between Matter and Function 197
J.Benveniste
14. Electromagnetic Techniques in Neural Therapy 202
K.A.Jenrow and A.R.Liboff
15. Is There an Electrical Circulatory System that Communicates Internally and Externally? 217
Paul J.Rosch and Björn E.W.Nordenström

IV. NEUROLOGIC, MUSCULOSKELETAL AND SOFT TISSUE APPLICATIONS

16. Magnetic and Electromagnetic Field Therapy: Basic Principles of Application for Pain Relief 238
Marko S.Markov
17. Deep Brain Stimulation for Parkinson's Disease and Movement Disorders 251
E.Oscar Richter and Andres M.Lozano

18. Noninvasive Pulsed Electromagnetic Therapy for Migraine and Multiple Sclerosis 263
Martha S.Lappin

19. Repetitive Transcranial Magnetic Stimulation (rTMS) for Depression and Other Indications 278
*Mark S.George, Ziad Nahas, F.Andrew Kozel, Xingbao Li,
Kaori Yamanaka, Alexander Mishory, Sarah Hill
and Daryl E.Bohning*

20. Repetitive Transcranial Magnetic Stimulation for Tinnitus 297
Paul J.Rosch

21. Low-Energy Emission Therapy: Current Status and Future Directions 304
*Boris Pasche
and Alexandre Barbault*

22. Vagus Nerve Stimulation for the Treatment of Epilepsy 311
Steven C.Schachter

23. Electrical Stimulation of the Internal Globus Pallidus in Advanced Generalized Dystonia 324
*Laura Cif, Nathalie Vayssiere, Simone Hemm,
Monique Azais,
Cédric Monnier
Eric Hardouin
Amandine Gannau
Michel Zanca
and Philippe Coubes*

24. Peripheral Stimulation for Pain Control and the Development of Modern Transcutaneous Stimulation for Pain 337
*Donlin M.Long
and Norman Hagfors*

25. Low-Frequency Electromagnetic Field Effects on Lymphocytes: Potential for Treatment of Inflammatory Diseases 350

Gabi Nindl
, Mary T. Johnson
, Walter X. Balcavage

- | | | |
|---|---|-----|
| 26. | Orthopedic Clinical Application of Biophysical Stimulation in Europe
<i>Ruggero Cadossi</i>
<i>and Gian Carlo Traina</i> | 370 |
| 27. | Electromagnetic Stimulation in Orthopaedics: Biochemical Mechanisms to Clinical Applications
<i>James T. Ryaby</i> | 389 |
| 28. | Application of Electromagnetic Fields in Traumatology and Orthopaedics
<i>Imants Detlavs</i> | 400 |
| 29. | Neurorehabilitation of Standing and Walking After Spinal Cord Injury
<i>Tadej Bajd</i> | 415 |
| 30. | Electromagnetic Linkages in Soft Tissue Wound Healing
<i>Harvey N. Mayrovitz</i> | 435 |
| 31. | Electric Current Wound Healing
<i>David Cukjati</i>
<i>and Rajmond Šavrin</i> | 457 |
| 32. | Pulsed Magnetic Therapy for the Treatment of Incontinence, Disuse Atrophy, Muscle Spasm, and Muscle Reeducation to Increase Mobility
<i>Kent Davey</i> | 478 |
| 33. | Coblation Radio-Frequency Discal Nucleoplasty: A Novel Approach to the Management of Acute Disk Herniation
<i>Arra S. Reddy</i>
<i>and Joshua A. Hirsch</i> | 488 |
| V. CARDIOVASCULAR DISORDERS AND CANCER | | |
| 34. | Electricity and the Heart: Innovation and the Evolution of Cardiac Pacing
<i>Kirk Jeffrey</i> | 495 |
| 35. | The Energetic Heart: Biomagnetic Communication Within and Between People | 511 |

Rollin McCraty

36. Static Magnetic Fields and Microcirculation 533
Chiyoji Ohkubo
and Hideyuki Okano
37. Magneto-Metabolic Therapy for Advanced Malignancy and Cardiomyopathy 560
Demetrio Sodi Pallares
and Paul J. Rosch
38. Electromagnetic Fields as an Adjuvant Therapy to Antineoplastic Chemotherapy 578
Joseph R. Salvatore
and Marko S. Markov
39. Can Magnetic Fields Inhibit Angiogenesis and Tumor Growth? 589
Marko S. Markov
Calvin D. Williams
Ivan L. Cameron
W. Elaine Hardman
and Joseph R. Salvatore
40. Electroporation for Electrochemotherapy and Gene Therapy 600
Damijan Miklavčič
and Tadej Kotnik
41. Electroporation Therapy: Treatment of Cancer and Other Therapeutic Applications 620
Dietmar Rabussay
Georg Widera
and Martin Burian
42. The Paradigm of Biologically Closed Electric Circuits and Its Clinical Applications 658
Björn E. W. Nordenström
and Jorgen Nordenström
43. Electrochemical Therapy of Tumors 668
Yuling Xin
Hongchang Zhao
Wei Zhang
Chaoyang Liang
Zaiyong Wang
and Ganzhong Liu

VI. CRANIOELECTRICAL STIMULATION AND OTHER INDICATIONS

44. Cranial Electrotherapy Stimulation for Anxiety, Depression, Insomnia, Cognitive Dysfunction, and Pain 687
Daniel L.Kirsch
and Ray B.Smith
45. Low-Intensity Millimeter Waves in Biology and Medicine 700
O.V.Betskii
and N.N.Lebedeva
46. The Use of Electrical Stimulation to Treat Morbid Obesity 718
Mitchell Roslin
and Marina Kurian
47. Biocurrent Therapy for Macular Degeneration 727
John B.Jarding
and George D.O'Clock

VI PERMANENT MAGNET APPLICATIONS

I.

48. Clinical Trials Involving Static Magnetic Field Applications 737
Agatha P.Colbert
49. Pain-Free and Mobility-Free Magnetic Force in Orthodontic Therapy 751
Abraham M.Blechman

VI CONCLUSION

II.

50. Concluding Comments: Some Late Breaking Developments and Future Directions 762
Paul J.Rosch
and Marko S.Markov
- Index* 778

Contributors

W.Ross Adey Loma Linda University School of Medicine, Loma Linda, California, U.S.A.
RAdey43450@aol.com

Monique Azais Unité de Recherche sur les Mouvements Anormaux de l'Enfant URMAE, Service de Neurochimie B, Centre Gui de Chauliac, CHU Montpellier, Montpellier, France

Tadej Badj University of Ljubljana, Ljubljana, Slovenia. tadej.badj@robo.fe.uni-lj.si

Walter X.Balcavage Cellular and Integrative Physiology, Indiana University School of Medicine, Terre Haute Center for Medical Education, Terre Haute, Indiana, U.S.A. wbalcava@medicine.indstate.edu

Alexandre Barbault Symtonic S.A., Renens, Switzerland

Alim-Louis Benabid Department of Clinical and Biological Neurosciences, INSERM, Joseph Fourier University, Grenoble, France. alimlouis.benabid@ujf-grenoble.fr

J.Benveniste Digital Biology Laboratory, Clamart, France. jbenveniste@digibio.com

O.V.Betskii Institute for Radio Engineering and Electronics of the Russian Academy of Sciences, Moscow, Russia

Abraham M.Blechman Columbia University, New York, New York, U.S.A. ifnyk@aol.com

Daryl E.Bohning The Brain Stimulation Laboratory (BSL), Psychiatry Department, and the Center for Advanced Imaging Research (CAIR), Medical University of South Carolina (MUSC), Charleston, South Carolina, U.S.A.

Martin Burian University of Vienna Medical School, Vienna, Austria. martin.burian@akh-wien.ac.at

Ruggero Cadossi Research and Development, Igea, Capri, Italy. cadossi@igea.it

Ivan L.Cameron University of Texas Health Science Center, San Antonio, Texas, U.S.A.

Laura Cif Unité de Recherche sur les Mouvements Anormaux de l'Enfant URMAE, Service de Neurochirurgie B, Centre Gui de Chauliac, CHU Montpellier, Montpellier, France. urmae@chu-montpellier.fr

Agatha P.Colbert Oregon Center for Complementary and Alternative Medicine, Portland, Oregon, U.S.A. apcolbert@attbi.com

Phillippe Coubes Unité de Recherche sur les Mouvements Anormaux de l'Enfant URMAE, Service de Neurochirurgie B, Centre Gui de Chauliac, CHU Montpellier, Montpellier, France. p-coubes@chu-montpellier.fr

David Cukjati Laboratory of Biocybernetics, Faculty of Electrical Engineering, University of Ljubljana, Ljubljana, Slovenia. david@svarnun.fe.uni-lj.si

Kent Davey American Maglev Technology, Edgewater, Florida, U.S.A. k.davey@mail.utexas.edu

Imants Detlavs Medical-Scientific Center “ELMA-LA”, Riga, Latvia. imants.detlavs@apollo.lv

Stefan Engström Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee, U.S.A. stefan.engstrom@vanderbilt.edu

Amandine Gannau Unité de Recherche sur les Mouvements Anormaux de l’Enfant URMAE, Service de Neurochirurgie B, Centre Gui de Chauliac, CHU Montpellier, Montpellier, France

Mark S.George The Brain Stimulation Laboratory (BSL), Psychiatry Department, and the Center for Advanced Imaging Research (CAIR), Medical University of South Carolina (MUSC), Charleston, South Carolina, U.S.A. georgem@musc.edu

Norman Hagfors St. Paul, Minnesota, U.S.A. hagfors@norsen.com

W.Elaine Hardman Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, Louisiana, U.S.A.

Eric Hardouin Unité de Recherche sur les Mouvements Anormaux de l’Enfant URMAE, Service de Neurochirurgie B, Centre Gui de Chauliac, CHU Montpellier, Montpellier, France

Simone Hemm Unité de Recherche sur les Mouvements Anormaux de l’Enfant URMAE, Service de Neurochirurgie B, Centre Gui de Chauliac, CHU Montpellier, Montpellier, France

Sarah Hill The Brain Stimulation Laboratory (BSL), Psychiatry Department, and the Center for Advanced Imaging Research (CAIR), Medical University of South Carolina (MUSC), Charleston, South Carolina, U.S.A. hill@musc.edu

Joshua S.Hirsch Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts, U.S.A.

John B.Jarding Black Hills Regional Eye Institute, Rapid City, South Dakota, U.S.A. lowvision@bhrei.com

K.A.Jenrow Department of Neurosurgery, Henry Ford Hospital, Detroit, Michigan, U.S.A.

Kirk Jeffrey Carleton College, Northfield, Minnesota, U.S.A. kirkjeffrey@yahoo.com

Mary T.Johnson Cellular and Integrative Physiology, Indiana University School of Medicine, Terre Haute Center for Medical Education, Terre Haute, Indiana, U.S.A. mjormson@medicine.indstate.edu

Daniel L.Kirsch Electromedical Products International, Inc., Mineral Wells, Texas, U.S.A. dan@epii.com

Tadej Kotnik Faculty of Electrical Engineering, University of Ljubljana, Ljubljana, Slovenia. tadej@svarun.fe.uni-lj.si

F.Andrew Kozel The Brain Stimulation Laboratory (BSL), Psychiatry Department, and the Center for Advanced Imaging Research (CAIR), Medical University of South Carolina (MUSC), Charleston, South Carolina, U.S.A. kozelfa@musc.edu

Marina Kurian Lenox Hill Hospital, New York, New York, U.S.A.

Martha S.Lappin Energy Medicine Developments, Burke, Virginia, U.S.A. Marlappin@aol.com

N.N.Lebedeva Institute for Higher Nerve Activity and Neurophysiology of the Russian Academy of Sciences, Moscow, Russia. N.Leb@relcom.ru

Xingbao Li The Brain Stimulation Laboratory (BSL), Psychiatry Department, and the Center for Advanced Imaging Research (CAIR), Medical University of South Carolina (MUSC), Charleston, South Carolina, U.S.A. lixi@musc.edu

Chaoyang Liang Department of Thoracic Surgery, Electrochemical Therapy Center for Tumors, China-Japan Friendship Hospital, Beijing, P.R. China.

A.R.Liboff Department of Physics, Oakland University, Rochester, Michigan, U.S.A.
ARLiboff@aol.com

Bernard S.Liss MEDI Consultants, Inc., Paterson, New Jersey, U.S.A.

Saul Liss MEDI Consultants, Inc., Paterson, New Jersey, U.S.A. lissmedi@aol.com

Ganzhong Liu Department of Thoracic Surgery, Electrochemical Therapy Center for Tumors, China-Japan Friendship Hospital, Beijing, P.R. China

Donlin M.Long Johns Hopkins Hospital, Baltimore, Maryland, U.S.A. dmlong@jhmi.edu

Andres M.Lozano Department of Surgery, University of Toronto, Toronto Western Hospital Research Institute, Toronto, Ontario, Canada. lozano@uhnres.utoronto.ca

Marko S.Markov Research International, Buffalo, New York, U.S.A. msmarkov@aol.com

Harvey N.Mayrovitz College of Medical Sciences, Nova Southeastern University, Ft. Lauderdale, Florida, U.S.A. mayrovit@ix.netcom.com

Rollin McCraty HeartMath Research Center, Institute of HeartMath, Boulder Creek, California, U.S.A. rollin@heartmath.org

Alexander Mishory The Brain Stimulation Laboratory (BSL), Psychiatry Department, and the Center for Advanced Imaging Research (CAIR), Medical University of South Carolina (MUSC), Charleston, South Carolina, U.S.A. mishory@musc.edu

Edgar Mitchell Lake Worth, Florida, U.S.A. edgarmitchell@msn.com

Damijan Miklavčič Faculty of Electrical Engineering, University of Ljubljana, Ljubljana, Slovenia. damijan@svarun.fe.uni-lj.si

Alon Y.Mogilner Department of Neurosurgery, New York Medical College, Valhalla, New York, U.S.A. alon_mogilner@nymc.edu

Cédric Monnier Unité de Recherche sur les Mouvements Anormaux de l'Enfant URMAE, Service de Neurochirurgie B, Centre Gui de Chauliac, CHU Montpellier, Montpellier, France

Ziad Nahas The Brain Stimulation Laboratory (BSL), Psychiatry Department, and the Center for Advanced Imaging Research (CAIR), Medical University of South Carolina (MUSC), Charleston, South Carolina, U.S.A. nahasz@musc.edu

Gabi Nindl Cellular and Integrative Physiology, Indiana University School of Medicine, Terre Haute Center for Medical Education, Terre Haute, Indiana, U.S.A. gnindl@medicine.indstate.edu

Björn E.W.Nordenström Professor Emeritus, Karolinska Institute and Hospital, Stockholm, Sweden

Jorgen Nordenström Huddinge University Hospital, Stockholm, Sweden. jorgen.nordenstrom@karo.ki.se

George D.O'Clock Electrical & Computer Engineering & Technology Department, Minnesota State University, Mankato, Minnesota, U.S.A. george.oclock@mankato.msus.edu

Chiyoji Ohkubo National Institute of Health, Tokyo, Japan. ohkubo@iph.go.jp

Hideyuki Okano* National Institute of Health, Tokyo, Japan

James L.Oschman Nature's Own Research Association, Dover, New Hampshire, U.S.A. joschman@aol.com

Boris Pasche Symtonic S.A., Renens, Switzerland. b-pasche@northwestern.edu

Frank S.Prato Lawson Health Research Institute and University of Western Ontario, London, Ontario, Canada. prato@lri.sjhc.london.on.ca

Dietmar Rabussay Research & Development, Genetronics, Inc., San Diego, California, U.S.A.
dietmarr@genetronics.com

Arra S.Reddy Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts, U.S.A.

Ali R.Rezai Department of Neurosurgery, Cleveland Clinic Foundation, Cleveland, Ohio, U.S.A.
rezaia@ccf.org

E.Oscar Richter Department of Neurosurgery, University of Florida, Gainesville, Florida, U.S.A.
richter372002@yahoo.com

Paul J.Rosch The American Institute of Stress, Yonkers, and New York Medical College, Valhalla, New York, U.S.A. stress124@optonline.net

Mitchell Roslin Lenox Hill Hospital, New York, New York, U.S.A.

James T.Ryaby OrthoLogic Corp., and Arizona State University, Tempe, Arizona, U.S.A.
jryaby@olgc.com

Joseph R.Salvatore Carl T.Hayden VA Medical Center, Phoenix, Arizona, U.S.A.
Joseph.Salvatore@med.va.gov

Rajmond Šavrin Institute of the Republic of Slovenia for Rehabilitation, Ljubljana, Slovenia

Steven C.Schachter Harvard Medical School, Boston, Massachusetts, U.S.A. ssschacht@caregroup.harvard.edu

C.Norman Shealy Holos Institutes of Health, Inc., Fair Grove, Missouri, U.S.A.
norm@shealyhealthnet.com

Ray B.Smith Electromedical Products International, Inc., Mineral Wells, Texas, U.S.A. ray@epii.com

Demetrio Sodi Pallares* Mexico City, Mexico

Dennis Stillings Archaeus Project, Kamuela, Hawaii, U.S.A. dstillings@kohalacenter.org

William A.Tiller Professor Emeritus, Department of Materials Science & Engineering, Stanford University, Stanford, California, U.S.A.

Gian Carlo Traina Department of Biomedical Sciences, Orthopaedic Clinic, University of Ferrara, Ferrara, Italy. tng@unife.it

Nathalie Vaysserie Unité de Recherche sur les Mouvements Anormaux de l'Enfant URMAE, Service de Neurochirurgie B, Centre Gui de Chauliac, CHU Montpellier, Montpellier, France

Georg Widera Research & Development, Genetronics, Inc., San Diego, California, U.S.A.
georg.widera@alza.com

Calvin D.Williams EMF Therapeutics, Inc., Chattanooga, Tennessee, U.S.A.

Zaiyong Wang Department of Thoracic Surgery, Electrochemical Therapy Center for Tumors, China-Japan Friendship Hospital, Beijing, P.R. China

Yuling Xin Department of Thoracic Surgery, Electrochemical Therapy Center for Tumors, China-Japan Friendship Hospital, Beijing, P.R. China. suime@public3.bta.net.cn

Kaori Yamanaka Stimulation Laboratory (BSL), Psychiatry Department, and the Center for Advanced Imaging Research (CAIR), Medical University of South Carolina (MUSC), Charleston, South Carolina, U.S.A. yamanakk@musc.edu

*Current affiliation: Pip Tokyo Co., Ltd., Tokyo, Japan.

Jacob Zabara Cyberonics, Inc., Houston, Texas, U.S.A.

Michel Zanca Service de Médecine Nucléaire, Centre Gui de Chauliac, CHU Montpellier, Montpellier, France. m-zanca@chu-montpellier.fr

Wei Zhang Department of Thoracic Surgery, Electrochemical Therapy Center for Tumors, China-Japan Friendship Hospital, Beijing, P.R. China

Hongchang Zhao Department of Thoracic Surgery, Electrochemical Therapy Center for Tumors, China-Japan Friendship Hospital, Beijing, P.R. China

*Deceased.

Bioelectromagnetic Medicine

1

Potential Therapeutic Applications of Nonthermal Electromagnetic Fields: Ensemble Organization of Cells in Tissue as a Factor in Biological Field Sensing*

W.Ross Adey

Loma Linda University School of Medicine, Loma Linda, California, U.S.A.

There are major unanswered questions about possible health risks that may arise from human exposures to various man-made electromagnetic fields where these exposures are intermittent, recurrent, and may extend over a significant portion of the lifetime of the individual. Current equilibrium thermodynamic models fail to explain an impressive spectrum of observed electromagnetic bioeffects at nonthermal exposure levels. Much of this signaling within and between cells may be mediated by free radicals of the oxygen and nitrogen species.

I.

INTRODUCTION

In our solar system, the natural electromagnetic environment varies greatly from planet to planet. In the case of the planet Earth, a semiliquid ferromagnetic core generates a major and slowly migrating *static* geomagnetic field. Concurrently, there are much weaker natural *oscillating* low-frequency electromagnetic fields that arise from two major sources: in thunderstorm activity in equatorial zones of Central Africa and the Amazon basin and in lesser degree from solar magnetic storms in years of high activity in the 11-year solar sunspot cycle.

A.

Comparison of Natural and Man-Made Electromagnetic Environments

All life on earth has evolved in these fields. Defining them in physical terms permits direct comparison with far stronger man-made fields that have come to dominate all civilized environments in the past century. Energy in the *oscillating* natural fields is almost entirely in the extremely low frequency (ELF) spectrum, with peaks at frequencies between 8 and 32 Hz, the Schumann resonances (1). Their electric components are around 0.01 V/m, with magnetic fields of 1–10 nT. These natural oscillations are ducted worldwide between the earth's surface and the ionosphere at an approximate height of 250 km. With a circumference of 41,000 km, the earth may act as a cavity resonator for this ducted propagation (at the velocity of light, 300,000 km/s), behaving resonantly at a frequency around 8Hz. Neither solar nor terrestrial sources contribute significant amounts of radiofrequency or microwave energy to the earth's biosphere, and we may

*Portions of this chapter were first published in D.Clements-Croome, ed. *Electromagnetic Environments and Safety in Buildings*, London: Spon Press, 2002.

contrast these weak ELF fields with the earth's much larger static geomagnetic field around 50 μT (0.5 gauss).

The earth's *static* magnetic field at 50 μT is 5000 times larger than the natural oscillations but still substantially less than a wide range of daily human exposures to static and oscillating fields in domestic and occupational environments.

Generation and distribution of electric power has spawned a vast and ever growing vista of new electronic devices and systems. They overwhelm the natural electromagnetic environment with more intense fields. They include oscillations far into the microwave spectrum, many octaves higher than the Schumann resonances. This growth of radio-frequency (RF) and/or microwave fields is further complicated by the advent of digital communication techniques. In many applications, these microwave fields, oscillating billions of times per second, are systematically interrupted (pulsed) at low frequencies. This has raised important biological and biomedical questions, still incompletely answered, about possible tissue mechanisms in detection of amplitude- and pulse-modulation of RF and/or microwave fields (2).

B.

Historical Evidence on Possible Health Effects of Man-Made Environmental Fields

There are major unanswered questions about possible health risks that may arise from human exposures to various man-made electromagnetic fields where these exposures are intermittent, recurrent, and may extend over a significant portion of the lifetime of the individual. Historical correlations have been reported between growth of rural electrification in the United States and the United Kingdom and an increased incidence of childhood leukemia. A peak in childhood leukemia at ages 2 through 4 emerged *de novo* in the 1920s. Using U.S. census data for 1930, 1940, and 1950, Milham and Osslander (3) concluded that the peak in the common childhood acute lymphoblastic leukemia (ALL) may be attributable to electrification.

Design of modern office buildings has led to their electrification through one or more large distribution transformers that may be located in basement vaults, or in some cases, located on each floor of the building. Milham (4) has examined cancer incidence in such a building over a 15-year period and found evidence for *cumulative risks*. An analysis of linear trend in cancer incidence, using average years employed as an exposure score, was positive ($P=0.00337$), with an odds ratio of 15.1 in workers employed longer than 5 years.

In large modern offices, the electromagnetic environment has been further complicated by introduction of local area networks (LANs) for local telephonic (voice) and data transmission. Workers may be continuously exposed to fields from a plethora of sources located on each computer and on local network controllers. Their power output is typically in the low milliwatt to microwatt range—so low that significant heating of workers' tissues is improbable. Any bioeffects attributable to their operation strongly suggest *nonthermal* mechanisms of interaction, and raise further important questions about mechanisms mediating a cumulative dose from repeated, intermittent exposures, possibly over months and years. None of these studies support tissue heating as an adequate model for bioeffects seen in a wide spectrum of laboratory experiments (see below) or in reported epidemiological findings.

The American National Standards Institute (1992) first recognized a tissue dose of 4.0 W/kg as a *thermal* (heating) tissue threshold possibly associated with adverse health effects and proposed an exposure limit in controlled environments (occupational) at 0.4 W/kg, thus creating a supposed "safety margin" of 10. For uncontrolled environments (civilian), a larger safety margin was set with a permissible exposure limit (PEL) 50 times lower at 0.08 W/kg. Since actual measurement of tissue SARs under environmental conditions is

not a practical technique, PELs are typically expressed as a function of *incident field power density*, the amount of energy falling on a surface per unit area, and expressed in mW/cm^2 .

More recently, the U.S. government Interagency Radio Frequency Working Group (1999) has emphasized the need for revisions recognizing nonthermal tissue microwave sensitivities:

Studies continue to be published describing biological responses to nonthermal ELF-modulated RF radiation exposures that are not produced by CW (unmodulated) radiation. These studies have resulted in concern that exposure guidelines based on thermal effects, and using information and concepts (time-averaged dosimetry, uncertainty factors) that mask any differences between intensity-modulated RF radiation exposure and CW exposure, do not directly address public exposures, and therefore may not adequately protect the public.

II. INITIAL TRANSDUCTION OF IMPOSED MICROWAVE FIELDS AT NONTHERMAL ENERGY LEVELS t

Tissue components of environmental RF and microwave fields are consistent with two basic models. Sources close to the body surface produce *near-field exposures*, as with users of mobile phones. The emitted field is magnetically coupled directly from the antenna into the tissues. At increasing distances from the source, the human body progressively takes on properties of a radio antenna, with absorption of radiated energy determined by physical dimensions of the trunk and limbs. This is a *far-field exposure*, defined as fully developed at 10 or more wavelengths from the source and based on interactions with the electric component of the radiated field. Permissible exposure limits (PELs) have rested on measurement of microwave field energy absorbed as heat, expressed as the *specific absorption rate (SAR)* in W/kg .

There is an initial dichotomy in possible modes of interaction of cells in tissue with environmental microwave fields. It is principally determined by the separation of responses attributed to tissue heating from those elicited by certain fields at levels where frank heating is not the basis of an observed interaction. Their interpretation and possible significance has required caution in both biological and biophysical perspectives. Many of these biological sensitivities run counter to accepted models of physiological thresholds based in equilibrium thermodynamics of kT thermal collision energies. In a physical perspective, the search also continues for biological systems compatible with a first transductive step in a range of functionally effective vibrational and electromagnetic stimuli that are orders of magnitude weaker than kT . Aspects of these findings are reviewed in (Sec. IV.) Their occurrence invites hypotheses on directions of future research (5).

A. Cell Membranes as the Site of Initial Field Transductive Coupling

Collective evidence points to cell membrane receptors as the probable site of first tissue interactions with both ELF and microwave fields for many neurotransmitters (6), hormones (7, 8), growth-regulating enzyme expression (9–12), and cancer-promoting chemicals (13). In none of these studies does tissue heating appear involved causally in the responses (2). Physicists and engineers have continued to offer microthermal, rather than athermal, models for these phenomena (14, 15) with views that exclude consideration of cooperative organization and coherent charge states, but it is difficult to reconcile experimental evidence for

factors such as modulation frequency dependence and required duration of an amplitude-modulated signal to elicit a response (*coherence time*) (11) with models based on the equilibrium dynamics of tissue heating.

B.

Evidence for Role of Free Radicals in Electromagnetic Field Bioeffects

Examination of vibration modes in biomolecules, or portions of these molecules (16) has suggested that resonant microwave interactions with these molecules, or with portions of their structure, is unlikely at frequencies below higher gigahertz spectral regions. This has been confirmed in studies showing collision-broadened spectra, typical of a heating stimulus, as the first discernible response of many of these molecules in aqueous solutions to microwave exposures at frequencies below 10 GHz.

However, there is an important option for biomolecular interactions with static and oscillating magnetic fields through the medium of *free radicals* (see Refs. 17 and 18 for summaries). Chemical bonds are magnetic bonds, formed between adjacent atoms through paired electrons having opposite spins and thus magnetically attracted. Breaking of chemical bonds is an essential step in virtually all chemical reactions, each atomic partner reclaiming its electron, and moving away as a free radical to seek another partner with an opposite electron spin. The brief lifetime of a free radical is about a nanosecond or less, before once again forming a *singlet pair* with a partner having an opposite spin or for electrons with similar spins, having options to unite in three ways, forming *triplet pairs* (reviewed in Ref. 2).

During this brief lifetime, imposed magnetic fields may delay the return to the singlet pair condition, thus influencing the *rate* and the *amount of product* of an ongoing chemical reaction (19). McLachlan points out that this model predicts a potentially enormous effect on chemical reactions for static fields in the low mT range. For oscillating fields, the evidence is less clear on their possible role as direct mediators in detection of ELF frequency-dependent bioeffects. *Spin-mixing* of orbital electrons and nuclear spins in adjacent nuclei is a possible mechanism for biosensitivities at extremely low magnetic field levels, but these interactions are multiple, complex, and incompletely understood (20). The highest level of free radical sensitivity may reside in hyperfine-dependent singlet-triplet state mixing in radical pairs with a small number of hyperfine states that describe their coupling to nearby nuclei (21, 22). Although sensitivities to magnetic fields in such a system might theoretically extend down to zero magnetic field levels, singlet-triplet interconversion would need to be sufficiently fast to occur before diffusion reduced the probability of radical re-encounter to negligible levels.

Lander (23) has emphasized that we are at an early stage of understanding free radical signal transduction. “Future work may place free radical signaling beside classical intra- and intercellular messengers and uncover a woven fabric of communication that has evolved to yield exquisite specificity.” A broadening perspective on actions of free radicals in all living systems emphasizes a dual role: first, as messengers and mediators in many key processes that regulate cell functions throughout life and second, in the pathophysiology of *oxidative stress diseases*.

At cell membranes, free radicals may play an essential role in regulation of receptor specificity, but not necessarily through a lock-and-key mechanism. As an example, Lander cites the location of cysteine molecules on the surface of P21-*ras* proteins at cell membranes. They may act as selective targets for nitrogen and oxygen free radicals, thereby inducing covalent modifications and thus setting the *redox potential* of this target protein molecule as the critical determinant for its highly specific interactions with antibodies, hormones, etc. Magnetochemistry studies have suggested a form of cooperative behavior in populations of free radicals that remain *spin-correlated* after initial separation of a singlet pair (24). Magnetic fields at 1 and 60 Hz destabilize rhythmic oscillations in brain hippocampal slices at 56 μT (0.35

to 3.5 nV mm^{-1}) via as yet unidentified nitric oxide mechanisms involving free radicals (23, 25). In a general biological context, these are some of the unanswered questions that limit free radical models as general descriptors of threshold events.

III. SENSITIVITIES TO NONTHERMAL STIMULI: TISSUE STRUCTURAL AND FUNCTIONAL IMPLICATIONS

A. Conductance Pathways in Multicellular Tissues

In its earliest forms, life on earth may have existed in the absence of cells, simply as a “soup” of unconstrained biomolecules at the surface of primitive oceans. It is a reasonable assumption that the first living organisms existed as single cells floating or swimming in these primordial seas. Concepts of a cell emphasize the role of a bounding membrane, surrounding an organized interior that participates in the chemistry of processes essential for all terrestrial life. This enclosing membrane is the organism’s window on the world around it.

For unicellular organisms that swim through large fluid volumes, the cell membrane is both a sensor and an effector. As a sensor, it detects altered chemistry in the surrounding fluid and provides a pathway for inward signals generated on its surface by a wide variety of stimulating ions and molecules, including hormones, antibodies, and neurotransmitters. These most elemental inward signals are susceptible to manipulation by a wide variety of natural or imposed electromagnetic fields that may also pervade the pericellular field. As effectors, cell membranes may also transmit a variety of electrical and chemical signals across intervening intercellular fluid to neighboring cells, thus creating a domain or ensemble of cells, often able to “whisper together” in a faint and private language. Experimental evidence suggests that these outward effector signals may also be sensitive to intrinsic and imposed electromagnetic fields.

Rather than being separated in a virtually limitless ocean, cellular aggregates that form tissues of higher animals are separated by narrow fluid channels that take on special importance in signalling from cell to cell. Biomolecules travel in these tiny “gutters,” typically not more than 150 \AA wide, to reach binding sites on cell membrane receptors. These gutters form the *intercellular space* (ICS). It is a preferred pathway for induced currents of intrinsic and environmental electromagnetic fields. Although it occupies only $\sim 10\%$ of the tissue cross section, it carries at least 90% of any imposed or intrinsic current, directing it along cell membrane surfaces. Whereas the ICS may have a typical impedance of $\sim 4\text{--}50 \text{ ohm cm}^{-1}$, transmembrane impedances are $\sim 10^4\text{--}10^6 \text{ ohm cm}^{-2}$.

B. Structural and Functional Organization of the Extracellular Space

The organization of cell membrane surfaces and intercellular gutters in detection of these tissue components of extrinsic and intrinsic electromagnetic fields enters the realm of *nonequilibrium* thermodynamics (26, 27), characterized by *cooperative processes*, mediated by *coherent states* of electric charges on cell membrane surface molecular systems.

Spaces in the ICS are not simple saline filled channels. Numerous stranded protein molecules protrude into these spaces from the cell interior and form a *glycocalyx* with specialized receptor sites that sense chemical and electrical stimuli in surrounding fluid. Their amino sugar tips are highly negatively charged

(*polyanionic*) and attract a *polycationic* atmosphere, principally of calcium and hydrogen ions. This Debye layer has an extremely high virtual dielectric constant at low frequencies ($D_k > 10^6$ at frequencies < 1 kHz) (28). Biological cooperative processes occur in systems where at least one energetic parameter in that system (e.g., temperature, electric charge) has been moved far from equilibrium by the addition of external energy. This added energy may induce a population of substrate elements, all at the same higher energy level—a *coherent* energetic state. In such a system, a weak external trigger may elicit a *cooperative* process, with an energy release far greater than in the initial trigger. Capping and patching on the lymphocyte cell surface (29) offers a striking example of such a cooperative response, based on intracellular metabolic energy.

The proteins of the glycocalyx offer an anatomical substrate for the first detection of weak electrochemical oscillations in pericellular fluid, including field potentials arising in activity of adjoining cells, or as tissue components of environmental fields. Research in molecular biology has increasingly emphasized essentially direct communication between cells due to their mutual proximity. Bands of *connexin* proteins form *gap junctions* directly uniting adjoining cell membranes. Experimental evidence supports their role in intercellular signaling.

C.

Tissue Detection of Low Frequency Fields and RF/Microwave Fields Amplitude-Modulated at Low Frequencies: Structural and Functional Options

Differential bioeffects, to be discussed below, have been reported between certain nonthermal RF or microwave fields with low-frequency amplitude or pulse modulation when compared to exposures to unmodulated continuous wave (CW) fields at similar power levels. The findings suggest, but do not yet establish unequivocally, that this frequency dependence may be a system property in a sequence of molecular hierarchies beyond the first transductive step. If the concept of modulation frequency-dependence continues to gain support in further research, answers must be sought as to the manner of its detection.

For ELF fields, models based on joint static-oscillating magnetic fields have been hypothesized. They include ion cyclotron resonance (30), where mono- and divalent cations, such as potassium and calcium (abundant in the cellular environment), may exhibit cyclotron resonance at ELF frequencies in the presence of ambient static fields of less than 100 μ T, such as the geomagnetic field. Other models describing ELF frequency dependence have considered phase transitions (31) and ion parametric resonance (32), but interpretation of this frequency dependence based on ion parametric resonance remains unclear (33).

For amplitude- or pulse-modulated RF and/or microwave fields, there is the implication that some form of *envelope demodulation* occurs in tissue recognition of ELF modulation components, but the tissue may remain essentially transparent to the same signal presented as an unmodulated carrier wave (2, -34). However, crucial questions remain unanswered. It is not known whether biological low-frequency dependence is established at the transductive step in the first tissue detection of the field, or whether it resides at some higher level in an hierarchical sequence of signal coupling to the biological detection system (35). For ELF magnetic fields, experimental evidence points to a slow time scale in inhibition of tamoxifen's antiproliferative action in human breast cancer cells (36).

It is a principle of radio physics that extraction of ELF modulation information from an amplitude-modulated signal requires a *nonlinear element* in the detection system. This required nonlinearity may involve a spatial component, such as differential conduction in certain directions along the signal path, or the path itself may exhibit nonlinearities with respect to such factors as spatial distribution of electric

charges at fixed molecular sites (so-called fixed charges), or conduction itself may involve a nonlinear quantum process, as in electron tunneling across the transverse dimensions of the cell membrane.

These constraints impose a further essential condition for demodulation to occur in the multicellular tissues of living organisms. There must be a *site for demodulation* to occur. Evidence supports a role for cell membranes to act in this way, based not only on their intrinsic structure, but also on their proximity to neighboring cells in the typical organization of tissues of the body. Typical tissue organization meets the three criteria outlined above but as a cautionary note, does not allow calculation of possible detection efficiency. Direct neighbor-neighbor cellular interactions will invite our further consideration of properties of cellular ensembles or domains in determining tissue threshold sensitivities.

1.

Directional Differences in Tissue Signal Paths

As already noted, the narrow gutters of the intercellular spaces offer preferred conduction pathways, with conductivity 10^2 – 10^4 higher through extracellular spaces than through cell membranes (37). Thus, the intercellular spaces become preferred pathways for *conduction along (parallel to) cell membrane surfaces* and will reflect the changing directions and cross sections of a myriad channels. Although predominantly an ionic (resistive) conduction pathway, it may also exhibit reactive components, due to the presence of protein molecules in solution.

2.

Nonlinearities in Extracellular Spaces Related to Electric Charge Distribution

A suggested basis for envelope demodulation at cell surfaces may reside in the intensely anionic charge distribution on strands of glycoprotein that protrude from the cell interior, forming the glycocalyx (2, 38). As already noted, they provide the structural basis for specific receptor sites, and they attract a surrounding cationic atmosphere composed largely of calcium and hydrogen ions. This charge separation creates a Debye layer. In models and experimental data from resin particles, Einolf and Carstensen (28) concluded that this physical separation creates a large virtual surface capacitance, with dielectric constants as high as 10^6 at frequencies below 1 kHz. Displacement currents induced in this region by ELF modulation of an RF field may then result in demodulation.

3.

Electron Tunneling in Transmembrane Conduction: Nonlinearities in Space and Time

Experimental studies of transmembrane charge tunneling by DeVault and Chance (39) and their more recent theoretical development by Moser et al. (40) offer an example of extreme functional nonlinearity within the cell membrane. Chance described temperature-independent millisecond electron transfer over a temperature range from 120K to 4K. Considering a cell membrane transverse dimension of 40 Å, Moser et al. noted that a variation of 20 Å in the distance between donors and acceptors in a protein changes the electron transfer rate by 10^{12} -fold. Concurrently in the time domain, the electron transfer rate is pushed from seconds to days, or a 10-fold change in rate for a 1.7 Å change in distance.

4.

Issues of Comparability Between Bioeffects of ELF Fields, ELF-Modulated RF Fields, and Unmodulated (CW) RF Fields

From the beginning of these studies in the 1970s, it was noted that there were similarities in responses of tissues and cultured cells to environmental fields that were either in the ELF spectrum or were RF and/or microwave fields modulated at ELF frequencies. Available evidence has indicated similarities between certain cell ionic and biochemical responses to ELF fields and to RF and/or microwave fields amplitude modulated at these same ELF frequencies, suggesting that tissue demodulation of RF and/or microwave fields may be a critical determinant in ensuing biological responses.

These findings have been reviewed in detail elsewhere (2, 18). They are briefly summarized here in experiments at progressively more complex levels in the hierarchies of cellular organization. Early studies described calcium efflux from brain tissue in response to ELF exposures (38, 41), and to ELF-modulated RF fields (38, 41–43). Calcium efflux from isolated brain subcellular particles (synaptosomes) with dimensions under 1.0 μm also exhibit an ELF modulation frequency dependence in calcium efflux, responding to 16-Hz sinusoidal modulation, but not to 50 Hz modulation, nor to an unmodulated RF carrier (44). In the same and different cell culture lines, the growth regulating and stress responsive enzyme ornithine decarboxylase (ODC) responds to ELF fields (11, 45) and to ELF-modulated RF fields (9, 11, 12).

In more recent studies also related to cellular stress responses, Goodman and Blank and their colleagues have reported rapid, transitory induction of heat shock proteins by microtesla-level 60-Hz magnetic fields (46). In human HL60 promyelocytic cells these exposures at normal growth temperatures activated heat shock factor 1 and heat shock element binding, a sequence of events that mediates stress-induced transcription of the stress gene HSP70 and increased synthesis of the stress response protein hsp70kd. Thus, the events mediating the field-stimulated response appeared similar to those reported for other physiological stressors (hyperthermia, heavy metals, oxidative stress), suggesting to the authors a general mechanism of electromagnetic field interaction with cells. Their further studies have identified endogenous levels of *c-myc* protein as a contributor to the induction of HSP70 in response to magnetic field stimulation (47), with the hypothesis that magnetic fields may interact directly with moving electrons in DNA (48–50).

Immune responses of lymphocytes targeted against human lymphoma tumor cells (allogeneic cytotoxicity) are sensitive to both ELF exposures (51) and to ELF-modulated fields, but not to unmodulated fields (52).

Communication between brain cells is mediated by a spectrum of chemical substances that both excite and inhibit transaction and transmission of information between them. Cerebral amino acid neurotransmitter mechanisms (glutamate, GABA and taurine) are influenced by ELF fields (25, 53), and also by ELF-modulated microwave fields, but not by unmodulated fields. Kolomytkin et al. (6) examined specific receptor binding of three neurotransmitters to rat brain synaptosomes exposed to either 880- or 915-MHz fields at maximum densities of 1.5 mW cm^{-2} . Binding to inhibitory gamma-aminobutyric acid (GABA) receptors decreased 30% at 16 pulses/s, but was not significantly altered at higher or lower pulse frequencies. Conversely, 16 pulses/s modulation significantly increased excitatory glutamate receptor binding. Binding to excitatory acetyl choline receptors increased 25% at 16 pulses/s, with similar trends at higher and lower frequencies. *Sensitivities* of GABA and glutamate receptors persisted at field densities as low as 50 $\mu\text{W cm}^{-2}$.

A selective absence of responses to unmodulated (CW) RF and/or microwave fields reported in many of these earlier studies has focused attention on establishment of threshold sensitivities to CW field exposures. De Pomerai et al. (54) have reported cellular stress responses in a nematode worm as a biosensor of prolonged CW microwave exposures at athermal levels. Tattersall et al. (55) exposed slices of rat

hippocampal cerebral tissue to 700-MHz CW fields for 5–15 min at extremely low SARs in the range 0.0016–0.0044 W kg⁻¹. No detectable temperature changes ($\pm 0.1^\circ\text{C}$) were noted during 15-min exposures. At low field intensities, a 20% potentiation of electrically evoked population potentials occurred, but higher field intensities evoked either increased or decreased responses. The exposures reduced or abolished chemically induced spontaneous epileptiform activity. Bawin et al. (25) also tested the rat hippocampal slice, using ELF magnetic fields. At 56 μT (0.35–3.5 nV mm⁻¹), magnetic fields destabilized rhythmic electrical oscillations via as yet unidentified nitric oxide mechanisms involving free radicals.

D.

The Roles of Field Intermittency and Exposure Duration in Seeking Optimal Therapeutic Responses: Possible “Time Windows” in Trans-Membrane Signaling Paths

It has been apparent from the earliest clinical applications of pulsed magnetic fields to such problems as delayed fracture healing that continuous exposure is not an optimal technique. For example, initial tests with FDA-approved 76-Hz magnetic field generators and cultured bone samples or osteoblast cell lines revealed a range of hormonal and enzymatic responses that occurred only at the onset or immediately after termination of field exposures. In turn, similar clinical testing of various exposure schedules in bone healing led to adoption of intermittent exposure regimes (56). In B-lineage lymphoid cells exposed to 60-Hz magnetic fields, Uckun et al. (57) reported an initial stimulation of tyrosine protein kinases (PTKs) Lyn and Syk. Activation of these Src proto-oncogene PTKs is a proximal and mandatory step in the later activation of protein kinase C. They play “a myriad roles” in signal cascades affecting proliferation and survival of B lymphoid cells.

How does a cell distinguish between transient and sustained signaling? Murphy et al. (58) have shown that in 3T3 fibroblasts, the immediate early gene *c-Fos* functions as a sensor for duration of activation of *extracellular-signal-regulated kinases* (ERK-1 and ERK-2). When ERK activation is transient (30–45 min), its activity declines before the *c-Fos* protein accumulates, and under these conditions *c-Fos* is unstable. However, when ERK signaling is sustained beyond 60 min, *c-Fos* is phosphorylated by still active ERK and by RSK (90K-ribosomal S6 kinase), thus exposing a docking site for ERK (the DEF domain). Together, these data identify a time-dependent general mechanism by which cells can interpret differences in ERK activation kinetics, including control of cell cycle progression towards either differentiation or proliferation.

Rudiger et al. (59) have reported an optimal timing sequence of 5 min ON, 10 min OFF in induction of DNA single and double strand breaks in human diploid fibroblasts and blood lymphocytes. The response to 50-Hz sinusoidal magnetic fields was dose dependent with a threshold at 70 μT . Also using cultured fibroblasts, Litovitz et al. (11) determined the minimal duration that a single low-frequency modulation frequency must be sustained (*coherence time*) in order to elicit activity in the enzyme ornithine decarboxylase (ODC). Using a 915-MHz field, switching modulation frequencies from 55 to 65-Hz at coherence times of 1 s or less abolished enhancement of ODC responses, while coherence times of 10 s or longer produced full enhancement.

It is abundantly clear that such a patchwork of observations fails to provide a database that would allow selection of optimal temporal stimulus patterns in specific clinical situations. Nevertheless, they may be considered the first pointers to crucial stimulus parameters, essential in the foundations of all magnetotherapy. They emphasize the importance of further research in that direction to define both the physical characteristics of an optimal stimulus pattern, and more importantly, the cell and molecular biology in underlying tissue substrates.

IV. THE ROLE OF CELLULAR ENSEMBLES IN SETTING TISSUE THRESHOLDS FOR INTRINSIC AND ENVIRONMENTAL STIMULI

Our pursuit of mechanisms mediating tissue electromagnetic sensitivities at nonthermal levels raises questions about the relevance of observed thresholds in the sensory physiology of other modalities. By extrapolation, do these data suggest the need to explore collective properties of populations of cells in setting thresholds by forms of intercellular communication? Do cooperative processes yield one or more faint and private languages that allow ensembles of cells to whisper together in one or more faint and private languages? Do observed tissue-sensory thresholds differ significantly from thresholds measured in single cells in isolation from their neighbors?

A. Evidence for Domain Functions as a General Biological Property in Tissues

Research in sensory physiology supports this concept, i.e., that some threshold properties may reside in highly cooperative properties of populations of elements rather than in a single detector (60). Seminal observations in the human auditory system point to a receptor vibrational displacement of 10^{-11} m, or approximately the diameter of a single hydrogen atom (61, 62); human olfactory thresholds for musk occur at 10^{-13} M, with odorant molecules distributed over 240 mm^2 (63); and human detection of single photons of blue-green light occurs at energies of 2.5 eV (64). In another context, pathogenic bacteria, long thought to operate independently, exhibit ensemble properties by communication through a system recognizing colony numbers as an essential step preceding release of toxins. These *quorum sensing* systems may control expression of virulence factors in the lungs of patients with cystic fibrosis (65).

1. *Domain Properties in Systems of Excitable Cells*

Bialek addressed the problem of the auditory receptor in quantum mechanical terms. He evaluated two distinct classes of quantum effects: a *macroquantum effect*, typified by the ability of the sensory system to detect signals near the quantum limits to measurement, and a *microquantum effect*, in which “the dynamics of individual biological macromolecules depart from predictions of a semiclassical theory.” Bialek concluded that quantum-limited sensitivity occurs in several biological systems, including displacements of sensory hair cells of the inner ear. Remarkably, quantum limits to detection are reached in the ear in spite of seemingly insurmountable levels of thermal noise.

To reach this quantum limit, these receptor cells must possess amplifiers with noise performance approaching limits set by the uncertainty principle. It is equally impressive that suppression of intrinsic thermal noise allows the ear to function as though close to 0K. Again, this suggests system properties inherent in the detection sequence. These “perfect” amplifiers could not be described by any chemical kinetic model nor by any quantum mechanical theory in which the random phase approximation is valid. The molecular dynamics of amplifiers in Bialek’s models would require preservation of quantum mechanical coherence for times comparable to integration times of the detector. It is not known whether comparable mechanisms may determine electromagnetic sensitivities as a more general tissue property at cellular and subcellular levels.

Behavioral electrosensitivity in sharks and rays may be as low as 0.5 nV mm^{-1} for tissue components of electrical fields in the surrounding ocean (66). These marine vertebrates sense these fields through

specialized jelly-filled tubular receptors (ampullae of Lorenzini) up to 10 cm in length, located near the snout and opening on the skin surface through minute pores. Sensing nerve cells lie in the wall of this ampullary tube. In support of a cooperative model of organization of these neurons, behavioral electrosensitivity in sharks and rays is 100 times below measurable thresholds of individual electroreceptor neurons (67).

2.

Domain Properties in System of Non-excitable Cells: Culture Dimensions and “Bystander” Effects

Jessup et al. (68) have pioneered studies on the role of gravitational fields in determining trends towards either apoptosis (programmed cell death) or towards cell proliferation. Concurrently, they tested the physical configuration of cell cultures in their influence on these same trends. Based on a colorectal cancer cell line, they compared cells cultured in adherent monolayers with three-dimensional (3-D) cultures.

Biochemical measures of apoptosis and cell proliferation were tested (1) in static cultures, (2) in cultures subjected to slow rotation, and (3) in cultures exposed to the microgravity of low-earth-orbital space flight. Over the course of 6 days on earth, static 3-D cultures displayed the highest rates of proliferation and lowest apoptosis. Rotation appeared to increase apoptosis and decrease proliferation, whereas static 3-D cultures in either unit gravity or microgravity had less apoptosis. Expression of the carcinoembryonic antigen (CEA) as a marker of cell differentiation was increased in microgravity.

For ionizing radiation, the U.S. National Council on Radiation Protection (NCRP) has recommended that estimates of cancer risk be extrapolated from higher doses by using a linear, no-threshold model. This recommendation is based on the dogma that the DNA of the nucleus is the main target of radiation-induced genotoxicity and, as fewer cells are directly damaged, the deleterious effects of ionizing radiation proportionally decline. Experimental evidence seriously challenges this concept (69). They used a precision microbeam of a particles to target an exact fraction (either 100% or $\leq 20\%$) of the cells in a confluent cell population and irradiated their nuclei with exactly one a particle each. The findings were consistent with non hit cells contributing significantly to the response, designated *the bystander effect*. Indeed, irradiation of 10% of a confluent mammalian cell population with a single a particle resulted in a mutant yield similar to that observed when all the cells in the population were irradiated. Importantly, this effect was eliminated in cells pretreated with 1 mM octanol, which inhibits intercellular communication mediated by gap-junction proteins. “The data imply that the relevant target for ionizing radiation mutagenesis is larger than an individual cell.”

V.

CONCLUSIONS

Epidemiological studies have evaluated ELF and radio-frequency fields as possible risk factors for human health, with historical evidence relating rising risks of such factors as progressive rural electrification and, more recently, methods of electric power distribution and utilization in commercial buildings. Appropriate models describing these bioeffects are based in nonequilibrium thermodynamics, with nonlinear electrodynamics as an integral feature. Heating models, based in equilibrium thermodynamics, fail to explain an impressive spectrum of observed electromagnetic bioeffects at nonthermal exposure levels. We face a new frontier of much greater significance.

In little more than a century, our biological vista has moved from organs to tissues, to cells, and most recently, to the molecules that form the exquisite fabric of living systems. We discern a biological organization based in physical processes at the atomic level, beyond the realm of chemical reactions between biomolecules. Much of this signaling within and between cells may be mediated by free radicals of the oxygen and nitrogen species. In their brief lifetimes, free radicals are sensitive to imposed magnetic fields, including microwave fields. Free radicals are involved in normal regulatory mechanisms in many tissues. Disordered free radical regulation is associated with oxidative stress diseases, including Parkinson's and Alzheimer's diseases, coronary heart disease, and cancer.

Although incompletely understood, tissue free radical interactions with magnetic fields may extend to zero field levels. Emergent concepts of tissue thresholds to imposed and intrinsic magnetic fields address ensemble or domain functions of populations of cells, cooperatively whispering together in intercellular communication and organized hierarchically at atomic and molecular levels.

REFERENCES

- Schumann WG. Über elektrische Eigenschwindungen des Hohlraumes Erd-Luft-Ionosphäre, erregt durch Blitzenzladungen. *Zeitschrift Angewiss J Physik* 1957; 9:373–378.
- Adey WR. Cell and molecular biology associated with radiation fields of mobile telephones. In: Stone WR, Ueno S, eds. *Review of Radio Science 1996–1999*. London: Oxford University Press, 1999:845–872.
- Milham S, Osslander EM. Historical evidence that residential electrification caused the emergence of the childhood leukemia peak. *Medical Hypotheses* 2001; 56:290–295.
- Milham S. Increased incidence of cancer in a cohort of office workers exposed to strong magnetic fields. *Am J Indust Med* 1996; 30:702–704.
- Saunders RD, Jefferys JG. Weak electric field interactions in the nervous system. *Health Phys* 2002; 83:366–375.
- Kolomytkin O, Yurinska M, Zharikov S. Response of brain receptor systems to microwave energy exposure. In: Frey AH, ed. *On the Nature of Electromagnetic Field Interactions with Biological Systems*. Austin, Texas: R.G.Landes, 1994:195–206.
- Liburdy RP. Cellular studies and interaction mechanisms of extremely low frequency fields. *Radio Science* 1995; 30:179–203.
- Ishido M, Nitta H, Kabuto M. Magnetic fields (MF) of 50 Hz at 1.2 μ T cause uncoupling of inhibitory pathways of adenylyl cyclase mediated by melatonin la receptor in MF-sensitive MCF-7 cells. *Carcinogenesis* 2001; 22:1043–1048.
- Byus CV, Pieper SE, Adey WR. The effects of low-energy 60 Hz environmental electromagnetic fields upon the growth-related enzyme ornithine decarboxylase. *Carcinogenesis* 1987; 8:1385–1389.
- Chen G, Upham BL, Sun W. Effect of electromagnetic field exposure on chemically induced differentiation of friend erythroleukemia cells. *Environmental Health Perspectives* 2000; 108:967–972.
- Litovitz TA, Krause D, Penafiel M. The role of coherence time in the effect of microwaves on ornithine decarboxylase activity. *Bioelectromagnetics* 1993; 14:395–403.
- Penafiel LM, Litovitz T, Krause D. Role of modulation effects on the effects of microwaves on ornithine decarboxylase activity in L929 cells. *Bioelectromagnetics* 1996; 18:132–141.
- Cain CD, Thomas DL, Adey WR. 60-Hz magnetic field acts as co-promoter in focus formation of C3H10T 1/2 cells. *Carcinogenesis* 1993; 14:955–960.
- Barnes FS. The effects of ELF on chemical reaction rates in biological systems. In: Ueno S, ed. *Biological Effects of Magnetic and Electromagnetic Fields*. New York: Plenum Press, 1996:37–44.
- Astumian RD, Weaver JC, Adair RK. Rectification and signal averaging of weak electric fields by biological cells. *Proc Nat Acad Sci USA* 1995; 92:3740–3743.

16. Illinger KH, ed. *Biological Effects of Nonionizing Radiation*. Washington, DC: American Chemical Society Symposium Series, No. 157, 1981:342.
17. Adey WR. Electromagnetics in biology and medicine. In: Matsumoto, H ed. *Modern Radio Science*. London: Oxford University Press, 1993:231–249.
18. Adey WR. Bioeffects of mobile communication fields; possible mechanisms for cumulative dose. In: Kuster N, Balzano Q, Lin JC, eds. *Mobile Communications Safety*. New York: Chapman and Hall, 1997:103–140.
19. McLauchlan KA. Are environmental electromagnetic fields dangerous? *Physics World*, 1992 January, 41–45.
20. McLauchlan KA, Steiner UE. The spin-correlated radical pairs a reaction intermediate. *Molecular Physics* 1994; 73:241–263.
21. Till U, Timmel CR, Brocklehurst B. The influence of very small magnetic fields on radical recombination reactions in the limit of slow recombination. *Chem Phys Let* 1998; 298:7–14.
22. Timmel CR, Till U, Brocklehurst B. Effects of weak magnetic fields on free radical recombination reactions. *Molecular Phys* 1998; 95:71–89.
23. Lander HM. An essential role for free radicals and derived species in signal transduction. *FASEB J* 1997; 11: 118–124.
24. Grundler W, Keilmann F, Putterlik V. Mechanics of electromagnetic interaction with cellular systems. *Naturwissenschaften* 1992; 79:551–559.
25. Bawin SM, Satmary WM, Jones RA. Extremely low frequency magnetic fields disrupt rhythmic slow activity in rat Hippocampal slices. *Bioelectromagnetics* 1996; 17:388–395.
26. Binhi VN. *Magnetobiology. Underlying Physical Problems*. New York: Academic Press, 2002:473.
27. Scott A. *Nonlinear Science: Emergence and Dynamics of Coherent Structures*. Series in Applied and Engineering and Mathematics. London: Oxford University Press, 1999:474.
28. Einolf CW, Carstensen EL. Low-frequency dielectric dispersion in suspensions of ion-exchange resins. *J Phys Chem* 1971; 75, 1091–1099.
29. Edelman GM, Yahara I, Wang JL. Receptor mobility and receptor-cytoplasmic interactions in lymphocytes. *Proc Nat Acad Sci USA* 1973; 70:1442–1446.
30. Liboff AR. The “cyclotron resonance” hypothesis: experimental evidence and theoretical constraints. In: Norden B, Ramel C, eds. *Interaction Mechanisms of Low-Level Electromagnetic Fields and Living Systems*. London: Oxford University Press, 1992:130–147.
31. Lednev W. Possible mechanism for the influence of weak magnetic fields on biological systems. *Bioelectromagnetics* 1991; 12:71–75.
32. Blackman CF, Blanchard JP, Benane SG. Empirical test of an ion parametric resonance model for magnetic field interactions with PC-12 cells. *Bioelectromagnetics* 1994; 15:239–260.
33. Adair RK. A physical analysis of the ion parametric resonance model. *Bioelectromagnetics* 1998; 19:181–191.
34. Adey WR. Tissue interactions with nonionizing electromagnetic fields. *Physiological Reviews* 1981; 61: 435–514.
35. Engstrom S. What is the time scale of magnetic field interaction in biological systems? *Bioelectromagnetics* 1997; 18:244–249.
36. Harland JD, Engstrom S, Liburdy R. Evidence for a slow time-scale of interaction for magnetic fields inhibiting tamoxifen’s antiproliferative action in human breast cancer cells. *Cellular Biochem Phys* 1999; 31:295–306.
37. Adey WR, Kado RT, Didio J. Impedance changes in cerebral tissue accompanying a learned discriminative performance in the cat. *Experimental Neurology* 1963; 7:259–281.
38. Bawin SM, Adey WR. Sensitivity of calcium binding in cerebral tissue to weak environmental electric fields at low frequency. *Proc Nat Acad Sci USA* 1976; 73:1999–2003.
39. DeVault D, Chance B. Studies of photosynthesis using a pulsed laser. I. temperature dependence of cytochrome oxidation rate in chromatin. Evidence of tunneling. *Biophys J* 1966; 6:825–847.
40. Moser CC, Keske JM, Warncke K. Nature of biological electron transfer. *Nature* 1992; 355:796– 802.
41. Blackman CF, Benane SG, House DE. Effects of ELF (1–120 Hz) and modulated (50 Hz) RF fields on the efflux of calcium ions from brain tissue in vitro. *Bioelectromagnetics* 1985; 6:327– 338.

42. Blackman CF, Elder JA, Weil CM. Induction of calcium efflux from brain tissue by radio frequency radiation. *Radio Science* 1979; 14:93–98.
43. Dutta SK, Ghosh B, Blackman CF. Radiofrequency radiation-induced calcium ion efflux enhancement from human and other neuroblastoma cells in culture. *Bioelectromagnetics* 1989; 10:7–20.
44. Lin-Liu S, Adey WR. Low frequency amplitude-modulated microwave fields change calcium efflux rates from synaptosomes. *Bioelectromagnetics* 1982; 3:309–322.
45. Byus CV, Kartun K, Pieper S. Increased ornithine decarboxylase activity in cultured cells exposed to low energy modulated microwave fields. *Cancer Res* 1988; 48:4222–4226.
46. Lin H, Opler M, Head M. Electromagnetic field exposure induces rapid transitory heat shock factor activation in human cells. *J Cell Biochem* 1997; 66:482–488.
47. Lin H, Head M, Blank M. Myc-activated transactivation of HSP70 expression following exposure to magnetic fields. *J Cell Biochem* 1998; 69:181–188.
48. Blank M, Goodman R. Electromagnetic fields may act directly on DNA. *J Cell Biochem* 1999; 75:369–374.
49. Blank M, Goodman R. Electromagnetic initiation of transcription at specific DNA sites. *J Cell Biochem* 2001; 81:689–692.
50. Blank M, Soo L. Electromagnetic acceleration of electron transfer reactions. *J Cell Biochem* 2001; 81:278–283.
51. Lyle DB, Ayotte RD, Sheppard AR. Suppression of T lymphocyte cytotoxicity following exposure to 60 Hz sinusoidal electric fields. *Bioelectromagnetics* 1988; 9:303–313.
52. Lyle DB, Schechter P, Adey WR. Suppression of T lymphocyte cytotoxicity following exposure to sinusoidally amplitude-modulated fields. *Bioelectromagnetics* 1983; 4:281–292.
53. Kaczmarek LK, Adey WR. Some chemical and electrophysiological effects of glutamate in cerebral cortex. *J Neurobiol* 1974; 5:231–241.
54. Di Pomerai D, Daniells C, David H. Non-thermal heat-shock response to microwaves. *Nature* 2000; 405:417–418.
55. Tattersall JE, Scott IR, Wood SJ. Effects of low intensity radiofrequency electromagnetic fields on electrical activity in rat hippocampal slices. *Brain Res* 2001; 904:43–53.
56. Bassett CA. The development and application of pulsed electromagnetic fields (PEMFs) for ununited fractures and arthrodeses. *Clin Plast Surg* 1985; 12:257–277.
57. Uckun FM, Kurosaki T, Jin J. Exposure of B-lineage lymphoid cells to low energy electromagnetic fields stimulates Lyn kinase. *J Biol Chem* 1995; 270:27666–27670.
58. Murphy LO, Smith S, Chen R-H. Molecular interpretation of ERK signal duration by immediate early gene products. *Nature Cell Biol* 2002; 4:556–564.
59. Rudiger HW, Ivancsists S, Diem E. Genotoxic effects of extremely-low-frequency electromagnetic fields on human cells in vitro. *Bioelectromagnetics Society, 24th Annual Meeting, Quebec City Proceedings, Abstract* 2002; 14–3:94.
60. Adey WR. Horizons in science: physical regulation of living matter as an emergent concept in health and disease. In: Bersani F, ed. *Electricity and Magnetism in Biology and Medicine*. New York: Kluwer/Plenum, 1998:53–57.
61. Bialek W. Macroquantum effects in biology; the evidence. Ph.D. thesis, Department of Chemistry, University of California, Berkeley, 1983:250.
62. Bialek W, Wit HP. Quantum limits to oscillator stability: theory and experiments on emissions from the human ear. *Physics Lett* 1984; 104A: 173–178.
63. Adey WR. The sense of smell. In: Field J, Magoun HW, Hall VE, eds. *Handbook of Physiology*. Vol. 1. Washington, DC: American Physiological Society, 1959:535–548.
64. Hagins WA. Excitation in vertebrate photoreceptors. In: Schmitt FO, Worden FG, eds. *The Neurosciences: Fourth Study Program*. Cambridge: MIT Press, 1979:183–192.
65. Erickson DL, Endersby R, Kirkham A. *Pseudomonas aeruginosa* quorum-sensing systems may control virulence factor expression in the lungs of patients with cystic fibrosis. *Infectious Immunology* 2002; 70:1783–1790.
66. Kalmijn AJ. The electric sense of sharks and rays. *J Experimental Biol* 1971; 55:371–382.

67. Valberg PA, Kavet R, Rafferty CN. Can low level 50/60 Hz electric and magnetic fields cause biological effects? *Radiation Res* 1997; 148:2–21.
68. Jessup JM, Frantz M, Sonmez-Alpin E. Microgravity culture reduces apoptosis and increases the differentiation of a human colorectal carcinoma cell line. *In Vitro Cell Development and Biology-Animal* 2000; 36:367–373.
69. Zhou H, Suzuki M, Randers-Pehrson G. Radiation risk to low fluences of a particles may be greater than we thought. *Proc Nat Acad Sci USA* 2001; 98:14410–14415.

References

Preface

1. Lawrence R, Rosch PJ, Plowden J. Magnet Therapy. Rocklin, CA: Prima Press, 1998.

1 Potential Therapeutic Applications of Nonthermal Electromagnetic Fields: Ensemble Organization of Cells in Tissue as a Factor in Biological Field Sensing

1. Schumann WG. Über elektrische Eigenschwingungen des Hohlraumes Erd-Luft-Ionosphäre, erregtdurch Blitzzentladungen. Zeitschrift Angewiss J Physik 1957; 9:373-378.
2. Adey WR. Cell and molecular biology associated with radiation fields of mobile telephones. In: Stone WR, Ueno S, eds. Review of Radio Science 1996-1999. London: Oxford University Press, 1999:845-872.
3. Milham S, Osslander EM. Historical evidence that residential electrification caused the emergence of the childhood leukemia peak. Medical Hypotheses 2001; 56:290-295.
4. Milham S. Increased incidence of cancer in a cohort of office workers exposed to strong magnetic fields. Am J Indust Med 1996; 30:702-704.
5. Saunders RD, Jefferys JG. Weak electric field interactions in the nervous system. Health Phys 2002; 83: 366-375.
6. Kolomytkin O, Yurinska M, Zharikov S. Response of brain receptor systems to microwave energy exposure. In: Frey AH, ed. On the Nature of Electromagnetic Field Interactions with Biological Systems. Austin, Texas: R.G.Landes, 1994:195-206.
7. Liburdy RP. Cellular studies and interaction mechanisms of extremely low frequency fields. Radio Science 1995; 30:179-203.
8. Ishido M, Nitta H, Kabuto M. Magnetic fields (MF) of 50 Hz at 1.2 μ T cause uncoupling of inhibitory pathways of adenylyl cyclase mediated by melatonin 1a receptor in MF-sensitive MCF-7 cells. Carcinogenesis 2001; 22: 1043-1048.
9. Byus CV, Pieper SE, Adey WR. The effects of low-energy 60 Hz environmental electromagnetic fields upon the growth-related enzyme ornithine decarboxylase. Carcinogenesis 1987; 8:1385- 1389.
10. Chen G, Upham BL, Sun W. Effect of electromagnetic

field exposure on chemically induced differentiation of friend erythroleukemia cells. *Environmental Health Perspectives* 2000; 108: 967-972.

11. Litovitz TA, Krause D, Penafiel M. The role of coherence time in the effect of microwaves on ornithine decarboxylase activity. *Bioelectromagnetics* 1993; 14:395-403.

12. Penafiel LM, Litovitz T, Krause D. Role of modulation effects on the effects of microwaves on ornithine decarboxylase activity in L929 cells. *Bioelectromagnetics* 1996; 18:132-141.

13. Cain CD, Thomas DL, Adey WR. 60-Hz magnetic field acts as co-promoter in focus formation of C3H10T 1/2 cells. *Carcinogenesis* 1993; 14:955-960.

14. Barnes FS. The effects of ELF on chemical reaction rates in biological systems. In: Ueno S, ed. *Biological Effects of Magnetic and Electromagnetic Fields*. New York: Plenum Press, 1996:37- 44.

15. Astumian RD, Weaver JC, Adair RK. Rectification and signal averaging of weak electric fields by biological cells. *Proc Nat Acad Sci USA* 1995; 92:3740-3743.

16. Illinger KH, ed. *Biological Effects of Nonionizing Radiation*. Washington, DC: American Chemical Society Symposium Series, No. 157, 1981:342.

17. Adey WR. Electromagnetics in biology and medicine. In: Matsumoto, H ed. *Modern Radio Science*. London: Oxford University Press, 1993:231-249.

18. Adey WR. Bioeffects of mobile communication fields; possible mechanisms for cumulative dose. In: Kuster N, Balzano Q, Lin JC, eds. *Mobile Communications Safety*. New York: Chapman and Hall, 1997:103-140.

19. McLauchlan KA. Are environmental electromagnetic fields dangerous? *Physics World*, 1992 January, 41-45.

20. McLauchlan KA, Steiner UE. The spin-correlated radical pairs a reaction intermediate. *Molecular Physics* 1994; 73:241-263.

21. Till U, Timmel CR, Brocklehurst B. The influence of very small magnetic fields on radical recombination reactions in the limit of slow recombination. *Chem Phys Let*

1998; 298:7-14.

22. Timmel CR, Till U, Brocklehurst B. Effects of weak magnetic fields on free radical recombination reactions. *Molecular Phys* 1998; 95:71-89.

23. Lander HM. An essential role for free radicals and derived species in signal transduction. *FASEB J* 1997; 11: 118-124.

24. Grundler W, Keilmann F, Putterlik V. Mechanics of electromagnetic interaction with cellular systems. *Naturwissenschaften* 1992; 79:551-559.

25. Bawin SM, Satmary WM, Jones RA. Extremely low frequency magnetic fields disrupt rhythmic slow activity in rat hippocampal slices. *Bioelectromagnetics* 1996; 17:388-395.

26. Binhi VN. *Magnetobiology. Underlying Physical Problems.* New York: Academic Press, 2002:473.

27. Scott A. *Nonlinear Science: Emergence and Dynamics of Coherent Structures.* Series in Applied and Engineering and Mathematics. London: Oxford University Press, 1999:474.

28. Einolf CW, Carstensen EL. Low-frequency dielectric dispersion in suspensions of ion-exchange resins. *J Phys Chem* 1971; 75, 1091-1099.

29. Edelman GM, Yahara I, Wang JL. Receptor mobility and receptor-cytoplasmic interactions in lymphocytes. *Proc Nat Acad Sci USA* 1973; 70:1442-1446.

30. Liboff AR. The "cyclotron resonance" hypothesis: experimental evidence and theoretical constraints. In: Norden B, Ramel C, eds. *Interaction Mechanisms of Low-Level Electromagnetic Fields and Living Systems.* London: Oxford University Press, 1992:130-147.

31. Lednev W. Possible mechanism for the influence of weak magnetic fields on biological systems. *Bioelectromagnetics* 1991; 12:71-75.

32. Blackman CF, Blanchard JP, Benane SG. Empirical test of an ion parametric resonance model for magnetic field interactions with PC-12 cells. *Bioelectromagnetics* 1994; 15:239-260.

33. Adair RK. A physical analysis of the ion parametric resonance model. *Bioelectromagnetics* 1998; 19:181-191.

34. Adey WR. Tissue interactions with nonionizing electromagnetic fields. *Physiological Reviews* 1981; 61: 435-514.
35. Engstrom S. What is the time scale of magnetic field interaction in biological systems? *Bioelectromagnetics* 1997; 18:244-249.
36. Harland JD, Engstrom S, Liburdy R. Evidence for a slow time-scale of interaction for magnetic fields inhibiting tamoxifen's antiproliferative action in human breast cancer cells. *Cellular Biochem Phys* 1999; 31:295-306.
37. Adey WR, Kado RT, Didio J. Impedance changes in cerebral tissue accompanying a learned discriminative performance in the cat. *Experimental Neurology* 1963; 7:259-281.
38. Bawin SM, Adey WR. Sensitivity of calcium binding in cerebral tissue to weak environmental electric fields at low frequency. *Proc Nat Acad Sci USA* 1976; 73:1999-2003.
39. DeVault D, Chance B. Studies of photosynthesis using a pulsed laser. I. temperature dependence of cytochrome oxidation rate in chromatin. Evidence of tunneling. *Biophys J* 1966; 6:825-847.
40. Moser CC, Keske JM, Warncke K. Nature of biological electron transfer. *Nature* 1992; 355:796- 802.
41. Blackman CF, Benane SG, House DE. Effects of ELF (1-120 Hz) and modulated (50 Hz) RF fields on the efflux of calcium ions from brain tissue in vitro. *Bioelectromagnetics* 1985; 6:327- 338.
42. Blackman CF, Elder JA, Weil CM. Induction of calcium efflux from brain tissue by radio frequency radiation. *Radio Science* 1979; 14:93-98.
43. Dutta SK, Ghosh B, Blackman CF. Radiofrequency radiation-induced calcium ion efflux enhancement from human and other neuroblastoma cells in culture. *Bioelectromagnetics* 1989; 10:7-20.
44. Lin-Liu S, Adey WR. Low frequency amplitude-modulated microwave fields change calcium efflux rates from synaptosomes. *Bioelectromagnetics* 1982; 3:309-322.
45. Byus CV, Kartun K, Pieper S. Increased ornithine

- decarboxylase activity in cultured cells exposed to low energy modulated microwave fields. *Cancer Res* 1988; 48:4222-4226.
46. Lin H, Opler M, Head M. Electromagnetic field exposure induces rapid transitory heat shock factor activation in human cells. *J Cell Biochem* 1997; 66:482-488.
47. Lin H, Head M, Blank M. Myc-activated transactivation of HSP70 expression following exposure to magnetic fields. *J Cell Biochem* 1998; 69:181-188.
48. Blank M, Goodman R. Electromagnetic fields may act directly on DNA. *J Cell Biochem* 1999; 75:369-374.
49. Blank M, Goodman R. Electromagnetic initiation of transcription at specific DNA sites. *J Cell Biochem* 2001; 81: 689-692.
50. Blank M, Soo L. Electromagnetic acceleration of electron transfer reactions. *J Cell Biochem* 2001; 81:278-283.
51. Lyle DB, Ayotte RD, Sheppard AR. Suppression of T lymphocyte cytotoxicity following exposure to 60 Hz sinusoidal electric fields. *Bioelectromagnetics* 1988; 9:303-313.
52. Lyle DB, Schechter P, Adey WR. Suppression of T lymphocyte cytotoxicity following exposure to sinusoidally amplitude-modulated fields. *Bioelectromagnetics* 1983; 4:281-292.
53. Kaczmarek LK, Adey WR. Some chemical and electrophysiological effects of glutamate in cerebral cortex. *J Neurobiol* 1974; 5:231-241.
54. Di Pomerai D, Daniells C, David H. Non-thermal heat-shock response to microwaves. *Nature* 2000; 405: 417-418.
55. Tattersall JE, Scott IR, Wood SJ. Effects of low intensity radiofrequency electromagnetic fields on electrical activity in rat hippocampal slices. *Brain Res* 2001; 904:43-53.
56. Bassett CA. The development and application of pulsed electromagnetic fields (PEMFs) for ununited fractures and arthrodeses. *Clin Plast Surg* 1985; 12:257-277.

57. Uckun FM, Kurosaki T, Jin J. Exposure of B-lineage lymphoid cells to low energy electromagnetic fields stimulates Lyn kinase. *J Biol Chem* 1995; 270:27666-27670.
58. Murphy LD, Smith S, Chen R-H. Molecular interpretation of ERK signal duration by immediate early gene products. *Nature Cell Biol* 2002; 4:556-564.
59. Rudiger HW, Ivancsists S, Diem E. Genotoxic effects of extremely-low-frequency electromagnetic fields on human cells in vitro. *Bioelectromagnetics Society, 24th Annual Meeting, Quebec City Proceedings, Abstract* 2002; 14-3:94.
60. Adey WR. Horizons in science: physical regulation of living matter as an emergent concept in health and disease. In: Bersani F, ed. *Electricity and Magnetism in Biology and Medicine*. New York: Kluwer/Plenum, 1998:53-57.
61. Bialek W. Macroquantum effects in biology; the evidence. Ph.D. thesis, Department of Chemistry, University of California, Berkeley, 1983:250.
62. Bialek W, Wit HP. Quantum limits to oscillator stability: theory and experiments on emissions from the human ear. *Physics Lett* 1984; 104A: 173-178.
63. Adey WR. The sense of smell. In: Field J, Magoun HW, Hall VE, eds. *Handbook of Physiology*. Vol. 1. Washington, DC: American Physiological Society, 1959:535-548.
64. Hagins WA. Excitation in vertebrate photoreceptors. In: Schmitt FO, Worden FG, eds. *The Neurosciences: Fourth Study Program*. Cambridge: MIT Press, 1979:183-192.
65. Erickson DL, Endersby R, Kirkham A. *Pseudomonas aeruginosa* quorum-sensing systems may control virulence factor expression in the lungs of patients with cystic fibrosis. *Infectious Immunology* 2002; 70:1783-1790.
66. Kalmijn AJ. The electric sense of sharks and rays. *J Experimental Biol* 1971; 55:371-382.
67. Valberg PA, Kavet R, Rafferty CN. Can low level 50/60 Hz electric and magnetic fields cause biological effects? *Radiation Res* 1997; 148:2-21.
68. Jessup JM, Frantz M, Sonmez-Alpin E. Microgravity culture reduces apoptosis and increases the differentiation of a human colorectal carcinoma cell line. *In Vitro Cell Development and Biology-Animal* 2000; 36:367-373.

69. Zhou H, Suzuki M, Randers-Pehrson G. Radiation risk to low fluences of a particles may be greater than we thought. Proc Nat Acad Sci USA 2001; 98:14410-14415.

2 Signal Shapes in Electromagnetic Therapies: A Primer

1. Rasmussen KG, Sampson SM, Rummans TA. Electroconvulsive therapy and newer modalities for the treatment of medication-refractory mental illness. *Mayo Clin Prov* 2002; 77:552-556.
2. Barker AT, Freeston IL, Jalinous R, Jarrett JA. Non-invasive stimulation of motor pathways within the brain using time-varying magnetic fields. *Electroencephalog Clin Neurophysiol* 1985; 61:S245.
3. Lavine LS, Lustrin I, Shamos MH, Rinaldi RA, Liboff AR. Electric enhancement of bone healing. *Science* 1972; 175:1118-1121.
4. Bassett CAL, Pawluk RJ, Pilla AA. Acceleration of fracture repair by electromagnetic fields: a surgically noninvasive method. In: Liboff AR, Rinaldi RA, eds. *Electrically Mediated Growth Mechanisms in Living Systems*. *Ann NY Acad Sci* 1974; 238:242-262.
5. Gmitrov J, Ohkubo C. Artificial static and geomagnetic field interrelated impact on cardiovascular regulation. *Bioelectromagnetics* 2002; 23:329-338.
6. Engstrom S, Markov MS, McLean MJ, Holcomb RR, Markov JM. Effects of nonuniform static magnetic fields on the rate of myosin phosphorylation. *Bioelectromagnetics* 2002; 23:475-479.
7. Liboff AR. Geomagnetic cyclotron resonance in living cells. *J Biol Physics* 1985; 13:99-102.
8. Williams CD, Markov MS. Therapeutic electromagnetic field effects on angiogenesis during tumor growth: a pilot study in mice. *Electro-Magneto Biology* 2001; 20:323-329.
9. Liss S, Liss B. Physiological and therapeutic effects of high frequency pulses. *Integrative Physiol Behavioral Sci* 1996; 31:88-94.
10. Reite M, Higgs L, Lebet J-P, Barbault A, Rossel C, Kuster N, Amato D, Dafni U, Pasche B. Sleep inducing effect of low energy emission therapy. *Bioelectromagnetics* 1994; 15:67-76.
11. Schwartz RG. Electric sympathetic block: current theoretical concepts and clinical results. *J Back*

Musculoskeletal Rehab 1998; 10:31-46.

12. Richards TL, Lappin MS, Acosta-urquidi J, Kraft GH, Heide AC, Lawrie FW, Merrill TE, Melton GB, Cunningham CA. Double-blind study of pulsing magnetic field effects on multiple sclerosis. *J Alternative Complementary Medicine* 1997; 3:21-29.

13. Trock DH, Bollet AJ, Dyer RH Jr, Fielding LP, Markoll RA. A double-blind trial of the clinical effects of pulsed electromagnetic fields in osteoarthritis. *J Rheum* 1993; 20:456-460.

14. Hedenius P, Odeblad E, Wahlstrom L. Some preliminary investigations on the therapeutic effect of pulsed short waves in intermittent claudication. *Current Therapeutic Res* 1966; 8:317-321.

15. Kirsch DL, Smith RB. The use of cranial magnetic stimulation in the management of chronic pain: a review. *Neurorehabilitation* 2000; 14:85-94.

3 Magnetic Field Generation and Dosimetry

1. Phillips JB. Magnetic Navigation. *J Theor Biol* 1996; 380:309-319.
2. Lohmann KJ, Hester JT, Lohmann CMF. Long-distance navigation in sea turtles. *Ethology Ecology Evolution* 1999; 11(1):1-23.
3. DiCarlo AL, Mullins JM, Litovitz TA. Thresholds for electromagnetic field-induced hypoxia protection: evidence for a primary electric field effect. *Bioelectrochemistry* 2000; 52:9-16.
4. Liburdy RP. Calcium signaling in lymphocytes and ELF fields. Evidence for an electric field metric and a site of interaction involving the calcium ion channel. *Febs Lett* 1992; 301:53-59.
5. McLean MJ, Holcomb RR, Wamil AW, Pickett JD. Blockade of sensory neuron action potentials by a static magnetic-field in the 10 mT range. *Bioelectromagnetics* 1995; 16:20-32.
6. Engström S, Markov MS, McLean MJ, Holcomb RR, Markov JM. Effects of non-uniform static magnetic fields on the rate of myosin phosphorylation. *Bioelectromagnetics* 2002; 23:475- 479.
7. Adair RK. Static and low-frequency magnetic field effects: health risks and therapies. *Rep Prog Phys* 2000; 63: 415-454.
8. Timmel CR, Cintolesi F, Brocklehurst B, Hore PJ. Model calculations of magnetic field effects on the recombination reactions of radicals with anisotropic hyperfine interactions. *Chem Phys Lett* 2001; 334:387-395.
9. Jackson JD. *Classical Electrodynamics*. 3rd ed. New York: Wiley, 1999.
10. Merritt R, Purcell C, Stroink G. Uniform magnetic field produced by three, four, and five square coils. *Rev Sci Instrum* 1983; 54:879-882.
11. Misakian M, Sheppard AR, Krause D, Frazier ME, Miller DL. Biological, physical, and electrical parameters for in-vitro studies with ELF magnetic and electric-fields—a primer. *Bioelectromagnetics Suppl* 1993; 2:1-73.
12. Engström S. A Green function method for calculating

properties of static magnetic fields. *Bioelectromagnetics* 2001; 22:511-518.

13. Engström S, Fitzsimmons R. Five hypotheses to examine the nature of magnetic field transduction in biological systems. *Bioelectromagnetics* 1999; 20:423-430.

14. Ptitsyna NG, Villoresi G, Dorman LI, Iucci N, Tyasto MI. Natural and man-made low-frequency magnetic fields as a potential health hazard. *Physics-Uspekhi* 1998; 41:687-709.

15. McLeod BR, Pilla AA, Sampsel MW. Electromagnetic-fields induced by helmholtz aiding coils inside salinefilled boundaries. *Bioelectromagnetics* 1983; 4:357-370.

16. Gandhi OP, Kang G, Wu D, Lazzi G. Currents induced in anatomic models of the human for uniform and nonuniform power frequency magnetic fields. *Bioelectromagnetics* 2001; 22:112- 121.

17. Choleris E, Del Seppia C, Thomas AW, Luschi P, Ghione S, Moran GR, Prato FS. Shielding, but not zeroing of the ambient magnetic field reduces stress-induced analgesia in mice. *Proc Royal Soc London Series B Biolog* 2002; 269:193-201.

4 Image-Guided Electromagnetic Therapy

1. Wong NN. Aggrenox: an aspirin and extended release dipyridamole combination. *Heart Disease* 2001; 3: 340-346.
2. Sharpe J, Ahlgren U, Perry P, Hill B, Ross A, Hecksher-Sorensen J, Baldock R, Davidson D. Optical projection tomography as a tool for 3D microscopy and gene expression studies. *Science* 2002; 296:541-545.
3. Blasberg R. Imaging gene expression and endogenous molecular processes: molecular imaging. *J Cereb Blood Flow Metab* 2002; 22:1157-1164.
4. Bulte JW, Duncan ID, Frank JA. In vivo magnetic resonance tracking of magnetically labeled cells after transplantation. *J Cereb Blood Flow Meta* 2002; 22:899-907.
5. Iwata R. Reference Book for PET Radiopharmaceuticals, 2001.
6. Wagner KJ, Willoch F, Kochs EF, Siessmeier T, Tolle TR, Schwaiger M, Bartenstein P. Dose-dependent regional cerebral blood flow changes during remifentanyl infusion in humans: a positron emission tomography study. *Anesthesiology* 2001; 94:732-739.
7. Smith JS, Zubieta JK, Price JC, Flesher JE, Madar I, Lever JR, Kinter CM, Dannals RF, Frost JJ. Quantification of delta-opioid receptors in human brain with N1'([11C]methyl) naltrindole and positron emission tomography. *J Cereb Blood Flow Metab* 1999; 19:956-966.
8. Koeppe MJ, Duncan JS. PET: Opiate neuroreceptor mapping. *Adv Neurol* 2000; 83:145-156.
9. Willoch F, Tolle TR, Wester HJ, Munz F, Petzold A, Schwaiger M, Conrad B, Bartenstein P. Central pain after pontine infarction is associated with changes in opioid receptor binding: a PET study with 11C-diprenorphine. *Am J Neuroradiol* 1999; 29:686-690.
10. Jones AK, Kitchen ND, Watabe H, Cunningham VJ, Jones T, Luthra SK, Thomas DG. Measurement of changes in opioid receptor binding in vivo during trigeminal neuralgic pain using (11C) diprenorphine and positron emission tomography. *J Cereb Blood Flow Metab* 1999; 19:803-808.
11. Wester HJ, Willoch F, Tolle TR, Munz F, Herz M, Oye I, Schadrack J, Schwaiger M, Bartenstein P. 6-O-(2-[18F]

- fluoroethyl)-6-O-desmethyldiprenorphine ([18F]DPN): synthesis, biologic evaluation, and comparison with [11C]DPN in humans. *J Nucl Med* 2000; 41:1279-1286.
12. Ueno S. Biomagnetic approaches to studying the brain. *IEEE Eng Med Biology* 1999; 108-120.
13. Clarke J. SQUIDS. *Scientific American*, 1994; 46-53.
14. Ryhanen T, Knuutila J. SQUID magnetometers for low-frequency applications. *J Low Temp Phys* 1989; 76: 287-288.
15. Babiloni F, Carducci F, Del Gratta C, Roberti GM, Cincotti F, Bagni D, Romani GL, Rossini PM, Babiloni C. Multimodal integration of high resolution EEG, MEG and functional magnetic resonance data. *IJBEM* 1999; 1: 62-74.
16. Paus T, Jech R, Thompson CJ, Comeau R, Peters T, Evans AC. Transcranial magnetic stimulation during positron emission tomography: a new method of studying connectivity of the human cerebral cortex. *J Neurosci* 1997; 17:3178-3184.
17. Ilmoniemi RJ, Virtanen J, Ruohonen J, Karhu J, Aronen JH, Naatanen R, Katila T. Neuronal responses to magnetic stimulation reveal cortical reactivity and connectivity. *Neuroreport* 1997; 8:3537-3540.
18. Cook CM, Thomas AQ, Prato FS. Human resting EEG is affected by exposure to a pulsed ELF magnetic field. *Neuroreport*, Oct. 2002. Submitted to.
19. Cook CM, Thomas AW, Prato FS. Human electrophysiological and cognitive effects of exposure to ELF magnetic and ELF modulated RF and microwave fields: a review of recent studies. *Bioelectromagnetics* 2002; 23: 144-157.
20. Slomka PJ, Mandel J, Downey D, Fenster A. Evaluation of a voxel-based registration of 3-D power Doppler ultrasound and 3-D magnetic resonance angiographic images of carotid arteries. *Ultrasound Med Biol* 2001; 27: 945-955.
21. Surry K, Smith W, Campbell L, Mills G, Downey D, Fenster A. The development and evaluation of a threedimensional ultrasound-guided breast biopsy apparatus. *Med Image Anal* 2002; 6:301.
22. Ling CC, Humm J, Larson S, Amols H, Fuks Z, Leibel S,

Koutcher JA. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. *Int J Radiation Oncology Biol Phys* 2000; 47: 551-560.

23. Theberge J, Bratha R, Drost DJ, Menon RS, Malla A, Takhar J, Neufeld RW, Rogers J, Pavlosky W, Schaefer B, Densmore M, Al-Semaan Y, Williamson PC. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. *Am J Psychiatry* 2002; 159:1944-1946.

24. Wassermann EM. Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines. *International Workshop on the Safety of Repetitive Transcranial Magnetic Stimulation* *Electroencephalography and Clinical Neurophysiology* 1998; 108:1-16.

25. Ueno S, Tashiro T, Harada K. Localized stimulation of neural tissues in the brain by means of paired configuration of time-varying magnetic fields. *J Appl Phys* 1988; 64:5862-5864.

26. Ueno S, Matsuda T, Fujiki M, Hori S. Localized stimulation of the human motor cortex by means of a pair of opposing magnetic field. *Digest of IEEE Intermag Conf GD-10*, Washington DC, 1989.

27. Ueno S, Matsuda T, Fujiki M. Vectorial and focal magnetic stimulation of the brain for the understanding of the functional organization of the brain. *IEEE Trans Magn* 1990; 26:1539- 1544.

28. Ueno S. Impedance magnetic resonance imaging: A method for imaging of impedance distributions based on magnetic resonance imaging. *J Appl Physics* 1998; 83:6450-6452.

29. Masaki, Sekino, Ueno S. Numerical calculations of current distributions in electric stimulation and magnetic stimulation of the brain. *Int Union Radio Science, 27th General Assembly*, August 17-24, 2002.

30. Liu R, Ueno S. Calculating the activating function of nerve excitation in inhomogeneous volume conductor during magnetic stimulation using the finite element method. *IEEE Trans Magn* 2000; 36:1700-1796.

31. Kimbrell TA, Dunn RT, George MS, Danielson AL, Willis MW, Repella JD, Benson BE, Herscovitch P, Post RM, Wassermann EM. Left prefrontal-repetitive transcranial

magnetic stimulation (rTMS) and regional cerebral glucose metabolism in normal volunteers. *Psychiatry Res* 2002; 115:101-113.

32. Strafella AP, Paus T, Barrett J, Dagher A. Repetitive transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus. *J Neurosci* 2001; 21:1-4.

33. Bourtros NN, Berman RM, Hoffman R, Miano AP, Campbell D, Ilmoniemi R. Electroencephalogram and repetitive transcranial magnetic stimulation. *Depression and Anxiety* 2000; 12:166-169.

34. Nobler MS, Teneback CC, Nahas Z, Bohning DE, Shastri A, Kozel FA, George MS. Structural and functional neuroimaging of electroconvulsive therapy and transcranial magnetic stimulation. *Depression and Anxiety* 2000; 12:144-156.

35. Thomas AW, Kavaliers M, Prato FS, Ossenkopp K-P. Analgesic effects of a specific pulsed magnetic field in the land snail, *cepaea nemoralis*: consequences of repeated exposures, relations to tolerance and cross-tolerance with DPDPE. *Peptides* 1998; 19:333-342.

36. Prato FS, Kavaliers M, Thomas AW. Extremely low frequency magnetic fields can either increase or decrease analgesia in the land snail depending on field and light conditions. *Bioelectromagnetics* 2000; 21:287-301.

37. Prato FS, Carson JJL, Ossenkopp K-P, Kavaliers M. Possible mechanisms by which extremely low frequency magnetic fields affect opioid function. *FASEB* 1995; 9:807-814.

38. Choleris E, Del Seppia C, Thomas AW, Luschi P, Ghione S, Moran GR, Prato FS. Shielding, but not zeroing of the ambient magnetic field reduces stress-induced analgesia in mice. *Proc R Soc Lond* 2002; 269:193-201.

39. Tolle TR, Kaufmann T, Siessmeier T, Lautenbacher S, Berthele A, Munz F, Zieglgansberger W, Willoch F, Schwaiger M, Conrad B, Bartenstein P. Region-specific encoding of sensory and affective components of pain in the human brain: a positron emission tomography correlation analysis. *Am Neuro Assoc* 1999, 40-47.

40. Bromm B. Brain images of pain. *News Physiol Soc* 2001; 16:244-249.

41. Treede R-D, Kenshalo DR, Gracely RH, Jones AKP. The cortical representation of pain. *Pain* 1999; 79:105-111.
42. Casey KL. Forebrain mechanisms of nociception and pain: analysis through imaging. *Proc Natl Acad Sci* 1999; 96:7668-7674.
43. Talbot JD, Marrett S, Evans AC, Meyer E, Bushnell MC, Duncan GH. Multiple representations of pain in human cerebral cortex. *Science* 1991; 1353-1355.
44. Hsieh J-C, Stone-Elander S, Ingvar M. Anticipatory coping of pain expressed in the human anterior cingulate cortex: a positron emission tomography study. *Neuroscience Letters* 1999; 262:61-64.
45. Derbyshire SWG, Jones AKP, Devani P, Friston KJ, Feinmann C, Harris M, Pearce S, Watson JDG, Frackowiak RSJ. Cerebral responses to pain in patients with atypical facial pain measured by positron emission tomography. *J Neurol Neurosurg Psychiatry* 1994; 57:1166- 1172.
46. Leuchter AF, Cook IA, Witte EA, Morgan M, Abrams M. Changes in brain function of depressed subjects during treatment with placebo. *Am J Psychiatry* 2002; 159:122-129.
47. Petrovic P, Kalso E, Petersson KP, Ingvar M. Placebo and opioid analgesia imaging a shared neuronal network. *Science* 2002; 295:1737-1740.
48. Zubieta JK, Smith YR, Bueller JA, Xu Y, Kilbourn MR, Jewett DM, Meyer CR, Koeppe RA, Stohler CS. Regional mu opioid receptor regulation of sensory and affective dimensions of pain. *Science* 2001; 293:311-315.
49. Jones AK, Liyi Q, Cunningham VV, Brown DW, Ha-Kawa S, Fujiwara T, Friston KF, Silva S, Luthra SK, Jones T. Endogenous opiate response to pain in rheumatoid arthritis and cortical and subcortical response to pain in normal volunteers using positron emission tomography. *Int J Clin Pharmacol Res* 1991; 11:261-266.
50. Goodman R, Blank M. Insights into electromagnetic interaction mechanisms. *J Cellular Physiol* 1992; 192: 16-22.
51. DiCarlo AL, Farrell JM, Litovitz T. Myocardial protection conferred by electromagnetic fields. *Circulation* 1999; 99:813-816.

52. Carmody S, Wu SL, Lin H, Blank M, Skopicki H, Goodman R. Cytoprotection by electromagnetic field-induced hsp70: a model for clinical application. *J Cellular Biochem* 2999; 79:453-459.
53. Ventura C, Maioli M, Pintus, Gottardi G, Bersani F. Elf-pulse magnetic fields modulate opioid peptide gene expression in myocardial cells. *Cardiovascular Res* 2000; 45:1054-1064.
54. Albertini A, Zucchini P, Noera G, Cadossi R, Napoleone CP, Pierangeli A. Protective effect of low frequency low energy pulsing electromagnetic fields on acute experimental myocardial infarcts in rats. *Bioelectromagnetics* 1999; 20:372-377.

5 The Theology of Electricity

1. The Bakken: A Library and Museum of Electricity in Life. 3537 Zenith Ave. S., Minneapolis, MN.
2. Stillings D. The early history of attempts at electrical control of the heart: Harvey to Hyman. *Acta Congressus internationalis XXIV Historiae Artis Medicinae*. Budapest: Museum Bibliotheca et Archivum Historiae Artis Medicinae de I. Ph. Semmelweis Nominata, 1976:73-80.
3. Published as Benz E. The theology of electricity. Allison Park, Pa: Pickwick Publications, 1989.
4. Benz E. The Theology of Electricity. Allison Park, Pa: Pickwick Publications, 1989:2.
5. "Process theology"—derived from the philosophy of Alfred North Whitehead—emphasizes evolutionary views of the cosmos ("God's body") and a dynamic, living God who participates in the world.
6. Two examples of cylinder seals made of magnetite, once in the Editor's collection, are now in The Bakken.
7. Kellaway P. The part played by electric fish in the early history of bioelectricity and electrotherapy. *Bull Hist Med* 1946; 20:112.
8. The Dictionary of National Biography, Vol. XVI, repr. Oxford 1967-1968:360.
9. Wickland CA. *Thirty Years Among the Dead*. London: Spiritualist Press, 1968. This book was first published in 1924.
10. Scribonius Largus. *De compositionibus medicamentorum*. Liber unus, antehac nusquam excusus: Joanne Ruellio. Paris, 1528.
11. Pedanius Dioscorides of Anazarbos. The Greek herbal of Dioscorides, illustrated by a Byzantine A.D. 512, Englished by John Goodyer A.D. 1655. London: Hafner, 1968. Facsimile of 1934 edition.

Figure 9 An alchemist and his soror mystica kneeling by the furnace and praying for God's blessing (Mutus liber, 1702).

12. Leibowitz JO. Electroshock therapy in Ibn-Sina's canon. *J Hist Med* 1957; 12:71.
13. Stillings D. Early attempts at electrical control of the heart: Harvey to Hyman. *Artifex* 1986; 5(3): 1.
14. Hoff HE. Galvani and the pre-galvanian electrophysiologists. *Ann Sci* 1936; 1:157.
15. Dibner B. Galvani-Volta: A Controversy that Led to the Discovery of Useful Electricity. Norwalk, Conn: Burndy Library, 1952.
16. Since most of these experiments were carried out in France during the Revolution, there was no shortage of such material.
17. Shelley M. *Frankenstein; or, the modern Prometheus*. London: Lackington, Hughes, Harding, Mayor, and Jones, 1818. A copy of the first edition may be seen at The Bakken.
18. Gould RT. Crosse's acari. In: Gould RT, ed. *Oddities: A Book of Unexplained Facts*. New Hyde Park, N.Y.: University Books, 1965:117-123.
19. Schechter DC. Background of clinical cardiac electrostimulation, pt. V: Direct electrostimulation of heart without thoracotomy. *New York State Journal of Medicine* March 1, 1972; 72(3):612-619.
20. It is noteworthy that one of the earliest electrical generators (c. 1734) was constructed from an alembic by Georg Matthias Bose. Both the neck and the spherical body of the vessel were used as electrical generators. See Hackmann WD. *Electricity from Glass: the History of the Frictional Electrical Machine 1600-1850*. Alphen aan den Rijn: Sijthoff & Noorhoff, 1978, pp. 68ff.
21. Of course, other exotic "energies" have been posited that are even more fundamental and efficacious—"odic force," "orgone energy," "eloptic energy," "scalar waves," "etheric waves," etc.
22. Jung CG. Psychology and alchemy. In: Jung CG, ed. *Collected Works* 1953; Vol. 12. CW 12. London: Routledge and Kegan Paul, 1953:406ff.
23. That is, the first light mentioned in Genesis I: 3-4.

24. Benz E. *The Theology of Electricity*. Allison Park, Pa: Pickwick Publications, 1989:46ff.
25. Jung CG. *Psychology and alchemy*. In: Jung CG, ed. *Collected Works*. Vol. 12. London: Routledge & Kegan Paul, 1953:453ff.
26. Mead GRS. *Summary of the contents of the so-called Pistis Sophia treatise*. In: Mead GRS, ed. *Fragments of a Faith Forgotten*. New Hyde Park, N.Y.: University Books, 467.
27. von Franz M-L. *Dreams*. Boston & London: Shambhala, 1991:85. For further discussion of this Manichaeic "machine," see Legge, F. *Forerunners and Rivals of Christianity*. New Hyde Park, N.Y.: University Books, 1964; II:297.
28. von Guericke, O. *Experimenta nova magdeburgica*. Amsterdam, 1672.
29. Making "terrellas" was a favorite pastime of the alchemists. See Jung CG. *Psychology and Alchemy*, *Collected Works*, vol. 12. London: Routledge & Kegan Paul, 1953.
30. Persinger MA. *The modern magnetotherapies*. In: Marino AA, ed. *Modern Bioelectricity*. New York: Marcel Dekker, 1988:590.
31. Becker RD, Marino AA. *Electromagnetism and Life*. Albany: State University of New York Press, 1982:4.
32. For a discussion of the electricity/Mercurius parallels, see Stillings D. *The primordial light: electricity to paraelectricity*. *Archaeus* 1984; 2(1):81-90.
33. For a clear and concise discussion of how science and technology arise from symbols and why early protosciences sometimes prefigure modern discoveries, see Jung CG. *On psychic energy*. In: Jung, CG, ed. *The Structure and Dynamics of the Psyche*, CW 8. New York: Pantheon Books, 1960:45ff.
34. Benz E. *The Theology of Electricity*. Allison Park, Pa: Pickwick Publications, 1989:56ff.
35. One is reminded hereof Goethe's "Two souls, alas, do dwell within my breast." St. Paul's version of this is to be found in Romans 7:19-20: "For the good that I would I do not: but the evil which I would not, that I do. Now if I do

that I would not, it is no more I that do it, but sin that dwelleth in me.”

36. Max Planck formulated quantum theory in 1900, the same year that Freud's *The Interpretation of Dreams* was published.

37. Jung CG. *Psychology of the transference*. In: Jung CG, ed. *The Practice of Psychotherapy*, CW 16. New York: Pantheon Books, 1954:315.

38. Jung CG. *Letters 1:1906-1950*. Princeton, N.J.: Princeton University Press, 1973:325f.

39. Jung CG. *Letters 1:1906-1950*. Princeton, N.J.: Princeton University Press, 1973:325n.

40. A considerable literature exists on this subject. Perhaps the best of these works is Jahn, RC and BJ Dunne's *Margins of Reality: The Role of Consciousness in the Physical World*. San Diego: Harcourt Brace Jovanovich, 1987. See also Jahn and Dunne's "Collected Thoughts on the Role of Consciousness in the Physical Representation of Reality"—"Appendix B" in their laboratory publication PEAR 83005.1B, *On the quantum mechanics of consciousness with application to anomalous phenomena*. Princeton, N.J.: Princeton Engineering Anomalies Research Laboratory, 1984. For a superb discussion of the Gnostic and alchemical roots of modern technology, electricity included, see Davis, E., *Techgnosis: Myth, Magic+Mysticism in the Age of Information*. New York: Three Rivers Press, 1998.

6 Recent Developments in Bioelectromagnetic Medicine

1. Bassett CAL, Chokshi HR, Hernandez E, Pawluk RJ, Strop M. In: Brighton CT, Black J, Pollack SR, eds. *Electrical Properties of Bone and Cartilage: Experimental Effects and Clinical Applications*. New York: Grune and Stratton, 1979:427.
2. Farrell DE. Assessment of iron in human tissue: The magnetic biopsy. In: Williamson SJ, Romani GL, Kaufman L, Modena I, eds. *Biomagnetism: An Interdisciplinary Approach*. New York: Plenum, 1983:483-500.
3. Scholz B. Towards virtual electrical breast biopsy: Space-frequency MUSIC for trans-admittance data. *IEEE Trans on Medical Imaging* 2002; 21(6):588-595.
4. Tearney GJ, Brezinski ME, Bouma BE, Boppart SA, Pitris C, Southern JF, Fujimoto JG. In vivo endoscopic optical biopsy with optical coherence tomography. *Science* 1997; 276(5321): 2002-2003.
5. The complete document from the NIH may be found on the World Wide Web by searching for National Institutes of Health Consensus Statement on Acupuncture, 1997.
6. Langevin HM, Churchill DL, Cipolla MJ. Mechanical signaling through connective tissue: a mechanism for the therapeutic effect of acupuncture. *FASEB J* 2001; 15:2275-2282.
7. Langevin HM, Churchill DL, Fox JR, Badger GJ, Garra BS, Krag MH. Biomechanical response to acupuncture needling in humans. *J Appl Physiol* 2001; 91(6):2471-2478.
8. Ho MW, Popp FA, Warnke U. *Bioelectrodynamics and Biocommunication*. Singapore: World Scientific, 1994.
9. Bassett CAL. Bioelectromagnetics in the service of medicine. In: Blank M, ed. *Electromagnetic fields: biological interactions and mechanisms*. *Advances in Chemistry Series 250*. Washington DC: American Chemical Society, 1995:261-275.
10. Lente RW. Cases of un-united fracture treated by electricity. *NY J Med* 1859; 5:317.
11. Yasuda I. Fundamental aspects of fracture treatment. *J Kyoto Med Soc* 1953; 4:395-406.

12. Bassett LS, Pawluk RJ, Becker RO. Effects of electric currents on bone in vivo. *Nature* 1964; 204:652.
13. Borgens RB. Exogenous ionic currents traverse intact and changed bone. *Science* 1984; 225(4661):478-482.
14. Brighton CT, Black J, FriedenberG ZB, Esterhai JL, Day LJ, Connolly JF. A multicenter study of the treatment of non-union with constant direct current. *J Bone Joint Surg Am* 1981; 63(1):2-13.
15. Mammi GI, Rocchi R, Cadossi R, Massari L, Traina GC. The electrical stimulation of tibial osteotomies. Double blind study. *Clin Orthop* 1993; 288:246-253.
16. Bassett CAL, Mitchell SUN, Gaston SR. Pulsing electromagnetic field treatment in ununited fractures and failed arthroeses. *JAMA* 1982; 247(5):623-628.
17. Bassett CAL. Fundamental and practical aspects of therapeutic uses of pulsed electromagnetic fields (PEMFs). *Crit Rev Biomed Eng* 1989; 17(5):451-529.
18. Bassett CAL, Chokshi HR, Hernandez E, Pawluk RJ, Strop M. In: Brighton CT, Black J, Pollack SR, eds. *Electrical Properties of Bone and Cartilage; Experimental Effects and Clinical Applications*. New York: Grune and Stratton, 1979:427.
19. Gilman AG. G proteins and regulation of adenylyl cyclase. Nobel Lecture presented December 8 1994. In: Ringertz N, ed. *Nobel Lectures Physiology or Medicine*. Singapore: World Scientific, 1991-1995:182-212.
20. Wiesenfeld AK, Moss F. Stochastic resonance and the benefits of noise. In: *Ice ages to crayfish and SQUID's*. *Nature* 1995; 373:33-36.
21. Bulsara AR, Gammaitoni L. Tuning into noise. *Physics Today*, March 1996:39-45.
22. Goodman R, Henderson A. Exposure of salivary gland cells to low-frequency electromagnetic fields alters polypeptide synthesis. *Proc Natl Acad Sci USA* 1988; 85(11):3928-3932.
23. Siskin BF, Walker J. Therapeutic aspects of electromagnetic fields for soft-tissue healing. In: Blank M, ed. *Electromagnetic fields: biological interactions and*

mechanisms. *Advances in Chemistry Series 250*. Washington DC: American Chemical Society, 1995:227-285.

24. Blackman CF, Elder JA, Weil CM, Bename SG, Eichinger DC, House DE. Induction of calcium-ion efflux from brain tissue by radio-frequency radiation: effects of modulation frequency and field strength. *Radio Science* 1979; 14(6S):93-98.

25. Bawin SM, Kaczmarek LK, Adey WR. Effects of modulated very high frequency fields on specific brain rhythms in cats. *Brain Research* 1975; 58:365-384.

26. Liboff A. Geomagnetic cyclotron resonance in living cells. *J Biol Phys* 1985; 13:99-102.

27. Becker RO. *Cross Currents*. Los Angeles: Jeremy P.Tarcher, 1990:236.

28. Trock DH, Bollet AJ, Markoll R. The effect of pulsed electromagnetic fields in the treatment of osteoarthritis of the knee and cervical spine. Report of randomized, double blind, placebo controlled trials. *J Rheumatol* 1994; 21 (10):1903-1911.

29. Trock DH, Bollet AJ, Dyer RH Jr, Felding LP, Miner WK, Markoll R. A double-blind trial of the clinical effects of pulsed electromagnetic fields in osteoarthritis. *J Rheumatol* 1993; 20(12): 2166-2167.

30. Melzack R, Wall PD. Pain mechanisms: a new theory. *Science* 1965; 150:971.

31. Shealy CN, Mortimer JT, Reswich JB. Electrical stimulation of pain by stimulation of the dorsal column: preliminary clinical reports. *Anesth Analg* 1967; 45:489.

32. Shealy CN, Cady RK, Cox RH. Pain, stress and depression: psychoneurophysiology and therapy. *Stress Medicine* 1995; 1:65-77.

33. Fricke H, Morse S. The electric capacity of tumors of the breast. *J Cancer Res* 1926; 16:310-376.

34. Burr HS, Smith GM, Strong LC. Electrometric studies of tumors induced in mice by the external application of benzpyrene. *Yale J Biol Medicine* 1940; 12:711-717.

35. Brewitt B. Quantitative analysis of electrical skin conductance in diagnosis: historical and current views of

- bioelectric medicine. *J Naturopathic Medicine* 1996; 6(1):66-75.
36. Szent-Györgyi A. The study of energy levels in biochemistry. *Nature* 1941; 148:157-159.
37. Rosenberg B, Postow E. Semiconduction in proteins and lipids-its possible biological import. *Annals of the New York Academy of Sciences* 1969; 158(1):161-190.
38. Swarup A, Stuchly SS, Surowiec A. Dielectric properties of mouse MCA1 fibrosarcoma at different stages of development. *Bioelectromagnetics* 1991; 12:1-8.
39. Smith SR, Foster KR, Wolf GL. Dielectric properties of VX-2 carcinoma versus normal liver tissue. *IEEE Trans Biomed Eng* 1986; BME-33:522-524.
40. Singh B, Smith CW, Hughes R. In vivo dielectric spectrometer. *Med Biol Eng Comput* 1979; 17:45-60.
41. Jossinet J. Variability of impedivity in normal and pathological breast tissue. *Med Biol Eng Comput* 1996; 34: 346-350.
42. Jossinet J. The impedivity of freshly excised human breast tissue. *Physiol Meas* 1998; 19:61-75.
43. Morimoto T, Kinouchi Y, Iritani T, Kimura S, et al. Measurement of the electrical bio-impedance of breast tumors. *Eur Surg Res* 1990; 22:86-92.
44. Morimoto T, et al. A study of the electrical bio-impedance of tumors. *J Invest Surg* 1993; 6(1):25- 32.
45. Cuzick J, Holland R, Barth V, Davies R, Faupel M, Fentiman I, Frischbier HJ, LaMarque JL, Merson M, Sacchini V, Vanel D, Veronesi U. Electropotential measurements as a new diagnostic modality for breast cancer. *Lancet* 1998; 352(9125):359-363.
46. Binggeli R, Weinstein RC. Membrane potentials and sodium channels: hypotheses for growth regulation and cancer formation based on changes in sodium channels and gap junctions. *J Theoretical Biol* 1986; 123(4): 340-377.
47. Goller DA, Weidema WF, Davies RJ. Transmural electrical potential difference as an early marker in colon cancer. *Arch Surg* 1986; 121:345-350.

48. Marino AA, Iliev IG, Schwalke MAA, Gonzales E, Marler KC, Flanagan CA. Association between cell membrane potential and breast cancer. *Tumor Biology* 1994; 15:82-89.
49. Cuzick J. Continuation of the International Breast Cancer Intervention Study (IBIS). *European Journal of Cancer* 1998; 34(11): 1647-1648.
50. Scholz B, Anderson LR. On electrical impedance scanning-principles and simulations. *Electromedica* 2000; 68: 35-44.
51. FDA Approves new breast imaging device. FDA Talk Paper 1999; T99-18, <http://www.fda.gov/bbs/topics/ANSWERS/ANS00950.html>.
52. Michaelson JS, Silverstein M, Wyatt J, Weber G, Moore R, Halpern E, Kopans DB, Hughes K. Predicting the survival of patients with breast carcinoma using tumor size. *Cancer* 2002; 95:713-723.
53. Electrical impedance tomography. *IEEE Trans Medical Imaging* 2002; 21(6): 1-712.
54. Horwitz AF. Integrins and health. Discovered only recently, these adhesive cell surface molecules have quickly revealed themselves to be critical to proper functioning of the body and to life itself. *Scientific American* 1997; 276:68-75.
55. Oschman JL. *Energy Medicine: the scientific basis*. Edinburgh: Churchill Livingstone, 2000: 41-68.
56. Ho M-W. Coherent energy, liquid crystallinity and acupuncture. Talk presented to British Acupuncture Society, 2 October 1999. <http://www.i-sis.org/acupunc.shtml>.
57. Ho M-W, Knight D. The acupuncture system and the liquid crystalline collagen fibers of the connective tissues. *Am J Chinese Medicine* 1988; 26:251-263.

7 Evolution of Electrotherapy: From TENS to Cyberpharmacology

1. Kellaway P. The part played by electric fish in the early history of bioelectricity and electrotherapy. *Bull Hist Med* 1946; 20:112-132.
2. Shealy CN, Mortimer JT, Becker DP. Electrical inhibition of pain by dorsal column stimulation: preliminary clinical report. *Anesthesia Analgesia. Current Researches* 1967; 46:489-491.
3. Shealy CN. Effects of transcranial neurostimulation upon mood and serotonin production: a preliminary report. II *dolore* 1979; 1:13-16.
4. Shealy CN, Cady RK, Wilkie RG, Cox RH, Liss S, Closson W. Depression: a diagnostic neurochemical profile and therapy with cranial electrical stimulation (CES). *J Neurol Orthopaedic Med Surg* 1989; 10(4):319-321.
5. Shealy CN, Cady RK, Veehoff D, Houston R, Burnett M, Cox RH, Closson W. The neurochemistry of depression. *Am J Pain Management* 1992; 2:13-16.
6. Shealy CN. The physical roots of depression. *Vision, Association of Unity Churches* 1990; 3:11-13.
7. Shealy CN. Depression: The common denominator in dis-ease. *Venture Inward* 1993; 9(3): 16- 19.
8. Shealy CN, Cady RK, Veehoff DC, Cox RH, Houston R, Atwell M. Nonpharmaceutical treatment of depression using a multimodal approach. *Subtle Energies* 1993; 4(2): 125-134.
9. Shealy CN, Cady RK, Cox RH. Pain stress and depression: Psychoneurophysiology and therapy. *Stress Medicine* 1995; 11:75-77.
10. Kirsch I, Moore TJ, Scoboria A, Nicholls SS. The Emperor's new drugs: An analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. *Prevention and Treatment* 2002; 5(article 23).
11. Shealy CN. Microwave resonance therapy: Innovations from the Ukraine. *Greene County Med Bull* 1993;47(3): 15-17.
12. Liss S, Liss B. Physiological and therapeutic effects of high frequency pulses. *Integrative Physiol Behavioral*

Sci 1996; 31(2):88-94.

13. Fromherz P. Neurons talk to chips and chips talks to nerve cells. J Phys Rev Lett, August 21, 1995.

14. Granbard K, Heartline DK. Full-wave rectification from a mixed electrical, chemical synapse. Science Rep 1987; 237:535-537.

15. Cassuto J, Liss S, Bennett A. The use of modulated energy carried on a high frequency wave for the relief of intractable pain. Int J Clin Pharmacol Res 1993; 13(4):239-241.

16. Graziano JM. Retrospective analysis of acute and chronic pain control in physical therapy and rehabilitation with the Pain Suppressor. Chicago Pain Conference, Chicago, IL, May 1997.

17. Shealy CN. Characteristics of pain reduction. Chicago Pain Conference, Chicago, IL, May 1997.

18. Shealy CN. External electrical stimulation: types, techniques and results. Neuroelectric News 1976; 6:4-9.

19. Closson W. Transcutaneous electrical nerve stimulation and adrenocorticotrophic hormone production. Polypeptide Meeting, George Washington University, Washington, DC, May 1997.

20. Closson W. Changes in blood biochemical levels, following treatment with TENS devices of differing frequency composition. Fourth International Montreux Congress on Stress, Montreux, Switzerland 1992.

21. Thomlinson P, Shealy CN. Successful holistic treatment of chronic depression. Twenty-second International Conference on the Unity of the Sciences, Seoul, Korea, February 9-13, 2000.

22. Shealy CN. Electrical stimulation raises DHEA and improves diabetic neuropathy. Stress Medicine 1995; 11: 215-217.

23. Rosch PJ. DHEA and the fountain of youth. Newsletter of the American Institute of Stress 1995; Number 8.

24. Solomon S, Guglielmo K. Treatment of headache by transcutaneous electrical stimulation. Headache J 1985; 25 (1).

25. Solomon S, Elkind A, Freitag F, Gallagher RM, Moore K, Swardlow B, Malkin S. Safety and effectiveness of cranial electrotherapy in the treatment of tension headaches. *Headache J* 1989; 29(7).
26. MacGregor EA, Bennett A, Liss S, Wilkinson MIP. Transcranial electrical stimulation in migraine prophylaxis. European Headache Conference, 1993.
27. Markovich SE. Post traumatic headaches. Nineth Annual Meeting of the Neuroelectric Society, Marco Beach, FL, December 1977.
28. Romanò TJ. The usefulness of cranial electrotherapy in the treatment of headache in fibromyalgia patients. *Am J Pain Management* 1993; 1(1).
29. Terezhalmay GT, Ross GR, Holmes-Johnson E. Transcutaneous electrical nerve stimulation treatment of TMJMPDS patients. *Ear, Nose, Throat J*, 1982.
30. Morrison H, Liss B, Liss S. Cranial electrical stimulation for treatment of stress-related pain. Sixth International Montreux Congress on Stress, Montreux, Switzerland, February 1994.
31. Malden JW, Charash LI. Transcranial stimulation for the inhibition of primitive reflexes in children with cerebral palsy. *Neurology Rep APTA* 1985; 9(2).
32. Logan MP. Improved mechanical efficiency in cerebral palsy patients treated with a cranial electrotherapy stimulator (CES). American Academy of Cerebral Palsy and Developmental Medicine Conference, October 1988.
33. Sornson R, Liverance D, Armstrong G, Zelt B. Neurotransmitter modulation benefits adolescent cerebral palsy students. *Am J Electromedicine*, February 1989.
34. Reilly MA, Light KE. Movement efficiency: Effects of transcranial stimulation on a single subject with cerebral palsy. Presented and published by the Forum on Efficacy of Physical Therapy Treatment for Patients with Brain Injury. Combined Sections Meeting of the American Physical Therapy Association, 1990.
35. Hunt TF. Senior Thesis: Transcranial electrical stimulation as a means of treating neuropathological disorders in children, University of Utah Division of

Physical Therapy, 1986.

36. Childs, A. Case Study: Fifteen-cycle cranial electrotherapy stimulation for spasticity. *Brain Injury* 1993; 7(2).
37. Okoye R, Malden JW. Use of neurotransmitter modulation to facilitate sensory integration. *Neurol Sec Am Phys Therapy Assoc* 1986; 10(4).
38. Cady R, Shealy CN. Cerebrospinal fluid and plasma neurochemicals: Response to cranial electrical stimulation. Study grant from the Charlson Foundation 1991.
39. Liss S, Liss BS, Closson WJ. Baseline analysis—normals with 20 minute transcranial treatment using LISS cranial stimulators (monopolar, bipolar and placebo). Fourth International Montreux Congress on Stress, Montreux, Switzerland 1992.
40. Liss S, Malden J. Average biochemical changes in 2 subjects following 20 minutes stimulation with LISS cranial stimulator #201-M. Fourth International Montreux Congress on Stress, Montreux, Switzerland, 1992.
41. Cox RH, Shealy CN, Cady RK, Cadle R, Richards G. Successful treatment of rheumatoid arthritis with GigaTENS™. *J Neurol Orthopaedic Med Surg* 1996; 17(1):31.
42. Shealy CN, Myss CM. The ring of fire and DHEA: A theory for energetic restoration of adrenal reserves. *Subtle Energies* 1995; 6(2): 167-175.
43. Shealy CN, Borgmeyer, V, Thomlinson P. Intuition, neurotensin and the ring of air. *Subtle Energies and Energy Medicine* 2002; 11 (2): 145-150.
44. Shealy CN, Borgmeyer VM. Calcitonin enhancement with electrical activation of a specific acupuncture circuit. *Am J Pain Management*. In press.
45. Shealy CN, Borgmeyer VM, Thomlinson RP. Reduction of free radicals by electrical stimulation of specific acupuncture points. Submitted for publication.
46. Shealy CN. *The Methuselah Potential for Health and Longevity*. Fair Grove, MO:Brindabella Books, 2002.

9 Chronic Therapeutic Brain Stimulation History, Current Clinical Indications, and Future Prospects

1. De Boulogne D. De l'électrisation localisée et son application à la physiologie, à la pathologie et à la thérapeutique. Paris: J.B.Bailliere, 1855.
2. Fritsch G, Hitzig E. On the electrical excitability of the cerebrum (translated from the German). In: Bonin Gv, ed. Some Papers on the Cerebral Cortex. Springfield, IL: Charles C.Thomas, 1960:73-96.
3. Thomas RK, Young CD. A note on the early history of electrical stimulation of the human brain. *J Gen Psychol* 1993; 120:73-81.
4. Morgan JP. The first reported case of electrical stimulation of the human brain. *J Hist Med Allied Sci* 1982; 37: 51-64.
5. Sheer DE. *Electrical Stimulation of the Brain*. Austin: University of Texas Press, 1961.
6. Zimmermann M. Electrical stimulation of the human brain. *Hum Neurobiol* 1982; 1:227-229.
7. Bartholow R. Experimental investigations into the functions of the human brain. *Am J Med Sci* 1874; 67: 305-313.
8. Bartholow R. Letter to the editor. *Brit Med J* 1874; 3:727.
9. Pool JL. Psychosurgery in older people. *J Am Geriat Soc* 1954; 2:456-465.
10. Heath R. *Studies in schizophrenia: a multidisciplinary approach to mind-brain relationships*. Cambridge, MA: Harvard University Press, 1954.
11. Heath R, Mickle W. Evaluation of 7 years' experience with depth electrode studies in human patients. In: Ramey E, O'Doherty D, eds. *Electrical Studies in Unanesthetized Brain*. New York: Harper & Brothers, 1960:214-217.
12. Spiegel EA, Wycis HT, Marks M, Lee AJ. Stereotaxic apparatus for operations on the human brain. *Science* 1947; 106:349-350.

13. Spiegel EA, Wycis HT. Chronic implantation of intracerebral electrodes in humans. In: Sheer DE, ed. *Electrical Stimulation of the Brain*. Austin: University of Texas Press, 1961:37-44.
14. Hassler R, Riechert TFM. Physiological observations in stereotaxic operations in extrapyramidal motor disturbances. *Brain* 1960; 83:337-350.
15. Hassler R. Thalamic regulation of muscle tone and the speed of movements. In: Purpura DP, Yahr MD, eds. *The Thalamus*. New York: Columbia University Press, 1966:419-438.
16. Spiegel EA, Wycis HT, Baird HW, Szekely EG. Physiopathologic observations on the basal ganglia. In: Ramey E, O'Doherty DS, eds. *Electrical Studies on the Unanesthetized Brain*. New York: Harper & Brothers, 1960: 192-213.
17. Cooper IS. Effect of chronic stimulation of anterior cerebellum on neurological disease. *Lancet* 1973; 1:206.
18. Benabid AL, Pollak P, Louveau A, Henry S, de Rougemont J. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. *Appl Neurophysiol* 1987; 50: 344-346.
19. Benabid AL, Benazzous A, Pollak P. Mechanisms of deep brain stimulation. *Mov Disord* 2002; 17 (suppl3):S73-S74.
20. Beurrier C, Bioulac Bernard, Audin J, Hammond C. High-frequency Stimulation produces a transient blockade of voltage-gated currents in subthalamic neurons. *J Neurophysiol* 2001; 85:1351-1356.
21. Dostrovsky JO, Lozano AM. Mechanisms of deep brain stimulation. *Mov Disord* 2002; 17(suppl 3):S63-S68.
22. Vitek JL. Mechanisms of deep brain stimulation: excitation or inhibition. *Mov Disord* 2002; 17(suppl 3):S69-S72.
23. Montgomery EB Jr, Baker KB. Mechanisms of deep brain stimulation and future technical developments. *Neurol Res* 2000; 22:259-266.
24. Vitek JL. Surgery for dystonia. *Neurosurg Clin N Am* 1998; 9:345-366.

25. Andrew J, Watkins ES. A Stereotaxic Atlas of the Human Thalamus. Baltimore: Williams and Wilkins, 1969.
26. Morel A, Magnin M, Jeanmonod D. Multiarchitectonic and stereotactic atlas of the human thalamus [published erratum appears in J Comp Neurol 1998 Feb 22;391(4):545]. J Comp Neurol 1997; 387:588-630.
27. Schaltenbrand G, Wahren W. Atlas for Stereotaxy of the Human Brain. Stuttgart: Thieme, 1977.
28. Talairach J, David M, Tournoux P, Corredor H, Kvasina T. Atlas d'Anatomie Stéréotaxique. Paris: Masson, 1957.
29. Benabid AL, Pollak P, Hommel M, Gaio JM, de Rougemont J, Perret J. [Treatment of Parkinson tremor by chronic stimulation of the ventral intermediate nucleus of the thalamus]. Rev Neurol 1989; 145:320-323.
30. Benabid AL, Pollak P, Gervason C. Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. Lancet 1991; 337:403-406.
31. Benabid AL, Pollak P, Gao D. Chronic electrical stimulation of the ventralis intermedialis nucleus of the thalamus as a treatment of movement disorders. J Neurosurg 1996; 84:203- 214.
32. Schuurman PR, Bosch DA, Bossuyt PM. A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor [see comments]. N Engl J Med 2000; 342:461-468.
33. Limousin P, Speelman JD, Gielen F, Janssens M. Multicentre European study of thalamic stimulation in parkinsonian and essential tremor. J Neurol Neurosurg Psychiatry 1999; 66:289- 296.
34. Koller W, Pahwa R, Busenbark K. High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. Ann Neurol 1997; 42:292-299.
35. Montgomery EB Jr, Baker KB, Kinkel RP, Barnett G. Chronic thalamic stimulation for the tremor of multiple sclerosis. Neurology 1999; 53:625-628.
36. Geny C, Nguyen JP, Pollin B. Improvement of severe postural cerebellar tremor in multiple sclerosis by chronic thalamic stimulation. Mov Disord 1996; 11:489-494.

37. Schulder M, Sernas T, Mahalick D, Adler R, Cook S. Thalamic stimulation in patients with multiple sclerosis. *Stereotact Funct Neurosurg* 1999; 72:196-201.
38. Koller WC, Lyons KE, Wilkinson SB, Pahwa R. Efficacy of unilateral deep brain stimulation of the VIM nucleus of the thalamus for essential head tremor. *Mov Disord* 1999; 14:847-850.
39. Berk C, Honey CR. Bilateral thalamic deep brain stimulation for the treatment of head tremor. Report of two cases. *J Neurosurg* 2002; 96:615-618.
40. Carpenter MA, Pahwa R, Miyawaki KL, Wilkinson SB, Searl JP, Koller WC. Reduction in voice tremor under thalamic stimulation. *Neurology* 1998; 50:796-798.
41. Lee MS, Marsden CD. Movement disorders following lesions of the thalamus or subthalamic region. *Mov Disord* 1994; 9:493-507.
42. Benazzouz A, Gross C, Feger J, Boraud T, Bioulac B. Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys. *Eur J Neurosci* 1993; 5: 382-389.
43. Bergman H, Wichmann T, DeLong M. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. *Science* 1990; 249:1346-1348.
44. Aziz TZ, Peggs D, Agarwal E, Sambrook MA, Crossman AR. Subthalamic nucleotomy alleviates parkinsonism in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed primate. *Brit J Neurosurg* 1992; 6: 575-582.
45. Aziz TZ, Peggs D, Sambrook MA, Crossman AR. Lesion of the subthalamic nucleus for the alleviation of 1methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate. *Mov Disord* 1991; 6: 288-292.
46. Pollak P, Benabid AL, Gross C. Effects of the stimulation of the subthalamic nucleus in Parkinson disease. *Rev Neurol* 1993; 149:175-176.
47. Group TD-BSfPds. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. *N Engl J Med* 2001; 345:956-963.

48. Limousin P, Krack P, Pollak P. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. *N Engl J Med* 1998; 339:1105-1111.
49. Krack P, Limousin P, Benabid AL, Pollak P. Chronic stimulation of subthalamic nucleus improves levodopa-induced dyskinesias in Parkinson's disease [letter]. *Lancet* 1997; 350:1676.
50. Bejjani BP, Damier P, Arnulf I. Transient acute depression induced by high-frequency deep-brain stimulation [see comments]. *N Engl J Med* 1999; 340:1476-1480.
51. Dujardin K, Krystkowiak P, Defebvre L, Blond S, Destee A. A case of severe dysexecutive syndrome consecutive to chronic bilateral pallidal stimulation. *Neuropsychologia* 2000; 38:305- 1315.
52. Perozzo P, Rizzone M, Bergamasco B. Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: comparison of pre- and postoperative neuropsychological evaluation. *J Neurol Sci* 2001; 192:9-15.
53. Pillon B, Ardouin C, Damier P. Neuropsychological changes between "off" and "on" STN or GPi stimulation in Parkinson's disease. *Neurology* 2000; 55:411-418.
54. Ardouin C, Pillon B, Peiffer E. Bilateral subthalamic or pallidal stimulation for Parkinson's disease affects neither memory nor executive functions: a consecutive series of 62 patients. *Ann Neurol* 1999; 46:217-223.
55. Laitinen L, ATB, Hariz M. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. *J Neurosurg* 1992; 76:53-61.
56. Ghika J, Villemure JG, Fankhauser H, Favre J, Assal G, Ghika-Schmid F. Efficiency and safety of bilateral contemporaneous pallidal stimulation (deep brain stimulation) in levodopa-responsive patients with Parkinson's disease with severe motor fluctuations: a 2-year follow-up review. *J Neurosurg* 1998; 89:713-718.
57. Volkmann J, Sturm V, Weiss P. Bilateral high-frequency stimulation of the internal globus pallidus in advanced Parkinson's disease. *Ann Neurol* 1998; 44:953-961.
58. Galvez-Jimenez N, Lozano A, Tasker R, Duff J, Hutchison W, Lang AE. Pallidal stimulation in Parkinson's disease patients with a prior unilateral pallidotomy. *Can J Neurol*

Sci 1998; 25:300- 305.

59. Burchiel KJ, Anderson VC, Favre J, Hammerstad JP. Comparison of Pallidal and Subthalamic Nucleus Deep Brain Stimulation for Advanced Parkinson's Disease: Results of a Randomized, Blinded Pilot Study. *Neurosurgery* 1999; 45:1375-1384.

60. Allert N, Volkmann J, Dotse S, Heftter H, Sturm V, Freund HJ. Effects of bilateral pallidal or subthalamic stimulation on gait in advanced Parkinson's disease. *Mov Disord* 2001; 16:1076- 1085.

61. Volkmann J, Allert N, Voges J, Weiss PH, Freund HJ, Sturm V. Safety and efficacy of pallidal or subthalamic nucleus stimulation in advanced PD. *Neurology* 2001; 56:548-551.

62. Krack P, Poepping M, Weinert D, Schrader B, Deuschl G. Thalamic, pallidal, or subthalamic surgery for Parkinson's disease? *J Neurol* 2000; 247(suppl 2):II 122-III134.

63. Kumar R, Dagher A, Hutchison WD, Lang AE, Lozano AM. Globus pallidus deep brain stimulation for generalized dystonia: clinical and PET investigation. *Neurology* 1999; 53:871- 874.

64. Krauss JK, Pohle T, Weber S, Ozdoba C, Burgunder JM. Bilateral stimulation of globus pallidus internus for treatment of cervical dystonia [letter]. *Lancet* 1999; 354:837-838.

65. Lozano AM, Kumar R, Gross RE, et al. Globus pallidus internus pallidotomy for generalized dystonia [see comments]. *Mov Disord* 1997; 12:865-870.

66. Islekel S, Zileli M, Zileli B. Unilateral pallidal stimulation in cervical dystonia. *Stereotact Funct Neurosurg* 1999; 72:248-252.

67. Thompson TP, Kondziolka D, Albright AL. Thalamic stimulation for choreiform movement disorders in children. Report of two cases. *J Neurosurg* 2000; 92:718-721.

68. Sellal F, Hirsch E, Barth P, Blond S, Marescaux C. A case of symptomatic hemidystonia improved by ventroposterolateral thalamic electrostimulation. *Mov Disord* 1993; 8:515-518.

69. Tronnier VM, Fogel W. Pallidal stimulation for

- generalized dystonia. Report of three cases. *J Neurosurg* 2000; 92:453-456.
70. Vercueil L, Krack P, Pollak P. Results of deep brain stimulation for dystonia: a critical reappraisal. *Mov Disord* 2002; 17(suppl 3):S89-S93.
71. Bonelli RM, Gruber A. Deep brain stimulation in Huntington's disease. *Mov Disord* 2002; 17:429-430. Discussion 431-432.
72. Vandewalle V, van der Linden C, Groenewegen HJ, Caemaert J. Stereotactic treatment of Gilles de la Tourette syndrome by high frequency stimulation of thalamus [letter]. *Lancet* 1999; 353:724.
73. Mazars GL, Merienne L, Ciolocca C. Stimulation thalamiques intermittents antalgiques. Note Préliminaire. *Revue Neurol* 1973; 128:273-279.
74. Mazars GL. Intermittent stimulation of nucleus ventralis posterolateralis for intractable pain. *Surgical Neurology* 1975; 4:93-95.
75. Mazars GL, Merienne L, Ciolocca C. Treatment of certain types of pain by implantable thalamic stimulators. *Neurochirurgie* 1974; 29:117-124.
76. Lenz F, Tasker R, Dostrovsky J. Abnormal single-unit activity recorded in the somatosensory thalamus of a quadriplegic patient with central pain. *Pain* 1987; 31:225-236.
77. Lis-Planells M, Tronnier V, Rinaldi P. Neural activity of medial and lateral thalamus in a deafferentation model. *Soc Neuroscience Abstr* 1992; 18:288.
78. Rinaldi P, Young R, Albe-Fessard D. Spontaneous neuronal hyperactivity in the medial and intralaminar thalamic nuclei of patients with deafferentation pain. *J Neurosurgery* 1991; 74: 415-421.
79. Gerhart K, Yeziarski R, Fang Z, Willis W. Inhibition of primate spinothalamic tract neurons by stimulation in ipsilateral or contralateral ventral posterior lateral (VPL) thalamic nucleus: Possible Mechanisms. *J Neurophysiol* 1983; 59:406-423.
80. Benabid AL, Henriksen SJ, McGinty JF, Bloom FE. Thalamic nucleus ventro-postero-lateralis inhibits nucleus

parafascicularis response to noxious stimuli through a non-opioid pathway. *Brain Res* 1983; 280:217-231.

81. Reynolds D. Surgery in the rat during electrical analgesia induced by focal brain stimulation. *Science* 1969; 164.

82. Richardson DE, Akil H. Pain reduction by electrical brain stimulation in man. Part 2: chronic self-administration in the periventricular gray matter. *J Neurosurg* 1977; 47:184-194.

83. Richardson DE, Akil H. Pain reduction by electrical brain stimulation in man. Part 1: acute administration in periaqueductal and periventricular sites. *J Neurosurg* 1977; 47:178-183.

84. Kumar K, Toth C, Nath RK. Deep brain stimulation for intractable pain: a 15-year experience. *Neurosurgery* 1997; 40:736-746. Discussion 746-747.

85. Tsubokawa T, Katayama Y, Yamamoto T, Hirayama T, Koyama S. Chronic motor cortex stimulation in patients with thalamic pain. *J Neurosurg* 1993; 78:393-401.

86. Tsubokawa T, Katayama Y, Yamamoto T, Hirayama T, Koyama S. Chronic motor cortex stimulation for the treatment of central pain. *Acta Neurochir Suppl* 1991; 52:137-139.

87. Nguyen JP, Lefaucheur JP, Decq P, et al. Chronic motor cortex stimulation in the treatment of central and neuropathic pain. Correlations between clinical, electrophysiological and anatomical data. *Pain* 1999; 82: 245-251.

88. Peyron R, Garcia-Larrea L, Deiber MP. Electrical stimulation of precentral cortical area in the treatment of central pain: electrophysiological and PET study. *Pain* 1995; 62:275-286.

89. Cooper IS. Effect of stimulation of posterior cerebellum on neurological disease. *Lancet* 1973; 1:1321.

90. Cooper IS, Amin I, Riklan M, Waltz JM, Tung PP. Chronic cerebellar stimulation in epilepsy. *Arch Neurol* 1976; 33:559-570.

91. Cooper IS, Amin I, Gilman S. The effect of chronic cerebellar stimulation upon epilepsy in man. *Trans Am Neurol Assoc* 1978; 98:192-196.

92. Cooper IS. Cerebellar Stimulation in Man. New York: Raven Press, 1978.
93. Cooper IS, Amin I, Gilman S, Waltz JM. The effect of chronic stimulation of cerebellar cortex on epilepsy in man. In: Cooper IS, Riklan M, Snider RS, eds. The Cerebellum, Epilepsy, and Behavior. New York: Plenum, 1974:122.
94. Van Buren JM, Wood JH, Oakley J, Hambrecht F. Preliminary evaluation of cerebellar stimulation by doubleblind stimulation and biological criteria in the treatment of epilepsy. J Neurosurg 1978; 48:407-416.
95. Wright G, McLellan D, Brice A. A double-blind trial of chronic cerebellar stimulation in twelve patients with epilepsy. J Neurol Neurosurg Psychiatry 1984; 47:769-774.
96. Cooper IS, Upton AR, Amin I. Reversibility of chronic neurologic deficits. Some effects of electrical stimulation of the thalamus and internal capsule in man. Appl Neurophysiol 1980; 43:244-258.
97. Cooper IS, Upton AR. Therapeutic implications of modulation of metabolism and functional activity of cerebral cortex by chronic stimulation of cerebellum and thalamus. Biol Psychiatry 1985; 20:811-813.
98. Velasco F, Velasco M, Ogarrio C, Fanghanel G. Electrical stimulation of the centromedian thalamic nucleus in the treatment of convulsive seizures: a preliminary report. Epilepsia 1987; 28:421-430.
99. Velasco F, Velasco M, Jimenez F. Predictors in the treatment of difficult-to-control seizures by electrical stimulation of the centromedian thalamic nucleus [In Process Citation]. Neurosurgery 2000; 47:295-304. Discussion 304-305.
100. Benabid AL, Koussié A, Pollak P. Future Prospects of Brain Stimulation. Neurological Research 2000; 22: 237-246.
101. Benabid AL, Minotti L, Koussié A, de Saint Martin A, Hirsch E. Antiepileptic effect of high-frequency stimulation of the subthalamic nucleus (corpus luyisi) in a case of medically intractable epilepsy caused by focal dysplasia: a 30-month follow-up: technical case report. Neurosurgery 2002; 50:1385-1391. Discussion 1391-1392.

102. Loddenkemper T, Pan A, Neme S. Deep brain stimulation in epilepsy. *J Clin Neurophysiol* 2001; 18:514-532.
103. Deransart C, Le BT, Marescaux C, Depaulis A. Role of the subthalamo-nigral input in the control of amygdalal kindled seizures in the rat. *Brain Res* 1998; 807:78-83.
104. Deransart C, Vercueil L, Marescaux C, Depaulis A. The role of basal ganglia in the control of generalized absence seizures. *Epilepsy Res* 1998; 32:213-223.
105. Vercueil L, Benazzouz A, Deransart C. High-frequency stimulation of the subthalamic nucleus suppresses absence seizures in the rat: comparison with neurotoxic lesions. *Epilepsy Res* 1998; 31:39-46.
106. Nuttin B, Cosyns P, Demeulemeester H, Gybels J, Meyerson B. Electrical stimulation in anterior limbs of internal capsules in patients with obsessive-compulsive disorder [letter]. *Lancet* 1999; 354:1526.
107. Anand BK, Brobeck JR. Hypothalamic control of food intake in rats and cats. *Yale J Biol Med* 1951; 24: 123-140.
108. Anand BK, Brobeck JR. Localization of a "feeding center" in the hypothalamus of the rat. *Proc Soc Exp Biol Med* 1951; 77:323-324.
109. Anand BK, Dua S. Feeding Responses induced by electrical stimulation of the hypothalamus in cat. *Indian J Med Res* 1955; 43:113-122.
110. Quaade F, Vaernet K, Larsson S. Stereotaxic stimulation and electrocoagulation of the lateral hypothalamus in obese humans. *Acta Neurochir* 1974; 30:111-117.
111. Moruzzi G, Magoun HW. Brainstem reticular formation and activation of the EEG. *Electroencephalogr Clin Neurophysiol* 1949; 1:455-473.
112. Magoun HW. *The Waking Brain*. Springfield, Ill: Charles C. Thomas, 1958.
113. Hassler R, Ore GD, Bricolo A, Dieckmann G, Dolce G. EEG and clinical arousal induced by bilateral long-term stimulation of pallidal systems in traumatic vigil coma. *Electroencephalogr Clin Neurophysiol* 1969; 27: 689-690.

114. Sturm V, Kuhner A, Schmitt HP, Assmus H, Stock G. Chronic electrical stimulation of the thalamic unspecific activating system in a patient with coma due to midbrain and upper brain stem infarction. *Acta Neurochir* 1979; 47:235-244.
115. Tsubokawa T, Yamamoto T, Katayama Y, Hirayama T, Maejima S, Moriya T. Deep-brain stimulation in a persistent vegetative state: follow-up results and criteria for selection of candidates. *Brain Inj* 1990; 4:315-327.
116. Cohadon F, Richer E. [Deep cerebral stimulation in patients with post-traumatic vegetative state. 25 cases]. *Neurochirurgie* 1993; 39:281-292.
117. Schiff ND, Rezai AR, Plum F. A neuromodulation strategy for rational therapy of complex brain injury states. *Neurol Res* 2000; 22:267-272.
118. Fins JJ. A proposed ethical framework for interventional cognitive neuroscience: a consideration of deep brain stimulation in impaired consciousness. *Neurol Res* 2000; 22:273-278.

10 Quantum Holography: A Basis for the Interface Between Mind and Matter

1. Wilson K. The renormalization group and critical phenomena. *Reviews of Modern Physics* July 1983; 55(3): 583-600.
2. Marcer P, Mitchell E, Schempp W. Self Reference, the dimensionality and scale of quantum mechanical effects, critical phenomena and qualia. Sixth International Conference on Computing Anticipatory Systems. In publication.
3. Chubylalo AE, Pope V, Smirnov-Reuda R, Eds. *Instantaneous Action at a Distance in Modern Physics: Pro and Contra*. Commack, NY: NOVA, 1999.
4. Schempp W. *Harmonic Analysis on the Heisenberg group with applications in signal theory*. Pitman Notes in Mathematics Series. 14. London: Longman Scientific and Technical, 1986.
5. Schempp W. *Magnetic Resonance Imaging Mathematical Foundations and Applications*. New York: John Wiley, 1998.
6. Schempp W. Sub-Reimannian geometry and clinical magnetic resonance tomography. *Math Meth Appl Sci* 1999; 22:867-922.
7. Marcer P, Schempp W. The model of the prokaryote cell as an anticipatory system working by quantum holography. In: Dubois D, ed. *Proceedings of the First International Conference on Computing Anticipatory Systems*, Liege, Belgium, August 11-15, 1997:307-313.
8. Marcer P, Schempp W. A mathematically specified template for dna and the genetic code, in terms of the physically realizable processes of quantum holography. In: Fedorec, Marcer, eds. *Proceeding of Greenwich (University) Symposium on Living Computers*, 1996:45-62.
9. Marcer P, Schempp W. Model of the neuron working by quantum holography. *Informatica* 1997; 21:519-534.
10. Noboli R. Schrodinger wave holography in the brain cortex. *Phys Rev A* 1985; 32(6):3618- 3626.
11. Noboli R. Ionic waves in animal tissue. *Phys Rev A* 1987; 35(4): 1901-1922.
12. Penrose R. Quantum computation, entanglement and state

reduction. Philosophical Transactions: Mathematical, Physical and Engineering Sciences, Aug 15, 1990; 356(1743): 1927-1939.

13. Hameroff S. Quantum computation in brain microtubules? The Penrose-Hameroff 'Orch Or' model of consciousness. Philosophical Transactions: Mathematical, Physical and Engineering Sciences, Royal Society of London, Aug 15, 1998; 356(1743):1869-1896.

14. Mitchell E. Nature's Mind: The Quantum Hologram. ISCAS, 1999:295-312.

15. Marcer P, Mitchell E. What is consciousness? In: Van Loocke Philip, ed. The Physical Nature of Consciousness. Advances in Consciousness Research series. Amsterdam: John Benjamins B.V., 2001:45-174.

16. McTaggart L. The Field. London: HarperCollins, 2001, Chap. 4.

17. Binz E, Schempp W. Quantum Holography and Its Symbols: A Conceptual Survey, Institute of Noetic Sciences. In publication.

18. Radin D. The Conscious Universe. New York: HarperEdge, 1997.

11 Subtle Energies and Their Roles in Bioelectromagnetic Phenomena

1. Tiller WA. Science and Human Transformation: Subtle Energies, Intentionality and Consciousness. Walnut Creek: Pavior Publishing, 1997.
 2. Tiller WA, Dibble WE Jr, Kohane MJ. Conscious Acts of Creation: The Emergence of a New Physics. Walnut Creek: Pavior Publishing, 2001.
 3. Eisenberg RM. Fundamentals of Modern Physics. New York: John Wiley & Sons, 1961:140-146.
 4. 't Hooft G. Gauge theories of forces between elementary particles. Scientific American 1980; 242(6): 104.
 5. Barrett TW. Comments on the Harmuth Ansatz: Use of a magnetic current density in the calculation of the propagation velocity of signals by amended Maxwell theory. IEEE Transactions on Electromagnetic Compatibility 1988; 30:419.
 6. Tiller WA, Dibble WE Jr, Kohane MJ. Conscious Acts of Creation: The Emergence of a New Physics. Walnut Creek: Pavior Publishing, 2001:170.
 7. Tiller WA, Dibble WE Jr, Kohane MJ. Conscious Acts of Creation: The Emergence of a New Physics. Walnut Creek: Pavior Publishing, 2001:248-249 and 302-304.
 8. Bernal JD. Proc Roy Soc 1964; A 280:299.
 9. Ludwig R. Water: From Clusters to the Bulk. Angew Chem Int 2001; 40:1808-1827.
- Figure 23 Average air, T-oscillation amplitude vs. distance plot for Fig. 17 geometry 1 and 2 days after removal of the FC and water vessel (the former FC edge was located at 0.5 ft).
10. Tiller WA. The Science of Crystallization: Microscopic Interfacial Phenomena. Cambridge: Cambridge University Press, 1991:327-347.
 11. Samal S, Geckler KE. Unexplained solute aggregation in water on dilution. Chem Comm 2001, 2224-2225.
 12. Jackson JD. Classical Electrodynamics. New York: John

Wiley & Sons, 1962:110-116.

13. Pohl HA. Dielectrophoresis. Cambridge: Cambridge University Press, 1978:5-18.

14. Yamashita M. Effects of Magnetic Fields and Electromagnetic Fields on Water and Aqueous Solutions: Experimental Study. Ph.D. dissertation, Geophysics, Stanford University, Stanford, CA, 2001.

15. Tiller WA, Dibble WE Jr, Kohane MJ. Conscious Acts of Creation: The Emergence of a New Physics. Walnut Creek: Pavior Publishing, 2001:62-68.

16. Colic M, Morse D. Effects of amplitude of RF EM radiation on aqueous suspensions and solutions. J Coll Interf Sci 1998; 200:265, and Mechanisms of the long term effects of EM radiation on solutions and suspended colloids. Langmuire 1998; 14:783.

17. Higashitani IK; Oshitani J. Measurement of magnetic effects on electrolyte solutions by atomic force microscope. Trans I Chem Eng 1977; 75B:115, and Magnetic effects on thickness of adsorbed layer in aqueous solutions evaluated directly by atomic force microscope. J Coll Interf Sci 1998; 204:363.

18. Radin DI. The Conscious Universe. San Francisco: Harper Edge, 1997.

19. Swann I. To Kiss Earth Goodbye. New York: Hawthorn Books Inc., 1975.

20. Sugrue T. There is a River: The Story of Edgar Cayce. New York: Holt, Rinehart and Winston, 1942.

21. Benson H, Stark M. Timeless Healing: The Power and Biology of Belief. New York: Scribner, 1996.

22. Wolf S. Educating Doctors. New Brunswick: Transaction Publishers, 1997.

23. Enserink M. Can the placebo be the cure? Science 1999; 284:238.

Figure 24 Average air, T-oscillation amplitude vs. distance plot on the phantom profile immediately after placing a

natural quartz crystal (c axis up) between position 0.0 and 0.5 ft as shown.

Figure 25 Comparison of air, T-oscillation amplitude, frequency, and waveform between the pre-quartz crystal

condition and the condition immediately after changing the orientation of the quartz crystal to the c-axis horizontal position.

24. Puthoff HE, Targ R. A perceptual channel for information transfer over kilometer distances: Historical perspective and recent research. *Proceedings of the IEEE* 1976; 64:329.

25. Dossey L. *Meaning and Medicine: Lessons From a Doctor's Tales of Breakthrough and Healing*. New York: Bantam Books, 1991.

26. Targ R, Katra J. *Miracles of Mind: Exploring Nonlocal Consciousness and Spiritual Healing*. Novato: New World Library, 1998.

27. Zuyin L. *Scientific QiGong Exploration: The Wonders and Mysteries of Qi*. Malvern: Amber Leaf Press, 1997.

28. Zuyin L. *Scientific QiGong Exploration: The Wonders and Mysteries of Qi*. Malvern: Amber Leaf Press, 1997: 91-98.

29. Tiller WA. *Subtle Energies*. *Sci Med* 1999; 6(3):28-33.

30. Tiller WA. *Science and Human Transformation: Subtle Energies, Intentionality and Consciousness*. Walnut Creek: Pavior Publishing, 1997 (Chap. 1).

31. Tiller WA, Green EE, Parks PA, Anderson S. Towards explaining anomalously large body voltage surges on exceptional subjects: Part I, The electrostatic approximation. *J Sci Expl* 1995; 9:331.

12 Electromagnetism Versus Bioelectromagnetism

1. Tiller WA. Subtle Energies and Their Roles in Bioelectromagnetic Phenomena, 2003. This book, previous chapter.
2. Barrett TW. Comments on the Harmuth Ansatz: Use of a magnetic current density in the calculation of the propagation velocity of signals by amended Maxwell theory. IEEE Trans Electromagnetic Compatibility 1988; 30:419.
3. Tiller WA. Science and Human Transformation: Subtle Energies, Intentionality and Consciousness. Walnut Creek, CA: Pavior Publishing, 1997.
4. Tiller WA, Dibble WE Jr, Kohane MJ. Conscious Acts of Creation: The Emergence of a New Physics. Walnut Creek, CA: Pavior Publishing, 2001.
5. Tiller WA, Dibble WE Jr. Anomalous temperature oscillation behavior near a "source" in a "conditioned" space. Part II: A biconformal base-space theoretical interpretation. www.tiller.org.
6. Tiller WA, Dibble WE Jr. Towards general experimentation and discovery in "conditioned" laboratory spaces. Part III: A theoretical interpretation of non-local information entanglement. www.tiller.org.

13 A Fundamental Basis for the Effects of EMFs in Biology and Medicine: The Interface Between Matter and Function

1. Tsong TY. Deciphering the language of cells. *Trend Biochem Sci* 1989; 14:89-92.

2. Thomas Y. Activation of human neutrophils by electronically transmitted phorbol-myristate acetate. *Medical Hypotheses* 2000; 54:33-39.

Figure 2 Molecular signaling.

14 Electromagnetic Techniques in Neural Therapy

1. Bassett CAL, Pawluk RJ, Pilla AA. Acceleration of fracture repair by electromagnetic fields: a surgically noninvasive method. In: Liboff AR, Rinaldi RA, eds. Electrically Mediated Growth Mechanisms in Living Systems. *Ann NY Acad Sci* 1974; 238:242-262.
2. Lavine LS, Lustrin I, Shamos MH, Rinaldi RA, Liboff AR. Electric enhancement of bone healing. *Science* 1972; 175:1118-1121.
3. Kirsch DL, Smith RB. The use of cranial electrotherapy stimulation in the management of chronic pain: a review. *Neurorehabilitation* 2000; 14:85-94.
4. Solomon S, Elkind A, Freitag F, Gallagher RA, More K, Swardlow B, Malkin S. Safety and effectiveness of cranial electrotherapy in the treatment of tension headaches. *Headache* 1989; 29:445-450.
5. Stanley TH, Cazalaa JA, Limoge A, Lowville Y. Transcutaneous cranial electrical stimulation increases the potency of nitrous oxide in humans. *Anesthesiology* 1982; 57:293-297.
6. Reite M, Higgs L, Lebet J-P, Barbault A, Rossell C, Kuster N, Dafni U, Anato D, Pache B. Sleep inducing effect of low energy emission therapy. *Bioelectromagnetics* 1994; 15:67-75.
7. Lisanby SH, Belmaker RH. Animal models of the mechanisms of action of repetitive transcranial magnetic stimulation (RTMS): comparisons with electroconvulsive shock (ECS). *Depression Anxiety* 2000; 12:178-187.
8. Limousin P, Krack P, Pollak P, Benazzouz A, Ardouin C, Hoffmann D, Benabid AL. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. *N Engl J Med* 1998; 339:1105-1111.
9. Dinner DS, Neme S, Nair D, Montgomery EB, Baker KB, Rezai A, Luders H. EEG and evoked potential recording from the subthalamic nucleus for deep brain stimulation of intractable epilepsy. *Clin Neurophysiol* 2002; 113:1391-1402.
10. Roth RM, Flashman LA, Saykin AJ, Roberts DW. Deep brain stimulation in neuropsychiatric disorders. *Current*

Psychiatry Rep 2001; 3:366-372.

11. Wilder BJ. Vagal nerve stimulation. In: Engle J Jr, Pedley TA, eds. *Epilepsy: a Comprehensive Textbook*. Philadelphia: Lippincott-Raven, 1997.
12. Sabara J. Inhibition of experimental seizures in canines by repetitive vagal stimulation. *Epilepsia* 1992; 33: 1005-1012.
13. George MS, Nahas Z, Bohning DE, Kozel FA, Anderson B, Chae J-H, Lomarov M, Denslow S, Li X, Mu C. Vagus nerve stimulation therapy: A research update. *Neurology* 2002; 59:S56- S61.
14. Meyerson BA. Neurosurgical approaches to pain treatment. *Acta Anesthesiol Scand* 2001; 45:1108-1113.
15. Holle J, Frey M, Gruber H, Kern H, Stohr H, Thoma H. Functional electrostimulation of paraplegics. *Orthop* 1984; 7:1145-1155.
16. Rattay F. Ways to approximate current-distance relations for electrically stimulated nerve fibers. *J Theor Biol* 1987; 125:339-349.
17. Barker AT, Freeston IL, Jalinous R, Jarratt JA. Noninvasive stimulation of motor pathways within the brain using time-varying magnetic fields. *Electroencephalogr Clin Neurophysiol* 1985; 61:S245.
18. Pasqual-Leone A, Catala MD. Lateralized effect of rapid rate transcranial magnetic stimulation of the prefrontal cortex on mood. *Neurology* 1996; 46:499-502.
19. Pasqual-Leone A, Rubio B, Pallardo F, Catala MD. Rapid-rise transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug resistant depression. *Lancet* 1996; 348: 233-237.
20. Grunhaus L, Dannon P, Schreiber S. Repetitive transcranial magnetic stimulation is as effective as electroconvulsive therapy in the treatment of nondelusional major depressive disorder: an open study. *Biol Psychiatry* 2000; 47:314-324.
21. Hasey GM. Transcranial magnetic stimulation: using a law of physics to treat psychopathology. *J Psychiatry Neurosci* 1999; 24:97-101.

22. Seibner HR, Mentschel C, Auer C, Conrad BR. Repetitive transcranial magnetic stimulation has a beneficial effect on bradykinesia in Parkinson's disease. *Neuroreport* 1999; 10:589-594.
23. Ben-Shachar D, Belmaker RH, Grisaru N, Klein E. Transcranial magnetic stimulation induces alteration in brain monoamines. *J Neural Transm* 1997; 104:191-197.
24. Ben-Shachar D, Gazawi H, Riboyad-Levin J, Klein E. Chronic repetitive transcranial magnetic stimulation alters β -adrenergic and 5-HT₂ receptor characteristics in rat brain. *Brain Res* 1999; 816:78-83.
25. Devyatkov ND. Influence of the millimeter wavelength range electromagnetic radiation upon biological objects. *Soviet Physics Uspekhi* 1973; 110:452-454 (in Russian).
26. Logani MK, Anga A, Szabo I, Agelan A, Irizarry AR, Zisken MC. Effect of millimeter waves on cyclophosphamide induced suppression of the immune system. *Bioelectromagnetics* 2002; 23:614-621.
27. Liboff AR. Ion cyclotron resonance in biological systems: Experimental evidence. In: Stavroulakis P, ed. *Biological Effects of Electromagnet Fields*. Berlin: Springer, 2002.
28. Diebert C, McLeod BR, Smith SD, Liboff AR. Ion resonance electromagnetic field stimulation of fracture healing in rabbits with a fibular osteotomy. *J Orthopedic Res* 1984; 32:878-885.
29. Zhadin MN, Deryugina ON, Pisachenko TM. Influence of combined DC and AC magnetic fields on rat behavior. *Bioelectromagnetics* 1999; 20:378-386.
30. Dobson JP, Fuller M, Moser S, Wieser HG, Dunn JR, Zoeger J. Evocation of epileptiform activity by weak DC magnetic fields and iron biomineralization in the brain. In: Deeke L, Baumgartner C, Stronik G, Williamson SJ, eds. *Advances in Biomagnetism*. New York: Plenum Press, 1993.
31. Fuller M, Dobson J, Weiser HG, Moser S. On the sensitivity of the human brain to magnetic fields: evocation of epileptiform activity. *Brain Res Bull* 1994; 36:155-159.
32. Dobson J, St Pierre TG, Schultheiss-Grassi PP, Weiser HG, Kuster N. Analysis of EEG data from weak-field magnetic

stimulation of mesial temporal lobe epilepsy patients.
Brain Res 2000; 868:386-391.

33. Kammer T, Beck S, Thielsher A, Laubis-Herrmann U, Topka H. Motor thresholds in humans: a transcranial magnetic stimulation study comparing different pulse waveforms, current densities and stimulation types. Clin Neurophysiol 2001; 112:250-258.

34. Nunez PL. Quantitative states of neocortex. In: Nunez PL, ed. Neocortical Dynamics Human EEG Rhythms. New York: Oxford Univ Press, 1995:31.

35. Harnalainen M, Hari R, Ilmoniemi R, Knuutila J, Lounasmaa O. Magnetoencephalography: theory instrumentation and applications to the noninvasive study of human brain function. Rev Mod Phys 1993; 65: 413-497.

36. DeArmond SJ, Fusco MM, Dewey MM. Structure of the human brain: A Photographic Atlas. 3rd ed. New York: Oxford Univ Press, 1989.

37. Ferree TC, Tucker DM. Development of high resolution EEG devices. Intl J Bioelectromagnetism 1999; 1:4-10.

38. Llinas RR. The intrinsic electrophysiological properties of mammalian neurons: insights into central nervous system function. Science 1988; 42:1654-1664.

39. Lisman JE, Idiart MAP. Storage of 7±2 short-term memories in oscillatory subcycles. Science 1995; 267: 1512-1515.

40. Singer W. Synchronization of cortical activity and its putative role in information processing and learning. Ann Rev Physiol 1993; 55:349-374.

41. Anderson P, Sears T. The role of inhibition in the phasing of spontaneous thalamo cortical discharge. J Physiol 1964; 173:459-480.

42. Shepherd GM. Neurobiology. New York: Oxford University Press, 1994.

43. Llinas RR. The role of intrinsic electrophysiological properties of central neurons in oscillation and resonance. In: Goldbetter A, ed. Cell to Cell Communication: Experiments to Theoretical Models. London: Academic Press, 1990.

44. Draguhn A, Traub RD, Schmitz D, Jefferys JGR. Electrical coupling underlies high-frequency oscillations in the hippocampus in vitro. *Nature* 1998; 394:189-192.
45. Taylor CP, Dudek FE. Excitation of hippocampal pyramidal cells by an electric field. *J Neurophysiol* 1984; 52: 126-142.
46. Jagadeesh B, Gray CM, Ferster D. Visually evoked oscillations of membrane potential in cells of cat visual cortex. *Science* 1992; 257:552-554.
47. Berridge MJ. Inositol triphosphate and calcium signaling. *Nature* 1993; 361:315-325.
48. Heffernan M. The effect of variable microcurrents on EEG spectrum and pain control. *Can J Clin Med* 1997; 4: 4-11.
49. Bell GB, Marino AA, Chasson AL. Frequency-specific responses in the human brain caused by electromagnetic fields. *J Neurol Sci* 1994; 123:21-32.
50. Jefferys JGR. Influence of electric fields on the excitability of granule cells in guinea-pig hippocampal slices. *J Physiol* 1981; 319:143-152.
51. Bawin SM, Satmary RA, Jones WR, Adey WR, Zimmerman G. Extremely low frequency magnetic fields disrupt rhythmic slow activity in rat hippocampal slices. *Bioelectromagnetics* 1996; 17:388-395.
52. Jenrow KA, Zhang X, Renehan WB, Liboff AR. Weak ELF magnetic field effects on hippocampal rhythmic slow activity. *Exp Neurol* 1998; 153:328-334.
53. Hasey G. Transcranial magnetic stimulation in the treatment of mood disorder: a review and comparison with electroconvulsive therapy. *Can J Psychiatry* 2001; 46:720-727.
54. Thomas JR, Schrot J, Liboff AR. Low-intensity magnetic fields alter operant behavior in rats. *Bioelectromagnetics* 1986; 7:349-357.
55. Lovely RH, Creim JA, Miller DL, Anderson LE. Behavior of rats in a radial arm maze during exposure to magnetic fields: evidence for effect of magnesium ion resonance. 15th Annual Meeting, Bioelectromagnetics Soc., Los Angeles, Abstract E-I-6, 1993.

56. Lyskov E, Chernyshev M, Makarova T, Vasilieava Yu, Michailov V, Sokolov G, Vishnevskiyi A. Behavioral effects of extremely low frequency (ELF) magnetic fields probably depend on the dc component. Proceedings of International Workshop of the European Bioelectromagnetics Association. Russian Academy of Sciences. Moscow Region, Puschino, Russia, 1995.
57. Liboff AR, Cherng S, Jenrow KA, Bull A. Calmodulin-dependent cyclic nucleotide phosphodiesterase activity is altered by 20 mT magnetostatic fields. *Bioelectromagnetics* 2003; 24:32-38.
58. Shuvalova LA, Ostrovskaja MV, Sosunov EA, Lednev VV. Effect of weak magnetic field in the parametric resonance mode on the rate of calmodulin-dependent phosphorylation of myosin in the solution. *Doklady Akademii Nauk SSSR (Reports of the Academy of Science of the USSR)* 1991; 317:227-230 (in Russian).
59. Liboff AR, Jenrow KA. Physical mechanisms in neuroelectromagnetic therapies. *Neurorehabilitation* 2002; 17: 9-22.
60. Hallett M. Transcranial magnetic stimulation and the human brain. *Nature* 2000; 406:147-150.
61. Mannheimer J, Lampe G. *Clinical Transcutaneous Electrical Nerve Stimulation*. Philadelphia: F A Davis, 1984.
62. Schwartz RG. Electric sympathetic block: current theoretical concepts and clinical results. *J Back Musculoskel Rehab* 1998; 10:31-46.
63. *Magnetic Fields, Environmental Health Criteria 69*. Geneva: World Health Organization, 1987: 20-21.
64. Fleischmann A, Sternheim A, Etgen AM, Li C, Grisaru N, Belmaker RH. Transcranial magnetic stimulation down-regulates beta-adrenoreceptors in rat cortex. *J Neural Transm* 1996; 103:1356-1361.
65. McGarvey KA, Zis AP, Brown EE, Nomikos GG, Fibiger HC. ECS-induced dopamine release: effects of electrode placement, anticonvulsant treatment, and stimulus intensity. *Biol Psychiatry* 1993; 34:152-157.
66. Jennum P, Winkel H, Fuglsang-Frederiksen A. Repetitive

- magnetic stimulation and motor evoked potentials. *Electroencephalogr Clin Neurophysiol* 1995; 97:96-101.
67. Levkovitz Y, Marx J, Grisaru N, Segal M. Long-term effects of transcranial magnetic stimulation on hippocampal reactivity to afferent stimulation. *J Neurosci* 1999; 19:3198-3203.
68. Kole MH, Fuchs E, Zeimann U, Paulus W, Ebert U. Changes in 5-HT_{1A} and NMDA binding sites by a single rapid transcranial magnetic stimulation procedure in rats. *Brain Res* 1999; 826:309-312.
69. George MS, Nahas Z, Bohning DE, Kozel FA, Anderson FA, Chae J-H, Lomarev M, Denslow S, Li X, Mu C. Vagus nerve stimulation therapy. *Neurology* 2002; 59:S56-S61.
70. Kiss ZHT, Mooney DM, Renaud L, Hu B. Neuronal response to local electrical stimulation in rat thalamus: physiological implications for mechanisms of deep brain stimulation. *Neuroscience* 2002; 113:137-143.
71. Benazzouz A, Hallett M. Mechanism of action of deep brain stimulation. *Neurology* 2000; 55:S13-S16.
72. Chen R, Classen J, Gerloff C, Celnik P, Wassermann EM, Hallett M, Cohen LG. Depression of motor cortex excitability by low-frequency transcranial magnetic stimulation. *Neurology* 1997; 48:1398-1403.
73. Lomarev M, Denslow S, Nahas Z, Chae JH, George MS, Bohning DE. Vagus nerve stimulation (VNS) synchronized BOLD fMRI suggests that VNS in depressed adults has frequency dependent effects. *J Psychiatric Res* 2002; 36:219-227.
74. Kirschvink JL, Kobayashi-Kirschvink A, Diaz-Ricci JC, Kirschvink JL. Magnetite in human tissues: a mechanism for the biological effects of weak ELF magnetic fields. *Bioelectromagnetics Suppl* 1992; 1:101-113.
75. Lednev VV. Possible mechanism of the effect of weak magnetic fields on biosystems. *Bioelectromagnetics* 1991; 12:71-75.
76. Bell GB, Marino AA, Chesson AL, Struve F. Electrical states in the rabbit brain can be altered by light and electromagnetic fields. *Brain Res* 1992; 570:307-315.
77. Adey WR. Fields, cell membrane amplification, and cancer promotion. In: Wilson BW, Stevens RG, Anderson LE,

eds. Extremely Low Frequency Electromagnetic Fields: The Question of Cancer. Columbus, OH: Battelle Press, 1990.

78. Nunez PL. The Electric Fields of the Brain: The Neurophysics of EEG. New York: Oxford University Press, 1981.

79. Collins JJ, Chow CC, Imhoff TT. Stochastic resonance without tuning. *Nature* 1995; 376:236- 238.

80. Jefferys JGR. Nonsynaptic modulation of neuronal activity in the brain: electric currents and extracellular ions. *Physiol Rev* 1995; 75:689-723.

81. Libet B, Gerard RW. Control of the potential rhythm of the isolated frog brain. *J Neurophysiol* 1939; 2:153-169.

82. Magora F, Beller A, Aladjemoff L, Magora A, Tannenebaum J. Observations on electrically induced sleep in man. *Brit J Anesthesiol* 1965; 37:480-491.

15 Is there an Electrical Circulatory System that Communicates Internally and Externally?

1. Nordenström BEW. *Biologically Closed Electric Circuits, Clinical, Experimental and Theoretical Evidence for an Additional Circulatory System*. Stockholm: Nordic Medical Publications, 1983.
2. Harvey W. *Excercitatio Anatomica de Motu Cordis et Sanguinis in Animalibus*. Frankfurt: Anatomical Treatise on the Movement of the Heart and Blood in Animals, 1628.
3. Nordenström BEW. *Exploring BCEC-Systems (Biologically Closed Electric Circuits)*. Stockholm: Nordic Medical Publications, 1998.
4. Rosch PJ. Stress and cancer: a disease of adaptation? In: Taché J, Selye H, Day SB, eds. *Cancer, Stress, and Death*. New York: Plenum Publishing, 1979:187-212.
5. Selye H. Foreword. In: Taché J, Selye H, Day SB, eds. *Cancer, Stress, and Death*. New York: Plenum Publishing, 1979:xii.
6. Rosch PJ. Some thoughts on the endemiology of cancer. In: Day SB, ed. *Cancer, Stress, and Death*. 2d ed. New York: Plenum Publishing, 1986:293-302.
7. Ikemi Y, Nagata K. The introduction of occidental and oriental approaches in biopsychosocial medicine. In: Day SB, ed. *Cancer, Stress, and Death*. 2d ed. New York: Plenum Publishing, 1986:303-312.
8. Ikemi Y, Nakagawa T, Sugita M. Psychosomatic considerations on cancer patients who have made a narrow escape from death. *Dynam Psychiatry* 1975; 31:77-92.
9. Cole WH. Spontaneous regression of cancer. The metabolic triumph of the host? *Ann NY Acad Sci* 1974; 230: 111-113.
10. Rosch PJ. Future directions in psychoneuroimmunology: psychoelectroneuroimmunology? In: Leonard B, Miller K, eds. *Stress, The Immune System and Psychiatry*. Chichester: John Wiley and Sons, 1994:207-232.
11. Ader R. Foreword. In: Leonard B, Miller K, eds. *Stress, The Immune System And Psychiatry*. Chichester: John Wiley and Sons, 1994:ix-xii.

12. Schweitzer A. Forest Hospital of Lamborene. Oxford: Holt, 1931.
13. Stefansson V. Cancer: Disease of Civilization? New York: Hill and Wang, 1960.
14. Hay WH. Cancer: a disease of either election or ignorance. *Am J Cancer* 1927; 6:410-422.
15. Berglas A. Cancer: Its Nature, Cause and Cure. Paris: Pasteur Institute, 1957.
16. Statistical researches on cancer. *South Med Sur J* 1846; 4:273-274. Cited in Le Cont.
17. Rosch PJ. Stress and cancer: Disorders of communication, control and civilization. In: Cooper CL, ed. *Handbook of Stress, Medicine, and Health*. Boca Raton: CRC Press, 1996:27-50.
18. Bernard C. Introduction to the Study of Experimental Medicine. Paris: Flammarion, 1945. Original edition 1865.
19. Cannon WB. *The Wisdom of the Body*. New York: Norton, 1932.
20. Selye H. *Stress Without Distress*. New York: J.B.Lippincott, 1974:65.
21. Rosch PJ. Stress and electromedicine. *Med Electron* 1989; 19:124-128.
22. Yamasaki H. Abberant expression and function of gap junctions during carcinogenesis. In: Butterworth BE, Slaga TJ, eds. *Nongenotoxic Mechanisms in Carcinogenesis*. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1987:279-316.
23. Kobasa S, Maddi S, Kahns S. Hardiness and health: a prospective study. *J Personality Soc Psychol* 1982; 42: 168-177.
24. Achterberg J, Matthews S, Simonton OC. Psychology of the exceptional cancer patient-a description of patients who outlive predicted life expectancies. *Psychother Theory Res Practice* 1976; 9:1-21.
25. Kune A, Kune S, Watson LF. Perceived religiousness is protective for colorectal cancer; data from the Melbourne Colorectal Cancer Study. *J R Soc Med* 1993; 86:645-647.

26. Meares A. A form of intensive meditation associated with the regression of cancer. *Am J Clin Hypn* 1982; 25: 114-121.
27. Meares A. Regression of osteogenic sarcoma metastases associated with intensive meditation. *Med J Aust* 1978; 2:433-434.
28. Meares A. Remission of massive metastasis from undifferentiated carcinoma of the lung associated with intensive meditation. *J Am Soc Psychosom Dent Med* 1980; 27:40-41.
29. Meares A. Regression of recurrence of carcinoma of the breast at mastectomy site associated with intensive meditation. *Aust Fam Physician* 1981; 10:218-219.
30. Meares A. Regression of cancer after intensive meditation. *Med J Aust* 1976; 2:184.
31. Meares A. The quality of meditation effective in the regression of cancer. *J Am Soc Psychosom Dent Med* 1978; 25:129-132.
32. Meares A. Vivid visualization and dim visual awareness in the regression of cancer in meditation. *J Am Soc Psychosom Dent Med* 1978; 25:85-88.
33. Bolen JS. Meditation and psychotherapy in the treatment of cancer. *Psychic* 1973; 4:19-22.
34. Achterberg J, Lawlis GF. *Imagery of Cancer*. Champaign, IL: Institute for Personality and Ability Testing, 1978.
35. Clawson TA, Swade R. The hypnotic control of blood flow and pain: the cure of warts and the potential for the use of hypnosis in the treatment of cancer. *Am J Clin Hypn* 1975; 17:160-169.
36. Hall HR. Hypnosis and the immune system: a review with implications for cancer and the psychology of healing. *Am J Clin Hypn* 1982; 25:92-103.
37. Hedge AR. Hypnosis in cancer. *Br J Med Hypn* 1960; 12:2-5.
38. Funch DP, Marshall J. The role of stress, social support and age in survival from breast cancer. *J Psychosom Res* 1983; 27:177-183.

39. Funch DP, Mettlin C. The role of support in relation to recovery from breast surgery. *Social Science and Medicine* 1982; 16:91-98.
40. Eli K, Nishimoto R, Mediansky L, Mantell J, Hamovitch M. Social relations, social support and survival among patients with cancer. *J Psychosom Res* 1992; 36:531-541.
41. Bagenal FS, Easton DF, Harris E, Chilvers CED, McElwain TJ. Survival of patients with breast cancer attending Bristol cancer help centre. *Lancet* 1990; 336:606-610.
42. Spiegel D, Bloom JR, Yalom ID. Group support for patients with metastatic cancer: a randomized prospective outcome study. *Arch Gen Psychiatry* 1981; 38:527-533.
43. Spiegel D, Bloom JR, Kraemer HC, Gottheil E. Effects of psychosocial treatment on survival of patients with metastatic breast cancer. *Lancet* 1989; 2:888-891.
44. Ogilvie H. The human heritage. *Lancet* 1957; ii:42.
45. Gordon-Taylor G. The incomputable factors in cancer prognosis. *BMJ* 1959; 1, 455.
46. Pendergrass EP. Host resistance and other intangibles in the treatment of cancer. *Am J Roentg and Rad Ther* 1961; 85:891-898.
47. Miller TR. Psychophysiological aspects of cancer. *Cancer* 1977; 39:413-422.
48. Levy SM, Herberman RB, Whiteside T. Perceived social support and tumor estrogen/progesterone receptor status as predictors of natural killer cell activity in breast cancer patients. *Psychosom Med* 1990; 52:73-85.
49. Rosch PJ. Stress: cause or cure of cancer. In: Goldberg J, ed. *Psychotherapeutic Treatment of Cancer Patients*. New York: Free Press, 1981:39-57.
50. Rosch PJ. Afterword. In: Nordenström BEW, ed. *Exploring BCEC-Systems (Biologically Closed Electric Circuits)*. Stockholm: Nordic Medical Publications, 1998:98-112.
51. Green EE, Parks PA, Guer BA, Fahrion SL, Coyne L. Anomalous electrostatic phenomena in exceptional subjects. *Subtle Energies* 1991; 2:69-94.

52. Muehsam DJ, Markov MS, Muehsam PA, Pilla A, Ronger S, Wu I. Static magnetic field modulation of myosin phosphorylation: preliminary experiment. *Subtle Energies* 1993; 4:1- 16.
53. Muehsam DJ, Markov MS, Muehsam PA, Pilla A, Ronger S, Wu I. Effects of Qigong on cell-free myosin phosphorylation: preliminary experiments. *Subtle Energies* 1994; 5:93-108.
54. Wu W, Bandilla A, Ciccone S, Yang J. Effects of Qigong on late stage complex regional pain syndrome. *Altern Ther Health Med* 1999; 5:45-54.
55. Keller E. Effects of therapeutic touch on tension headache pain. *Nursing Res* 1986; 35:101-105.
56. Redner R, Briner B, Snellman L. Effects of a bioenergy healing technique on chronic pain. *Subtle Energies* 1991; 2:43-68.
57. Wirth DP. The effect of non-contact therapeutic touch on the healing rate of full thickness dermal wounds. *Subtle Energies* 1990; 1:1-20.
58. Krieger D. The response of in vivo human hemoglobin to an active healing therapy by direct laying on of hands. *Human Dimensions* 1972; 1:12-15.
59. Krieger D. Healing by the laying on of hands as a facilitator of bio-energetic change: the response of in vivo human hemoglobin. *Psychoenergetic Systems* 1974; 1:4121-4129.
60. Rein G, McCraty R. Structural changes in water and DNA associated with new physiologically measurable states. *J Sci Explor* 1994; 8:438-439.
61. Quinn J. Therapeutic touch as an energy exchange: testing the theory. *Adv Nursing Sci* 1984; 4:42-49.
62. Stroink G. Principles of Cardiomagnetism. In: Williamson SJ, ed. *Advances in Biomagnetism*. New York: Plenum Press, 1999:47-57.
63. McCraty R. The electricity of touch: Detection and measurement of cardiac energy exchange between people. In: Pribram K, ed. *Brain and Values: Is a Biological Science of Values Possible*. Mahwah, NJ: Lawrence Erlbaum Associates, Inc., 1998:359-379.

64. Russek L, Schwartz G. Interpersonal heart-brain registration and the perception of parental love: a 42 year followup of the Harvard Mastery of Stress Study. *Subtle Energies* 1994; 5:195- 208.
65. Russek L, Schwartz G. Energy cardiology: a dynamical energy systems approach for integrating conventional and alternative medicine. *Advances* 1996; 12:4-24.
66. Rosch PJ. Stress and subtle energy medicine. *Stress Medicine* 1994; 10:1-3.
67. Lawrence R, Rosch PJ, Plowden J. *Magnet Therapy*. Rocklin, CA: Prima Press, 1998.
68. Darras JC. Isotopic and cytologic assays in acupuncture. *Energy Fields in Medicine: A Study of Device Technology Based on Acupuncture Meridians and Chi Energy*. Kalamazoo, MI: The John E.Fetzer Foundation, 1989:45-65.
69. Boorstin DJ. *The Discoverers*. New York: Random House, 1983:365.

16 Magnetic and Electromagnetic Field Therapy: Basic Principles of Application for Pain Relief

1. Wartenberg D, Savitz DA. Evaluating exposure cutpoint bias in epidemiological studies of electric and magnetic fields. *Bioelectromagnetics* 1993; 14:237-245.
2. Deno DW, Carpenter DO. Sources and characteristics of electric and magnetic fields in the environment. In: Carpenter DO, Ayrapetyan S, eds. *Biological Effects of Electric and Magnetic Fields*. Vol. 1. San Diego: Academic Press, 1994:7-52.
3. Werheimer N, Savitz DA, Leper E. Childhood cancer in relation to indicators of magnetic fields from ground current sources. *Bioelectromagnetics* 1995; 16:86-96.
4. Rubik B, Becker RO, Flower RG, Hazlewood CF, Liboff AR, Walleczek J. *Bioelectromagnetics. Applications in Medicine. Alternative Medicine: Expanding Medical Horizons*. Washington DC: US Government Printing Office, 1996:45-65.
5. Markov MS, Colbert A. Magnetic and electromagnetic field therapy. *J Back Musculoskeletal Rehab* 2000; 14: 1-13.
6. Markov M, Kleinkort J. Magnetic and electromagnetic field—new frontier in biology and medicine. In: Van Paten JJ, ed. *Challenges and Opportunities for a New Millennium*. Fayetteville: University of Arkansas Press, 1998:184-203.
7. Lawrence R, Rosch PJ, Plowden J. *Magnet Therapy*. Rocklin, CA: Prima Publishing, 1998:241.
8. Todorov N. *Magnetotherapy*. Sofia: Meditzina i Physcultura Publishing House, 1982:106.
9. Bassett CAL, Pawluk RJ, Pilla AA. Acceleration of fracture repair by electromagnetic fields (a surgically noninvasive method). *Ann NY Acad Sci* 1974; 238:242-247.
10. Bassett CAL. Pulsing electromagnetic fields: a new approach to surgical problems. In: Buchwald H, Varco RL, eds. *Metabolic Surgery*. New York: Grune and Stratton, 1978:255.
11. Markov MS, Todorov NG. Electromagnetic field stimulation of some physiological processes. *Studia Biophysica* 1984; 99:151-156.

12. Detlavs I, ed. Electromagnetic Therapy in Traumas and Diseases of The Support-motor Apparatus. Riga RMI, 1987:198.
13. Bassett CAL. Fundamental and practical aspects of therapeutic uses of pulsed electromagnetic fields (PEMFs). Critical Review of Biomedical Engineering 1989; 17:451-529.
14. O'Connor ME, Bental RHC, Monaham JC, eds. Emerging Electromagnetic Medicine. New York: Springer Verlag, 1990.
15. Brighton CT, Pollack SR, eds. Electromagnetics in Medicine and Biology. San Francisco: San Francisco Press, 1991:365.
16. Polk C, Postow E, eds. Handbook of Biological Effects of Electromagnetic Fields. Boca Raton, Fl: CRC Press, 1986:618.
17. Blank M, ed. Electromagnetic fields. Biological Interactions and Mechanisms. Washington DC: American Chemical Society, 1975:497.
18. Markov MS. Electric current and electromagnetic field effects on soft tissues. Wounds 1995; 7:94-110.
19. Bassett CAL. Therapeutic Uses of electric and magnetic fields in orthopedics. In: Karpenter D, Ayrapetyan S, eds. Biological Effects of Electric and Magnetic Fields. San Diego: Academic Press, 1994:13-48.
20. Markov MS, Pilla AA. Electromagnetic field stimulation of soft tissues. Wounds 1995; 7:143- 151.
21. Dayton PD, Palladino SJ. Electrical stimulation of cutaneous ulcerations. J Am Podiatr Med Assoc 1989; 79: 318-321.
22. Pilla AA. State of the art in electromagnetic therapeutics. In: Blank M, ed. Electricity and Magnetism in Biology and Medicine. San Francisco: San Francisco Press, 1993:17-22.
23. Jerabek J. An overview of present research in magnetotherapy. In: Coghil R, ed. Proceedings of First World Congress on Magnetotherapy. Pontypool: Lower Race, 1994:5-78.
24. Bental RH, Cobban RM. Post operative use of radiofrequency emitting spectacles for control of edema and

bruising following blepharoplasty. Proc Seventh BEMS Meeting, San Francisco CA, 1985:H-3.

25. Bental RHC. Electromagnetic energy: a historical therapeutic perspective. In: O'Connor ME, Bental RHC, Monahan JC, eds. *Emerging Electromagnetic Medicine*. New York: Springer Verlag, 1990:1-17.

26. Vodovnik L, Karba R. Treatment of chronic wounds by means of electric and electromagnetic fields. *Med Biol Eng Comput* 1992; 30:257-266.

27. Detlavs I, Dombrovska I, Klavinsh I, Turauska A, Shkirmante B, Slutskii L. Experimental study of the effect of electromagnetic fields in early stage of wound healing. *Bioelectrochem Bioenergetics* 1994; 35:13-17.

28. Bassett CAL. Bioelectromagnetics in the service of medicine. *Bioelectromagnetics* 1992; 13:7-18.

29. Bassett CAL. Bioelectromagnetics in the service of medicine. In: Blank M, ed. *Electromagnetic Fields. Biological Interactions and Mechanisms*. Washington DC: Amer Chem Soc DC, 1995:261-276.

30. Jerabek J, Pawluk W. *Magnetic Therapy in Eastern Europe: A Review of 30 Years of Research*. ISBN 0-9664227-0-8

31. Markov MS. Magnetic and electromagnetic fields—a new frontier in clinical biology and medicine. In: Kostarakis P, ed. *Proc Millennium International Workshop on Biological Effects of Electromagnetic Fields*. Crete, Greece, 2000:365-372, ISBN 960-86733-0-5.

32. Markov M. Biological effects of extremely low frequency magnetic fields. In: Ueno S, ed. *Biomagnetic Stimulation*. New York: Plenum Press, 1994:91-103.

33. Markov MS. Biophysical aspects of the application of electromagnetic fields in orthopedics and traumatology. In: Detlav I, ed. *Electromagnetic Therapy in traumas and diseases of the support-motor apparatus*. Riga: Zinatie, 1987:76-86.

34. Polk C. Therapeutic application of low frequency electric and magnetic fields. In: Lin JC, ed. *Advances in Electromagnetic Fields in Living Systems*. New York: Plenum Press, 1994:129- 154.

35. Dunn MG, Doillon CH, Berg RA. Wound healing using a collagen matrix: effect of DC electrical stimulation. *J Biomed Mater Res* 1988; 22A: 191-206.
36. Zukov BN, Lasarovich VG. *Magnetotherapy in Angiology*. Zdorovie: Kiev, 1989:111.
37. Seaborne D, Quirion-deGirardi C, Rousseau M, Rivest M, Lambert J. The treatment of pressure sores using pulsed electromagnetic energy (PEME). *Physiotherapy Canada* 1996; 48:131-137.
38. Valbona C, Hazlewood C, Jurida G. Response of pain to static magnetic fields in postpolio patients: a double blind pilot study. *Arch Phys Med Rehab* 1997; 78:1200-1203.
39. Weintraub M. Chronic submaximal magnetic stimulation in peripheral neuropathy: is there a beneficial therapeutic relationship. *Am J Pain Management* 1998; 8:12-16.
40. Man D, Man B, Plosker H. The influence of permanent magnetic field therapy on wound healing in suction lipectomy patients: a double-blind study. *Plastic and Reconstructive Surgery* 1999; 104:2261-2266.
41. Colbert AP, Markov MS, Banerji M, Pilla AA. Magnetic mattress pad use in patients with fibromialgia: a randomized double blind trial. *J Back Musculoskeletal Rehab* 1999; 13:19-31.
42. Collacott EA, Zimmerman JT, White DW, Rindole JP. Bipolar permanent magnets for the treatment of chronic pain. A pilot study. *JAMA* 2000; 283:1322-1325.
43. Valbona C, Richards T. Evolution of magnetic therapy from alternative to traditional medicine. *Phys Med Rehab Clin NA* 1999; 10:729-754.
44. Pilla AA. State of the art in electromagnetic therapeutics. In: Blank M, ed. *Electricity and Magnetism in Biology and Medicine*. San Francisco: San Francisco Press, 1993:17-22.
45. Pilla AA. State of the art in electromagnetic therapeutics: soft tissue applications. In: Bersani F, ed. *Electricity and Magnetism in Biology and Medicine*. New York: Kluwer Academic/Plenum Publishing House, 1999: 871-874.
46. Battisti E, Fortunato M, Giananneshi F, Rigato M.

- Efficacy of the Magnetotherapy in idiopathic carpal tunnel syndrome. In: Suminic D, ed. Proc IV EBEA Congress, Zagreb, 1998:34-35.
47. Binder A, Parr G, Hazelman B. Pulsed electromagnetic field therapy of persistent rotator cuff tendinitis. *Lancet* March 1984; 695-698.
48. Folley-Nolan D, Barry C, Coughan RJ, O'Connor P, Roden D. Pulsed high frequency (27 MHz) electromagnetic therapy for persistent neck pain. *Orthopedics* 1990; 13(4):445-451.
49. Folley-Nolan D, Moore K, Codd M, Barry C, Coughan RJ, O'Connor P. Low energy high frequency pulsed electromagnetic therapy for acute whiplash injuries. *Scand J Rehab Med* 1992; 24:51-59.
50. Leclaire R, Bourgoin J. Electromagnetic treatment of shoulder periarthritis: a randomized controlled trial of the efficiency and tolerance of magnetotherapy. *Arch Phys Med Rehab* 1991; 72:284-287.
51. Trock DH, Bollet AJ, Dyer RH, Fielding LP, Miner WK, Markoll R. A double-blind trial of the clinical effects of pulsed electromagnetic fields in osteoarthritis. *J Rheumatol* 1993; 20:456- 460.
52. Trock DH, Bollet AJ, Markoll R. The effect of pulsed electromagnetic fields in the treatment of osteoarthritis of the knee and cervical spine. *J Rheumatol* 1994; 21:1903-1911.
53. Owen RD. MYC mRNA abundance is unchanged in subcultures of HL60 cells exposed to power-line frequency magnetic fields. *Radiat Res* 1998; 150:23-30.
54. World Health Organization (WHO). Magnetic fields. United Nations Environmental Programme, World Health Organization and The International Radiation Protection Association- Environmental Health Criteria 69, 1987: 25-33, 119-127.
55. World Health Organization (WHO). Magnetic fields health and safety guide. United Nations Environmental Programme, World Health Organization and The International Radiation Protection Association-Health and Safety Guide #27, 1987:7-24
56. Siskin BF, Walker J. Therapeutic aspects of electromagnetic fields for soft tissue healing. In: Blank

M, ed. *Electromagnetic Fields: Biological Interactions and Mechanisms*. Adv Chem Vol. 250. Washington, DC: American Chemical Society, 1995:277-286.

57. Nordenstrom BE. *Biologically Closed Electrical Circuits: Clinical, Experimental and Theoretical Evidence for an Additional Circulatory System*. Stockholm: Nordic Medical Publications, 1983:358.

58. Bourguignon GL, Bourguignon LYW. Electrical stimulation of protein and DNA synthesis. *Med Rehab* 1989; 70: 624-627.

59. Rodeman HP, Bayreuther K, Pfleiderer G. The differentiation of normal and transformed human fibroblasts in vitro is influenced by electromagnetic fields. *Exp Cell Res* 1989; 182:610- 621.

60. Karba R, Vodovnik L, Jercinovic A, Trontelj K, Benko H, Šavrin R. Promotion of wound healing by electrical stimulation. *Biomedizinische Technik* 1995; 40:20-24.

61. Hudlicka O, Brown M, Cotter M. The effect of long-term stimulation of fast muscle of their blood flow, metabolism, and ability to withstand fatigue. *Pflugers Arch* 1977; 369:141-149.

62. Markov M, Pilla AA. Modulation of cell-free myosin light chain phosphorylation with weak low frequency and static magnetic fields. In: Frey AH, ed. *On the Nature of Electromagnetic Field Interactions with Biological Systems*. Austin TX: R.G.Landes Co., 1994:127-141.

63. Polk C. Electric and magnetic fields for bone and soft tissue repair. In: Polk C, Postow E, eds. *Handbook of Biological Effects of Electromagnetic Fields*. Boca Raton, FL: CRC Press, 1996:231-246.

64. Ginsberg AJ. Ultrashort radio waves as a therapeutic agent. *Med Record* 1934; 19:1-8.

65. Wilson DH. Comparison of short-wave diathermy and pulsed electromagnetic energy in treatment of soft tissue injuries. *Physiother* 1974; 80:309-310.

66. Barclay V, Collier RJ, Jones A. Treatment of various hand injuries by pulsed electromagnetic energy (Diapulse). *Physiother* 1983; 69:186-188.

67. Ross Adey W. Nonlinear electrodynamics in cell membrane transductive coupling. In: Aloia RC, Curtain CC, Gordon LM,

eds. Membrane Transport and Information Storage. Vol. 4 New York: Wiley-Liss, 1990:1-27.

68. Tenforde TS. Biological interactions of extremely low frequency electromagnetic fields. In: Ueno S, ed. Biological Effects of Magnetic and Electromagnetic Fields. New York: Plenum Press, 1996:23-35.

69. Blank M. Electric and magnetic field signal transduction in the membrane Na⁺ -K⁺ adenosinetriphosphatase. In: Blank M, ed. Electromagnetic Field: Biological Interactions and Mechanisms. Washington DC: Amer Chem Soc, 1995:339-348.

70. Bawin SM, Adey WR. Sensitivity of calcium binding in cerebral tissue to weak environmental electric fields oscillating at low frequency. Proc Natl Acad Sci USA 1976; 73:1999-2003.

71. Markov MS, Todorov SI, Ratcheva MR. Biomagnetic effects of the constant magnetic field action on water and physiological activity. In: Jensen K, Vassileva Yu, eds. Physical Bases of Biological Information Transfer. New York: Plenum Press, 1975:441-445.

17 Deep Brain Stimulation for Parkinson's Disease and Movement Disorders

1. Lang AE, Lozano AM. Parkinson's disease. First of two parts. *N Engl J Med* 1998; 339(15): 1044-1053.
2. Lang AE, Lozano AM. Parkinson's disease. Second of two parts. *N Engl J Med* 1998; 339(16): 1130-1143.
3. Meyers R. The modification of alternating tremor, rigidity and festination by surgery of the basal ganglia. *Res Publ Assoc Nerv Ment Dis* 1941; 21:602.
4. Meyers R. A surgical procedure for the alleviation of postencephalitic tremor, with notes on the physiology of the premotor fires. *Arch Neurol Psychiatry* 1940; 44:445-459.
5. Cooper IS. Ligation of the anterior choroidal artery for involuntary movements of parkinsonism. *Psychiatr Q* 1953; 27:317-319.
6. Hariz M. Complications of movement disorder surgery and how to avoid them. In: Lozano A, ed. *Movement disorder surgery*. Karger: Basel, 2000:256-265.
7. Pahapill PA, Levy R, Dostrovsky JO, et al. Tremor arrest with thalamic microinjections of muscimol in patients with essential tremor. *Ann Neurol* 1999; 46(2):249-252.
8. Benabid A. Subthalamic nucleus deep brain stimulation. In: Lozano A, ed. *Movement Disorder Surgery*. Karger: Basel, 2000:196-226.
9. Pollak P, Fraix V, Krack P, et al. Treatment results: Parkinson's disease. *Mov Disord* 2002; 17(suppl 3):S75-S83.
10. Benabid AL, Koukssie A, Benazzouz A, et al. Deep brain stimulation of the corpus luyisi (subthalamic nucleus) and other targets in Parkinson's disease. Extension to new indications such as dystonia and epilepsy. *J Neurol* 2001; 248(suppl 3):Iii37-47.
11. Pahwa R, Lyons KE, Wilkinson SB, et al. Comparison of thalamotomy to deep brain stimulation of the thalamus in essential tremor. *Mov Disord* 2001; 16(1): 140-143.
12. Lozano AM. Vim thalamic stimulation for tremor. *Arch Med Res* 2000; 31(3):266-269.

13. Lenz FA, Tasker RR, Kwan HC, et al. Single unit analysis of the human ventral thalamic nuclear group: correlation of thalamic "tremor cells" with the 3-6 Hz component of parkinsonian tremor. *J Neurosci* 1988; 8(3): 754-764.
14. Schuurman PR, Bosch DA, Bossuyt PM, et al. A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. *N Engl J Med* 2000; 342(7):461-468.
15. Tasker RR. Deep brain stimulation and thalamotomy for tremor compared. *Acta Neurochir Suppl (Wien)* 1997; 68:49-53.
16. Lozano A. Thalamic deep brain stimulation for the control of tremor. In: Rengachary S, Wilkins R, eds. *Neurosurgical Operative Atlas*. Chicago: American Association of Neurological Surgeons, 1998:125-133.
17. Benabid AL, Pollak P, Gao D, et al. Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders. *J Neurosurg* 1996; 84(2):203-214.
18. Koller W, Pahwa R, Busenbark K, et al. High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. *Ann Neurol* 1997; 42(3):292-299.
19. Shahzadi S, Tasker RR, Lozano A. Thalamotomy for essential and cerebellar tremor. *Stereotact Funct Neurosurg* 1995; 65(1-4):11-17.
20. Bakay RAE. Rational basis for pallidotomy in the treatment of parkinson's disease. In: Lozano AM, ed. *Movement Disorder Surgery*. Karger: Basel, 2000:118-131.
21. Vercueil L, Krack P, Pollak P. Results of deep brain stimulation for dystonia: a critical reappraisal. *Mov Disord* 2002; 17(suppl 3):S89-S93.
22. Gross RE, Lombardi WJ, Lang AE, et al. Relationship of lesion location to clinical outcome following microelectrode-guided pallidotomy for Parkinson's disease. *Brain* 1999; 122(pt 3):405- 416.
23. Lozano A, Hutchinson W, Kiss Z, Tasker R, Davis K, Dostrovsky J. Methods for microelectrode-guided posteroventral pallidotomy. *J Neurosurg* 1996; 84(2):

194-202.

24. Bejjani B, Damier P, Arnulf I, et al. Pallidal stimulation for Parkinson's disease. Two targets? *Neurology* 1997; 49(6): 1564-1569.

25. Krack P, Pollak P, Limousin P, et al. Opposite motor effects of pallidal stimulation in Parkinson's disease. *Ann Neurol* 1998; 43(2): 180-192.

26. Kumar R. Pallidotomy and deep brain stimulation of the pallidum and subthalamic nucleus in advanced Parkinson's disease. *Mov Disord* 1998; 13(suppl 1):73-82.

27. Kirschman DL, Milligan B, Wilkinson S, et al. Pallidotomy microelectrode targeting: neurophysiology-based target refinement. *Neurosurgery* 2000; 46(3):613-622.

28. Tronnier VM, Fogel W. Pallidal stimulation for generalized dystonia. Report of three cases. *J Neurosurg* 2000; 92 (3):453-456.

29. Kumar R, Dager A, Hutchinson WD, Lang AE, Lozano AM. Globus pallidus deep brain stimulation for generalized dystonia: clinical and PET investigation. *Neurology* 1999; 53(4):871-874.

30. Volkmann J, Benecke R. Deep brain stimulation for dystonia: patient selection and evaluation. *Mov Disord* 2002; 17(suppl 3):S112-S115.

31. Lozano AM. Deep brain stimulation for parkinson's disease. *Parkinsonism & Related Disorders* 2001; 7: 199-203.

32. Thobois S, Mertens P, Guenot M, et al. Subthalamic nucleus stimulation in Parkinson's disease: clinical evaluation of 18 patients. *J Neurol* 2002; 249(5):529-534.

33. Simuni T, Jaggi JL, Mulholland H, et al. Bilateral stimulation of the subthalamic nucleus in patients with Parkinson disease: a study of efficacy and safety. *J Neurosurg* 2002; 96(4):666- 672.

34. Voges J, Volkmann J, Allert N, et al. Bilateral high-frequency stimulation in the subthalamic nucleus for the treatment of Parkinson disease: correlation of therapeutic effect with anatomical electrode position. *J Neurosurg* 2002; 96(2):269-279.

35. Yokoyama T, Sugiyama K, Nishizawa S, et al. Subthalamic

nucleus stimulation for gait disturbance in Parkinson's disease. *Neurosurgery* 1999; 45(1):41-47.

36. Burchiel KJ, Anderson VC, Favre J, Hammerstand JP. Comparison of pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson's disease: results of a randomized, blinded pilot study. *Neurosurgery* 1999; 45(6):1375-1382.

37. Krack P, Pollak P, Limousin P, et al. Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease. *Brain* 1998; 121(pt 3):451-457.

38. Kumar R, Lozano AM, Kim YJ, et al. Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. *Neurology* 1998; 51(3):850-855.

39. Vingerhoets FJG, Villemure JG, Temperli P, Pollo C, Pralong E, Ghika J. Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up. *Neurology* 2002; 58(3):396-401.

40. Volkmann J, Allert N, Voges J, Weiss PH, Freund HJ, Sturm V. Safety and efficacy of pallidal or subthalamic nucleus stimulation in advanced PD. *Neurology* 2001; 56(4):548-551.

41. Limousin P, Krack P, Pollak P, et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. *N Engl J Med* 1998; 339(16):1105-1111.

42. Houeto JL, Damier P, Bejjani PB, et al. Subthalamic stimulation in Parkinson disease: a multidisciplinary approach. *Arch Neurol* 2000; 57(4):461-465.

43. Molinuevo JL, Valldeoriola F, Tolosa E, et al. Levodopa withdrawal after bilateral subthalamic nucleus stimulation in advanced Parkinson disease. *Arch Neurol* 2000; 57(7):983-988.

44. Fraix V, Pollak P, Van Blercom N, et al. Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson's disease. *Neurology* 2000; 55(12):1921-1923.

45. Rezaei A, Hutchinson W, Lozano A. Chronic subthalamic nucleus stimulation for parkinson's disease. In: Rengachary S, Wilkins R, eds. *Neurosurgical Operative Atlas*. The American Association of Neurological Surgeons: Chicago,

1999:195-207.

46. Benabid A, et al. Subthalamic nucleus deep brain stimulation. In: Lozano A, ed. Movement Disorder Surgery. Karger: Basel, 2001:196-226.

47. Dostrovsky JO, Lozano AM. Mechanisms of deep brain stimulation. *Mov Disord* 2002; 17(suppl 3):S63-S68.

48. Benabid AL, Benazzous A, Pollak P. Mechanisms of deep brain stimulation. *Mov Disord* 2002; 17(suppl 3):S73-S74.

49. Vitek JL. Mechanisms of deep brain stimulation: excitation or inhibition. *Mov Disord* 2002; 17(suppl 3):S69-S72.

50. Ranck JB Jr. Which elements are excited in electrical stimulation of mammalian central nervous system: a review. *Brain Res* 1975; 98(3):417-440.

51. Ashby P, Paradiso G, Saint-Cyr JA, et al. Potentials recorded at the scalp by stimulation near the human subthalamic nucleus. *Clin Neurophysiol* 2001; 112(3):431-437.

52. Bastian J, Chacron MJ, Maler L. Receptive field organization determines pyramidal cell stimulus-encoding capability and spatial stimulus selectivity. *J Neurosci* 2002; 22(11):4577-4590.

53. Nambu A, Tokuno H, Takada M. Functional significance of the cortico-subthalamo-pallidal 'hyperdirect' pathway. *Neurosci Res* 2002; 43(2): 111-117.

54. Kaji R. Basal ganglia as a sensory gating device for motor control. *J Med Invest* 2001; 48(3-4): 142-146.

55. Beurrier C, Bioulac B, Audin J, Hammond C. High-frequency stimulation produces a transient blockade of voltage-gated currents in subthalamic neurons. *J Neurophysiol* 2001; 85(4):1351- 1356.

56. Bikson M, Lian J, Hahn PJ, Stacey WC, Sciortino C, Durand DM. Suppression of epileptiform activity by high frequency sinusoidal fields in rat hippocampal slices. *J Physiol* 2001; 531(pt 1): 181-191.

57. Lozano A, Dostrovsky J, Chen R, Ashby P. Deep brain stimulation for parkinson's disease: disrupting the disruption. *Lancet Neurol* 2002; 1(4):225-231.

58. Richardson AG, McIntyre CC, Grill WM. Modeling the effects of electric fields on nerve fibres: influence of the myelin sheath. *Med Biol Eng Comput* 2000; 38(4):438-446.
59. McIntyre CC, Grill WM. Modeling of thalamic DBS: cellular and network effects. In: *Neuromodulation 2002: Defining the Future*. France: Aix-Les-Bains, 2002.
60. McIntyre CC, Grill WM. Selective microstimulation of central nervous system neurons. *Ann Biomed Eng* 2000; 28(3):219-233.
61. McIntyre CC, Grill WM. Finite element analysis of the current-density and electric field generated by metal microelectrodes. *Ann Biomed Eng* 2001; 29(3):227-235.
62. McIntyre CC, Richardson AG, Grill WM. Modeling the excitability of mammalian nerve fibers: influence of afterpotentials on the recovery cycle. *J Neurophysiol* 2002; 87(2):995-1006.
63. Tasker RR, Vilela Filho O. Deep brain stimulation for neuropathic pain. *Stereotact Funct Neurosurg* 1995; 65(1-4): 122-124.
64. Price BH, Baral I, Cosgrove GR, et al. Improvement in severe self-mutilation following limbic leucotomy: a series of 5 consecutive cases. *J Clin Psychiatry* 2001; 62(12):925-932.
65. Feldman RP, Alterman RL, Goodrich JT. Contemporary psychosurgery and a look to the future. *J Neurosurg* 2001; 95(6):944-956.
66. Montoya A, Weiss AP, Price BH, et al. Magnetic resonance imaging-guided stereotactic limbic leukotomy for treatment of intractable psychiatric disease. *Neurosurgery* 2002; 50(5): 1043-1049.
67. Dougherty DD, et al. Prospective long-term follow-up of 44 patients who received cingulotomy for treatment-refractory obsessive-compulsive disorder. *Am J Psychiatry* 2002; 159(2):269-275.
68. Nuttin B, et al. Electrical stimulation in anterior limbs of internal capsules in patients with obsessive-compulsive disorder. *Lancet* 1999; 354(9189): 1526.

69. Garcia Larrea L, et al. Functional imaging and neurophysiological assessment of spinal and brain therapeutic modulation in humans. *Arch Med Res* 2000; 31(3):248-257.
70. Zamponi N, et al. Intermittent vagal nerve stimulation in paediatric patients: 1-year follow-up. *Childs Nerv Syst* 2002; 18(1-2):61-66.
71. Sucholeiki R, et al. fMRI in patients implanted with a vagal nerve stimulator. *Seizure* 2002; 11(3):157-162.
72. Bernard EJ, et al. Insertion of vagal nerve stimulator using local and regional anesthesia. *Surg Neurol* 2002; 57(2):94-98.
73. Cramer JA, Ben Menachem E, French J. Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation. *Epilepsy Res* 2001; 47(1-2): 17-25.

18 Noninvasive Pulsed Electromagnetic Therapy for Migraine and Multiple Sclerosis

1. Bassett CA. Therapeutic uses of electric and magnetic fields in orthopedics. In: Carpenter DO, Ayrapetyan S, eds. *Biological Effects of Electric and Magnetic Fields: Beneficial and Harmful Effects*. New York: Academic P, 1994:14-48.
2. Markoll R. Pulsed signal therapy: a practical guide for clinicians. In: Weiner R, ed. *Pain Management: A Practical Guide for Clinicians*. Boca Raton: CRC Press, 2001:715-728.
3. Bickford RG, Guidi M, Fortesque P, Swenson MR. Magnetic stimulation of human peripheral nerve and brain: response enhancement by combined magnetoelectrical technique. *Neurosurgery* 1987; 20:110.
4. Shealy CN, Cady RK, Wilkie RG, Cox RH, Liss S, Closson W. Depression: a diagnostic neurochemical profile and therapy with cranial electric stimulation (CES). *J Neurol Orthoped Med Surg* 1989; 10:319-321.
5. Pascual-Leone A, Rubio B, Pallardo F, Catala MD. Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. *Lancet* 1996; 348:233- 237.
6. Rush AJ, George MS, Sackeim HA, Marangell LB, Husain MM, Giller C, Nahas Z, Haines S, Simpson RK Jr, Goodman R. Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. *Biol Psychiatry* 2000; 47:276-286.
7. Lozano A. Deep brain stimulation: challenges to integrating stimulation technology with human neurobiology, neuroplasticity, and neural repair. *J Rehabil Res Dev* 2001; 38:x-xix.
8. Goodman R, Henderson AS. Effects of electric and magnetic fields on transcription. In: Carpenter DO, Ayrapetyan S, eds. *Biological Effects of Electric and Magnetic Fields: Beneficial and Harmful Effects*. New York: Academic, 1994:157-176.
9. Fierro B, Piazza A, Brighina F, La Bua V, Buffa D, Oliveri M. Modulation of intracortical inhibition induced by low- and high-frequency repetitive transcranial magnetic stimulation. *Exp Brain Res* 2001; 138:452-457.

10. Modugno N, Nakamura Y, MacKinnon CD, Filipovic SR, Bestmann S, Berardelli A, Rothwell JC. Motor cortex excitability following short trains of repetitive magnetic stimuli. *Exp Brain Res* 2001; 140:453-459.
11. Bassett CA. Beneficial effects of electromagnetic fields. *J Cell Biochem* 1993; 51:387-393.
12. Adey WR. Biological effects of electromagnetic fields. *J Cell Biochem* 1993; 51:410-416.
13. Ferrari MD. The economic burden of migraine to society. *Pharmacoeconomics* 1998; 13:667- 676.
14. Stewart WF, Lipton RB, Celentano DD. Prevalence of migraine headache in the United States: Relation to age, income, race and other sociodemographic factors. *JAMA* 1992; 267:64- 69.
15. Ferrari MD. Migraine. *Lancet* 1998; 351:1043-1051.
16. Young S, Davey R. Pilot study concerning the effects of extremely low frequency electromagnetic energy on migraine. *Int J Alt Complement Med*, October 1993.
17. Lappin MS. Research on the Utility of the Medigen Device as a Treatment for Migraines. Vancouver, BC: Energy Medicine Developments, 1995.
18. Benedetto C, Allais G, Ciocchetto D, De Lorenzo C. Pathophysiological aspects of menstrual migraine. *Cephalalgia* 1997; 17(suppl 20):32-34.
19. Sherman RA, Robson L, Marden LA. Initial exploration of pulsing electromagnetic fields for treatment of migraine. *Headache* 1998; 38:208-213.
20. Sherman RA, Acosta NM, Robson L. Treatment of migraine with pulsing electromagnetic fields: a double-blind, placebo controlled study. *Headache* 1999; 39:567-575.
21. Baumann RJ. Behavioral treatment of migraine in children and adolescents. *Paediatr Drugs* 2002; 4:555-561.
22. Reid GJ, McGrath PJ. Psychological treatments for migraine. *Biomed Pharmacother* 1996; 50:58-63.
23. Goodin DS. Survey of multiple sclerosis in northern California. Northern California MS Study Group. Multiple

Sclerosis 1999; 5:78-88.

24. Branas P, Jordan R, Fry-Smith A, Burls A, Hyde C. Treatments for fatigue in multiple sclerosis: a rapid and systematic review. *Health Technol Assess*, 2000, 4.

25. Comi G, Leocani L, Rossi P, Colombo B. Physiopathology and treatment of fatigue in multiple sclerosis. *J Neurol* 2001; 248:174-179.

26. Richards TL, Lappin MS, Acosta-Urquidi J, Kraft GH, Heidi BS, Lawrie FW, Merrill BS, Melton GB, Cunningham CA. Double-blind study of pulsing magnetic field effects on multiple sclerosis. *J Alt Complement Med* 1997; 3:21-29.

27. Schwartz CE, Vollmer T, Lee H. Reliability and validity of two self-report measures of impairment and disability for MS North American Research Consortium on Multiple Sclerosis Outcomes Study Group. *Neurology* 1999; 52:63-70.

28. Lappin M, Richards T, Lawrie F, Kramer E. Effects of a pulsed electromagnetic therapy on multiple sclerosis fatigue and quality of life: A double-blind, placebo controlled crossover trial. *Altern Ther Health Med* 2003; 9: 38-48.

29. Rivto PG, Fischer JS, Miller DM, Andrews H, Paty DW, LaRocca NG. Multiple Sclerosis Quality of Life Inventory: A User's Manual. New York: National Multiple Sclerosis Society, 1997.

30. Lappin MS. Emermed Patient Survey Results. Vancouver, BC: Energy Medicine Developments, 1998.

31. Guseo A. Pulsing electromagnetic field therapy of multiple sclerosis by the Gyuling-Bordacs device: Doubleblind, crossover and open studies. *J Bioelectricity* 1987; 6:23-35.

32. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). *Neurology* 1983; 33:1444-1452.

33. Sandyk R. Therapeutic effects of alternating current pulsed electromagnetic fields in multiple sclerosis. *J Altern Complement Med* 1997; 3:365-386.

34. Kavaliers M, Ossenkopp KP. Magnetic field inhibition of morphine-induced analgesia and behavioral activity in mice: evidence for involvement of calcium ions. *Brain Res* 1986;

379:30- 38.

35. Kavaliers M, Ossenkopp KP. Magnetic fields differentially inhibit mu, delta, kappa and sigma opiate-induced analgesia in mice. *Peptides* 1986; 7:449-453.

36. Levine RL, Dooley JK, Bluni TD. Magnetic field effects on spatial discrimination and melatonin levels in mice. *Physiol Behav* 1995; 58:535.

37. Reiter RJ. Electromagnetic fields and melatonin production. *Biomed Pharmacotherapy* 1993; 47:439-444.

38. Reiter RJ. Static and extremely low frequency electromagnetic field exposure: reported effects on the circadian production of melatonin. *J Cell Biochem* 1993; 51:394.

39. Chance WT, Grossman CJ, Newrock R, Bovin G, Yerian S, Schmitt G, Mendenhall C. Effects of electromagnetic fields and gender on neurotransmitters and amino acids in rats. *Physiol Behav* 1995; 58:743-748.

40. Massot O, Grimaldi B, Bailly JM, Kochanek M, Deschamps F, Lambrozo J, Fillion G. Magnetic field desensitizes 5-HT(1B) receptor in brain: pharmacological and functional studies. *Brain Res* 2000; 858:143-150.

41. Seegal RF, Wolpaw JR, Dowman R. Chronic exposure of primates to 60-Hz electric and magnetic fields: II. Neurochemical effects. *Bioelectromagnetics* 1989; 10:289-301.

42. Ben-Shachar D, Belmaker RH, Grisaru N, Klein E. Transcranial magnetic stimulation induces alterations in brain monoamines. *J Neural Transm* 1997; 104:191-197.

43. Ben-Shachar D, Gazawi H, Riboyad-Levin J, Klein E. Chronic repetitive transcranial magnetic stimulation alters beta-adrenergic and 5-HT2 receptor characteristics in rat brain. *Brain Res* 1999; 816:78-83.

44. Keck ME, Sillaber I, Ebner K, Welt T, Toschi N, Kaehler ST, Singewald N, Philippu A, Elbel GK, Wotjak CT, Holsboer F, Landgraf R, Engelmann M. Acute transcranial magnetic stimulation of frontal brain regions selectively modulates the release of vasopressin, biogenic amines and amino acids in the rat brain. *Eur J Neurosci* 2000; 12:3713-3720.

45. Strafella AP, Paus T, Barrett J, Dagher A. Repetitive

transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus. *J Neurosci* 2001; 21:RC157.

46. Diamond S, Wenzel R. Practical approaches to migraine management. *CNS Drugs* 2002; 16:385-403.

47. Chugani DC, Niimura K, Chaturvedi S, Muzik D, Fakhouri M, Lee ML, Chugani HT. Increased brain serotonin synthesis in migraine. *Neurology* 1999; 53:1473.

48. Del Zompo M. Dopaminergic hypersensitivity in migraine: clinical and genetic evidence. *Funct Neurol* 2000; 15:163-170.

49. Fanciullacci M, Alessandri M, Del Rosso A. Dopamine involvement in the migraine attack. *Funct Neurol* 2000; 15:171-181.

50. Nappi G, Costa A, Tassorelli C, Santorelli FM. Migraine as a complex disease: heterogeneity, comorbidity and genotype-phenotype interactions. *Funct Neurol* 2000; 15:87-93.

51. Ophoff RA, van den Maagdenberg AM, Roon KJ, Ferrari MD, Frants RR. The impact of pharmacogenetics for migraine. *Eur J Pharmacol* 2001; 413:1-10.

52. Peroutka SJ. Dopamine and migraine. *Neurology* 1997; 49:650-656.

53. Lai M, Loi V, Pisano MR, Del Zompo M. Therapy of migraine by modulating dopamine hypersensitivity: its effect on mood and pain. *Int J Clin Pharmacol Res* 1997; 17:101-103.

54. Brun J, Claustrat B, Saddinger P, Chazot G. Nocturnal melatonin excretion is decreased in patients with migraine without aura attacks associated with menses. *Cephalalgia* 1995; 15:136-139.

55. Claustrat B, Loisy C, Brun J, Beorchia S, Arnaud JL, Chazot G. Nocturnal plasma melatonin levels in migraine: a preliminary report. *Headache* 1989; 29:241-244.

56. Breslau N, Schultz LR, Stewart WF, Lipton RB, Lucia VC, Welch KM. Headache and major depression: is the association specific to migraine? *Neurology* 2000; 54:308-313.

57. Silberstein SD, Lipton RB, Breslau N. Migraine:

association with personality characteristics and psychopathology. *Cephalalgia* 1995; 15:337-369.

58. Othmer S, Othmer SF, Kaiser DA. EEG Biofeedback: An Emerging Model for its Global Efficacy. In: Evans J, Abarbanel A, eds. *Introduction to Quantitative EEG and Neurofeedback*. New York: Academic P, 1999.

59. Keck ME, Engelmann M, Muller MB, Henniger MS, Hermann B, Rupprecht R, Neumann ID, Toschi N, Landgraf R, Post A. Repetitive transcranial magnetic stimulation induces active coping strategies and attenuates the neuroendocrine stress response in rats. *J Psychiatr Res* 2000; 34:265-276.

60. Keck ME, Welt T, Post A, Muller MB, Toschi N, Wigger A, Landgraf R, Holsboer F, Engelmann M. Neuroendocrine and behavioral effects of repetitive transcranial magnetic stimulation in a psychopathological animal model are suggestive of antidepressant-like effects. *Neuropsychopharmacology* 2001; 24:337-349.

61. Evers S, Hengst K, Pecuch PW. The impact of repetitive transcranial magnetic stimulation on pituitary hormone levels and cortisol in healthy subjects. *J Affect Disord* 2001; 66:83-88.

62. George MS, Wassermann EM, Williams WA, Steppel J, Pascual-Leone A, Basser P, Hallett M, Post RM. Changes in mood and hormone levels after rapid-rate transcranial magnetic stimulation (rTMS) of the prefrontal cortex. *J Neuropsych Clin Neurosci* 1996; 8:172-180.

63. Grasser A, Moller A, Backmund H, Yassouridis A, Holsboer F. Heterogeneity of hypothalamic-pituitary-adrenal system response to a combined dexamethasone-CRH test in multiple sclerosis. *Exp Clin Endocrinol Diabetes* 1996; 104:31-37.

64. Kumpfel T, Then Bergh F, Friess E, Uhr M, Yassouridis A, Trenkwalder C, Holsboer F. Dehydroepiandrosterone response to the adrenocorticotropin test and the combined dexamethasone and corticotropin-releasing hormone test in patients with multiple sclerosis. *Neuroendocrinology* 1999; 70:431-438.

65. Fassbender K, Schmidt R, Mossner R, Kischka U, Kuhnen J, Schwartz A, Hennerici M. Mood disorders and dysfunction of the hypothalamic-pituitary-adrenal axis in multiple sclerosis: association with cerebral inflammation. *Arch Neurol* 1998; 55:66-72.

66. Heesen C, Gold SM, Raji A, Wiedemann K, Schulz KH. Cognitive impairment correlates with hypothalamopituitary-adrenal axis dysregulation in multiple sclerosis. *Psychoneuroendocrinology* 2002; 27:505-517.
67. Then Bergh F, Kumpfel T, Trenkwalder C, Rupprecht R, Holsboer F. Dysregulation of the hypothalamopituitary-adrenal axis is related to the clinical course of MS. *Neurology* 1999; 53:772-777.
68. Peres MF, Sanchez del Rio M, Seabra ML, Tufik S, Abucham J, Cipolla-Neto J, Silberstein SD, Zukerman E. Hypothalamic involvement in chronic migraine. *J Neurol Neurosurg Psychiatry* 2001; 71:747-751.
69. Fitzgerald PB, Brown TL, Daskalakis ZJ, Chen R, Kulkarni J. Intensity-dependent effects of 1 Hz rTMS on human corticospinal excitability. *Clin Neurophysiol* 2002; 113:1136-1141.
70. Muellbacher W, Ziemann U, Boroojerdi B, Hallett M. Effects of low-frequency transcranial magnetic stimulation on motor excitability and basic motor behavior. *Clin Neurophysiol* 2000; 111:1002-1007.
71. Romero JR, Anselmi D, Sparing R, Gangitano M, Pascual-Leone A. Subthreshold low frequency repetitive transcranial magnetic stimulation selectively decreases facilitation in the motor cortex. *Clin Neurophysiol* 2002; 113:101-107.
72. Gangitano M, Valero-Cabre A, Tormos JM, Mottaghy FM, Romero JR, Pascual-Leone A. Modulation of input-output curves by low and high frequency repetitive transcranial magnetic stimulation of the motor cortex. *Clin Neurophysiol* 2002; 113:1249-1257.
73. Maeda F, Gangitano M, Thall M, Pascual-Leone A. Inter- and intra-individual variability of paired-pulse curves with transcranial magnetic stimulation (TMS). *Clin Neurophysiol* 2002; 113:376-382.
74. Bohotin V, Fumal A, Vandenheede M, Gerard P, Bohotin C, Maertens De Noordhout A, Schoenen J. Effects of repetitive transcranial magnetic stimulation on visual evoked potentials in migraine. *Brain* 2002; 125:912-922.
75. Brighina F, Piazza A, Daniele O, Fierro B. Modulation of visual cortical excitability in migraine with aura:

effects of 1 Hz repetitive transcranial magnetic stimulation. *Exp Brain Res* 2002; 145:177-181.

76. Samii A, Wassermann EM, Ikoma K, Mercuri B, George MS, O'Fallon A, Dale JK, Straus SE, Hallett M. Decreased postexercise facilitation of motor evoked potentials in patients with chronic fatigue syndrome or depression. *Neurology* 1996; 47:1410-1414.

77. Shajahan PM, Glabus MF, Gooding PA, Shah PJ, Ebmeier KP. Reduced cortical excitability in depression. Impaired post-exercise motor facilitation with transcranial magnetic stimulation. *Br J Psychiatry* 1999; 174: 449-454.

78. Speer AM, Kimbrell TA, Wassermann EM, J DR, Willis MW, Herscovitch P, Post RM. Opposite effects of high and low frequency rTMS on regional brain activity in depressed patients. *Biol Psychiatry* 2000; 48:1133-1141.

79. Bell GB, Marino AA, Chesson AL. Frequency-specific responses in the human brain caused by electromagnetic fields. *J Neurol Sci* 1994; 123:26-32.

80. Bell GB, Marino AA, Chesson AL. Frequency-specific blocking in the human brain caused by electromagnetic fields. *Neuroreport* 1994; 5:510-512.

81. Heusser K, Telschaft D, Thoss F. Influence of an alternating 3 Hz magnetic field with an induction of 0.1 millitesla on chosen parameters of the human occipital EEG. *Neurosci Lett* 1997; 239:57-60.

82. Bell G, Marino A, Chesson A, Struve F. Electrical states in the rabbit brain can be altered by light and electromagnetic fields. *Brain Res* 1992; 570:307-315.

83. Pigeau RA, Frame AM. Steady-state visual evoked responses in high and low alpha subjects. *Electroencephalogr Clin Neurophysiol* 1992; 84:101-109.

84. Rosenfeld J, Rienhart A, Srivastava S. The effects of alpha (10 Hz) and beta (22 Hz) "entrainment" stimulation on the alpha and beta EEG bands: individual differences are critical to prediction of effects. *Appl Psychophysiol Biofeedback* 1997; 22:3-20.

85. Richards T, Acosta-Urquidi J. Pulsing magnetic field effects on brain electrical activity in multiple sclerosis. *Biologic Effects of Light Conference*. Basel, Switzerland. Boston: Kluwer Academic Publishers, 1998:337-342.

86. Gerber WD, Schoenen J. Biobehavioral correlates in migraine: the role of hypersensitivity and information processing dysfunction. *Cephalalgia* 1998; 18(suppl 21):5-11.
87. Afra J, Cecchini AP, De Pasqua V, Albert A, Schoenen J. Visual evoked potentials during long periods of pattern reversal stimulation in migraine. *Brain* 1998; 121:233-241.
88. Afra J, Proietti Cecchini A, Sandor PS, Schoenen J. Comparison of visual and auditory evoked cortical potentials in migraine patients between attacks. *Clin Neurophysiol* 2000; 111:1124-1129.
89. Schoenen J. Deficient habituation of evoked cortical potentials in migraine: a link between brain biology, behavior and trigeminovascular activation? *Biomed Pharmacother* 1996; 50:71-78.
90. Ambrosini A, De Pasqua V, Afra J, Sandor PS, Schoenen J. Reduced gating of middle-latency auditory evoked potentials (P50) in migraine patients: another indication of abnormal sensory processing? *Neurosci Lett* 2001; 306:132-134.
91. Wang W, Timsit-Berthier M, Schoenen J. Intensity dependence of auditory evoked potentials is pronounced in migraine: an indication of cortical potentiation and low serotonergic neurotransmission? *Neurology* 1996; 46:1404-1409.
92. Wang W, Schoenen J. Interictal potentiation of passive "oddball" auditory event-related potentials in migraine. *Cephalalgia* 1998; 18:261-265. discussion 241.
93. Kropp P, Gerber WD. Is increased amplitude of contingent negative variation in migraine due to cortical hyperactivity or to reduced habituation? *Cephalalgia* 1993; 13:37-41.
94. Siniatchkin M, Gerber WD, Kropp P, Voznesenskaya T, Vein AM. Are the periodic changes of neurophysiological parameters during the pain-free interval in migraine related to abnormal orienting activity? *Cephalalgia* 2000; 20:20-29.
95. Siniatchkin M, Kirsch E, Kropp P, Stephani U, Gerber WD. Slow cortical potentials in migraine families.

Cephalalgia 2000; 20:881-892.

96. Siniatchkin M, Hierundar A, Kropp P, Gerber WD, Stephani U. Self-regulation of slow cortical potentials in children with migraine: an exploratory study. *Applied Psychophysiology and Biofeedback* 2000; 25:13-32.

97. Judit A, Sandor PS, Schoenen J. Habituation of visual and intensity dependence of auditory evoked cortical potentials tends to normalize just before and during the migraine attack. *Cephalalgia* 2000; 20:714-719.

98. Kropp P, Gerber WD. Contingent negative variation during migraine attack and interval: evidence for normalization of slow cortical potentials during the attack. *Cephalalgia* 1995; 15:123-128. discussion 178-129.

99. Kropp P. Prediction of migraine attacks. *Cephalalgia* 1999; 19:477.

100. Siniatchkin M, Kropp P, Gerber WD, Stephani U. Migraine in childhood—are periodically occurring migraine attacks related to dynamic changes of cortical information processing? *Neurosci Lett* 2000; 279:1-4.

101. Basar-Eroglu C, Warecka K, Schurmann M, Basar E. Visual evoked potentials in multiple sclerosis: frequency response shows reduced alpha amplitude. *Int J Neurosci* 1993; 73:235-258.

102. Schurmann M, Warecka K, Basar-Eroglu C, Basar E. Auditory evoked potentials in multiple sclerosis: alpha responses are reduced in amplitude, but theta responses are not altered. *Int J Neurosci* 1993; 73:259-276.

103. Brau H, Ulrich G. Electroencephalographic vigilance dynamics in multiple sclerosis during an acute episode and after remission. *Eur Arch Psychiatry Neurol Sci* 1990; 239:320-324.

104. Colon E, Hommes OR, de Weerd JP. Relation between EEG and disability scores in multiple sclerosis. *Clin Neurol Neurosurg* 1981; 83:163-168.

105. Roelcke U, Kappos L, Lechner-Scott J, Brunnschweiler H, Huber S, Ammann W, Plohmann A, Della S, Maguire RP, Missimer J, Radu EW, Steck A, Leemders KL. Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a ¹⁸F-fluorodeoxyglucose positron emission tomography study.

Neurology 1997; 48:1566-1571.

106. Leocani L, Locatelli T, Martinelli V, Rovaris M, Falautano M, Filippi M, Magnani G, Comi G. Electroencephalographic coherence analysis in multiple sclerosis: correlation with clinical, neuropsychological, and MRI findings. *J Neurol Neurosurg Psychiatry* 2000; 69:192-198.

107. Conca A, Peschina W, Konig P, Fritzsche H, Hausmann A. Effect of chronic repetitive transcranial magnetic stimulation on regional cerebral blood flow and regional cerebral glucose uptake in drug treatment-resistant depressives. A brief report. *Neuropsychobiology* 2002; 45:27-31.

108. Mottaghy F, Keller C, Gangitano M, Ly J, Thall M, Parker J, Pascual-Leone A. Correlation of cerebral blood flow and treatment effects of repetitive transcranial magnetic stimulation in depressed patients. *Psychiatry Res* 2002; 115:1.

19 Repetitive Transcranial Magnetic Stimulation (rTMS) for Depression and Other Indications

1. Barker AT, Jalinous R, Freeston IL. Non-invasive magnetic stimulation of the human motor cortex. *Lancet* 1985; 1:1106-1107.
2. Wassermann EM. Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the International Workshop in the Safety of Repetitive Transcranial Magnetic Stimulation, June 5-7, 1996. *Electroencephalogr Clin Neurophysiol* 1998; 108:1-16.
3. Roth BJ, Saypol JM, Hallett M, Cohen LG. Theoretical calculation of the electric field induced in the cortex during magnetic stimulation. *Electroencephalo Clin Neurophysiol* 1991; 81:47-56.
4. Faraday M. Effects on the production of electricity from magnetism (1831). In: Williams LP, ed. *Michael Faraday*. New York: Basic Books, 1965:531.
5. George MS, Belmaker RH. Transcranial magnetic stimulation in neuropsychiatry. In: George MS, Belmaker RH, eds. *Washington, DC: American Psychiatric Press, 2000*.
6. George MS, Lisanby SH, Sackeim HA. Transcranial magnetic stimulation: applications in neuropsychiatry. *Arch Gen Psychiatry* 1999; 56:300-311.
7. Barker AT, Freeston IL, Jarratt JA, Jalinous R. Magnetic stimulation of the human nervous system: an introduction and basic principles. In: Chokroverty S, ed. *Magnetic Stimulation in Clinical Neurophysiology*. Boston: Butterworths, 1989:55-72.
8. Bohning DE. Introduction and overview of TMS physics. In: George MS, Belmaker RH, eds. *Transcranial Magnetic Stimulation in Neuropsychiatry*. Washington, DC: American Psychiatric Press, 2000:13-44.
9. Council NR. *Possible Health Effects of Exposure to Residential Electric and Magnetic Fields*. Washington, DC: National Academy Press, 1996.
10. Ajmone-Marsan C. Focal electrical stimulation. In: Purpura DP, Penry JK, Tower DB, Woodbury DM, Walter RD, eds. *Experimental Models of Epilepsy*. New York: Raven Press, 1972:147-172.

11. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. *Annu Rev Neurosci* 1986; 9:357-381.
12. Stewart LM, Walsh V, Rothwell JC. Motor and phosphene thresholds: a transcranial magnetic stimulation correlation study. *Neuropsychologia* 2001; 39:415-419.
13. Ziemann U, Hallett M. Basic neurophysiological studies with TMS. In: George MS, Belmaker RH, eds. *Transcranial Magnetic Stimulation in Neuropsychiatry*. Washington, DC: American Psychiatric Press, 2000: 45-98.
14. Pridmore S, Filho JAF, Nahas Z, Liberatos C, George MS. Motor threshold in transcranial magnetic stimulation: a comparison of a neurophysiological and a visualization of movement method. *J ECT* 1998; 14:25-27.
15. Amassian VE, Eberle L, Maccabee PJ, Cracco RQ. Modelling magnetic coil excitation of human cerebral cortex with a peripheral nerve immersed in a brain-shaped volume conductor: the significance of fiber bending in excitation. *Electroencephalo Clin Neurophysiol* 1992; 85:291-301.
16. Davey KR, Cheng CH, Epstein CM. Prediction of magnetically induced electric fields in biologic tissue. *IEEE Trans Biomed Eng* 1991; 38:418-422.
17. Penfield W, Jasper H. *Epilepsy and the Functional Anatomy of the Human Brain*. Boston: Little, Brown and Company, 1954.
18. George MS, Nahas Z, Lisanby SH, Schlaepfer T, Kozel FA, Greenberg BD. Transcranial magnetic stimulation. *Neurosurg Clin N Am* 2003. In press.
19. Greenberg BD, Ziemann U, Harmon A, Murphy DL, Wassermann EM. Reduced intracortical inhibition in obsessive-compulsive disorder on transcranial magnetic stimulation. *Lancet* 1998; 352:881-882.
20. Ziemann U, Steinhoff BJ, Tergau F, Paulus W. Transcranial magnetic stimulation: its current role in epilepsy research. *Epilepsy Res* 1998; 30:11-30.
21. Bohning DE, Walker JA, Mu Q, Li X, Denslow S, George MS. Interleaved Paired Pulse TMS and BOLD fMRI [abstract]. *Magn Res Med* 2003.

22. Epstein CM, Lah JJ, Meador K, Weissman JD, Gaitan LE, Dihenia B. Optimum stimulus parameters for lateralized suppression of speech with magnetic brain stimulation. *Neurology* 1996; 47:1590-1593.
23. Grill WM, McIntyre CC. Extracellular excitation of central neurons: implications for the mechanisms of deep brain stimulation. *Thalamus & Related Systems* 2001; 1:269-277.
24. Bear MF. Homosynaptic long-term depression: a mechanism for memory? *Proceedings of the National Academy of Sciences of the United States of America* Aug 17, 1999; 96(17):9457-9458.
25. Stanton PK, Sejnowsky TJ. Associative long-term depression in the hippocampus induced by hebbian covariance. *Nature* 1989; 339:215-218.
26. Malenka RC, Nicoll RA. Long-term potentiation: a decade of progress? *Science* Sep 17, 1999; 285(5435): 1870-1974.
27. Wang H, Wang X, Scheich H. LTD and LTP induced by transcranial magnetic stimulation in auditory cortex. *NeuroReport* 1996; 7:521-525.
28. Chen R, Classen J, Gerloff C. Depression of motor cortex excitability by low-frequency transcranial magnetic stimulation. *Neurology* 1997; 48:1398-1403.
29. Wu T, Sommer M, Tergau F, Paulus W. Lasting influence of repetitive transcranial magnetic stimulation on intracortical excitability in human subjects. *Neuroscience Letters* 2000; 287:37- 40.
30. Desmurget M, Epstein CM, Turner RS, Prablanc C, Alexander GE, Grafton ST. Role of the posterior parietal cortex in updating reaching movements to a visual target. *Nature Neurosci* 1999; 2:563-567.
31. Epstein CM, Verson R, Zangaladze A. Magnetic coil stimulation suppresses visual perception at an extracalcarine site. *J Clin Neurophysiol* 1996; 13:247-252.
32. Grafman J, Wassermann E. Transcranial magnetic stimulation can measure and modulate learning and memory. *Neuropsychologia* 1999; 37(2): 159-167.
33. Flitman SS, Grafman J, Wassermann EM. Linguistic

processing during repetitive transcranial magnetic stimulation. *Neurology* 1998; 50:175-181.

34. George MS, Wassermann EM, Williams W. Changes in mood and hormone levels after rapidrate transcranial magnetic stimulation of the prefrontal cortex. *J Neuropsychiatry Clin Neuro* 1996; 8:172-180.

35. Grafman J. TMS as a primary brain mapping tool. In: George MS, Belmaker RH, eds. *Transcranial Magnetic Stimulation (TMS) in Neuropsychiatry*. Washington, DC: American Psychiatric Press, 2000:115-140.

36. George MS, Lisanby SH, Sackeim HA. Transcranial magnetic stimulation—Applications in neuropsychiatry. *Arch Gen Psychiatry* 1999; 56:300-311.

37. Lisanby SH, Luber B, Finck D. Primate models of transcranial magnetic stimulation. *Biological Psychiatry* 1998; 41:76s.

38. Amassian VE, Quirk GJ, Stewart M. A comparison of corticospinal activation by magnetic coil and electrical stimulation of monkey motor cortex. *Electroencephalo Clin Neurophysiol* 1990; 77:390-401.

39. Edgley SA, Eyre JA, Lemon RN, Miller S. Excitation of the corticospinal tract by electromagnetic and electrical stimulation of the scalp in the macaque monkey. *J Physiol (London)* 1990; 425:301-320.

40. Lemon RN, Johansson RS, Wrestling G. Modulation of corticospinal influence over hand muscles during gripping tasks in man and monkey. *Canadian J Physiol Pharmacol* 1996; 74:547-558.

41. Baker SN, Olivier E, Lemon RN. Task-related variation in corticospinal output evoked by transcranial magnetic stimulation in the macaque monkey. *J Physiol* 1995; 488:795-801.

42. Ghaly RF, Stone JL, Aldrete A, Levy W. Effects of incremental ketamine hydrochloride doses on motor evoked potentials (MEPs) following transcranial magnetic stimulation: a primate study. *J Neurosurg Anesthesiol* 1990; 2:79-85.

43. Stone JL, Ghaly RF, Levy WJ, Kartha R, Krinsky L, Roccaforte P. A comparative analysis of enflurane anesthesia on primate motor and somatosensory evoked

potentials. *Electroencephalo Clin Neurophysiol* 1992; 84: 180-197.

44. Baker SN, Olivier E, Lemon RN. Recording an identified pyramidal volley evoked by transcranial magnetic stimulation in a conscious macaque monkey. *Experimental Brain Res* 1995; 99:529-532.

45. Fleischmann A, Sternheim A, Etgen AM, Li C, Grisaru N, Belmaker RH. Transcranial magnetic stimulation downregulates beta-adrenoreceptors in rat cortex. *J Neural Transm* 1996; 103:1361-1366.

46. Ben-Sachar D, Belmaker RH, Grisaru N, Klein E. Transcranial magnetic stimulation induces alterations in brain monoamines. *J Neural Transm* 1997; 104:191-197.

47. Jennum P, Klitgaard H. Effect of acute and chronic stimulations on pentylenetetrazoleinduced clonic seizures. *Epilepsy Res* 1996; 23:115-122.

48. Pope A, Keck ME. TMS as a therapeutic tool in psychiatry: what do we know about neurobiological mechanisms? *J Psychiatr Res* 2001; 35:193-215.

49. Weissman JD, Epstein CM, Davey KR. Magnetic brain stimulation and brain size: relevance to animal studies. *Electroencephalo Clin Neurophysiol* 1992; 85:215-219.

50. Nobler MS, Oquendo MA, Kegeles LS. Decreased regional brain metabolism after ECT. *Am J Psychiatry* 2001; 158:305-308.

51. Teneback CC, Nahas Z, Speer AM. Two weeks of daily left prefrontal rTMS changes prefrontal cortex and paralimbic activity in depression. *J Neuropsychiatry Clin Neurosci* 1999; 11:426-435.

52. Shajahan PM, Glabus MF, Steele JD. Left dorso-lateral repetitive transcranial magnetic stimulation affects cortical excitability and functional connectivity, but does not impair cognition in major depression. *Progress in Neuropsychopharmacology and Biological Psychiatry* 2002; 26:945-954.

53. Speer AM, Kimbrell TA, Wasserman EM. Opposite effects of high and low frequency rTMS on regional brain activity in depressed patients. *Biological Psychiatry* 2000; 48(23): 1133- 1141.

54. Mitchel P. 15 Hz and 1 Hz TMS have different acute effects on cerebral blood flow in depressed patients. *Int J Neuropsychopharmacol* 2002; 5:S7 (s.08.02).
55. Shastri A, George MS, Bohning DE. Performance of a system for interleaving transcranial magnetic stimulation with steady state magnetic resonance imaging. *Electroencephalo Clin Neurophysiol Suppl* 1999; 51:55-64.
56. Bohning DE, Shastri A, Nahas Z. Echoplanar BOLD fMRI of brain activation induced by concurrent transcranial magnetic stimulation (TMS). *Invest Radiol* 1998; 33(6):336-340.
57. Bohning DE, Shastri A, McConnell K. A combined TMS/fMRI study of intensity-dependent TMS over motor cortex. *Biological Psychiatry* 1999; 45:385-394.
58. Bohning DE, Shastri A, Wassermann EM. BOLD-fMRI response to single-pulse transcranial magnetic stimulation (TMS). *J Magnetic Resonance Imaging* 2000; 11:569-574.
59. Bohning DE, Shastri A, McGavin L. Motor cortex brain activity induced by 1-Hz transcranial magnetic stimulation is similar in location and level to that for volitional movement. *Invest Radiol* 2000; 35(11):676-683.
60. Baudewig J, Siebner HR, Bestmann S. Functional MRI of cortical activations induced by transcranial magnetic stimulation (TMS). *NeuroReport* 2001; 12:3543-3548.
61. Nahas Z, Lomarev M, Roberts DR. Unilateral left prefrontal transcranial magnetic stimulation (TMS) produces intensity-dependent bilateral effects as measured by interleaved BOLD fMRI. *Biological Psychiatry* 2001; 50(9): 712-720.
62. Strafella AP, Paus T, Barrett J, Dagher A. Repetitive transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus. *J Neurosci* 2001; 21:RC157.
63. Paus T, Castro-Alamancos MA, Petrides M. Cortico-cortical connectivity of the human middorsolateral frontal cortex and its modulation by repetitive transcranial magnetic stimulation. *European J Neurosci* 2001; 14: 1405-1411.
64. George MS, Bohning DE. Measuring brain connectivity with functional imaging and transcranial magnetic

- stimulation (TMS). In: Desimone B, ed. Neuropsychopharmacology, Fifth Generation of Progress. New York: Lipincott, Williams and Wilkins, 2002:393-410.
65. Paus T, Jech R, Thompson CJ, Comeau R, Peters T, Evans AC. Transcranial magnetic stimulation during positron emission tomography: a new method for studying connectivity of the human cerebral cortex. *J Neurosci* 1997; 17:3178-3184.
66. Kimbrell TA, Ketter TA, George MS. Regional cerebral glucose utilization in patients with a range of severities of unipolar depression. *Biological Psychiatry* 2002; 51:237-252.
67. George MS, Huggins T, McDermut W, Parekh PI, Rubinow D, Post RM. Abnormal facial emotion recognition in depression: serial testing in an ultra-rapid-cycling patient. *Behavior Mod* 1998; 22:192-204.
68. George MS. An introduction to the emerging neuroanatomy of depression. *Psychiatr Ann* 1994; 24:635-636.
69. George MS, Ketter TA, Parekh PI. Regional brain activity when selecting a response despite interference: an H2150 PET study of the stroop and an emotional stroop. *Human Brain Mapping* 1994; 1:194-209.
70. George MS, Ketter TA, Parekh PI, Horwitz B, Herscovitch P, Post RM. Brain activity during transient sadness and happiness in healthy women. *Am J Psychiatry* 1995; 152:341-351.
71. George MS, Ketter TA, Post RM. What Functional Imaging Studies Have Revealed About the Brain Basis of Mood and Emotion. In: Panksepp J, ed. *Advances in Biological Psychiatry*. Greenwich, Conn: JAI Press, 1996: 63-113.
72. George MS, Ketter TA, Parekh PI. Blunted left cingulate activation in mood disorder subjects during a response interference task (The Stroop). *J Neuropsychiatry Clin Neuro* 1997; 9:55- 63.
73. Ketter TA, Andreason PJ, George MS. Anterior paralimbic mediation of procaine-induced emotional and psychosensory experiences. *Arch Gen Psychiatry* 1996; 53:59-69.
74. George MS, Ketter TA, Post RM. Prefrontal cortex dysfunction in clinical depression. *Depression* 1994; 2: 59-72.

75. George MS, Post RM, Ketter TA, Kimbrell TA. Neural mechanisms of mood disorders. *Current Review of Mood and Anxiety Disorders* 1997; 1:71-83.
76. Mayberg HS, Liotti M, Brannan SK. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. *Am J Psychiatry* May 1999; 156(5): 675-682.
77. Beer B. Uber das Auftreten einer objectiven Lichtempfindung in magnetischen Felde. *Klinische Wochenzeitschrift* 1902; 15:108-109.
78. Kolbinger HM, Hoflich G, Hufnagel A, Moller H-J, Kasper S. Transcranial Magnetic Stimulation (TMS) in the treatment of major depression—a pilot study. *Human Psychopharmacol* 1995; 10:305-310.
79. Grisaru N, Yaroslavsky U, Abarbanel J, Lamberg T, Belmaker RH. Transcranial magnetic stimulation in depression and schizophrenia. *European Neuropsychopharmacol* 1994; 4:287- 288.
80. Nobler MS, Sackeim HA, Prohovnik I. Regional cerebral blood flow in mood disorders, III. Treatment and clinical response. *Arch Gen Psychiatry* 1994; 51:884-897.
81. George MS, Wassermann EM, Williams WA. Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. *NeuroReport* 1995; 6:1853-1856.
82. George MS, Wassermann EM, Williams WE. Mood improvements following daily left prefrontal repetitive transcranial magnetic stimulation in patients with depression: a placebocontrolled crossover trial. *Am J Psychiatry* 1997; 154:1752-1756.
83. George MS, Wassermann EM. Rapid-rate transcranial magnetic stimulation (rTMS) and ECT. *Convulsive Therapy* 1994; 10(4):251-253.
84. Loo C, Mitchell P, Sachdev P, McDarmon B, Parker G, Gandevia S. A double-blind controlled investigation of transcranial magnetic stimulation for the treatment of resistant major depression. *Am J Psychiatry* 1999; 156: 946-948.
85. Holtzheimer PE, Russo J, Avery D. A meta-analysis of repetitive transcranial magnetic stimulation in the

- treatment of depression. *Psychopharmacol Bull* 2001; 35:149-169.
86. Kozel FA, George MS. Meta-analysis of left prefrontal repetitive transcranial magnetic stimulation (rTMS) to treat depression. *J Psychiatr Practice* 2002; 8:S56-S61.
87. Burt T, Lisanby SH, Sackeim HA. Neuropsychiatric applications of transcranial magnetic stimulation. *Int J Neuropsychopharmacol* 2002; 5:73-103.
88. McNamara B, Ray JL, Arthurs OJ, Boniface S. Transcranial magnetic stimulation for depression and other psychiatric disorders. *Psychological Medicine* 2001; 31:1141-1146.
89. Martin JLR, Barbanoj MJ, Schlaepfer TE. Transcranial magnetic stimulation for treating depression (Cochrane Review). *The Cochrane Library*. Oxford: Update Software, 2002.
90. Thase ME. The need for clinically relevant research on treatment-resistant depression. *J Clin Psychiatry* 2001; 62: 221-224.
91. Grunhaus L, Dannon PN, Schreiber S. Repetitive transcranial magnetic stimulation is as effective as electroconvulsive therapy in the treatment of nondelusional major depressive disorder: an open study. *Biological Psychiatry* 2000; 4(47):314-324.
92. Grunhaus L, Schreiber S, Dolberg OT, Polack D, Dannon PN. Randomized controlled comparison of ECT and rTMS in severe and resistant non-psychotic major depression. *Biological Psychiatry* 2003; 53(4):324-331.
93. Janicak PG, Dowd SM, Martis B. Repetitive transcranial magnetic stimulation versus electroconvulsive therapy for major depression: preliminary results of a randomized trial. *Biological Psychiatry* 2002; 51:659-667.
94. Pridmore S. Substitution of rapid transcranial magnetic stimulation treatments for electroconvulsive therapy treatments in a course of electroconvulsive therapy. *Depress Anxiety* 2000; 12(3):118-123.
95. Dannon PN, Dolberg OT, Schreiber S, Grunhaus L. Three and six-month outcome following courses of either ECT or rTMS in a population of severely depressed individuals-preliminary report. *Biological Psychiatry* 2002;

51:687-690.

96. Klein E, Kreinin I, Chistyakov A. Therapeutic efficacy of right prefrontal slow repetitive transcranial magnetic stimulation in major depression: a double-blind controlled study. *Arch Gen Psychiatry* 1999; 56:315-320.

97. Herwig U, Padberg F, Unger J, Spitzer M, Schonfeldt-Lecuona C. Transcranial magnetic stimulation in therapy studies: examination of the reliability of "standard" coil positioning by neuronavigation. *Biological Psychiatry* 2001; 50(1):58-61.

98. McConnell KA, Nahas Z, Shastri A. The transcranial magnetic stimulation motor threshold depends on the distance from coil to underlying cortex: a replication in healthy adults comparing two methods of assessing the distance to cortex. *Biological Psychiatry* 2001; 49(5):454-459.

99. Mosimann UP, Marre SC, Werlen S. Antidepressant effects of repetitive transcranial magnetic stimulation in the elderly: correlation between effect size and coil-cortex distance. *Arch Gen Psychiatry* 2002; 59:560-561.

100. Padberg F, Zwanzger P, Keck ME. Repetitive transcranial magnetic stimulation (rTMS) in major depression: Relation between efficacy and stimulation intensity. *Neuropsychopharmacology* 2002; 27:638-645.

101. Kozel FA, Nahas Z, DeBrux C. How the distance from coil to cortex relates to age, motor threshold and possibly the antidepressant response to repetitive transcranial magnetic stimulation. *J Neuropsychiatry Clin Neurosci* 2000; 12:376-384.

102. Nahas Z, Oliver NC, Johnson M. Feasibility and efficacy of left prefrontal rTMS as a maintenance antidepressant. *Biological Psychiatry* 2000, (abstract) 57.

103. Belmaker RH, Grisaru N. Antibipolar potential for transcranial magnetic stimulation. *Bipolar Disord* 1999; 1(2): 71-72.

104. Li X, Teneback CC, Nahas Z. Lamotrigine inhibits the functional magnetic resonance imaging response to transcranial magnetic stimulation in healthy adults. *Biological Psychiatry* 2002; 51:8S (#567).

105. George MS, Stallings LE, Speer AM. Prefrontal

repetitive transcranial magnetic stimulation (rTMS) changes relative perfusion locally and remotely. *Human Psychopharmacol* 1999; 14:161-170.

106. Szuba MP, O'Reardon JP, Rai AS. Acute mood and thyroid stimulating hormone effects of transcranial magnetic stimulation in major depression. *Biological Psychiatry* 2001; 50:22- 57.

107. Szuba MP, Rai A, Kastenber J. Rapid mood and endocrine effects of TMS in major depression. *Proceedings of the American Psychiatric Association Annual Meeting*. 1999:201.

108. Nahas Z, Kozel FA, Li X, Anderson B, George MS. Left prefrontal transcranial magnetic stimulation (TMS) treatment of depression in bipolar affective disorder: a pilot study of acute safety and efficacy. *J Bipolar Disorders*. Under review.

109. Grunhaus L, Dolberg OT, Polak D, Dannon PN. Monitoring the response to rTMS in depression with visual analog scales. *Human Psychopharmacol* 2002; 17:349-352.

110. Sackeim HA, Decina P, Malitz S, Resor SR, Prohovnik I. Anticonvulsant and antidepressant properties of electroconvulsive therapy: a proposed mechanism of action. *Biological Psychiatry* 1983; 18:1301-1310.

111. Fujiki M, Steward O. High frequency transcranial magnetic stimulation mimics the effects of ECS in upregulating astroglial gene expression in the murine CNS. *Molecular Brain Res* 1997; 44:301-308.

112. Belmaker RH, Grisaru N. Magnetic stimulation of the brain in animal depression models responsive to ECS. *J ECT* 1998; 14(3): 194-205.

113. Ebert U, Ziemann U. Altered seizure susceptibility after high-frequency transcranial magnetic stimulation in rats. *Neurosci Lett* 1999; 273:155-158.

114. Triggs WJ, McCoy KJ, Greer R. Effects of left frontal transcranial magnetic stimulation on depressed mood, cognition, and corticomotor threshold. *Biological Psychiatry* 1999; 45:1440- 1446.

115. Padberg F, Haag C, Zwanzger P. Rapid and slow transcranial magnetic stimulation are equally effective in medication-resistant depression: a placebo-controlled

study. CINF Abstracts 1998; 21st Congress:103-st0306.

116. George MS, Nahas Z, Molloy M. A Controlled trial of daily transcranial magnetic stimulation (TMS) of the left prefrontal cortex for treating depression. *Biological Psychiatry* 2000; 48(10):962-970.

117. Pascual-Leone A, Valls-Sole J, Brasil-Neto JP, Cohen LG, Hallett M. Akinesia in Parkinson's disease. I Shortening of simple reaction times with focal, single-pulse transcranial magnetic stimulation. *Neurology* 1994; 44:884-891.

118. Ghabra MB, Hallett M, Wassermann EM. Simultaneous repetitive transcranial magnetic stimulation does not speed fine movement in PD. *Neurology* 1999; 52:768-770.

119. Boylan LS, Pullman SL, Lisanby SH, Spicknall KE, Sackeim HA. Repetitive transcranial magnetic stimulation to SMA worsens complex movements in Parkinson's disease. *Clin Neurophysiol* 2001; 112:259-264.

120. Mally J, Stone TW. Therapeutic and "dose-dependent" effect of repetitive microelectroshock induced by transcranial magnetic stimulation in Parkinson's disease. *J Neurosci Res* 1999; 57(6):935-940.

121. Shimamoto H, Morimitsu H, Sugita S, Nakahara K, Shigemori M. Therapeutic Effect of repetitive transcranial magnetic stimulation in Parkinson's disease. *Rinsho Shinkeigaku* 1999; 39:1264-1267.

122. Siebner HR, Tormos JM, Ceballos-Baumann AO. Low frequency repetitive transcranial magnetic stimulation of motor cortex in patients with writer's cramp. *Neurology* 1999; 52:529- 537.

123. Chae JH, Nahas Z, Wassermann EM. Pilot study using rTMS to probe the functional neuroanatomy of tics in Tourette syndrome. *Neuropsychiatry Neuropsychol Behavioral Neurol* 2003.

124. Reutens DC, Puce A, Berkovic SF. Cortical hyperexcitability in progressive myoclonus epilepsy: a study with transcranial magnetic stimulation. *Neurology* 1993; 43:186-192.

125. Wedegaertner F, Garvey M, Cohen LG, Hallett M, Wassermann EM. Low frequency repetitive transcranial magnetic stimulation can reduce action myoclonus. *Neurology*

1997; 48:A119.

126. Ziemann U, Paulus W, Rothenberger A. Decreased motor inhibition in Tourette's disorder: evidence from transcranial magnetic stimulation. *Am J Psychiatry* 1997; 154:1277-1284.

127. Feinsod M, Sreinin B, Chistyakov A, Klein E. Preliminary evidence for a beneficial effect of low-frequency, repetitive transcranial magnetic stimulation in patients with major depression and schizophrenia. *Depression Anxiety* 1998; 7:65-68.

128. Nahas Z, McConnell K, Collins S. Could left prefrontal rTMS modify negative symptoms and attention in schizophrenia? *Biological Psychiatry* 1999; 45:37S #120.

129. Hoffman R, Boutros N, Berman R, Krystal J, Charney D. Transcranial magnetic stimulation and hallucinated 'voices'. *Biological Psychiatry* 1998; 43:93s. #310.

130. Greenberg BD, George MS, Dearing J. Effect of prefrontal repetitive transcranial magnetic stimulation (rTMS) in obsessive compulsive disorder: a preliminary study. *Am J Psychiatry* 1997; 154:867-869.

131. Cora-Locatelli G, Greenberg BD, Harmon A. Cortical excitability and augmentation strategies in OCD. *Biological Psychiatry* 1998; 43:77s (#258).

132. Greenberg BD, Ziemann U, Cora-Locatelli G. Altered cortical excitability in obsessive-compulsive disorder. *Neurology* 2000; 54:142-147.

133. Alonso P, Pujol J, Cardoner N. Right prefrontal TMS in OCD: a double-blind, placebo-electrical study. *Am J Psychiatry* 2001; 158:1143-1145.

134. Sachdev PS, McBride R, Loo CK, Mitchell PB, Malhi GS, Croker VM. Right versus left prefrontal transcranial magnetic stimulation for obsessive-compulsive disorder: a preliminary investigation. *J Clin Psychiatry* 2001; 62: 981-984.

135. McCann UD, Kimbrell TA, Morgan CM. Repetitive transcranial magnetic stimulation for posttraumatic stress disorder (letter). *Arch Gen Psychiatry* 1998; 55:276-279.

136. Grisar N, Amir M, Cohen H, Kaplan Z. Effect of transcranial magnetic stimulation in posttraumatic stress

disorder: a preliminary study. *Biological Psychiatry* 1998; 44:52-55.

137. Wassermann EM. Report on risk and safety of repetitive transcranial magnetic stimulation (rTMS): suggested guidelines from the International Workshop on Risk and Safety of rTMS (June 1996). *Electroencephalogr Clin Neurophysiol* 1997; 108:1-16.

138. Wassermann EM, Cohen LG, Flitman SS, Chen R, Hallett M. Seizures in healthy people with repeated safe trains of transcranial magnetic stimuli. *Lancet* 1996; 347:825-826.

139. Lorberbaum JP, Wassermann EM. Safety concerns of transcranial magnetic stimulation. In: George MS, Belmaker RH, eds. *Transcranial Magnetic Stimulation in Neuropsychiatry*. Washington, DC: American Psychiatric Press, 2000:141-162.

140. Jennum P, Winkel H. Transcranial magnetic stimulation. Its role in the evaluation of patients with partial epilepsy. *Acta Neurol Scand Suppl* 1994; 152:93-96.

141. Lisanby SH, Schlaepfer TE, Fisch HU, Sackeim HA. Magnetic seizure therapy for major depression. *Arch Gen Psychiatry* 2001; 58:303-305 (let).

142. Little JT, Kimbrell TA, Wassermann EM. Cognitive effects of 1 and 20 Hz repetitive transcranial magnetic stimulation in depression: Preliminary report. *Neuropsychiatry Neuropsychol Behavioral Neurol* 2000; 13: 119-124.

20 Repetitive Transcranial Magnetic Stimulation for Tinnitus

1. Konopka W, Zalewski P, Olszewski J, Olszewska-Ziaber A, Pietkiewicz P. Tinnitus suppression by electrical promontory stimulation (EPS) in patients with sensorineural hearing loss. *Auris Nasus Larynx* 2001 Jan; 28(1): 35-40.
2. Aldini J. Essai theorique et expérimantal sur le galvanisme, avec une série d'expériences faites en presence des commissaires de l'Institut national de France, et en divers amphithéatres anatomiques de Londres Paris, De l'Impr. de Fournier, 1804.
3. Lockwood AH, Salvi RJ, Burkard RF. Tinnitus. *N Engl J Med* 2002; 347:904-910.
4. Zenner HR, Ernst A. Cochlea-motor, transduction and signal-transfer tinnitus: models for three types of cochlear tinnitus. *Eur Arch Otorhinolaryngol* 1993; 249:447-454.
5. Eggermont JJ. On the pathophysiology of tinnitus: a review and a peripheral model. *Hear Res* 1990; 48:111-124.
6. Ito J, Sakakihara J. Suppression of tinnitus by cochlear implantation. *Am J Otolaryngol* 1994 Mar-Apr; 15(2): 145-148.
7. Vernon JA. Masking of tinnitus through a cochlear implant. *J Am Acad Audiol* 2000 Jun; 11(6):293-294.
8. Sakajiri M, Imamura T, Hirata Y, Izumi T, Ifukube T, Matsushima J. A method for suppressing tinnitus by electrical stimulation to cochlea and remedial value. *Journal of the Acoustical Soc Japan* 1993; 14(6):453-455.
9. Matsushima JI, Fujimura H, Sakai N, Sugauma T, Hayashi M, Ifukube T, Hirata Y, Miyoshi S. A study of electrical promontory stimulation in tinnitus patients. *Auris Nasus Larynx* 1994; 21(1):17-24.
10. House JW. Therapies for tinnitus. *Am J Otol* 1989; 10(3):163-165. Ito J, Sakahikara J. Tinnitus suppression by electrical stimulation of the cochlear wall and by cochlear implantation. *Laryngoscope* 1994;104(6):752-754.
11. Balkany T, Banti H. Direct electrical stimulation of the inner ear for the relief of tinnitus. *Am J Otol* 1987; 8(3): 207-1212.

12. Okusa M, Shiraishi T, Kubo T, Matsunaga T. Tinnitus suppression by electrical promontory stimulation in sensorineural deaf patients. *Acta Otolaryngol* 1993; 501:54-58.
13. Hazell JW, Meerton LJ, Conway MJ. Electrical tinnitus suppression (ETS) with a single channel cochlear implant. *J Laryngol Otol* 1989; 18:39-4.
14. Zwolan TA, Kileny PR, Souliere CR JR, Kemink H. Tinnitus suppression following cochlear implantation. In: Aran J-M, Dauman R, eds. *Tinnitus 91: Proceedings of the Fourth International Tinnitus Seminar*. The Netherlands. Amsterdam: Kugler Publications, 1992:417-442.
15. Portman M, Casals Y, Negrevergne M, Aran JM. Temporary tinnitus suppression in man through electrical stimulation of the cochlea. *Acta Otolaryngol* 1979; 87:294-299.
16. Matsushima J, Sakai N, Sakajiri M, Miyoshi S, Uemi N, Ifukube T. An experience of the usage of electrical tinnitus suppressor. *Artificial Organs* 1996; 20(8):955-958.
17. Battner RD, Heerman R, Laszig R. Suppression of tinnitus by electric stimulation in cochlear implant patients. *HNO* 1989; 37(4): 148-152.
18. Casals Y, Negrevergne M, Aran JM. Electrical stimulation of the cochlea in man: hearing introduction and tinnitus suppression. *J Am Audiol Soc* 1978; 3:209-213.
19. Hazell JW, Jastreboff PJ, Meerton LE, Conway MJ. Electrical tinnitus suppression: frequency dependence of effects. *Audiology* 1993; 32(1):68-77.
20. Watanabe K, Okawara D, Baba S, Yagi T. Electrocochleographic analysis of the suppression of tinnitus by electrical promontory stimulation. *Audiology* 1997; 36(3): 147-154.
21. Roddy J, Hubbard AE, Mountain DC, Xue S. Effects of electrical biasing on electrically-evoked otoacoustic emissions. *Hear Res* 1994; 73(2): 148-154.
22. Vavrina J, Muller W. Therapeutic effect of hyperbaric oxygenation in acute acoustic trauma. *Rev Laryngol Otol Rhinol* 1995; 116(5):377-380.
23. Engelberg M, Bauer W. Transcutaneous electrical

stimulation for tinnitus. *Laryngoscope* 1985; 95(10): 1167-1173.

24. Steenerson RL, Cronin GW. Treatment of tinnitus with electrical stimulation. *Otolaryngol Head Neck Surg* 1999 Nov; 121(5):511-513.

25. Rahko T, Kotti V. Tinnitus treatment by transcutaneous nerve stimulation (TNS). *Acta Otolaryngol Suppl* 1997; 529:88-89.

26. Shi Y-B, Martin WH. Deep brain stimulation for tinnitus. *Neurology* 2000; 54(7 suppl 3):A169.

27. Soussi T, Otto SR. Effects of electrical brainstem stimulation on tinnitus. *Acta Otolaryngol* 1994; 114(2): 135-140.

28. Nakashima T, Ueda H, Misawa H, Suzuki T, Tominaga M. Transmeatal low-power laser irradiation for tinnitus. *Otol Neurotol* May 2002; 23(3):296-300.

29. Kuk FK, Tyler RS, Rustad N, Harker LA, Tye-Murray N. Alternating current at the eardrum for tinnitus reduction. *J Speech Hearing Res* 1989; 32(2):393-400.

30. Roland NJ, Hughes JB, Daley MB, Cook JA, Jones AS, McCormick MS. Electromagnetic stimulation as a treatment of tinnitus: a pilot study. *Clini Otolaryngol* 1993; 18:278-281.

31. Gelb H, Gelb ML, Wagner ML. The relationship of tinnitus to craniocervical mandibular disorders. *Cranio* 1997 Apr; 15(2): 136-143.

32. Vernon J, Griest S, Press L. Attributes of tinnitus that may predict temporomandibular joint dysfunction. *Cranio* 1992 Oct; 10(4):282-287. Discussion 287-288.

33. Vernon J, Griest S, Press L. Attributes of tinnitus associated with the temporomandibular joint syndrome. *Eur Arch Otorhinolaryngol* 1992; 249(2):93-94.

34. Marsot-Dupuch K. Pulsatile and nonpulsatile tinnitus. *Semin Ultrasound* 2001; 22:250-270.

35. Moller AR. Similarities between chronic pain and tinnitus. *Am J Otol* 1997 Sep; 18(5):577-585.

36. Moller AR. Similarities between severe tinnitus and

- chronic pain. *J Am Acad Audiol* 2000 Mar; 11(3):115-124.
37. Stoufler JL, Tyler RS. Characteristics of tinnitus by tinnitus patients. *J Speech Hear Disord* 1990; 55:439-453.
38. Fox GN, Baer MT. Palatal myoclonus and tinnitus in children. *West J Med* 1991; 154:98-102.
39. Adams PE, Hendershot GE, Marano MA. Current Estimates from the National Health Inventory Survey, 1996. Hyatsville Md.: National Center for Health Statistics, 1999.
40. Baguley DM, McFerran DJ. Tinnitus in childhood. *Int J Pediatr Otorhinolaryngol* 1999; 49:99- 105.
41. Sanders BT. There is something you can do about tinnitus (www.healthyhearing.com).
42. Recent tinnitus surveys (www.ata.com).
43. Voss M. Tinnitus. In: Jafek B, ed. *ENT Secrets*. Philadelphia, Pa: Hanley & Belfus, 1996:58- 61.
44. Holgers KM, Erlandsson ST, Barrenas Ml. Predictive factors for the severity of tinnitus. *Audiology* 2000; 39: 284-291.
45. Sullivan M, Katon W, Russo J, Dobie R, Sakal C. A randomized trial of nortriptyline for severe chronic tinnitus: effects on depression, disability and tinnitus symptoms. *Arch Int Med* 1993; 153:2251-2259.
46. Folmer RG, Griest SG, Meikle MB, Martin WH. Tinnitus severity, loudness and depression. *Otolaryngol Head Neck Surg* 1999; 121:48-51.
47. Matthies C, Samii M. Management of 1000 vestibular schwannomas (acoustic neuromas): clinical presentation. *Neurosurgery* 1997; 40:1-9.
48. Lenarz T, Schreiner C, Snyder RL. Neural mechanisms of tinnitus. *Eur Arch Otorhinolaryngol* 1993; 249: 441-446.
49. Newman CW, Wharton JA, Jacobson GP. Self-focused and somatic attention in patients with tinnitus. *J Am Acad Audiol* 1997; 8:143-149.
50. Rauschecker JP. Auditory cortical plasticity: a comparison with other sensory systems. *Trends Neurosci* 1999; 22: 74-80.

51. Jastreboff PJ. Phantom auditory perception (tinnitus): mechanisms of generation and perception. *Neurosci Res* 1990; 8:221-254.
52. Folmer RL, Griest SE, Martin WH. Chronic tinnitus as phantom auditory pain. *Otolaryngol Head Neck Surg* 2001; 124:39-400.
53. Moller AR. Similarities between severe tinnitus and chronic pain. *J Am Acad Audiol* 2000; 11:115-124.
54. Muhlmeckel W, Ebert T, Taub E. Reorganization of auditory cortex in tinnitus. *Proc Soc Nat Acad Sci USA* 1998; 95:10340-10343.
55. Giraud AL, Chery CS, Fischer G. A selective imaging of tinnitus. *Neuroreport* 1999; 10:1-5.
56. Mirz F, Pederson B, Ishizu K. Positron emission tomography of cortical centers of tinnitus. *Hear Res* 1999; 134: 133-144.
57. Ochi K, Kinoshita H, Kenmochi M, Nishino H, Ohashi T. Zinc deficiency and tinnitus. *Auris Nasus Larynx* 2003; 30:25-28.
58. Eggermont JJ. Central tinnitus. *Auris Nasus Larynx* 2003; 30:7-12.
59. Plewnia C, Bartels M, Gerloff C. Transient suppression of tinnitus by transcranial magnetic stimulation. *Ann Neurol* 2003; 53:263-266.
60. Arnold W, Bartenstein P, Oestricher E. Focal metabolic activation in the predominant left auditory cortex in patients with suffering from tinnitus: a PET study with [18F]deoxyglucose. *ORL (Basel)* 1996; 58:195-199.
61. Andersson G, Lyttkens L, Hirvela C. Regional cerebral blood flow during tinnitus: a PET case study with lidocaine and auditory stimulation. *Acta Otolaryngol* 2000; 120:967-972.
62. Gardener A, Pagani M, Jacobson H. Differences in resting state regional cerebral blood flow assessed with 99mTcHMPAO SPECT and brain atlas matching between depressed patients with and without tinnitus. *Nucl Med Commun* 2002; 23:429-439.

63. Siebner HR, Tormos JM, Ceballos-Baumann AO. Low frequency repetitive magnetic stimulation of the motor cortex in writer's cramp. *Neurology* 1999; 52:529-537.

64. Poremba A, Saunders RC, Crane M, Cooke M, Sokoloff L, Mishkin M. Functional mapping of the primate auditory system. *Science* 2003; 299:568-572.

65. Brody J. New hope for quieting the roaring in the ears. *New York Times* 2002 October 29; F7.

21 Low-Energy Emission Therapy: Current Status and Future Directions

1. Reite M, Higgs L, Lebet JP, Barbault A, Rossel C, Kuster N, Dafni U, Amato D, Pasche B. Sleep inducing effect of low energy emission therapy. *Bioelectromagnetics* 1994; 15:67-75.
2. Lebet JP, Barbault A, Rossel C, Tomic Z, Reite M, Higgs L, Dafni U, Amato D, Pasche B. Electroencephalographic changes following low energy emission therapy. *Ann Biomed Eng* 1996; 24:424-429.
3. Higgs L, Reite M, Barbault A, Lebet J-P, Rossel C, Amato D, Dafni U, Pasche B. Subjective and objective relaxation effects of low energy emission therapy. *Stress Med* 1994; 10:5-13.
4. Pasche B, Erman M, Hayduk R, Mitler M, Reite M, Higgs L, Dafni U, Amato D, Rossel C, Kuster N, Barbault A, Lebet JP. Effects of low energy emission therapy in chronic psychophysiological insomnia. *Sleep* 1996; 19: 327-336.
5. Lesh MD. Interventional electrophysiology-state-of-the-art 1993. *Am Heart J* 1993; 126:686- 698.
6. Adey WR. Biological effects of electromagnetic fields. *J Cell Biochem* 1993; 51:410-416.
7. Rosch P.J. Electromagnetic waves and neurobehavioral function: comments from clinical medicine. In: O'Connor ME, Lovely H, eds. *Electromagnetic Fields and Neurobehavioral Function*. New York: Alan R.Liss, 1988:377-388.
8. Pasche B. The physiological effects of low energy emission therapy (LEET). *First International Montreux Congress on Stress*, 1988.
9. Pasche B, Erman M, Mitler M. Diagnosis and management of insomnia. *N Engl J Med* 1990; 323:486-487.

Figure 3 Comparison of power density ranges for diathermy, cellular phones, MRI, and LEET. Estimated absorbed

power density ranges for therapeutic diathermy, cellular phones, and magnetic resonance imaging (MRI), as compared

to low-energy emission therapy (LEET). Incident power density for MRI is highly dependent on frequency and pulse

characteristics. The range shown here is for a 100-MHz device. Approximate brain and heart metabolic rates are shown

for comparison. This plot is on a log scale.

10. Koziol JA, Erman M, Pasche B, Hajdukovic R, Mitler MM. Assessing a changepoint in a sequence of repeated measurements with application to a low-energy emission therapy sleep study. *J Applied Statistics* 1993; 20: 393-400.

11. Amato D, Pasche B. An evaluation of the safety of low energy emission therapy [published erratum appears in *Compr Ther* 1994; 20(12):681]. *Compr Ther* 1993; 19:242-247.

22 Vagus Nerve Stimulation for the Treatment of Epilepsy

1. Lhatoo SD, Wong IC, Polizzi G, Sander JW. Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy. *Epilepsia* 2000; 41:1592-1596.
2. Fisher RS, Vickrey BG, Gibson P, Hermann B, Penovich P, Scherer A, Walker SG. The impact of epilepsy from the patient's perspective II. Views about therapy and health care. *Epilepsy Res* 2000; 41:53-61.
3. Kemeny AA. Surgery for epilepsy. *Seizure* 2001; 10:461-465.
4. Loddenkemper T, Pan A, Neme S, Baker KB, Rezai AR, Dinner DS, Montgomery EB, Luders HO. Deep brain stimulation in epilepsy. *J Clin Neurophysiol* 2001; 18:514-532.
5. Velasco M, Velasco F, Velasco AL. Centromedian-thalamic and hippocampal electrical stimulation for the control of intractable epileptic seizures. *J Clin Neurophysiol* 2001; 18:495-513.
6. Saper CB, Kibbe MR, Hurley KM, Spencer S, Holmes HR, Leahy KM, Needleman P. Brain natriuretic peptidelike immunoreactive innervation of the cardiovascular and cerebrovascular systems in the rat. *Circ Res* 1990; 67:1345-1354.
7. Saper CB. The central autonomic system. In: Paxinos G, ed. *The Rat Nervous System*. 2d ed. San Diego: Academic, 1995:107-131.
8. Cechetto DF, Saper CB. Evidence for a viscerotopic sensory representation in the cortex and thalamus in the rat. *J Comp Neurol* 1987; 262:27-45.
9. Fulwiler CE, Saper CB. Subnuclear organization of the efferent connections of the parabrachial nucleus in the rat. *Brain Res Rev* 1984; 7:229-259.
10. Saper CB. Diffuse cortical projection systems: anatomical organization and role in cortical function. In: Plum F, ed. *Handbook of Physiology. The Nervous System* V. Bethesda: American Physiological Society, 1987:169-210.
11. Naritoku DK, Terry WJ, Helfert RH. Regional induction of fos immunoreactivity in the brain by anticonvulsant stimulation of the vagus nerve. *Epilepsy Res* 1995;

22:53-62.

12. Krahl SE, Clark KB, Smith DC, Browning RA. Locus coeruleus lesions suppress the seizure-attenuating effects of vagus nerve stimulation. *Epilepsia* 1998; 39:708-714.

13. Chase MH, Sterman MB, Clemente CD. Cortical and subcortical patterns of response to afferent vagal stimulation. *Exp Neurol* 1966; 16:36-49.

14. Chase MH, Nakamura Y, Clemente CD, Sterman MB. Afferent vagal stimulation: neurographic correlates of induced EEG synchronization and desynchronization. *Brain Res* 1967; 5:236-249.

15. Chase MH, Nakamura Y, Clemente CD, Sterman MB. Cortical and subcortical EEG patterns of response to afferent abdominal vagal stimulation: neurographic correlates. *Physiol Behav* 1968; 3:605-610.

16. Zagon A, Kemeny AA. Slow hyperpolarization in cortical neurons: a possible mechanism behind vagus nerve stimulation therapy for refractory epilepsy? *Epilepsia* 2000; 41:1382-1389.

17. Krahl SE, Senanayake SS, Handforth A. Destruction of peripheral C-fibers does not alter subsequent vagus nerve stimulation-induced seizure suppression in rats. *Epilepsia* 2001; 42:586- 589.

18. Olejniczak PW, Fisch BJ, Carey M, Butterbaugh G, Happel L, Tardo C. The effect of vagus nerve stimulation on epileptiform activity recorded from hippocampal depth electrodes. *Epilepsia* 2001; 42:423-429.

19. Garnett ES, Nahmias C, Scheffel A, Firnau G, Upton ARM. Regional cerebral blood flow in man manipulated by direct vagal stimulation. *Pacing Clin Electrophysiol* 1992; 15(10 Pt 2): 1579-1580.

20. Ko D, Heck C, Grafton S, Apuzzo MLJ, Couldwell WT, Chen T, Day JD, Zelman V, Smith T, DeGiorgio CM. Vagus nerve stimulation activates central nervous system structures in epileptic patients during PET H₂ 15 O blood flow imaging. *Neurosurgery* 1996; 39(2):426-431.

21. Ferris EB, Capps RB, Weiss S. Carotid sinus syncope and its bearing on the mechanism of the unconscious state and convulsions. *Medicine* 1934; 14:377-453.

22. Reis DJ, Iadecola C, Nakai M. Control of cerebral blood flow and metabolism by intrinsic neural systems in brain. In: Plum F, Pulsinelli W, eds. Cerebrovascular Diseases. New York: Raven Press, 1985:1-25.
23. Ring HA, White S, Costa DC, Pottinger R, Dick JPR, Koeze T, Sutcliffe J. A SPECT study of the effect of vagal nerve stimulation on thalamic activity in patients with epilepsy. *Seizure* 2000; 9:380-384.
24. Vonck K, Boon P, Van Laere K, D'Have M, Vandekerchhove T, O'Connor S, Brans B, Dierckx R, De Reuck J. Acute single photon emission computed tomographic study of vagus nerve stimulation in refractory epilepsy. *Epilepsia* 2000; 41:601-609.
25. Henry TR, Votaw JR, Pennell PB, Epstein CM, Bakay RAE, Faber TL, Grafton ST, Hoffman JM. Acute blood flow changes and efficacy of vagus nerve stimulation in partial epilepsy. *Neurology* 1999; 52:1166-1173.
26. Henry TR, Bakay RAE, Votaw JR, Pennell PB, Epstein CM, Faber TL, Grafton ST, Hoffman JM. Brain blood flow alterations induced by therapeutic vagus nerve stimulation in partial epilepsy: I. Acute effects at high and low levels of stimulation. *Epilepsia* 1998; 39:983-990.
27. Henry TR, Votaw JR, Bakay RAE, Pennell PB, Epstein CM, Faber TL, Grafton ST, Hoffman JM. Vagus nerve stimulation-induced cerebral blood flow changes differ in acute and chronic therapy of complex partial seizures [abstr]. *Epilepsia* 1998; 39(suppl 6):92.
28. Bohning DE, Lomarev MP, Denslow S, Nahas Z, Shastri A, George MS. Feasibility of vagus nerve stimulationsynchronized blood oxygenation level-dependent functional MRI. *Invest Radiol* 2001; 36:470-479.
29. McLachlan RS. Suppression of interictal spikes and seizures by stimulation of the vagus nerve. *Epilepsia* 1993; 34:918-923.
30. Woodbury DM, Woodbury JW. Effects of vagal stimulation on experimentally induced seizures in rats. *Epilepsia* 1990; 31(suppl 2):S7-S19.
31. Woodbury JW, Woodbury DM. Vagal stimulation reduces the severity of maximal electroshock seizures in intact rats: use of a cuff electrode for stimulating and recording. *Pacing Clin Electrophysiol* 1991; 14:94-107.

32. Zabara J. Inhibition of experimental seizures in canines by repetitive vagal stimulation. *Epilepsia* 1992; 33: 1005-1012.
33. Lockard JS, Congdon MC, DuCharme LL. Feasibility and safety of vagal stimulation in monkey model. *Epilepsia* 1990; 31(suppl 2):S20-S26.
34. Takaya M, Terry WJ, Naritoku DK. Vagus nerve stimulation induces a sustained anticonvulsant effect. *Epilepsia* 1996; 37:1111-1116.
35. Penry JK, Dean JC. Prevention of intractable partial seizures by intermittent vagal stimulation in humans: preliminary results. *Epilepsia* 1990; 31(suppl 2):S40-S43.
36. Ben-Menachem E, Manon-Espaillat R, Ristanovic R, Wilder BJ, Stefan H, Mirza W, Tarver WB, Wernicke JF. Vagus nerve stimulation for treatment of partial seizures: 1. A controlled study of effect on seizures. *Epilepsia* 1994; 35:616-626.
37. Ramsay RE, Uthman BM, Augustinsson LE, Upton ARM, Naritoku D, Willis J, Treig T, Barolat G, Wernicke JF. Vagus nerve stimulation for treatment of partial seizures: 2. Safety, side effects, and tolerability. *Epilepsia* 1994; 35:627-636.
38. George R, Salinsky M, Kuzniecky R, Rosenfeld W, Bergen D, Tarver WB, Wernicke JF. Vagus nerve stimulation for treatment of partial seizures: 3. Long-term follow-up on first 67 patients exiting a controlled study. *Epilepsia* 1994; 35:637-643.
39. The Vagus Nerve Stimulation Study Group. A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures. *Neurology* 1995; 45:224-230.
40. Handforth A, DeGiorgio CM, Schachter SC, Uthman BM, Naritoku DK, Tecoma ES, Henry TR, Collins SD, Vaughn BV, Gilmartin RC, Labar DR, Morris GL, Salinsky MC, Osorio I, Ristanovic RK, Labiner DM, Jones JC, Murphy JV, Ney GC, Wheless JW. Vagus nerve stimulation therapy for partial-onset seizures: a randomized active control trial. *Neurology* 1998; 51:48-55.
41. Labar D, Murphy J, Tecoma E. Vagus nerve stimulation for medication-resistant generalized epilepsy. E04 VNS

Study Group. *Neurology* 1999; 52:1510-1512.

42. Michael JE, Wegener K, Barnes DW. Vagus nerve stimulation for intractable seizures: one year follow-up. *J Neurosci Nurs* 1993; 25:362-366.

43. Salinsky MC, Uthman BM, Ristanovic RK, Wernicke JF, Tarver WB. Vagus nerve stimulation for the treatment of medically intractable seizures. Results of a 1-year open-extension trial. *Arch Neurol* 1996; 53:1176-1180.

44. DeGiorgio CM, Schachter SC, Handforth A, Salinsky M, Thompson J, Uthman B, Reed R, Collins S, Tecoma E, Morris GL, Vaughn B, Naritoku DK, Henry T, Labar D, Gilmartin R, Labiner D, Osorio I, Ristanovic R, Jones J, Murphy J, Ney G, Wheless J, Lewis P, Heck C. Prospective long-term study of vagus nerve stimulation for the treatment of refractory seizures. *Epilepsia* 2000; 41:1195-1200.

45. DeGiorgio CM, Thompson J, Lewis P, Arrambide S, Naritoku D, Handforth A, Labar D, Mullin P, Heck C. Vagus nerve stimulation: analysis of device parameters in 154 patients during the long-term XE5 study. *Epilepsia* 2001; 42:1017-1020.

46. Tatum WO. Vagus nerve stimulation and drug reduction: reply. *Neurology* 2001; 57:938- 939.

47. Tatum WO, Johnson KD, Goff S, Ferreira JA, Vale FL. Vagus nerve stimulation and drug reduction. *Neurology* 2001; 56:561-563.

48. Rafael H, Moromizato P. Vagus nerve stimulation (VNS) may be useful in treating patients with symptomatic generalized epilepsy. *Epilepsia* 1998; 39:1018.

49. Hornig G, Murphy JV. Vagal nerve stimulation: updated experience in 60 pediatric patients [abstr]. *Epilepsia* 1998; 39(suppl 6):169.

50. Murphy JV, Hornig G, Schallert G. Left vagal nerve stimulation in children with refractory epilepsy. Preliminary observations. *Arch Neurol* 1995; 52:886-889.

51. Lundgren J, Amark P, Blennow G, Stromblad LG, Wallstedt L. Vagus nerve stimulation in 16 children with refractory epilepsy. *Epilepsia* 1998; 39:809-813.

52. Parker AP, Polkey CE, Binnie CD, Madigan C, Ferrie CD, Robinson RO. Vagal nerve stimulation in epileptic

encephalopathies. *Pediatrics* 1999; 103:778-782.

53. Helmers SL, Al-Jayyousi M, Madsen J. Adjunctive treatment in Lennox-Gastaut syndrome using vagal nerve stimulation [abstr]. *Epilepsia* 1998; 39(suppl 6): 169.

54. Murphy JV, Hornig G. Chronic intermittent stimulation of the left vagal nerve in nine children with Lennox-Gastaut syndrome [abstr]. *Epilepsia* 1998; 39(suppl 6): 169.

55. Frost M, Gates J, Helmers SL, Wheless JW, Levisohn P, Tardo C, Conry JA. Vagus nerve stimulation in children with refractory seizures associated with Lennox-Gastaut syndrome. *Epilepsia* 2001; 42:1148-1152.

56. Murphy JV. Left vagal nerve stimulation in children with medically refractory epilepsy. *J Pediatr* 1999; 134: 563-566.

57. Hosain S, Nikalov B, Harden C, Li M, Fraser R, Labar D. Vagus nerve stimulation treatment for Lennox-Gastaut syndrome. *J Child Neurol* 2000; 15:509-512.

58. Patwardhan RV, Stong B, Bebin EM, Mathisen J, Grabb PA. Efficacy of vagal nerve stimulation in children with medically refractory epilepsy. *Neurosurgery* 2000; 47:1353-1358.

59. Andriola MR, Vitale SA. Vagus nerve stimulation in the developmentally disabled. *Epilepsy Behav* 2001; 2: 129-134.

60. Sirven JI, Sperling M, Naritoku D, Schachter S, Labar D, Holmes M, Wilensky A, Cibula J, Labiner DM, Bergen D, Ristanovic R, Harvey J, Dasheiff R, Morris GL, O'Donovan CA, Ojemann L, Scales D, Nadkarni M, Richards B, Sanchez JD. Vagus nerve stimulation therapy for epilepsy in older adults. *Neurology* 2000; 54:1179-1182.

61. Clark KB, Smith DC, Hassert DL, Browning RA, Naritoku DK, Jensen RA. Posttraining electrical stimulation of vagal afferents with concomitant vagal efferent inactivation enhances memory storage processes in the rat. *Neurobiol Learn Mem* 1998; 70:364-373.

62. Clark KB, Naritoku DK, Smith DC, Browning RA, Jensen RA. Enhanced recognition memory following vagus nerve stimulation in human subjects. *Nat Neurosci* 1999; 2:94-98.

63. Helmstaedter C, Hoppe C, Elger CE. Memory alterations during acute high-intensity vagus nerve stimulation.

Epilepsy Res 2001; 47:37-42.

64. Elger G, Hoppe C, Falkai P, Rush AJ, Elger CE. Vagus nerve stimulation is associated with mood improvements in epilepsy patients. *Epilepsy Res* 2000; 42:203-210.

65. Harden CL, Pulver MC, Ravdin LD, Nikolov B, Halper JP, Labar DR. A pilot study of mood in epilepsy patients treated with vagus nerve stimulation. *Epilepsy Behav* 2000; 1:93-99.

66. Hoppe C, Helmstaedter C, Scherrmann J, Elger CE. Self-reported mood changes following 6 months of vagus nerve stimulation in epilepsy patients. *Epilepsy Behav* 2001; 2:335-342.

67. Aldenkamp AP, Van de Veerdonk SHA, Majoie HJM, Berfelo MW, Evers SMAA, Kessels AGH, Renier WD, Wilmink J. Effects of 6 months of treatment with vagus nerve stimulation on behavior in children with LennoxGastaut syndrome in an open clinical and nonrandomized study. *Epilepsy Behav* 2001; 2:343-350.

68. Murphy JV, Wheless JW, Schmoll CM. Left vagal nerve stimulation in six patients with hypothalamic hamartomas. *Pediatr Neurol* 2000; 23:167-168.

69. Dodrill CB, Morris GL. Effects of vagal nerve stimulation on cognition and quality of life in epilepsy. *Epilepsy Behav* 2001; 2:46-53.

70. Hoppe C, Helmstaedter C, Scherrmann J, Elger CE. No evidence for cognitive side effects after 6 months of vagus nerve stimulation in epilepsy patients. *Epilepsy Behav* 2001; 2:351-356.

71. Malow BA, Edwards J, Marzec M, Sagher O, Ross D, Fromes G. Vagus nerve stimulation reduces daytime sleepiness in epilepsy patients. *Neurology* 2001; 57:879-884.

72. Terry RS, Tarver WB, Zabara J. The implantable neurocybernetic prosthesis system. *Pacing Clin Electrophysiol* 1991; 14:86-93.

73. Agnew WF, McCreery DB. Considerations for safety with chronically implanted nerve electrodes. *Epilepsia* 1990; 31(suppl 2):S27-S32.

74. Tarver WB, George RE, Maschino SE, Holder LK, Wernicke JF. Clinical experience with a helical bipolar stimulating

lead. *Pacing Clin Electrophysiol* 1992; 15:1545-1556.

75. Morris GL, Mueller WM. Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy. *Neurology* 1999; 53:1731-1735.

76. Cramer JA. Exploration of changes in health-related quality of life after 3 months of vagus nerve stimulation. *Epilepsy Behav* 2001; 2:460-465.

77. Morrow JI, Bingham E, Craig JJ, Gray WJ. Vagal nerve stimulation in patients with refractory epilepsy. Effect on seizure frequency, severity and quality of life. *Seizure* 2000; 9:442-445.

78. Annegers JF, Coan SP, Hauser WA, Leestma J. Epilepsy, vagal nerve stimulation by the NCP system, all-cause mortality, and sudden, unexpected, unexplained death. *Epilepsia* 2000; 41: 549-553.

79. Asconape JJ, Moore DD, Zipes DP, Hartman LM, Duffell MH. Bradycardia and asystole with the use of vagus nerve stimulation for the treatment of epilepsy: a rare complication of intraoperative device testing. *Epilepsia* 1999; 40:1452-1454.

80. Tatum WO, Moore DB, Stecker MM, Baltuch GH, French JA, Ferreira JA, Carney PM, Labar DR, Vale F. Ventricular asystole during vagus nerve stimulation for epilepsy in humans. *Neurology* 1999; 52:1267-1269.

81. Andriola MR, Rosenzweig T, Vlay S. Vagus nerve stimulator (VNS): induction of asystole during implantation with subsequent successful stimulation [abstr], *Epilepsia* 2000; 41(suppl 7):223.

82. Frei MG, Osorio I. Left vagus nerve stimulation with the Neurocybernetic Prosthesis has complex effects on heart rate and on its variability in humans. *Epilepsia* 2001; 42:1007-1016.

83. Binks AP, Paydarfar D, Schachter SC, Guz A, Banzett RB. High strength stimulation of the vagus nerve in awake humans: a lack of cardiorespiratory effects. *Respir Physiol* 2001; 127:125- 133.

84. Sanossian N, Haut S. Chronic diarrhea associated with vagal nerve stimulation. *Neurology* 2002; 58:330.

85. Kim W, Clancy RR, Liu GT. Horner syndrome associated

- with implantation of a vagus nerve stimulator. *Am J Ophthalmol* 2001; 131:383-384.
86. Leijten FSS, Van Rijen PC. Stimulation of the phrenic nerve as a complication of vagus nerve pacing in a patient with epilepsy. *Neurology* 1998; 51:1224-1225.
87. Malow BA, Edwards J, Marzec M, Sagher O, Fromes G. Effects of vagus nerve stimulation on respiration during sleep: a pilot study. *Neurology* 2000; 55:1450-1454.
88. Blumer D, Davies K, Alexander A, Morgan S. Major psychiatric disorders subsequent to treating epilepsy by vagus nerve stimulation. *Epilepsy Behav* 2001; 2:466-472.
89. Prater JF. Recurrent depression with vagus nerve stimulation. *Am J Psychiatry* 2001; 158:816- 817.
90. Schallert G, Foster J, Lindquist N, Murphy JV. Chronic stimulation of the left vagal nerve in children: effect on swallowing. *Epilepsia* 1998; 39:1113-1114.
91. Lundgren J, Ekberg O, Olsson R. Aspiration: a potential complication to vagus nerve stimulation. *Epilepsia* 1998; 39:998-1000.
92. Ben-Menachem E, Ristanovic R, Murphy J. Gestational outcomes in patients with epilepsy receiving vagus nerve stimulation [abstr]. *Epilepsia* 1998; 39(suppl 6): 180.
93. Doerksen K, Klassen L. Vagus nerve stimulation therapy: nurses role in a collaborative approach to a program. *Axone* 1998; 20:6-9.
94. McLachlan RS. Vagus nerve stimulation for treatment of seizures? Maybe. *Arch Neurol* 1998; 55:232-233.
95. Boon P, Vonck K, D'Have R, O'Connor S, Vandekerckhove T, De Reuck J. Cost benefit of vagus nerve stimulation for refractory epilepsy. *Acta Neurol Belg* 1999; 99:275-280.
96. Ben-Menachem E. Vagus nerve stimulation for treatment of seizures? Yes. *Arch Neurol* 1998; 55:231-232.
97. DeGiorgio CM, Amar A, Apuzzo MLJ. Surgical anatomy, implantation technique, and operative complications. In: Schachter SC, Schmidt D, eds. *Vagus Nerve Stimulation*. London: Martin Dunitz, 2001:31-50.
98. Patil A-A, Chand A, Andrews R. Single incision for

implanting a vagal nerve stimulator system (VNSS):
technical note. *Surg Neurol* 2001; 55:103-105.

99. Vaughn BV, Bernard E, Lannon S, Mann B, D'Cruz OF,
Shockley W, Passanante A. Intraoperative methods for
confirmation of correct placement of the vagus nerve
stimulator. *Epileptic Disord* 2001; 3:75-78.

100. Ortler M, Luef G, Kofler A, Bauer G, Twerdy K. Deep
wound infection after vagus nerve stimulator implantation:
treatment without removal of the device. *Epilepsia* 2001;
42:133-135.

101. Liporace J, Hucko D, Morrow R, Barolat G, Nei M,
Schnur J, Sperling M. Vagal nerve stimulation: adjustments
to reduce painful side effects. *Neurology* 2001; 57:885-886.

102. Chadwick D. Vagal-nerve stimulation for epilepsy.
Lancet 2001; 357:1726-1727.

103. Binnie CD. Vagus nerve stimulation for epilepsy: a
review. *Seizure* 2000; 9:161-169.

104. Schmidt D. Vagus nerve stimulation for the treatment
of epilepsy. *Epilepsy Behav* 2001; 2:S1- S5.

23 Electrical Stimulation of the Internal Globus Pallidus in Advanced Generalized Dystonia

1. Laitinen LV. Brain targets in surgery for Parkinson's disease. Results of a survey of neurosurgeons. *J Neurosurg* 1985; 62(march):349-351.
2. Laitinen LV, Bergenheim AT, Hariz ML. Ventroposterolateral pallidotomy can abolish all parkinsonian symptoms. *Stereotact Funct Neurosurg* 1992; 58(1-4): 14-21.
3. Benabid AL, Pollak P, Louveau A, Henry S, de Rougemont J. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. *Appl Neurophysiol* 1987; 50(1- 6):344-346.
4. Benabid AL, Benazzouz A, Hoffmann D, Limousin P, Krack P, Pollak P. Long-term electrical inhibition of deep brain targets in movement disorders. *Mov Disord* 1998; 13(suppl 3):119-125.
5. Limousin P, Pollak P, Benazzouz A, Hoffmann D, Le Bas JF, Broussolle E, Perret JE, Benabid AL. Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. *Lancet* 1995; 345(8942):91-95.
6. Vayssiere N, Hemm S, Zanca M, Picot MC, Bonafe A, Cif L, Frerebeau P, Coubes P. Magnetic resonance imaging stereotactic target localization for deep brain stimulation in dystonic children. *J Neurosurg* 2000; 93(5): 784-790.
7. Derosier C, Buee C, Ledour O, Horf F, Desgeorges M, Cosnard G. MRI and stereotaxis. Choice of an approach route on an independent console. *J Neuroradiol* 1991; 18(4):333-339.
8. Burke R, Fahn S, Marsden C. Validity and reliability of a rating scale for the primary torsion dystonia. *Neurology* 1985; 35:73-77.
9. Burke RE. Idiopathic torsion dystonia. *Mov Disord* 1992; 7(4):387-388.
10. Fahn S. Concept and classification of dystonia. *Adv Neurol* 1988; 50(2): 1-8.
11. Kramer PL, de Leon D, Ozelius L, Risch N, Bressman SB, Brin MF, Schuback DE, Burke RE, Kwiatkowski DJ, Shale H.

Dystonia gene in Ashkenazi Jewish population is located on chromosome 9q32-34. *Ann Neurol* 1990; 27(2): 114-120.

12. Ozelius LJ, Hewett JW, Page CE, Bressman SB, Kramer PL, Shalish C, de Leon D, Brin MF, Raymond D, Corey DP, Fahn S, Risch NJ, Buckler AJ, Gusella JF, Breakefield XO. The earlyonset torsion dystonia gene (DYT1) encodes an ATP-binding protein. *Nat Genet* 1997; 17(1):40- 48.

13. Fletcher NA. The genetics of idiopathic torsion dystonia. *J Med Genet* 1990; 27(7):409-412.

14. Zhou B, Westaway SK, Levinson B, Johnson MA, Gitschier J, Hayflick SJ. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. *Nat Genet* 2001; 28(4):345- 349.

15. Hemm S, Cif L, Monnier C, Diakonova N, Hardouin E, Ganau A, Vayssiere N, Roubertie A, Azais M, Tuffery S, Mansour M, Claustres M, Echenne, B.P.C. Dystonies généralisées primitives: traitement par stimulation électrique chronique du globus pallidus interne. *Mouvements* 2001; 8:4-13.

16. Coubes P, Cif L, Azais M, Roubertie A, Hemm S, Diakonoya N, Vayssiere N, Monnier C, Hardouin E, Ganau A, Tuffery S, Claustre M, Echenne B. Traitement des syndromes dystoniques par stimulation électrique chronique du globus pallidus interne. *Arch Pediatr* 2002; 9(suppl 2):84s-86s.

17. Coubes P, Roubertie A, Vayssiere N, Hemm S, Echenne B. Treatment of DYT1-generalised dystonia by stimulation of the internal globus pallidus. *Lancet* 2000; 355(9222):2220-2221.

24 Peripheral Stimulation for Pain Control and the Development of Modern Transcutaneous Stimulation for Pain

1. Abraham SE, Reynolds AC, Cusick JF. Failure to naloxonee to reverse analgesia from transcutaneous electrical stimulation in patients with chronic pain. *Anesth Analg* 1981; 60:81- 84.
2. Anderson SA, Holmgren E. Pain threshold effects of peripheral conditioning stimulation. In Bonica JJ, AlbeFesard DG, eds. *Advances in Pain Research and Therapy. Proc. First World Congr Pain. Vol 1.* New York: Raven Press, 1976:761-768.
3. Arendt-Nielsen L, Bjerring P. Long-term effect of low and high frequency TNS on pain related cortical responses. *Pain* 1987; 4(suppl):S366.
4. Augustinsson L-E, Bohlin P, Bundsen P, Carlsson CA, Forssman I. Pain relief during delivery by transcutaneous electrical nerve stimulation. *Pain* 1977; 4:59-65.
5. Callaghan M, Sternback RA, Nyquist JK, Timmermans G. Changes in somatic sensitivity during transcutaneous electrical analgesia. *Pain* 1978; 5:115-128.
6. Campbell JN, Taub A. Local analgesia from percutaneous electrical stimulation: A peripheral mechanism. *Arch Neurol* 1973; 28:347-350.
7. Carlsson CA, Augustinsson L-E, Lund S, Roupe G. Electrical transcutaneous nerve stimulation for the relief of itch. *Experientia* 1975; 31:191.
8. Chapman CR, Benedetti C. Analgesia following transcutaneous electrical stimulation and its partial reversal by a narcotic antagonist. *Life Sci* 1977; 21:1645-1648.
9. Cheng RSS, Pomeranz B. Electracupuncture analgesia could be mediated by at least two pain-relieving mechanisms: Endorphin and non-endorphin systems. *Life Sci* 1979; 25:1957- 1962.
10. Finch L, Melzak R, Birks RI, Davis MWL. Comparison of conventional versus short burst TENS. *Pain* 1987; 4 (suppl):S365.
11. Ekblom A, Hansson P. Extrasegment transcutaneous

- electrical nerve stimulation and mechanical vibratory stimulation as compared to placebo for the relief of acute oro-facial pain. *Pain* 1985; 23:223-229.
12. Fall M. Conservative management of chronic interstitial cystitis: transcutaneous electrical nerve stimulation and transurethral resection. *J Urol* 1985; 133:774-777.
13. Fields HL, Adams JE, Hosobuchi Y. Peripheral nerve and cutaneous electrohypalgesia. *Adv Neurol* 1974; 4: 749-754.
14. Finsen V, Persen L, Lovlien M, Veslegaard EK, Simensen M, Gasvann AK, Benum P. Transcutaneous electrical nerve stimulation after major amputation. *J Bone Joint Surg* 1988; 70B:109- 112.
15. Golding JF, Ashton H, Marsh R, Thomson JW. Transcutaneous electrical nerve stimulation produces variable changes in somatosensory evoked potentials, sensory perception and pain threshold: clinical implications for pain relief. *J Neurol Neurosurg Psychiatry* 49:1397-1406.
16. Hagfors NR, Schwartz SI. Implantable Electronic Carotid Sinus Nerve Stimulators for Reducing Hypertension. *Proceedings of the Nineteenth Annual Conference on Engineering in Medicine and Biology* 1966; 8:36.
17. Hansson P, Ekblom A, Thomsson M, Fjellner B. Influence of naloxone on relief of acute orofacial pain by transcutaneous electrical nerve stimulation (TENS) or vibration. *Pain* 1986; 24: 323-329.
18. Harrison RF, Woods T, Shore M, Mathews G, Unwin A. Pain relief in labour using transcutaneous electrical nerve stimulation (TENS). A TENS/TENS placebo controlled study in two parity groups. *Br J Obstet Gynaecol* 1986; 93:739-746.
19. Hymes AC, Raab DE, Yonehiro EG, Nelson G, Printy A. Electrical surface stimulation for control of acute postoperative pain and prevention of ileus. *Surg Forum* 1973; 24:447-449.
20. Ignelzi RJ, Nyquist JK. Direct effect of electrical stimulation on peripheral nerve evoked activity: implications in pain relief. *J Neurosurg* 1976; 45:159-165.
21. Ignelzi RJ, Nyquist JK. Excitability changes in peripheral nerve fibers after repetitive electrical stimulation. *J Neurosurg* 1979; 51:824-833.

22. Jeans ME. Relief of chronic pain by brief, intense transcutaneous electrical stimulation—a double-blind study. In: Bonica JJ, Liebeskind JC, Albe-Fessard DG, eds. *Advances in Pain Research and Therapy*. Vol 3. New York: Raven Press, 1979:601-606.
23. Johansson F, Almay BGL, von Knorring L. Personality factors related to the outcome of treatment with transcutaneous nerve stimulation. *Psychiatr Clin North Am* 1981; 14:96-104.
24. Linzer M, Long DM. Transcutaneous neural stimulation for relief of pain. *IEEE Trans Biomed Eng* 1976; 23: 341-345.
25. Loewenstein WR. Modulation of cutaneous mechanoreceptors by sympathetic stimulation. *J Physiol* 1956; 132: 40-60.
26. Long DM. External electrical stimulation as a treatment of chronic pain. *Minn Med* 1974; 57:195-198.
27. Long DM. Fifteen years of transcutaneous electrical stimulation for pain control. *Stereotactic Funct Neurosurg* 1991; 56:2-19.
28. Long DM, Campbell JN, Guver G. Transcutaneous electrical stimulation for relief of chronic pain. In: Bonica JJ, Liebeskind JC, Albe-Fessard DG, eds. *Advances in Pain Research and Therapy*. Vol 3. New York: Raven Press, 1979:593-599.
29. Long DM, Hagfors N. Electrical stimulation in the nervous system: The current status of electrical stimulation of the nervous system for relief of pain. *Pain* 1975; 1:109-123.
30. Mannheimer C, Augustinsson L-E, Carlsson C-A, Manhem K, Wilhelmsson C. Epidural spinal electrical stimulation in severe angina pectoris. *Br Heart J* 1988; 59:56-61.
31. Melzak R. Prolonged relief of pain by brief intense transcutaneous stimulation. *Pain* 1975; 1:357- 373.
32. Melzak R, Vetere P, Finch L. Transcutaneous electrical nerve stimulation for low back pain. *Phys Ther* 1983; 63: 489-493.
33. Melzak R, Wall PD. Pain mechanism: a new theory.

Science 1965; 150:971-979.

34. Meyerson BA. Electrostimulation procedure: effects, presumed rationale, and possible mechanisms. In: Bonica JJ, Lindblom U, Iggo A, eds. *Advances in Pain and Research and Therapy. Proceedings of Third World Congress on Pain. Vol. 5.* New York: Raven Press, 1983:495-534.

35. Satran R, Goldstein MN. Pain perception: modification of threshold of intolerance and cortical potentials by cutaneous stimulation. *Science* 1973; 180:1201-1202.

36. Schwartz SI, Griffith LSC, Neilstadt A, Hagfors N. Chronic carotid sinus nerve stimulation in the treatment of essential hypertension. *Am J Surg* 1967; 114:5-15.

37. Shealy CN, Maurer D. Transcutaneous nerve stimulation for control of pain: a preliminary technical note. *Surg Neurol* 1974; 2:45-47.

38. Shealy CN, Mortimer JT, Hagfors NR. Dorsal column electroanalgesia. *J Neurosurg* 1970; 32:560-564.

39. Sjolund B, Eriksson M. The influence of natoxone analgesia from peripheral conditioning stimulation. *Brain Res Sep 14, 1979; 173(2):295-301.*

40. Solomon RA, Viernstein MC, Long DM. Reduction of postoperative pain and narcotic use by transcutaneous electrical nerve stimulation. *Surgery* 1980; 87:142-146.

41. Sweet WH, Wepsic JG. Treatment of chronic pain by stimulation of fibers of primary different neurons. *Trans Am Neurol Assoc* 1968; 93:103-107.

42. Treede R-D, Rolke R, Andrews K, Magerl W. Pain elicited by blunt pressure: neurobiological basis and clinical relevance. *Pain* 2002; 98:235-240.

43. Wall PD, Sweet WH. Temporary abolition of pain in man. *Science* 1967; 155:108-109.

25 Low-Frequency Electromagnetic Field Effects on Lymphocytes: Potential for Treatment of Inflammatory Diseases

1. Propovic M, Caballero-Bleda M, Puelles L, Popovic N. Importance of immunological and inflammatory processes in the pathogenesis and therapy of Alzheimer's disease. *Int J Neurosci* 1998; 95(3-4):203-236.
2. Winkler JD. *Apoptosis in Inflammation*. Basel, Boston: Birkaeuser Verlag, 1999.
3. Jasti AC, Wetzel BJ, Aviles H, Vesper DN, Nindl G, Johnson MT. Effect of a wound healing electromagnetic field on inflammatory cytokine gene expression in rats. *Biomed Sci Instrum* 2001; 37:209-214.
4. Wetzel BJ, Nindl G, Swez JA, Vesper DN, Johnson MT. Quantitative characterization of rat tendinitis to evaluate the efficacy of therapeutic interventions. *Biomed Sci Instrum* 2002; 38:157- 162.
5. Nindl G, Hughes EF, Johnson MT, Spandau DF, Vesper DN, Balcavage WX. Effect of ultraviolet B radiation and 100 Hz electromagnetic fields on proliferation and DNA synthesis of Jurkat cells. *Bioelectromagnetics* 2002; 23:455-463.
6. Wertheimer N, Leeper E. Electrical wiring configurations and childhood cancer. *Am J Epidemiol* 1979; 109: 273-284.
7. Feychting M, Ahlbohm A. Magnetic fields and cancer in children residing near Swedish high-voltage power lines. *Am J Epidemiol* 1993; 138:467-481.
8. Adair RK. Static and low-frequency magnetic field effects: health risks and therapies. *Rep Prog Phys* 2000; 63: 415-454.
9. Korzh-Sleptsova IL, Lindstroem E, Hansson Mild K, Berglund A, Lundgren E. Low frequency MFs increased inositol 1,4,5-triphosphate levels in the Jurkat cell line. *FEBS Lett* 1995; 359:151- 154.
10. Lindstroem E, Berglund A, Mild KH, Lindstroem P, Lundgren E. CD45 phosphatase in Jurkat cells is necessary for response to applied ELF magnetic fields. *FEBS Lett* 1995; 370:118-122.
11. Lindstroem E, Hansson Mild K, Lundgren E. Analysis of the T cell activation signaling pathway during ELF magnetic

field exposure, p56 lck and [Ca²⁺]_i -measurements.
Bioelectrochem Bioenerg 1998; 46:129-137.

12. Lindstroem E, Still M, Mattsson M-O, Hansson Mild K, Luben RA. ELF magnetic fields initiate protein tyrosine phosphorylation of the T cell receptor complex.
Bioelectrochem 2000; 53:73-78.

13. Holian O, Astumian RD, Lee RC, Reyes HM, Attar BM, Walter RJ. Protein kinase C activity is altered in HL60 cells exposed to 60 Hz AC electric fields.
Bioelectromagnetics 1996; 17(6):504- 509.

14. Walter RJ, Shtil AA, Roninson IB, Holian O. 60-Hz electric fields inhibit protein kinase C activity and multidrug resistance gene (MDR1) up-regulation. Radiat Res 1997; 147:369-375.

15. Balcavage WX, Alvager T, Swez J A, Goff CW, Fox MT, Abdullyava S, King MW. A mechanism for action of extremely low frequency electromagnetic fields on biological systems.
Biochem Biophys Res Comm 1996; 222: 374-378.

16. Liburdy RP, Eckert V. Preliminary evidence for receptor-ligand binding during calcium signal transduction as an interaction site for ELF magnetic fields. Annual review of research on biological effect of electric and magnetic fields. From the generation delivery & use of electricity, Albuquerque, NM, 1994:67.

17. Nindl G, Balcavage WX, Vesper DN, Swez JA, Wetzel BJ, Chamberlain JK, Fox MT. Experiments showing that electromagnetic fields can be used to treat inflammatory diseases. Biomed Sci Instrum 2000; 36:7-13.

18. Uckun FM, Kurosaki T, Jin J, Jun X, Morgan A, Takata M, Bolen J, Luben R. Exposure of B-lineage lymphoid cells to low energy electromagnetic fields stimulates lyn kinase. J Biol Chem 1995; 270:27666-27670.

19. Dibirdik I, Kristupaitis D, Kurosaki T, Tuel-Ahlgren L, Chu A, Pond D, Tuong D, Luben R, Uckun FM. Stimulation of Src family protein-tyrosine kinases as a proximal and mandatory step for SYK kinase-dependent phospholipase C γ 2 activation in lymphoma B cells exposed to low energy electromagnetic fields. J Biol Chem 1998; 273:4035-4039.

20. Kristupaitis D, Dibirdik I, Vassilev A, Mahajan S, Kurosaki T, Chu A, Tuel-Ahlgren L, Tuong D, Pond D, Luben R, Uckun FM. Electromagnetic field-induced stimulation of

Bruton's tyrosine kinase. *J Biol Chem* 1998; 273 (20): 12397-12401.

21. Santoro N, Lisi A, Pozzi D, Pasquali E, Serafino A, Grimaldi S. Effect of extremely low frequency (ELF) magnetic field exposure on morphological and biophysical properties of human lymphoid cell line (Raji). *Biochim Biophys Acta* 1997; 1357:281-290.

22. Miller SC, Furniss MJ. Bruton's tyrosine kinase activity and inositol 1,4,5-triphosphate production are not altered in DT40 lymphoma B cells exposed to power line frequency magnetic fields. *J Biol Chem* 1998; 273(49): 32618-32626.

23. Woods M, Bobanović F, Brown D, Alexander DR. Lyn and syk tyrosine kinases are not activated in B-lineage lymphoid cells exposed to low-energy electromagnetic fields. *FASEB J* 2000; 14:2284-2290.

24. Miller SC, Haberer J, Venkatachalam U, Furniss MJ. NF- κ B or AP-1-dependent reporter gene expression is not altered in human U937 cells exposed to power-line frequency magnetic fields. *Radiat Res* 1999; 151:310-318.

25. Dibirdik I, Bofenkamp M, Skeben P, Uckun F. Stimulation of Bruton's tyrosine kinase (BTK) and inositol 1,4,5-triphosphate production in leukemia and lymphoma cells exposed to low energy electromagnetic fields. *Leuk Lymph* 2000; 40(1-2): 149-156.

26. Westphal RS, Anderson KA, Means AR, Wadzinski BE. A signaling complex of Ca²⁺-calmodulin-dependent protein kinase IV and protein phosphatase 2A. *Science* 1998; 280:1258- 1261.

27. Bhalla US, Ram PT, Iyengar R. MAP kinase phosphatase as a locus of flexibility in a mitogen-activated protein kinase signaling network. *Science* 2002; 297:1018-1023.

28. Nindl G, Swez JA, Miller JM, Balcavage WX. Growth stage dependent effect of electromagnetic fields on DNA synthesis of Jurkat cells. *FEBS Lett* 1997; 414:501-506.

29. Loeschinger M, Thumm S, Haemmerle H, Rodemann HP. Induction of intracellular calcium oscillations in human skin fibroblast populations by sinusoidal extremely low-frequency magnetic fields (20 Hz, 8 mT) is dependent on the differentiation state of the single cell. *Radiat Res* 1999; 151:195-200.

30. McCreary CR, Thomas AW, Prato FS. Factors confounding cytosolic calcium measurements in Jurkat E6.1 cells during exposure to ELF magnetic fields. *Bioelectromagnetics* 2002; 23:315-328.
31. Hackstadt T. Redirection of host vesicle trafficking pathways by intracellular parasites. *Traffic* 2000; 1:93-99.
32. Mattsson M-O, Lindstroem E, Still M, Lindstroem P, Hansson Mild K, Laudgren E. $[Ca^{2+}]_i$ rise in Jurkat E6-1 cell lines from different sources as a response to 50 Hz magnetic field exposure is a reproducible effect and independent of poly-L-lysine treatment. *Cell Biol Internat* 2001; 25(9): 901-907.
33. Walleczek J. Electromagnetic field effects on cells of the immune system: the role of calcium signaling. *FASEB J* 1992; 6:3177-3185.
34. Blank M, Soo L. Electromagnetic acceleration of electron transfer reactions. *J Cell Biochem* 2001; 81(2): 278-283.
35. Bentsman J, Dardynskaya IV, Shadyro O, Pellegrinetti G, Blauwkamp R, Gloushonok G. Mathematical modeling and stochastic H(infinity) identification of the dynamics of the MF-influenced oxidation of hexane. *Math Biosci* 2001; 169(2): 129-151.
36. Walleczek J. Self-organized biological dynamics and nonlinear control. Cambridge: Cambridge University Press, 2000.
37. Marino AA, Wolcott RM, Chervenak R, Jourdeuil F, Nilsen E, Frilot II C. Nonlinear dynamical law governs magnetic field induced changes in lymphoid phenotype. *Bioelectromagnetics* 2001; 22:529-546.
38. Nindl G, Miller JM, Voehringer P, Balcavage WX. Electromagnetic 60 Hz fields increase apoptosis of lymphocytes—a new area for possible therapeutic employment of EMFs. Twenty-first annual meeting of the Bioelectromagnetics Society, Long Beach, CA, June, 1999.
39. Johnson MT, Vanscoy-Cornett A, Vesper DN, Swez JA, Chamberlain JK, Seaward MB, Nindl G. Electromagnetic fields used clinically to improve bone healing also impact lymphocyte proliferation in vitro. *Biomed Sci Instrum* 2001; 37:215-220.

40. Thun-Battersby S, Westermann J, Loscher W. Lymphocyte subset analyses in blood, spleen and lymph nodes of female Sprague-Dawley rats after short or prolonged exposure to a 50-Hz 100- μ T magnetic field. *Radiat Res* 1999; 152(4):436-443.
41. Selmaoui B, Bogdan A, Auzéby A, Lambrozo J, Touitou Y. Acute exposure to 50 Hz magnetic field does not affect hematologic or immunologic functions in healthy young men: a circadian study. *Bioelectromagnetics* 1996; 17(5):364-372.
42. Skyberg K, Hansteen IL, Vistnes AI. Chromosomal aberrations in lymphocytes of employees in transformer and generator production exposed to electromagnetic fields and mineral oil. *Bioelectromagnetics* 2001; 22(3): 150-160.
43. Trock DH. Electromagnetic fields and magnets. Investigational treatment for musculoskeletal disorders. *Rheum Dis Clin North Am* 2000; 26(1):51-62.
44. Bassett CA, Pawluk RJ, Pilla AA. Augmentation of bone repair by inductively coupled electromagnetic fields. *Science* 1974; 184:575-577.
45. Pilla AA, Muehsam DJ, Markov MS, Siskin BF. EMF signals and ion/ligand binding kinetics: predictions of bioeffective waveform parameters. *Bioelectrochem Bioenerg* 1999; 48:27-34.
46. Jerabek J. Pulsed magnetotherapy in Czechoslovakia-a review. *Rev Environ Health* 1994; 10:127-134.
47. Zhadin MN. Review of Russian literature on biological action of DC and low-frequency AC magnetic fields. *Bioelectromagnetics* 2001; 22:27-45.
48. Nindl G, Johnson MT, Hughes EF, Markov MS. Therapeutic electromagnetic field effects on normal and activated Jurkat cells. Proceedings of the Second International Workshop on Biological Effects of Electromagnetic Fields. Rhodes, Greece, October 7-11, 2002. In press.
49. Chiabrera A, Cadossi R, Bersani F, Franceschi C, Bianco B. Electric and magnetic field effects on the immune system. In: Carpenter DO, Ayrapetyan S, eds. *Biological Effects of Electric and Magnetic Fields*. London: Academic Press, 1994:121-145.
50. Pessina GP, Aldinucci C. Pulsed electromagnetic fields

enhance the induction of cytokines by peripheral blood mononuclear cells challenged with phytohemagglutinin. *Bioelectromagnetics* 1998; 19(8):445-451.

51. Cossarizza A, Monti D, Bersani F, Paganelli R, Montagnani G, Cadossi R, Cantini M, Franceschi C. Extremely low frequency pulsed electromagnetic fields increase interleukin-2 (IL-2) utilization and IL-2 receptor expression in mitogen-stimulated human lymphocytes from old subjects. *FEBS Lett* 1989; 248(1-2): 141-144.

52. Cossarizza A, Monti D, Bersani F, Scarfi MR, Zanotti M, Cadossi R, Franceschi C. Exposure to low-frequency pulsed electromagnetic fields increases mitogen-induced lymphocyte proliferation in Down's syndrome. *Aging (Milano)* 1991; 3(3):241-246.

53. Fam WZ, Mikhail EL. Lymphoma induced in mice chronically exposed to very strong low-frequency electromagnetic field. *Cancer Lett* 1996; 105(2):257-269.

54. Mandeville R, Franco E, Sidrac-Ghali S, Paris-Nadon L, Rocheleau N, Mercier G, Desy M, Gaboury L. Evaluation of the potential carcinogenicity of 60 Hz linear sinusoidal continuous-wave magnetic fields in Fischer F344 rats. *FASEB J* 1997; 11(13):1127-1136.

55. Berg H. Problems of weak electromagnetic field effects in cell biology. *Bioelectrochem Bioenerget* 1999; 48: 355-360.

56. Binhi VN, Goldman RJ. Ion-protein dissociation predicts 'windows' in electric field-induced wound-cell proliferation. *Biochim Biophys Acta* 2000; 1474:147-156.

57. Fitzsimmons RJ, Ryaby JT, Magee FP, Baylink DJ. Combined magnetic fields increased net calcium flux in bone cells. *Calcif Tissue Internat* 1994; 55(5):376-380.

58. Lindstroem E, Lindstroem P, Berglund A, Lundgren E, Mild KH. Intracellular calcium oscillations in a T-cell line after exposure to extremely-low-frequency magnetic fields with variable frequencies and flux densities. *Bioelectromagnetics* 1995; 16:41-47.

59. Belyaev IY, Alipov ED. Frequency-dependent effects of ELF magnetic field on chromatin conformation in *Escherichia coli* cells and human lymphocytes. *Biochim Biophys Acta* 2001; 1526:269-276.

60. Liboff AR, McLeod BR, Smith SD. Resonance transport in membranes. In: Brighton CT, Pollack SR, eds. *Electromagnetic in Biology and Medicine*. San Francisco: San Francisco Press, 1991:67-77.
61. Blanchard JP, Blackman CF. Clarification and application of an ion parametric resonance model for magnetic field interactions with biological systems. *Bioelectromagnetics* 1994; 15:217-238.
62. Lyle DB, Wang X, Ayotte R, Sheppard A, Adey WR. Calcium uptake by leukemic and normal T-lymphocytes exposed to low frequency magnetic fields. *Bioelectromagnetics* 1991; 12:145-156.
63. Phillips JL, Haggren W, Thomas WJ, Ishida-Jones T, Adey WR. Effect of 72 Hz pulsed magnetic field exposure on ras p21 expression in CCRF-CEM cells. *Cancer Biochem Biophys* 1993; 13(3):187-193.
64. Philipp A, Wolf GK, Rzany B, Dertinger H, Jung EG. Interferential current is effective in palmar psoriasis: an open prospective trial. *Europ J Dermatol* 2000; 10(3): 195-198.
65. Hintenlang DE. Synergistic effects of ionizing radiation and 60 Hz magnetic fields. *Bioelectromagnetics* 1993; 14:545-551.
66. Narita K, Hanakawa K, Kasahara T, Hisamitsu T, Asano K. Induction of apoptotic cell death in human leukemic cell line, HL-60, by extremely low frequency electric magnetic fields: analysis of the possible mechanisms in vitro. *In Vivo* 1997; 11(4):329-335.
67. Robinson JG, Pendleton A, Monson KO, Murray BK, O'Neill K. Decreased DNA repair rates and protection from heat induced apoptosis mediated by electromagnetic field exposure. *Bioelectromagnetics* 2002; 23: 106-112.
68. Maes A, Collier M, Vandoninck S, Scarpa P, Verschaeve L. Cytogenic effects of 50 Hz magnetic fields of different magnetic flux densities. *Bioelectromagnetics* 2000; 21(8):589-596.
69. Iashchenko LV, Chistiakov IV, Gakh LM, Ostapiak ZN, Siurin SA. Low-frequency magnetic fields in the combined therapy of inflammatory lung diseases. *Probl Tuberk* 1988; 3:53-56.

70. Gerasimenko MY. Effect of red laser and alternative magnetic field on repair process after palatoplasty. *Vopr Kurortol Fizioter Lech Fiz Kult* 1993; 4:34-35.

71. Alyshev VA, Viaznikov AL, Gertsen IG, Krylov NL, Rutsksii VV, Roizin VL, Serdiuk VV, Ushakov AA, Sheliakhovskii MV. Magnetotherapy in the complex treatment of patients with suppurative wounds and osteomyelitis. *Vestn Khir* 1988; 140(4): 141-143.

72. Vesper DN, Swez JA, Nindl G, Fox MT, Sandrey MA, Balcavage WX. Models of the uniformity of electromagnetic fields generated for biological experiments by Merritt Coils. *Biomed Sci Instrum* 2000; 36: 409-415.

73. Vesper DN, Nindl G, Johnson MT, Spandau DF, Swez JA, Balcavage WX. A system for simultaneous ultraviolet light and electromagnetic field exposure in in vitro experiments. *Biomed Sci Instrum* 2001; 37:221-226.

26 Orthopaedic Clinical Application of Biophysical Stimulation in Europe

1. Galvani L. De viribus electricitatis in motu muscolari commentaries. Bologna: Instit. Scient., 1791.
2. Fukada E, Yasuda I. On the piezoelectric effect of bone. J Phys Soc Japan 1957; 12:121-128.
3. Bassett CAL, Becker RO. Generation of electric potentials in bone in response to mechanical stress. Science 1962; 137:1063-1064.
4. Black J. Electrical Stimulation. New York: Praeger, 1987.
5. Guzelsu N. Piezoelectric- and electrokinetic effects in bone tissue-review. Electro and Magnetobiol 1993; 12 (1):51-82.
6. Green J, Kleeman CR. Role of bone in regulation of systemic acid-base balance. Kidney Int 1991; 39:9-26.
7. Otter MW, Vincent R, Palmieri VR, Dadong DWu, Seiz KG, Mac Ginitie LA, Cochran GVB. A comparative analysis of streaming potentials in vivo and in vitro. J Orthopaedic Res 1992; 10:710-719.
8. Pollack SR. Bioelectrical properties of bone. Endogenous electrical signals. Orthop Clin North Am 1984; 15: 3-14.
9. Behari J. Electrostimulation and bone fracture healing. Biomed Eng 1992; 18:235-254.
10. Wolff J. Das Gesetz der Transformation der Knochen. Berlin: Hirschwald, 1892.
11. Friedenberg ZB, Brighton CT. Bioelectric potentials in bone. J Bone Joint Surg 1966; 48A:915- 923.
12. Friedenberg ZB, Dyer R, Brighton CT. Electro-osteograms of long bones of immature rabbits. J Dent Res 1971; 50:635-640.
13. Friedenberg ZB, Harlow MC, Heppenstall R, Brighton CT. The cellular origin of bioelectric potentials in bone. Calcif Tissue Res 1973; 13:53-62.
14. Rubinacci A, Brigatti L, Tessari L. A reference curve for axial bioelectric potentials in adult rabbit tibia. Bioelectromagnetics 1984; 5:193-202.

15. Chakkalakal DA, Wilson RF, Connolly JF. Epidermal and endosteal sources of endogenous electricity in injured canine limbs. *IEEE Trans Biomed Eng* 1988; 35:19-29.
16. Lokietek W, Pawluk RF, Bassett CAL. Muscle injury potentials: a source of voltage in the undeformed rabbit tibia. *J Bone Joint Surg* 1974; 56B:361-369.
17. Borgens RB. Endogenous ionic currents traverse intact and damaged bone. *Science* 1984; 225:478-482.
18. De Ponti A, Villa I, Boniforti F, Rubinacci A. Ionic currents at the growth plate of intact bone: occurrence and ionic dependence. *Electro-MagnetoBiol* 1996; 15(1):37-48.
19. Rubinacci A, De Ponti A, Shipley A, Samaja M, Karplus E, Jaffe LF. Bicarbonate dependence of ion current in damaged bone. *Calcif Tissue Int* 1996; 58:423-428.
20. Becker RD, Murray DG. The electrical control system regulating fracture healing in amphibians. *Clin Orthop Rel Res* 1970; 73:169-209.
21. Chiabrera A, Grattarola M, Parodi G, Marcer M. Interazione tra campo elettromagnetico e cellule. *Le Scienze* 1984; 192:78-94.
22. Frost HM. The biology of fracture healing: an overview for clinicians. Part I and II. *Clin Orthop Rel Res* 1989; 248:283-309.
23. O'Sullivan ME, Chao EY, Kelly PJ. The effects of fixation on fracture-healing. *J Bone Joint Surg* 1989; 71-A: 306-310.
24. Bianco B, Chiabrera A. From the Longevin-Lorentz to the Zeeman model of em effects on ligand-receptor binding. *Bioelectrochem Bioenerg* 1992; 28:355-365.
25. Varani K, Gessi S, Merighi S, Iannotta V, Cattabriga E, Spisani S, Cadossi R, Borea PA. Effect of low frequency electromagnetic fields on A_{2A} adenosine receptors in human neutrophils. *Brit J Pharmacol* 2002; 136:57-66.
26. Brighton CT, Wang W, Seldes R, Zhang G, Pollack SR. Signal transduction in electrically stimulated bone cells. *J Bone Joint Surg Am* 2001; 83:1514-1523.
27. Guerkov HH, Lohmann CH, Liu Y, Dean DD, Simon BJ,

- Heckman JD, Schwartz Z, Boyan BD. Pulsed electromagnetic fields increase growth factor release by nonunion cells. *Clin Orthop* 2001; 384:265-279.
28. Cadossi R, Bersani F, Cossarizza A, Zucchini P, Emilia G, Torelli G, Franceschi C. Lymphocytes and lowfrequency electromagnetic fields. *FASEB J* 1992; 6:2667-2674.
29. Aaron RK, Ciombor MD, Jolly G. Stimulation of experimental endochondral ossification by low-energy pulsing electromagnetic fields. *J Bone Miner Res* 1989b; 4:227-233.
30. Bassett CAL, Valdez MG, Hernandez E. Modification of fracture repair with selected pulsing electromagnetic fields. *J Bone Joint Surg* 1982a; 64A:888-895.
31. Brighton CT, Hozcack WJ, Brager MD, Windsor RE, Pollack SR, Vreslovic EJ, Kotwick JE. Fracture healing in rabbit fibula when subjected to various capacitively coupled electrical fields. *J Orthop Res* 1985a; 3:331-340.
32. Pienkowski D, Pollack SR, Brighton CT, Griffith NJ. Comparison of asymmetrical and symmetrical pulse waveforms in electromagnetic stimulation. *J Orthop Res* 1992; 10:247-255.
33. Bassett CAL, Pawluk RJ, Pilla AA. Augmentation of bone repair by inductively coupled electromagnetic fields. *Science* 1974; 184:575-577.
34. Cane V, Botti P, Farneti D, Soana S. Electromagnetic stimulation of bone repair: a histomorphometric study. *J Orthop Res* 1991; 9:908-917.
35. Cane V, Botti P, Soana S. Pulsed magnetic fields improve osteoblast activity during the repair of an experimental osseous defect. *J Orthop Res* 1993; 11:664.
36. Cane V, Zaffe D, Botti B, Cavani F, Soana S. Correlation between PEMF exposure time and new bone formation. IV Congresso Nazionale Società Italiana Chirurgia Veterinaria, Napoli, Maggio: 1997.
37. FriedenberG ZB, Andrews ET, Smolenski BI, Pearl BW, Brighton CT. Bone reaction to varying amounts of direct current. *Surg Gynecol Obstet* 1970; 131:894-899.
38. Traina GC, Gulino G. Medullary rods as electrical conductors for osteogenic stimuli in human bone. In:

Brighton CT, Black J, Pollack S, eds. *Electrical Properties of Bone and Cartilage*. New York: Grune and Stratton, 1979: 567-579.

39. Jorgensen TE. Electrical stimulation of human fracture healing by means of a slow pulsating asymmetrical direct current. *Clin Orthop* 1977; 124:124-127.

40. Zichner L. Repair of nonunions by electrically pulsed current stimulation. *Clin Orthop* 1981; 161:115-121.

41. Liboff AR, Parkinson WC. Search for ion-cyclotron resonance in an Na⁺-transport system. *Bioelectromagnetics* 1991; 12:77-83.

42. Sollazzo V, Massari L, Caruso A, De Mattei M, Pezzetti F. Effects of low-frequency pulsed electromagnetic fields on human osteoblast-like cells in vitro. *Electro MagnetoBiol* 1996; 15:75- 83.

43. Pezzetti F, De Mattei M, Caruso A, Cadossi R, Zucchini P, Carinci F, Traina GC, Sollazzo V. Effects of pulsed electromagnetic fields on human chondrocytes: an in vitro study. *Calcif Tissue Int* 1999; 65:396-401.

44. Fontanesi G, Traina GC, Giancetti F, Tartaglia I, Rotini R, Virgili B, Cadossi R, Ceccherelli G, e Marino AA. La lenta evoluzione del processo riparativo di una frattura puo' essere prevenuta? *G.I.O.T.* 1986; XII(3): 389-404.

45. Kraus W, Lechner F. Die Heilung von Pseudarthrosen und Spontanfrakturen durch strukturbildende elektrodynamische Potentiale. *Munchen Mudizinische Woch* 1972; 114:1814- 1817.

46. Hinsenkamp M, Ryaby J, Burny F. Treatment of nonunion by pulsing electromagnetic field: European multicenter study of 308 cases. *Reconstr Surg Traumatol* 1985; 19:147-156.

47. Brighton CT, Pollack SR. Treatment of recalcitrant nonunion with a capacitively coupled electric field. *J Bone Joint Surgery* 1985; 67A:577-585.

48. Hartig M, Joos U, Wiesmann HP. Capacitively coupled electric fields accelerate proliferation of osteoblast-like primary cells and increase bone extracellular matrix formation in vitro. *Eur Biophys J* 2000; 29:499-506.

49. Wang SJ, Lewallen DG, Bolander ME, Chao EY, Ilstrup DM, Greenleaf JF. Low intensity ultrasound treatment increases

strength in a rat femoral fracture model. *J Orthop Res* 1994; 12:40-47.

50. Jingushi S, Azuma V, Ito M, Harada Y, Takagi H, Ohta T, Komoriya K. Effect of noninvasive pulsed lowintensity ultrasound on rat femoral fracture. *Proceedings of the Third World Congress of Biomechanics*. 1998; 140.

51. Rubin C, Bolander M, Ryaby JP, Hadjiargyrou M. The use of low-intensity ultrasound to accelerate the healing of fractures. *J Bone Joint Surg Am* 2001; 83:259-270.

52. Takikawa S, Matsui N, Kokubu T, Tsunoda M, Fujioka H, Mizuno K, Azuma Y. Low-intensity pulsed ultrasound initiates bone healing in rat nonunion fracture model. *J Ultrasound Med* 2001; 20:197-205.

53. Corradi C, Cozzolino A. The action of ultrasound on the evolution of an experimental fracture in rabbits. *Minerva Ortop* 1952; 55:44-45.

54. Sharrard HJW. Treatment of congenital and infantile pseudoarthrosis with pulsing electro magnetic fields. *Othop Clin North Am* 1984; 15(1):143-162.

55. Sharrard HJW. Treatment of congenital and infantile pseudoarthrosis of the tibia with pulsing electromagnetic fields. *Biological Effects of Nonionizing Electromagnetic Radiation*. 1985; IX(3):42.

56. Sutcliffe ML, Goldberg AAJ. The treatment of congenital pseudoarthrosis of the tibia with pulsing electromagnetic fields. A survey of 52 cases. *Clin Orthop Rel Res* 1982; 166:45-52.

57. Dal Monte A, Fontanesi G, Giancetti F, Poli G, Cadossi R. Treatment of congenital pseudoarthrosis and acquired nonunion with pulsing electromagnetic fields (PEMFs). *Orthop Trans JBJS* 1986; 10(3):452.

58. Bassett CAL, Schinkasani M. Long-term pulsed electromagnetic field results in congenital pseudoarthrosis. *Calcif Tissue Int* 1991; 49:3-12.

59. Kort J, Schink MM, Mitchell SN, Bassett CAL. Congenital pseudoarthrosis of the tibia: Treatment with pulsing electromagnetic fields. The international experience. *Clin Orthop Rel Res* 1982; 165:124-137.

60. Lavine LS, Lustrin I, Shamos MH. Treatment of

congenital pseudoarthrosis of the tibia with direct current. Clin Orthop Rel Res 1977; 124:69-74.

61. Poli G, Verni E, Dal Monte A. A double approach to the treatment of congenital pseudoarthrosis: Endomedullary nail fixation and stimulation with low frequency pulsing electromagnetic fields (PEMFs). Bioelectrochem Bioenerget 1985; 14:151.

62. Sedel L, Christel P, Duriez J, Duriez R, Evard J, Ficat C, Cauchoix J, Witvoet J. Resultats de la stimulation par champ electromagnetique de la consolidation des pseudarthroses. Rev Chir Orthop Traum 1981; 67:11-23.

63. Marcer M, Musatti G, Bassett CAL. Results of pulsed electromagnetic fields (pemfs) in ununited fractures after external skeletal fixation. Clin Orthop Rel Res 1984; 190:260-265.

64. Sharrard WJW. A double-blind trial of pulsed electromagnetic field for delayed union of tibial fractures. J Bone Joint Surg 1990; 72B:347-355.

65. DeHaas WG, Watson J, Morrison DM. Non-invasive treatment of ununited fracture of the tibia using electrical stimulation. J Bone Joint Surg 1980; 62B:465-470.

66. Watson J. A battery-operated portable orthopaedic stimulator. San Francisco: BRAGS 3, 1983:55.

67. Vaquero DH. Resultados y factores pronósticos de la electrestimulación en los trasftornos de la consolidación ósea, ATTI VII curso internazionale sulla stimolazione biofisica della riparazione endogena nel tessuto osseo e cartilagineo, Pescatina, 2001:8-9.

68. Fontijne WPJ, Konings PC. Botgroeistimulatie met PEMF bij gestoorde fractuurgenezing. Ned Tijdschr Traum 1998; 5:114-119.

69. Scott G, King JB. A prospective double blind trial of electrical capacitive coupling in the treatment of non-union of long bones. J Bone Joint Surg 1994; 76A:820-826.

70. Mattei A, Spurio Pompili GF, Impagliazzo A. Experience with the treatment of delayed unions and pseudoarthrodosis with capacitive coupled electric fields. Seventh International course, Biophysical Stimulation of Endogenous

Repair in Bone and Cartilage. 2001:14.

71. Mayr E, Wagner S, Ecker M, Ruter A. Treatment of non unions by means of low-intensity ultrasound. *Unfallchirurg* 1997; 268:958-962.

72. Romanò C, Messina J, Meani E. Low-intensity ultrasound for the treatment of infected nonunions. In: Agazzi M, ed. *Quaderni di Infezioni Otseoarticolari*. Milan: Masson, 1999:83-93.

73. Benazzo F, Mosconi M, Beccarisi G, Galli U. Use of capacitive coupled electric fields in stress fractures in athletes. *Clin Orthop Rel Res* 1995; 310:145-149.

74. Hinsenkamp M, Bourgois R, Bassett C, Chiabrera A, Burny F, Ryaby J. Electromagnetic stimulation of fracture repair. Influence on healing of fresh fracture. *Acta Orthop Belg* 1978; 44:671-698.

75. Luna GF, Arevalo RL, Labajos UV. La EEM en las elongaciones y transportes oseos. In: Vaquero H, Stern L, eds. *La Estimulacion Electromagnetica en la Patologia Osea*. Madrid: San Martin IG, 1999:236-246.

76. Emami A, Petren-Mallmin M, Larsson S. No effect of low-intensity ultrasound on healing time of intramedullary fixed tibial fractures. *J Orthop Trauma* 1999; 13:252-257.

77. Borsalino G, Bagnacani M, Bettati E, Fornaciari G, Rocchi R, Uluhogian S, Ceccherelli G, Cadossi R, Traina G. Electrical stimulation of human femoral intertrochanteric osteotomies: double blind study. *Clin Orthop Rel Res* 1988; 237:256-263.

78. Mammi GI, Rocchi R, Cadossi R, Traina GC. Effect of PEMF on the healing of human tibial osteotomies: a double blind study. *Clin Orthop Rel Res* 1993; 288:246-253.

79. Capanna R, Donati D, Masetti C, Manfrini M, Panozzo A, Cadossi R, Campanacci M. Effect of electromagnetic fields on patients undergoing massive bone graft following bone tumor resection: a double-blind study. *Clin Orthop Rel Res* 1994; 306:213-221.

80. Eyres KS, Saleh M, Kanis JA. Effect of pulsed electromagnetic-fields on bone-formation and bone loss during limb lengthening. *Bone* 1996; 18:505-509.

81. Guizzardi S, Di Silvestre M, Govoni P, Scandroglia R.

- Pulsed electromagnetic field stimulation on posterior spinal fusions: a histological study in rats. *J Spinal Disord* 1994; 7(1):36-40.
82. Savini R, Di Silvestre M, Gargiulo G, Bettini N. The use of pulsing electromagnetic fields in posterolateral lumbosacral spinal fusion. *J Bioelectricity* 1990; 9:9-17.
83. Mammi GI, Rocchi R, Di Silvestre M. Effect of PEMF on spinal fusion: a prospective study with a control group. In: Blank M, ed. *Electricity and Magnetism in Biology and Medicine*. San Francisco Press, 1993: 800-803.
84. Ficat RP. Idiopathic bone necrosis of the femoral head: early diagnosis and treatment. *J Bone Joint Surg* 1985; 67 (B):3-9.
85. Bassett CAL, Schink-Ascani M, Lewis SM. Effects of pulsed electromagnetic fields of Steinberg ratings of the femoral head osteonecrosis. *Clin Orthop Rel Res* 1989; 246:172-185.
86. Santori FS, Vitullo A, Manili M, Montemurro G, Stopponi M. Necrosi avascolare della testa del femore: l'associazione dei CEMP al trattamento chirurgico di decompressione e innesti ossei autoplastici, Impiego dei Campi Elettromagnetici Pulsati In *Ortopedia e Traumatologia*, Walberti Editore, Ferrara 12 Maggio 1995 e Roma 20 Maggio 1995:75-83.
87. Hinsenkamp M, Hauzeur JP, Sintzoff S. Preliminary results in electromagnetic field treatment of osteonecrosis. *Bioelectrochem Bioenergetics* 1993; 30:229-235.
88. Hinsenkamp M, Hauzeur JP, Sintzoff S. Long term results in electromagnetic fields (EMF) treatment of osteonecrosis. In: Schoutens A, ed. *Bone Circulation and Vascularization in Normal and Pathological Conditions*. New York: Plenum Press, 1993:331-336.
89. Garcia-Andrade G, Esteban DI, Lluch CB, Stern LD. La EEM en el tratamiento de la necrosis avascular de la cabeza femoral. In: Vaquero H, Stern L, eds. *La Estimulacion Electromagnetica en la Patologia Osea*. Madrid: San Martin I.G., 1999:219-235.
90. Aaron RK, Lennox D, Bunce GE. The conservative treatment of osteonecrosis of the femoral head: a comparison of core decompression and PEMF. *Clin Orthop Rel*

Res 1989; 249:209-218.

91. Steinberg ME, Brighton CT, Corces A, Hayken GD, Steinberg DR, Strafford B, Tooze SE, Fallon M. Osteonecrosis of the femoral head. Results of core decompression and grafting with and without electrical stimulation. Clin Orthop Rel Res 1989; 249:199-208.

92. Steinberg ME, Brighton CT, Bands RE, Hartman KM. Capacitive coupling and adjunctive treatment for avascular necrosis. Clin Orthop Rel Res 1990; 261:11-18.

93. Fini M, Cadossi R, Cane V, Cavani F, Giavaresi G, Krajewski A, Martini L, Nicoli Aldini N, Ravaglioli A, Rimondini L, Torricelli P, Giardino R. The effect of PEMFs on the osteointegration of HA implants in cancellous bone: a morphogenetic and microstructural in vivo study. JOR 2002; 20:756-763.

94. Rispoli FP, Corolla FM, Mussner R. The use of low-frequency pulsing electromagnetic fields in patients with painful hip prosthesis. J Bioelectricity 1988; 7:181-187.

95. Pipino F, Molfetta L, Losito A, Capozzi M. Sui risultati della stimolazione con campi elettromagnetici in ortopedia e traumatologia, ATIII Corso Avanzato di Bioelettricità, Venezia, April 1990:91-98.

96. Fontanesi G, Giancetti F, Rotini R, e Cadossi R. Terapia dei Ritardi di Consolidazione e Pseudoartrosi con Campi Elettromagnetici Pulsati a Bassa Frequenza. G.I.O.T. 1983; IX:319- 333.

97. Traina GC, Fontanesi G, Costa P, Mammi GI, Pisano F, Giancetti F, Adravanti P. Effect of electromagnetic stimulation on patients suffering from nonunion. A retrospective study with a control group. J Bioelectricity 1991; 10:101-117.

27 Electromagnetic Stimulation in Orthopaedics: Biochemical Mechanisms to Clinical Applications

1. Fukada E, Yasuda I. On the piezoelectric effect of bone. *J Phys Soc Japan* 1957; 12:121-128.
2. Bassett CAL, Becker RO. Generation of electric potentials in bone in response to mechanical stress. *Science* 1962; 137:1063-1064.
3. Friedenberg ZB, Brighton CT. Bioelectric potentials in bone. *J Bone Joint Surg* 1966; 48A:915- 923.
4. Shamos MH, Lavine LS. Piezoelectricity as a fundamental property of biological tissues. *Nature* 1967; 212: 267-268.
5. Williams WS, Perletz L. P-n junctions and the piezoelectric response of bone. *Nature* 1971; 233:58-59.
6. Anderson JC, Eriksson C. Electrical properties of wet collagen. *Nature* 1968; 227:166-168.
7. Bassett CAL, Pawluk RJ. Electrical behavior of cartilage during loading. *Science* 1974; 814:575-577.
8. Grodzinsky AJ, Lipshitz H, Glimcher MJ. Electromechanical properties of articular cartilage during compression and stress relaxation. *Nature* 1978; 275:448-450.
9. Duncan RL, Turner CH. Mechanotransduction and the functional response of bone to mechanical strain. *Calcif Tissue Intl* 1995; 57:344-358.
10. Pilla AA, Markov MS. Bioeffects of weak electromagnetic fields. *Rev Environ Health* 1994; 10:55-69.
11. Donahue HJ. Gap junctions and biophysical regulation of bone cell differentiation. *Bone* 2000; 26:417-422.
12. Ryaby JT. Clinical effects of electromagnetic and electrical fields on fracture healing. *Clin Orthop* 1998; 355S: 205-215.
13. Aaron RK, Lennox D, Bunce GE, Ebert T. The conservative treatment of osteonecrosis of the femoral head. A comparison of core decompression and pulsing electromagnetic fields. *Clin Orthop* 1989; 249:209-218.

14. Steinberg ME, Brighton CT, Corces A, Hayken GD, Steinberg DR, Strafford B, Tooze SE, Fallon M. Osteonecrosis of the femoral head. Results of core decompression and grafting with and without electrical stimulation. *Clin Orthop* 1989; 249:199-208.
15. Binder A, Parr G, Hazelman B, Fitton-Jackson S. Pulsed electromagnetic field therapy of persistent rotator cuff tendinitis: a double-blind controlled assessment. *Lancet* 1984; 1:695-697.
16. Tabrah F, Hoffmeier M, Gilbert F, Batkin S, Bassett CAL. Bone density changes in osteoporosis-prone women exposed to pulsed electromagnetic fields (PEMFs). *J Bone Min Res* 1990; 5:437-442.
17. Garland DE, Adkins RH, Matsuno NN, Stewart CA. The effect of pulsed electromagnetic fields on osteoporosis at the knee in individuals with spinal cord injury. *J Spinal Cord Med* 1999; 22:239-245.
18. Trock DH, Bollet AJ, Markoll R. The effect of pulsed electromagnetic fields in the treatment of osteoarthritis of the knee and cervical spine. Report of randomized, double blind, placebo controlled trials. *J Rheumatol* 1994; 21: 1903-1911.
19. Zizic TM, Hoffman KC, Holt PA, Hungerford DS, O'Dell JR, Jacobs MA, Lewis GC, Deal LC, Caldwell JR, Cholewczynski JG, Free SM. The treatment of osteoarthritis of the knee with pulsed electrical stimulation. *J Rheumat* 1995; 22:1757-1761.
20. Otter MW, McLeod KJ, Rubin CT. Effects of electromagnetic fields in experimental fracture repair. *Clin Orthoped* 1998; 355S:90-104.
21. McLeod BR, Liboff AR. Cyclotron resonance in cell membranes: the theory of the mechanism. In: Blank MJ, Findl E, eds. *Mechanistic Approaches to Interactions of Electromagnetic Fields with Living Systems*. New York: Plenum, 1987:97-108.
22. Fitzsimmons RJ, Ryaby JT, Magee FP, Baylink DJ. Combined magnetic fields increase net calcium flux in bone cells. *Calcif Tissue Int* 1994; 55:376-380.
23. Fitzsimmons RJ, Baylink DJ, Ryaby JT, Magee FP. EMF-stimulated bone cell proliferation. In: Blank MJ, ed. *Electricity and Magnetism in Biology and Medicine*. San

Francisco: San Francisco Press, 1993:899-902.

24. Fitzsimmons RJ, Ryaby JT, Mohan S, Magee FP, Baylink DJ. Combined magnetic fields increase IGF-II in TE-85 human bone cell cultures. *Endocrinology* 1995; 136:3100-3106.

25. Fitzsimmons RJ, Ryaby JT, Magee FP, Baylink DJ. IGF-II receptor number is increased in TE-85 cells by lowamplitude, low-frequency combined magnetic field (CMF) exposure. *J Bone Min Res* 1995; 10:812-819.

26. Ryaby JT, Fitzsimmons RJ, Khin NA, Culley PL, Magee FP, Weinstein AM, Baylink DJ. The role of insulin-like growth factor in magnetic field regulation of bone formation. *Bioelectrochem Bioenerg* 1994; 35:87-91.

27. Aaron RK, Wang S, Mck.Ciombor D. Upregulation of basal TGFb1 levels by EMF coincident with chondrogenesis-implications for skeletal repair and tissue engineering. *J Orthop Res* 2002; 20:233-240.

28. Aaron RK, Mck.Ciombor D. Acceleration of experimental endochondral ossification by biophysical stimulation of the progenitor cell pool. *J Orthop Res* 1996; 14:582-589.

29. Lohmann CH, Schwartz Z, Liu Y, Guerkov H, Dean DD, Simon B, Boyan BD. Pulsed electromagnetic field stimulation of MG63 osteoblast-like cells affects differentiation and local factor production. *J Orthop Res* 2000; 18:637-646.

30. Guerkov HH, Lohmann CH, Liu Y, Dean DD, Simon BJ, Heckman JD, Schwartz Z, Boyan BD. Pulsed electromagnetic fields increase growth factor release by nonunion cells. *Clin Orthop* 2001; 180:265-279.

31. Zhuang H, Wang W, Seldes RM, Tahernia AD, Fan H, Brighton CT. Electrical stimulation induces the level of TGF-B1 mRNA in osteoblastic cells by a mechanism involving calcium/ calmodulin pathway. *Biochem Biophys Res Comm* 1997; 237:225-229.

32. Brighton CT, Wang W, Seldes R, Zhang G, Pollack SR. Signal transduction in electrically stimulated bone cells. *J Bone Joint Surg* 2001; 83A: 1514-1523.

33. Cane V, Botti P, Farnetti P, Soana S. Electromagnetic stimulation of bone repair: a histomorphometric study. *J Orthop Res* 1991; 9:908-917.

34. Cane V, Botti P, Soana S. Pulsed magnetic fields

improve osteoblast activity during the repair of an experimental osseous defect. J Orthop Res 1993; 11:664-670.

35. Brighton CT, Katz MJ, Goll SR, Nichols CE III, Pollack SR. Prevention and treatment of sciatic denervation disuse osteoporosis in the rat tibia with capacitively coupled electrical stimulation. Bone 1985; 6:87-97.

36. McLeod KJ, Rubin CT. The effect of low frequency electrical fields on osteogenesis. J Bone Joint Surg 1992; 74A:920-929.

37. Ryaby JT, Jurischk E, Haupt DL, Kinney JH. Combined magnetic fields reverse osteopenia and restore strength in a rodent model of osteoporosis. Proceedings of the Third International Congress on Bioelectricity 2000; 3: 153-154.

38. Ryaby JT, Jurischk E, Haupt DL, Kinney JH. Reversal of experimental osteopenia with combined magnetic field treatment. 2002. Submitted for publication.

39. Brighton CT, FriedenberG ZB, Mitchell EI, Booth RE. Treatment of nonunion with constant direct current. Clin Orthop 1977; 124:106-123.

40. Patterson D. Treatment of nonunion with a constant direct current: a totally implantable system. Orthop Clin North Am 1984; 15:47-59.

41. Brighton CT, Pollack SR. Treatment of recalcitrant nonunion with a capacitively coupled electric field. J Bone Joint Surg 1985; 67A:577-585.

42. Bassett CAL, Pawluk RJ, Pilla AA. Augmentation of bone repair by inductively coupled electromagnetic fields. Science 1974; 184:575-577.

43. Bassett CAL, Mitchell SN, Gaston SR. Treatment of ununited tibial diaphyseal fractures with pulsing electromagnetic fields. J Bone Joint Surg 1981; 63A:511-523.

44. Heckman JD, Ingram AJ, Lloyd RD, Luck JV, Mayer PW. Nonunion treatment with pulsed electromagnetic fields. Clin Orthop 1981; 161:58-66.

45. Bassett CAL. Fundamental and practical aspects of therapeutic uses of pulsed electromagnetic fields (PEMFS). CRC Crit Rev Biomed Eng 1989; 17:451-529.

46. Gossling HR, Bernstein RA, Abbott J. Treatment of ununited tibial fractures: a comparison of surgery and pulsed electromagnetic fields. *Orthopedics* 1992; 16:711-717.
47. Longo JA. The management of recalcitrant nonunions with combined magnetic field stimulation. *Orthop Trans* 1998; 22:408-409.
48. Borsalino G, Bagnacani M, Bettati E, Fornaciari F, Rocchi R, Uluhogian S, Ceccherelli G, Cadossi R, Traina GC. Electrical stimulation of human femoral intertrochanteric osteotomies: double-blind study. *Clin Orthop* 1988; 237:256-263.
49. Sharrard WJW. A double-blind trial of pulsed electromagnetic fields for delayed union of tibial fractures. *J Bone Joint Surg* 1990; 72B:347-355.
50. Mammi GI, Rocchi R, Cadossi R, Traina GC. Effect of PEMF on the healing of human tibial osteotomies: a double blind study. *Clin Orthop* 1993; 288:246-253.
51. Scott G, King JB. A prospective double blind trial of electrical capacitive coupling in the treatment of nonunion of long bones. *J Bone Joint Surg* 1994; 76A:820-826.
52. Brighton CT, Shaman P, Heppenstall RB, Esterhai JL Jr, Pollack SR, FriedenberG ZB. Tibial nonunion treated with direct current, capacitive coupling, or bone graft. *Clin Orthop* 1995; 321:223-234.
53. Kane WJ. Direct current electrical bone growth stimulation for spinal fusion. *Spine* 1988; 13:363- 365.
54. Mooney V. A randomized double blind prospective study of the efficacy of pulsed electromagnetic fields for interbody lumbar fusions. *Spine* 1990; 15:708-715.
55. Goodwin CB, Brighton CT, Guyer RD, Johnson JR, Light KI, Yuan HA. A double blind study of capacitively coupled electrical stimulation as an adjunct to lumbar spinal fusions. *Spine* 1999; 24:1349-1357.
56. Linovitz RJ, Pathria M, Bernhardt M, Green D, Law MD, McGuire RA, Montesano PX, Rehtine G, Salib RM, Ryaby JT, Faden JS, Ponder R, Muenz LR, Magee FP, Garfin SA. Combined magnetic fields accelerate and increase spine fusion: a double-blind, randomized, placebo controlled study. *Spine* 2002; 27:1383-1389.

57. Hanft JR, Goggin JP, Landsman A, Surprenant M. The role of combined magnetic field bone growth stimulation as an adjunct in the treatment of neuroarthropathy/Charcot joint: an expanded pilot study. *J Foot Ankle Surg* 1998; 37:510-515.

28 Application of Electromagnetic Fields in Traumatology and Orthopaedics

1. Bassett CAL, Pawluk RJ, Pilla AA. Acceleration of fracture repair by electromagnetic fields: a surgically noninvasive method. *Ann NY Acad Sci* 1974; 238:242-261.
2. Delport F, Cheng N, Mulier JC. Clinical analysis of 90 patients with pulsed electromagnetics fields. In: *Bone Healing with Electrical and Electromagnetical Stimulation. Dresden Symposium. Dresden, 1984:73-74.*
3. Mitbreit IM, Lavrishcheva GI, Manjahin VD, Mihailovska LH. Reparative regeneration of bones under the influence of alternating magnetic field. *Orthop Traumatol*, 1978:55-64. In Russian.
4. Shaposhnikov JG, Devjatkov ND, Kamenev JF. Clinical evaluation of application of millimetric radiation of low intensity to patients suffering from wound infection of extremities. *Millimeter waves in Medicine and Biology. IRE AN SSSR, Moscow, 1989:16-20.* In Russian.
5. Slutskii LI, Sevastjanova NA, Ozolanta IL, Kuzmina IV, Dombrovska LE. Reactogenicity of biomaterials as studied by biochemical, morphological and ultrastructural techniques. *Cells Mater* 1992; 2:119-134.
6. Detlavs I, Dombrovska I, Klavinsh I, Turauska A, Shkirmante B, Slutskii L. Experimental study of the effect of electromagnetic fields in the early stage of wound healing. *Bioelectrochem Bioenergetics* 1994; 35(1):13-17.
7. Liepa ME, Slutskii LJ, Dombrovska LZ. Peculiarities of the influence of static magnetic field in the healing process of wound and bone fractures depending on intensity and application time. Application of magnetic fields in clinic. Theses of reports of Kuibishev regional conference, Kuibishev, June 1976:54-55. In Russian.
8. Detlavs I, Dombrovska L, Turauska A, Slutskii L. The influence of a static magnetic field (SMF) on biochemical parameters of granulation-fibrous tissue (GFT) in wound defects. Abstracts Book of Third International Congress of European Bioelectromagnetic Association in Nancy, France, February 29-March 3, 1996; 7:140.
9. Detlavs I, Dombrovska L, Turauska A, Shkirmante B, Slutskii L. Experimental study of the effects of radiofrequency electromagnetic fields on animals with soft

tissue wounds. The Science of the Environment 1996;
180:35-42.

10. Man D, Plosker H, Markov M. Application of tectonic permanent magnets for treatment of surgical flaps. Proceedings of the Fourth EBEA Congress, Zagreb, November 19-21, 1998:30-31.

11. Detlavs I, Dombrovska L, Shkirmante B, Turauska A, Slutskii L. Effects of radiofrequency electromagnetic fields on granulation-fibrous tissue. Abstracts Book of COST 244 Workshop in Kuopio, Finland, September 3-4, 1995:17.

12. Degen IL. Possibilities and perspectives (prospects) of magnetic therapy. Materials of III AllUnion Symposium: The influence of magnetic fields to the biological objects. Kaliningrad 1975:167-168. In Russian.

13. Bruvele MS, Junson RK, Liepa ME, Slutskii LI. The application of static magnetic fields for treatment of keloid cicatrix. Materials of III Congress of Traumatologists and Orthopaedists of Estonia, Latvia, Lithuania. Tallin, 1978:135-136. In Russian.

14. Liepa ME, Dombrovska LE, Sluckii LI. The influence of SMF to the cohesion of skin scar and to the break (tensile) and chemical contents of granulated fiber tissue. Materials of the III All-Union Symposium: The Influence of Magnetic Fields to the Biological Objects. Kaliningrad, 1975:180. In Russian.

15. Detlav IE, Aboltina MJ, Turauska AV, Erdmanis JV. The influence of constant and pulsing electromagnetic fields on muscle oxidation in experimental animals. In: Detlav IE ed. Electromagnetic Therapy in Traumas and Diseases of the Support-Motor Apparatus, Riga: RMI, 1987:12-16. In Russian.

16. Mitbreit IM, Dirin HA. Oxygenization of muscles of injured extremities of animals in the process of reparative regeneration of bones under the influence of low frequency magnetic field. Magnetic biology and magnetic therapy in the field of medicine. Report from the all-union scientific-practical conference in Vitebsk, September 1-3, 1980:218-219. In Russian.

17. Bassett CAL, Pawluk RJ, Pilla AA. Augmentation of bone repair by inductively-coupled electromagnetic fields. Science 1974; 184:575-577.

18. Bassett CAL, Pilla AA, Pawluk RJ. A non operative salvage of surgically-resistant pseudoarthrosis and nonunions by pulsing electromagnetic field. Clin Orthop 1977; 124:128-143.
19. Cadossi R, Fontanesi G, Rinaldi E. Non invasive treatment of pseudo-arthrosis with low frequency pulsing electromagnetic fields. A multicenter study. Evidence of periosteal bone callus formation. Bone Healing with Electrical and Electromagnetical Stimulation. Dresden Symposium, Dresden, 1984:72.
20. Giancecchi F, Poli G, Cadossi R. Use of low frequency pulsing electromagnetic fields for treatment of congenital and acquired pseudarthrosis. In: Detlav IE, ed. Electromagnetic Therapy in Traumas and Diseases of the SupportMotor Apparatus, Riga: RMI, 1987:124- 134.
21. Nahoda J, Koudela K, Freyova J. Heilung von Pseudarthrosen der langen Röhrenknochen mit Hilfe eines pulsierenden elektromagnetischen Feldes. In: Detlav IE, ed. Electromagnetic Therapy in Traumas and Diseases of the Support-Motor Apparatus, Riga: RMI, 1987:135-145.
22. Bassett CAL, Mitchell SN, Schink MM. Treatment of therapeutically resistant non-unions with bone grafts and pulsing electromagnetics fields. J Bone Joint Surg 1982; 64-A(8):1214- 1220.
23. Hinsenkamp M, Ryaby J, Burny F. Treatment of non-union by pulsing electromagnetic field: European multicenter study of 308 cases. Reconstr Surg Traumat 1985; 19:147-151.
24. Marger M, Musatti G, Bassett CAL. Results of Pulsed Electromagnetic Fields (PEMFs) in Ununited Fractures After External Skeletal Fixation. Clin Orthop Rel Res 1984; 190:260-265.
25. Tkachenko SS, Rutzky VV. Basis and experience in use of electromagnetic stimulation in operative treatment of fractures and pseudarthroses. Orthop Traumatol Prosthetics 1975; 1:6. In Russian.
26. Hinsenkamp M, Bourgois R, Bassett CAL. Electromagnetic stimulation of fracture repair. Influence on healing of fresh fractures. Acta Orthop Belg 1978; 44(5):672-698.
27. Wahlström O. Stimulation of fresh fracture healing with electromagnetic fields of extremely low frequency. In: Detlav IE, ed. Electromagnetic Therapy in Traumas and

Diseases of the Support-Motor Apparatus, Riga: RMI, 1987:146-150.

28. Mitbreit IM, Manjahin VD. The influence of low frequency magnetic field to the reparative regeneration of bone. The application of magnetic fields in medicine, biology and agriculture, Saratov: Publ. Saratov's University, 1978:139-140. In Russian.

29. Saveljev VN, Muravjov MF. Electromagnetic stimulation in the consolidation process of ununion fractures and pseudoarthrosis of long tubular bones. Application of magnetic fields in clinic. Theses of reports of Kuibishev regional conference, Kuibishev, June 1976:151-152. In Russian.

30. Bassett CAL, Valdes MG, Hernandez E. Modification of fracture repair with selected pulsing electromagnetic fields. J Bone Joint Surg July, 1982; 64-A(6):888-895.

31. Garland DE, Moses B, Salyer W. Long-term follow-up of fractures nonunions treated with PEMFs. Contemp Orthop 1991; 22(3):295-302.

32. Stosh NV, Harlampovich SI, Artjomov GS, Levdikova SS. Revascularization of bone fragments and forming regenerate in reparative osteogenesis after SMF therapy. Application of magnetic fields in clinic. Theses of reports of Kuibishev regional conference, Kuibishev, June 1976:79-80.

33. Demetskaja NA, Nadgerijeva VM, Kameneva JF. Clinical aspects of the use of electromagnetic therapy in the treatment of patients with closed fractures of long tubular bones. In: Detlav IE ed. Electromagnetic Therapy in Traumas and Diseases of the Support-Motor Apparatus, Riga: RMI, 1987:102-109. In Russian.

34. Detlav IE, Blaus AP, Naudinja IJ, Turauska AV. Magnetic therapy in the treatment of long tubular bone fractures and lengthening of extremities. In: Detlav IE, ed. Electromagnetic Therapy in Traumas and Diseases of the Support-Motor Apparatus, Riga: RMI, 1987:110- 123. In Russian.

35. Grande DA, Magee FP, Ryaby JT, Weinstein AM, Mcleod B. The effect of ion specific magnetic fields on articular cartilage metabolism. First Congress EBEA. Brussels, Januray 23-25, 1992.

36. Ryaby JT, Cai FF, DiDonato JA. Combined magnetic fields

inhibit IL-1 α and TNF- α dependent NF- κ B activation in osteoblast-like cells. Trans Third Congress EBEA, Nancy, 1996.

37. Meskens WA, Stuyck JAR, Feys H, Mulier JC. Treatment of non-union using pulsed electromagnetic fields: A retrospective follow-up study. Acta Orthop Belg 1990; 2(56):483-488.

38. Anisimov AN, Karpov VI, Jemeljanov VG. Application of electromagnetic fields of sound range frequencies to optimize osteoregeneration. Actual problems associated with application of magnetic and electromagnetic fields in medicine. Theses from Reports of All-Union Conference, Leningrad, 1990:49-50. In Russian.

39. Eyres KS, Saleh M, Kanis JA. Effect of pulsed electromagnetic fields on bone formation and bone loss during limb lengthening. Bone 1996; 18(6):505-509.

40. Artjomov GS, Fedosjutkin BF, Goljahovskij VJ, Stosh NV. The influence of local and continuous SMF to the reparative osteogenesis. Application of magnetic fields in clinic. Theses of reports of Kuibishev regional conference, Kuibishev, June, 1976:143-145. In Russian.

41. Kuchemenko AE, Shevchuk VJ. The application of magnetoelasts in traumatology and orthopaedics. Application of magnetic fields in clinical medicine and in the experiment. Theses of report of 2. Povolshkij Conference, Kuibishev, 1979:71-72. In Russian.

42. Nikolsky MA, Aleksejev AP. The influence of static magnetic fields on the consolidation of fractures in after operation period in the experiment and in clinics. Clinical application of magnetic fields. Theses of reports of allunion scientific-practical conference, Izhevsk, 1977:61-62. In Russian.

43. Liepa ME, Slutskii LI, Dombrovska LE. Peculiarities of the influence of static magnetic field in the healing process of wound and bone fractures depending on intensity and application time. Application of magnetic fields in clinic. Theses of reports of Kuibishev regional conference, Kuibishev, June, 1976:54-55.

44. Habirova GF. Use of magnetic field in the therapy of intraarticular injuries. Orthop Traumatol Prosthetics 1978; 12:53-57. In Russian.

45. Gurbo SA, Nikitenko IK. Magnetic therapy in complex treatment of knee joint traumatic arthritis. Actual problems associated with application of magnetic and electromagnetic fields in medicine. Theses from reports of all-union conference, Leningrad, 1990:57-58. In Russian.
46. Degen IL. Treatment of traumatic oedema with magnetic field. *Orthop Traumatol Prosthetics* 1970; 11:47-49.
47. Fjodorova RI, Zheleznyak VA, Nikolsky MA. Antiinflammation influence of SMF of elastic magnets on treating wounds, traumatic oedema in experiment and clinic. *Magnetobiology and magnetotherapy in medicine. Theses of reports of all-union scientific-practical conference, Vitebsk 1980:50-51. In Russian.*
48. Nikolsky MA, Demetzky AM. Static magnetic field of elastic magnetics in the complex therapy of patients in operative interventions on the spine. *Orthop Traumatol Prosthetics* 1980; 4:22- 25. In Russian.
49. Stokov VI. The application of SMF for healing fractures of long tubular bones. Theses of report of region scientific-practical conference in traumatology and orthopaedics, Orenburg 1982:24-26. In Russian.
50. Markov MS. Clinical application of permanent magnets:dosimetry. *Proceedings of the Fourth EBEA Congress, Zagreb, Croatia, November 19-21, 1998:99-100.*
51. Markov MS. Clinical application of permanent magnets: USA experience. *Proceedings of the Fourth EBEA Congress, Zagreb, Croatia, November 19-21, 1998:20-21.*
52. Ibragimova AG, Nikonova LV, Baigildejeva FM, Ledovskih NM. Magnetotherapy in clinics of rheumatic diseases. Theses of reports of regional scientific-practical conference, Kuibishev, November 1984:24-29. In Russian.
53. Nikonova LV. Microcirculation of patients suffering from rheumatic arthritis undergoing a course of treatment of alternating low frequency magnetic field. *Application of magnetic fields in medicine, biology, agriculture, Russia: Saratov University, 1978:148. In Russian.*
54. Dumbere RT, Liepa ME. The use of constant magnetic field in the treatment of carpal tunnel syndrome. In: *Detlav IE, ed. Electromagnetic Therapy in Traumas and Diseases of the SupportMotor Apparatus, Riga: RMI, 1987:179. In Russian.*

55. Battisti E, Fortunato M, Ginanneschi F, Rigato M. Efficacy of the magnetotherapy in idiopathic carpal tunnel syndrome. Proceedings of the Fourth EBEA Congress, Zagreb, Croatia, November 19-21, 1998:34-35.
56. Detlav IE, Ivashenko MV, Naudinja IJ, Turauska AV. Magnetotherapy in the treatment of osteochondrosis of the spine. Theses from reports of all-union congress of traumatology and orthopaedics, Moscow 1988; 1:165-166.
57. Imamaliyev AS, Askerov LD, Gnetetskaja LN, Stepnova NV. The "Travelling" impulse magnetic field (TIMF) in the treatment of orthopaedic patients. Abstracts of Second International school. Electromagnetic Fields and Biomembranes, Pleven, October 2-8, 1989:102.
58. Savchenko AP, Mitbreit IM. Low-frequency magnetic field in the complex treatment of the patients with spine osteochondrosis. Application of Magnetic Fields in Clinical Medicine and Experiments, Kuibishev, 1979:99. In Russian.
59. Nikitenko IK, Zhilnikov VM. The treatment of spine osteochondrosis with a constant magnetic field. Application of Magnetic Fields in Medicine, Biology and Agriculture. Saratov, 1978:147-148. In Russian.
60. Stokov VN, Safronov AA, Vlasenko IV. The application of constant magnetic field in treating of arthritis and synovits of knee joint. Theses from reports of regional scientific-practical conference of traumatology. Orenburg, 1984:27-28. In Russian.
61. Detlav IE, Turauska AV, Grase AA. The application of constant magnetic field in treatment of patients with coxarthrosis. Theses of reports of regional scientific-practical conference, Kuibishev, November 1984:100-103. In Russian.
62. Arishenskaja AM, Osipov VV, Vershcher EL, Jagodzinska VV. The indications of applying SMF in treatment infectious non-specific poliartthritis. Application of magnetic fields in clinic. Theses of reports of Kuibishev regional conference, Kuibishev, June 1976:147-148. In Russian.
63. Aaron Rk, Ciombor DMCK. Therapeutic effects of electromagnetic fields in the stimulation of connective tissue repair. J Cell Biochem 1993; 52:42-46.
64. Harrison MH, Bassett CA. The results of a double-blind

trial of pulsed electromagnetic frequency in the treatment of Perthes' disease. *J Pediatr Orthop* 1997; 17(2):264-265.

65. Trock DH, Bollet AJ, Dyer RH, Fielding LP, Miner WK, Markoll R. A double-blind trial of the clinical effects of pulsed electromagnetic fields in osteoarthritis. *J Rheumatol* 1993; 20:456-460.

66. Ciombor KJ, Ciombor DMCK. Stimulation of proteoglycan synthesis in human osteoarthritic cartilage by PEMF. Abstract Book of BEMS Sixteenth Annual Meeting, Copenhagen, Denmark, June 1994; 40:12-17.

67. Grigorjeva VL, Parfis PG, Gerasimova VN. Application of alternative magnetic field in treating patients with osteochondrosis deformies. Theses of report of all-union scientificpractical conference, Vitebsk, 1980:204.

68. Bassett CAL, Schink-Ascani M, Lewis SM. Effects of Pulsed Electromagnetic Fields on Steinberg Ratings of Femoral Head Osteonecrosis. *Clin Orthop Rel Res* 1989; 246:172-183.

69. Hinsenkamp M, Hauzeur JP, Sintzoff S. Preliminary results electromagnetic field treatment of osteonecrosis. *Bioelectrochem Bioenergetics* 1993; 30:229-235.

70. Aaron RK, Lennox D, Bunce GE, Ebert T. The Conservative Treatment of Osteonecrosis of the Femoral Head. *Clin Orthop Rel Res* 1989; 249:209-218.

71. Golubenko GN. The influence of low frequency magnetic field on the intra-osseous microcirculation in patients with idiopathic aseptic necrosis of the femoral head in adults (preliminary announcement). In: Detlav IE, ed. *Electromagnetic Therapy in Traumas and Diseases of the Support-Motor Apparatus*, Riga: RMI, 1987:162-163. In Russian.

72. Kennedy WF, Roberts CG, Zuege RC, Dicus WT. Use of pulsed electromagnetic fields in the treatment of loosened hip prostheses. In: Brighton CT, Pollack SR, eds. *Electromagnetics in medicine and biology*, San Francisco: San Francisco Press, 1991:313-322.

73. Konrad K, Sevcic K, Foldes K, Piroaska E, Molnar E. Therapy with pulsed electromagnetic fields in aseptic loosening of total hip prostheses: a prospective study. *Clin Rheumatol* 1996; 15(4):325-328.

74. Kamenev YF, Shitikov VA, Baptenov ND, Kozhakmatova GS. Clinical methods of mm wave application and the principles of increasing their therapeutic potency in traumatology and orthopaedics. Digest papers 11 Russian symposium millimeter waves in medicine and biology, Moscow, April 21-24, 1997:31-32. In Russian.
75. Kamenev JF, Sarkisjan AG, Urazgiljdejevs ZI. The application of millimetric waves for treating complicated infections of injured extremities. Millimeter waves in Medicine and Biology, Moscow: IRE AN SSSR, 1989: 21-23. In Russian.
76. Deyjatkov ND. The possibility of application EMF mm range for treatment laser wounds. Millimeter waves in Medicine and Biology, Moscow: IRE AN SSSR, 1989:5-9. In Russian.
77. Polyak EV, Shitikov VA, Lyalin LL. Experience of application of EHF-Therapy in the complex treatment of the sick at chronic osteomyelitis. Millimeter waves in Medicine and Biology, Moscow. 1994; 4:46-48. In Russian.
78. Shevchenko SD, Makolinets VI, Kiselyov VK, Gruntovsky 6ch, Grashchenkova TN. Experience in treatment of some orthopaedic diseases with low intensity electromagnetic radiation of mmband. Digest of Papers 11 Russian symposium millimeter Waves in Medicine and Biology, Moscow, April 21-24, 1997:32-35.
79. Aleshchenko VV, Pisanko OI. EHF-Therapy of hemophilic arthropathy and hemoarthritis of knee joints. Millimeter waves in Medicine and Biology. Digest of Papers 10 Russian Symposium, Moscow, April 24-26 1995:61-63. In Russian.
80. Detlavs I, Turauska A. The application of modulated electromagnetic field therapy. Proceedings of the Latvian Academy of Sciences. In press.

29 Neurorehabilitation of Standing and Walking After Spinal Cord Injury

1. Kralj A, Bajd T. Functional Electrical Stimulation: Standing and Walking after Spinal Cord Injury. Boca Raton: CRC Press, 1989.
2. Popović D, Sinkjaer T. Control of Movement for the Physically Disabled. London: Springer, 2000.
3. Issekutz B, Blizzard NC, Rodhal K. Effect of prolonged bed rest on urinary calcium output. *J Applied Physiol* 1966; 21:1013-1020.
4. Odeen I, Knutsson E. Evaluation of the effects of muscle stretch and weight load in patients with spastic paraplegia. *Scand J Rehab Med* 1981; 13:117-121.
5. Krebs M, Ragnarsson K, Tuckman J. Orthostatic vasomotor response in spinal man. *Paraplegia* 1983; 21:72-80.
6. Vodovnik L, Bajd T, Gračanin F, Kralj A, Strojnik P. Functional electrical stimulation for control of locomotor systems. *CRC Critical Rev Bioeng* 1981; 6:63-131.
7. Kantrowitz A. Electronic Physiologic Aids. A report of the Maimonides Hospital, Brooklyn, NY1960.
8. Wilemon WK, Mooney V, McNeal D, Reswick J. Surgically Implanted Peripheral Neuroelectric Stimulation. Rancho Los Amigos Hospital internal report, Downey, CA, 1970.
9. Kralj A, Bajd T, Turk R, Benko H. Paraplegic patients standing by functional electrical stimulation. XII International Conference on Medical and Biological Engineering, Jerusalem, Israel, Aug 19-24, 1979.
10. Bajd T, Kralj A, Šega J, Turk R, Benko H, Strojnik P. Use of a two-channel electrical stimulator to stand paraplegic patients. *Phys Ther* 1981; 61:526-527.
11. Triolo RJ, Reilley BMB, Freedman W, Betz RR. The functional standing test. *IEEE Eng Med Biol Mag* 1992; 11: 32-34.
12. Kralj A, Bajd T, Turk R. Enhancement of gait restoration in spinal injured patients by functional electrical stimulation. *Clin Orthop* 1988; 233:34-43.
13. Bajd T, Munih M, Kralj A. Problems associated with

FES-standing in paraplegia. Techn Health Care 1999; 7: 301-308.

14. Matjačić Z, Jensen PL, Riso RR, Voigt M, Bajd T, Sinkjaer T. Development and evaluation of a two-dimensional electrocutaneous cognitive feedback system for use in paraplegic standing. J Med Eng Technol 2000; 24: 215-226.

15. Bajd T, Kralj A, Turk R, Benko H, Šega J. The use of a four-channel electrical stimulator as an ambulatory aid for paraplegic patients. Phys Ther 1983; 63:1116-1120.

16. Kralj AR, Bajd T, Munih M, Turk R. FES gait restoration and balance control in spinal cord injured patients. Progress in Brain Research 1993; 97:387-396.

17. Kobetic R. Advancing step by step. IEEE Spectrum 1994; 32:27-31.

18. Chizeck HJ, Kobetic R, Marsolais EB, Abbas JJ, Donner IH, Simon E. Control of functional neuromuscular stimulation systems for standing and locomotion in paraplegics. Proc IEEE 1988; 76:1155-1165.

19. Triolo RJ, Bogie K. Lower extremity applications of functional electrical stimulation after spinal cord injury. Top Spinal Cord Inj Rehabil 1999; 5:44-65.

20. Bajd T, Cikajlo I, Šavrin R, Erzin R, Gider F. FES rehabilitative systems for re-education of walking in incomplete spinal cord injured persons. Neuromodulation 2000; 3:167-174.

21. Bajd T, Kralj A, Turk R, Benko H, Šega J. Use of functional electrical stimulation in the rehabilitation of patients with incomplete spinal cord injuries. J Biomed Eng 1989; 11:96-102.

22. Granat MH, Ferguson ACB, Andrews BJ, Delargy M. The role of functional electrical stimulation in the rehabilitation of patients with incomplete spinal cord injury—observed benefits during gait studies. Paraplegia 1993; 31:207-215.

23. Stein RB, Belanger M, Wheeler G, Wieler M, Popović DB, Prochazka A, Davis LA. Electrical systems for improving locomotion after incomplete spinal cord injury: an assessment. Arch Phys Med Rehabil 1993; 74: 954-959.

24. Crozier KS, Cheng LL, Graziani V, Zorn G, Herbison G,

Ditunno JF. Spinal cord injury: prognosis for ambulation based on quadriceps recovery. *Paraplegia* 1992; 30:762-767.

25. Waters RL, Ien S, Adkins RH, Yakura JS. Injury pattern effect on motor recovery after traumatic spinal cord injury. *Arch Phys Med Rehabil* 1995; 76:440-443.

26. Jacobs SR, Yeane NK, Herbison GJ, Ditunno JF. Future ambulation prognosis as predicted by somatosensory evoked potentials in motor complete and incomplete quadriplegia. *Arch Phys Med Rehabil* 1995; 76:635-641.

27. Kato S, El Masry WS. Motor recovery of patients presenting with motor paralysis and sensory sparing following cervical spinal cord injuries. *Paraplegia* 1995; 33:506-509.

28. Tang SFT, Tuel SM, Mc Kay BW, Dimitrijević MR. Correlation of motor control in the supine position and assistive device used for ambulation in chronic incomplete spinal cord-injured persons. *Am J Phys Med Rehabil* 1994; 73: 268-274.

29. Bajd T, Gregorič M, Vodovnik L, Benko H. Electrical stimulation in treating spasticity resulting from spinal cord injury. *Arch Phys Med Rehabil* 1985; 66:515-517.

30. Štefančič M, Kralj A, Turk R, Bajd T, Benko H, Šega J. Neurophysiological background of the use of functional electrical stimulation in paraplegia. *Electromyogr Clin Neurophysiol* 1986; 26:423-435.

31. Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and regression trees. Belmont: Wadsworth Int. Group, 1984.

32. Bajd T, Kralj A, Štefančič M, Lavrač N. Use of FES in the lower extremities of incomplete SCI patients. *Artif Organs* 1999; 23:403-409.

33. Matjačić Z, Munih M, Bajd T, Kralj A. Voluntary telemetry control of functional electrical stimulators. *J Med Eng Technol* 1996; 20:11-15.

34. MacGregor J. The evaluation of patient performance using long-term ambulatory monitoring technique in the domiciliary environment. *Physiotherapy* 1981; 67:30-33.

35. Benko H, Obreza P, Burger H. FES as an orthotic aid in patients with spinal injury. In: Marinčler C, Knops H,

Andrich R, eds. Assistive Technology-Added Value to the Quality of Life. Amsterdam: IOS Press, 2000: 518-521.

36. Wiener N. Cybernetics or Control and Communication in the Animal and the Machine. Paris: Herman & C^{le} Editeurs, 1948.

37. Cikajlo I, Bajd T. Use of telekinesthetic feedback in walking assisted by functional electrical stimulation. J Med Eng Technol 2000; 24:14-19.

38. Cikajlo I, Bajd T. Swing phase estimation in paralyzed persons walking. Technol Health Care. In press.

39. Bajd T, Munih M, Šavrin R, Benko H, Cikajlo I. Dermatome electrical stimulation as a therapeutic ambulatory aid for incomplete spinal cord injured patients. Artif Organs 2002; 26:260-262.

30 Electromagnetic Linkages in Soft Tissue Wound Healing

1. Becker RO. Augmentation of regenerative healing in man. A possible alternative to prosthetic implantation. *Clin Orthop* 1972; 83:255-262.
2. Nordenstrom BE. Impact of biologically closed electric circuits (BCEC) on structure and function. *Integr Physiol Behav Sci* 1992; 27:285-303.
3. Burr HS, Harvey SC, Taffel M. Bio-electric correlates of wound healing. *Yale J Biol Med* 1938; 11:104-107.
4. Grimes DI, Lennard RF, Swithenby SJ. Macroscopic ionic currents within the human leg. *Phys Med Biol* 1985; 30:1101-1112.
5. Foulds IS, Barker AT. Human skin battery potentials and their possible role in wound healing. *Br J Dermatol* 1983; 109:515-522.
6. Barker AT, Jaffe LF, Vanable JW Jr. The glabrous epidermis of cavies contains a powerful battery. *Am J Physiol* 1982; 242:R358-366.
7. Vanable JW Jr. Integumentary potentials and wound healing. *Electric Fields in Vertebrate Repair: Alan R Liss, Inc.* 1989:171-224.
8. Lee RC, Canaday DJ, Doong H. A review of the biophysical basis for the clinical application of electric fields in soft-tissue repair. *J Burn Care Rehabil* 1993; 14:319-335.
9. Carley PJ, Wainapel SF. Electrotherapy for acceleration of wound healing: low-intensity direct current. *Arch Phys Med Rehabil* 1985; 66:443-446.
10. Gentzkow GD. Electrical stimulation to heal dermal wounds. *J Dermatol Surg Oncol* 1993; 19:753-758.
11. Bentall RHC. Low-level pulsed radiofrequency fields and the treatment of soft-tissue injuries. *Bioelectr Bioenergetics* 1986; 16:531-548.
12. Gardner SE, Frantz RA, Schmidt FL. Effect of electrical stimulation on chronic wound healing: a meta-analysis. *Wound Repair Regen* 1999; 7:495-503.
13. Akai M, Hayashi K. Effect of electrical stimulation on

musculoskeletal systems: A Metaanalysis of controlled clinical trials. *Bioelectromagnetics* 2002; 23:132-143.

14. Vodovnik L, Karba R. Treatment of chronic wounds by means of electric and electromagnetic fields. Part 1. Literature review. *Med Biol Eng Comput* 1992; 30:257-266.

15. Yamaguchi Y, Yoshikawa K. Cutaneous wound healing: an update. *J Dermatol* 2001; 28:521- 534.

16. Holzheimer RG, Steinmetz W. Local and systemic concentrations of pro- and antiinflammatory cytokines in human wounds. *Eur J Med Res* 2000; 5:347-355.

17. Gillitzer R, Goebeler M. Chemokines in cutaneous wound healing. *J Leukoc Biol* 2001; 69:513- 521.

18. Nagaoka T, Kaburagi Y, Hamaguchi Y, Hasegawa M, Takehara K, Steeber DA, Tedder TF, Sato S. Delayed wound healing in the absence of intercellular adhesion molecule-1 or L-selectin expression. *Am J Pathol* 2000; 157:237-247.

19. Efron DT, Most D, Barbul A. Role of nitric oxide in wound healing. *Curr Opin Clin Nutr Metab Care* 2000; 3: 197-204.

20. Tenaud I, Sainte-Marie I, Jumbou O, Litoux P, Dreno B. In vitro modulation of keratinocyte wound healing integrins by zinc, copper and manganese. *Br J Dermatol* 1999; 140:26-34.

21. Knighton DR, Hunt TK, Scheuenstuhl H, Halliday BJ, Werb Z, Banda MJ. Oxygen tension regulates the expression of angiogenesis factor by macrophages. *Science* 1983; 221:1283-1285.

22. Lee RH, Efron D, Tantry U, Barbul A. Nitric oxide in the healing wound: a time-course study. *J Surg Res* 2001; 101:104-108.

23. Frank S, Kampfer H, Metzler C, Pfeilschifter J. Nitric oxide drives skin repair: novel functions of an established mediator. *Kidney Int* 2002; 61:882-888.

24. Laplante AF, Germain L, Auger FA, Moulin V. Mechanisms of wound reepithelialization: hints from a tissueengineered reconstructed skin to long-standing questions. *Faseb J* 2001; 15:2377-2389.

25. O'Toole EA. Extracellular matrix and keratinocyte

- migration. *Clin Exp Dermatol* 2001; 26:525-530.
26. Spravchikov N, Sizyakov G, Gartsbein M, Accili D, Tennenbaum T, Wertheimer E. Glucose effects on skin keratinocytes: implications for diabetes skin complications. *Diabetes* 2001; 50:1627-1635.
27. Shi HP, Most D, Efron DT, Tantry U, Fischel MH, Barbul A. The role of iNOS in wound healing. *Surgery* 2001; 130:225-229.
28. Akcay MN, Ozcan O, Gundogdu C, Akcay G, Balik A, Kose K, Oren D. Effect of nitric oxide synthase inhibitor on experimentally induced burn wounds. *J Trauma* 2000; 49:327-330.
29. Stacey MC, Mata SD. Lower levels of PAI-2 may contribute to impaired healing in venous ulcers—a preliminary study. *Cardiovasc Surg* 2000; 8:381-385.
30. Markov M. Electric current and electromagnetic field effects on soft tissue: Implications for wound healing. *Wounds* 1995; 7:94-110.
31. McCulloch JM, Kloth LC, Feedar JA. Wound healing alternatives in management. In: Wolf SE, ed. *Contemporary Perspectives in Rehabilitation*. Philadelphia: F.A.Davis, 1995:275- 310.
32. Sussman C, Bates-Jensen BM. *Wound Care: A Collaborative Practice Manual for Physical Therapists and Nurses*. Aspen Publishers, 2001.
33. Markov M, Pilla AA. Electromagnetic stimulation of soft tissues: pulsed radio frequency treatment of postoperative pain and edema. *Wounds* 1995; 7:143-151.
34. Liboff AR, Jenrow KA. Physical mechanisms in neuroelectromagnetic therapies. *NeuroRehabilitation* 2002; 17: 9-22.
35. Fowkes FG, Evans CJ, Lee AJ. Prevalence and risk factors of chronic venous insufficiency. *Angiology* 2001; 52 (Suppl 1):S5-S15.
36. Peschen M, Lahaye T, Hennig B, Weyl A, Simon JC, Vanscheidt W. Expression of the adhesion molecules ICAM-1, VCAM-1, LFA-1 and VLA-4 in the skin is modulated in progressing stages of chronic venous insufficiency. *Acta Derm Venereol* 1999; 79:27-32.

37. Tassiopoulos AK, Golts E, Oh DS, Labropoulos N. Current concepts in chronic venous ulceration. *Eur J Vasc Endovasc Surg* 2000; 20:227-232.
38. Smith PD. Update on chronic-venous-insufficiency-induced inflammatory processes. *Angiology* 2001; 52(Suppl 1):S35-42.
39. Valencia IC, Falabella A, Kirsner RS, Eaglstein WH. Chronic venous insufficiency and venous leg ulceration. *J Am Acad Dermatol* 2001; 44:401-421. quiz 422-404.
40. Gschwandtner ME, Ehringer H. Microcirculation in chronic venous insufficiency. *Vasc Med* 2001; 6:169-179.
41. Junger M, Steins A, Hahn M, Hafner HM. Microcirculatory dysfunction in chronic venous insufficiency (CVI). *Microcirculation* 2000; 7:S3-S12.
42. Mayrovitz HN, Larsen PB. Leg blood flow in patients with venous ulcers: relationship to site and ulcer area. *Wounds* 1994; 6:195-200.
43. Steins A, Hahn M, Junger M. Venous leg ulcers and microcirculation. *Clin Hemorheol Microcirc* 2001; 24: 147-153.
44. Powell CC, Rohrer MJ, Barnard MR, Peyton BD, Furman MI, Michelson AD. Chronic venous insufficiency is associated with increased platelet and monocyte activation and aggregation. *J Vasc Surg* 1999; 30:844-851.
45. Saharay M, Shields DA, Porter JB, Scurr JH, Coleridge Smith PD. Leukocyte activity in the microcirculation of the leg in patients with chronic venous disease. *J Vasc Surg* 1997; 26:265- 273.
46. Flemming K, Cullum N. Electromagnetic therapy for the treatment of venous leg ulcers. *Cochrane Database Syst Rev* 2001; 1.
47. Ieran M, Zaffuto S, Bagnacani M, Annovi M, Moratti A, Cadossi R. Effect of low frequency pulsing electromagnetic fields on skin ulcers of venous origin in humans: a double-blind study. *J Orthop Res* 1990; 8: 276-282.
48. Stiller MJ, Pak GH, Shupack JL, Thaler S, Kenny C, Jondreau L. A portable pulsed electromagnetic field (PEMF) device to enhance healing of recalcitrant venous ulcers: a

doubleblind, placebo controlled clinical trial. Br J Dermatol 1992; 127:147-154.

49. Kenkre JE, Hobbs FD, Carter YH, Holder RL, Holmes EP. A randomized controlled trial of electromagnetic therapy in the primary care management of venous leg ulceration. Fam Pract 1996; 13:236-241.

50. Franek A, Polak A, Kucharzewski M. Modern application of high voltage stimulation for enhanced healing of venous crural ulceration. Med Eng Phys 2000; 22:647-655.

51. Canedo-Dorantes L, Garcia-Cantu R, Barrera R, Mendez-Ramirez I, Navarro VH, Serrano G. Healing of chronic arterial and venous leg ulcers with systemic electromagnetic fields. Arch Med Res 2002; 33:281-289.

52. Goldman R, Brewley B, Golden M. Electrotherapy reoxygenates inframalleolar ischemic wounds on diabetic patients. Advances in Skin and Wound Care 2002; 15:112-120.

53. Erdman WJ. Peripheral blood flow measurements during application of pulse high-frequency currents. Amer J Orthop 1960; 2:196-197.

54. Hedenius P, Odeblad E, Wahlstrom L. Some preliminary investigations on the therapeutic effect of pulsed short waves in intermittent claudication. Current Therapeutic Research 1966; 8:317- 321.

55. Mayrovitz HN, Larsen PB. Peri wound skin microcirculation of venous leg ulcers. Microvasc Res 1994; 48: 114-123.

56. Mayrovitz HN, Larsen PB. Standard and near-surface laser-Doppler perfusion in foot dorsum skin of diabetic and nondiabetic subjects with and without coexisting peripheral arterial disease. Microvasc Res 1994; 48:338-348.

57. Mayrovitz HN, Larsen PB. Functional microcirculatory impairment: a possible source of reduced skin oxygen tension in human diabetes mellitus. Microvasc Res 1996; 52:115-126.

58. Mayrovitz HN, Larsen PB. Effects of pulsed electromagnetic fields on skin microvascular blood perfusion. Wounds 1992; 4:197-202.

59. Mayrovitz HN, Macdonald J, Sims N. Effects of pulsed radio frequency diathermy on postmastectomy arm lymphedema

and skin blood flow: A pilot investigation. *Lymphology*, 2002.

60. Mayrovitz HN, Groseclose EE, Markov M, Pilla AA. Effects of permanent magnets on resting skin blood perfusion in healthy persons assessed by laser Doppler flowmetry and imaging. *Bioelectromagnetics* 2001; 22: 494-502.

61. Mayrovitz HN, Groseclose EE, Sims N. Assessment of the short-term effects of a permanent magnet on normal skin blood circulation via laser-Doppler flowmetry. *Scientific Rev Altern Med* 2002; 6:5-9.

62. Jacobs MJ, Jorning PJ, Joshi SR, Kitslaar PJ, Slaaf DW, Reneman RS. Epidural spinal cord electrical stimulation improves microvascular blood flow in severe limb ischemia. *Ann Surg* 1988; 207:179-183.

63. Jacobs MJ, Jorning PJ, Beckers RC, Ubbink DT, van Kleef M, Slaaf DW, Reneman RS. Foot salvage and improvement of microvascular blood flow as a result of epidural spinal cord electrical stimulation. *J Vasc Surg* 1990; 12:354-360.

64. Graber JN, Lifson A. The use of spinal cord stimulation for severe limb-threatening ischemia: a preliminary report. *Ann Vasc Surg* 1987; 1:578-582.

65. Mingoli A, Sciacca V, Tamorri M, Fiume D, Sapienza P. Clinical results of epidural spinal cord electrical stimulation in patients affected with limb-threatening chronic arterial obstructive disease. *Angiology* 1993; 44: 21-25.

66. Horsch S, Claeys L. Epidural spinal cord stimulation in the treatment of severe peripheral arterial occlusive disease. *Ann Vasc Surg* 1994; 8:468-474.

67. Claeys LG. Improvement of microcirculatory blood flow under epidural spinal cord stimulation in patients with nonreconstructible peripheral arterial occlusive disease. *Artif Organs* 1997; 21:201-206.

68. Kumar K, Toth C, Nath RK, Verma AK, Burgess JJ. Improvement of limb circulation in peripheral vascular disease using epidural spinal cord stimulation: a prospective study. *J Neurosurg* 1997; 86:662-669.

69. Fromy B, Abraham P, Bouvet C, Bouhanick B, Fressinaud P, Saumet JL. Early decrease of skin blood flow in response

to locally applied pressure in diabetic subjects. *Diabetes* 2002; 51:1214-1217.

70. Gonzalez ER, Oley MA. The management of lower-extremity diabetic ulcers. *Manag Care Interface* 2000; 13: 80-87.

71. Abbott CA, Carrington AL, Ashe H, Bath S, Every LC, Griffiths J, Hann AW, Hussein A, Jackson N, Johnson KE, Ryder CH, Torkington R, Van Ross ER, Whalley AM, Widdows P, Williamson S, Boulton AJ. The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. *Diabet Med* 2002; 19:377-384.

72. Gilcreast DM, Stotts NA, Froelicher ES, Baker LL, Moss KM. Effect of electrical stimulation on foot skin perfusion in persons with or at risk for diabetic foot ulcers. *Wound Repair Regen* 1998; 6:434-441.

73. Muller IS, de Grauw WJ, van Gerwen WH, Bartelink ML, van Den Hoogen HJ, Rutten GE. Foot ulceration and lower limb amputation in type 2 diabetic patients in dutch primary health care. *Diabetes Care* 2002; 25:570-574.

74. Peters EJ, Lavery LA, Armstrong DG, Fleischli JG. Electric stimulation as an adjunct to heal diabetic foot ulcers: a randomized clinical trial. *Arch Phys Med Rehabil* 2001; 82:721-725.

75. Baker LL, Chambers R, DeMuth SK, Villar F. Effects of electrical stimulation on wound healing in patients with diabetic ulcers. *Diabetes Care* 1997; 20:405-412.

76. Lundeberg TC, Eriksson SV, Malm M. Electrical nerve stimulation improves healing of diabetic ulcers. *Ann Plast Surg* 1992; 29:328-331.

77. Sarma GR, Subrahmanyam S, Deenabandhu A, Babu CR, Madhivathanan S, Kesavaraj N. Exposure to pulsed magnetic fields in the treatment of plantar ulcers in leprosy patients—a pilot, randomized, double-blind, controlled clinical trial. *Indian J Lepr* 1997; 69:241-250.

78. Barczak CA, Barnett RI, Childs EJ, Bosley LM. Fourth national pressure ulcer prevalence survey. *Adv Wound Care* 1997; 10:18-26.

79. Margolis DJ, Bilker W, Knauss J, Baumgarten M, Strom BL. Venous leg ulcer: incidence and prevalence in the elderly. *Ann Epidemiol* 2002; 12:321-325.

80. Tourtual DM, Riesenbergr LA, Korutz CJ, Semo AH, Asef A, Talati K, Gill RD. Predictors of hospital acquired heel pressure ulcers. *Ostomy Wound Manage* 1997; 43:24-28, 30, 32-24 passim.
81. Byers PH, Carta SG, Mayrovitz HN. Pressure ulcer research issues in surgical patients. *Adv Skin Wound Care* 2000; 13:115-121.
82. Mayrovitz HN, Sims N. Biophysical effects of water and synthetic urine on skin. *Adv Skin Wound Care* 2001; 14:302-308.
83. Mayrovitz HN, Smith JR. Adaptive skin blood flow increases during hip-down lying in elderly women. *Adv Wound Care* 1999; 12:295-301.
84. Mayrovitz HN, Macdonald J, Smith JR. Blood perfusion hyperaemia in response to graded loading of human heels assessed by laser-Doppler imaging. *Clin Physiol* 1999; 19:351-359.
85. Mayrovitz HN, Smith J. Heel-skin microvascular blood perfusion responses to sustained pressure loading and unloading. *Microcirculation* 1998; 5:227-233.
86. Mayrovitz HN, Smith J, Delgado M, Regan MB. Heel blood perfusion responses to pressure loading and unloading in women. *Ostomy Wound Manage* 1997; 43:16-20, 22, 24 passim.
87. Mayrovitz HN. Pressure and blood flow linkages and impacts on pressure ulcer development. *Adv Wound Care* 1998; 11:4.
88. Mayrovitz HN, Sims N, Taylor MC. Sacral skin blood perfusion: A factor in pressure ulcers? *Ostomy Wound Manage* 2002; 48:34-42.
89. Peirce SM, Skalak TC, Rodeheaver GT. Ischemia-reperfusion injury in chronic pressure ulcer formation: a skin model in the rat. *Wound Repair Regen* 2000; 8:68-76.
90. Sheffet A, Cytryn AS, Louria DB. Applying electric and electromagnetic energy as adjuvant treatment for pressure ulcers: a critical review. *Ostomy Wound Manage* 2000; 46:28-33, 36-40, 42-24.
91. Flemming K, Cullum N. Electromagnetic therapy for the

treatment of pressure sores. *Cochrane Database Syst Rev*, 2001; 1.

92. Comorosan S, Vasilco R, Arghiropol M, Paslaru L, Jieanu V, Stelea S. The effect of diapulse therapy on the healing of decubitus ulcer. *Rom J Physiol* 1993; 30:41-45.

93. Salzberg CA, Cooper-Vastola SA, Perez F, Viehbeck MG, Byrne DW. The effects of nonthermal pulsed electromagnetic energy on wound healing of pressure ulcers in spinal cordinjured patients: a randomized, doubleblind study. *Ostomy Wound Manage* 1995; 41:42-44, 46, 48 passim.

94. Itoh M, Montemayor JS Jr, Matsumoto E, Eason A, Lee MH, Folk FS. Accelerated wound healing of pressure ulcers by pulsed high peak power electromagnetic energy (Diapulse). *Decubitus* 1991; 4:24-25, 29-34.

95. Seaborne D, Quirion-DeGirardi C, Rousseau MMRJL. The treatment of pressure sores using pulsed electromagnetic energy (PEME). *Physiotherapy Canada* 1996; 48:131-137.

96. Wood JM, Evans PE III, Schallreuter KU, Jacobson WE, Sufit R, Newman J, White C, Jacobson M. A multicenter study on the use of pulsed low-intensity direct current for healing chronic stage II and stage III decubitus ulcers. *Arch Dermatol* 1993; 129:999-1009.

97. Griffin JW, Tooms RE, Mendijs RA, Clifft JK, Vander Zwaag R, el-Zeky F. Efficacy of high voltage pulsed current for healing of pressure ulcers in patients with spinal cord injury. *Phys Ther* 1991; 71:433-442, discussion 442-434.

98. Stefanovska A, Vodovnik L, Benko H, Turk R. Treatment of chronic wounds by means of electric and electromagnetic fields. Part 2. Value of FES parameters for pressure sore treatment. *Med Biol Eng Comput* 1993; 31:213-220.

99. Levine SP, Kett RL, Cederna PS, Brooks SV. Electric muscle stimulation for pressure sore prevention: tissue shape variation. *Arch Phys Med Rehabil* 1990; 71:210-215.

100. Bogie KM, Reger SI, Levine SP, Sahgal V. Electrical stimulation for pressure sore prevention and wound healing. *Assist Technol* 2000; 12:50-66.

101. Levine SP, Kett RL, Gross MD, Wilson BA, Cederna PS, Juni JE. Blood flow in the gluteus maximus of seated individuals during electrical muscle stimulation. *Arch Phys Med Rehabil* 1990; 71:682-686.

102. Mawson AR, Siddiqui FH, Connolly BJ, Sharp CJ, Stewart GH, Summer WR, Biundo JJ Jr. Effect of high voltage pulsed galvanic stimulation on sacral transcutaneous oxygen tension levels in the spinal cord injured. *Paraplegia* 1993; 31:311-319.
103. Yen-Patton GP, Patton WF, Beer DM, Jacobson BS. Endothelial cell response to pulsed electromagnetic fields: stimulation of growth rate and angiogenesis in vitro. *J Cell Physiol* 1988; 134:37-46.
104. Vodovnik L, Miklavčič D, Sersa G. Modified cell proliferation due to electrical currents. *Med Biol Eng Comput* 1992; 30:CE21-28.
105. Goodman E, Greenebaum B, Frederiksen J. Effect of pulsed magnetic fields on human umbilical endothelial vein cells. *Bioelectricity and Bioenergetics* 1993; 32:125-132.
106. Amaral SL, Linderman JR, Morse MM, Greene AS. Angiogenesis induced by electrical stimulation is mediated by angiotensin II and VEGF. *Microcirculation* 2001; 8:57-67.
107. Greenough CG. The effects of pulsed electromagnetic fields on blood vessel growth in the rabbit ear chamber. *J Orthop Res* 1992; 10:256-262.
108. Geary GG, Maeda G, Gonzalez RR Jr. Endothelium-dependent vascular smooth muscle relaxation activated by electrical field stimulation. *Acta Physiol Scand* 1997; 160:219-228.
109. Nikolaev AV, Shekhter AB, Mamedov LA, Novikov AP, Manucharov NK. [Use of a sinusoidal current of optimal frequency to stimulate the healing of skin wounds.] *Biull Eksp Biol Med* 1984; 97:731-734.
110. Katsir G, Baram SC, Parola AH. Effect of sinusoidally varying magnetic fields on cell proliferation and adenosine deaminase specific activity. *Bioelectromagnetics* 1998; 19:46-52.
111. Glassman LS, McGrath MH, Bassett CA. Effect of external pulsing electromagnetic fields on the healing of soft tissue. *Ann Plast Surg* 1986; 16:287-295.
112. Supino R, Bottone MG, Pellicciari C, Caserini C, Bottiroli G, Belleri M, Veicsteinas A. Sinusoidal 50 Hz magnetic fields do not affect structural morphology and

proliferation of human cells in vitro. *Histol Histopathol* 2001; 16:719-726.

113. Bourguignon GJ, Bourguignon LY. Electric stimulation of protein and DNA synthesis in human fibroblasts. *Faseb J* 1987; 1:398-402.

114. Cruz NI, Bayron FE, Suarez AJ. Accelerated healing of full-thickness burns by the use of highvoltage pulsed galvanic stimulation in the pig. *Ann Plast Surg* 1989; 23:49-55.

115. Goldman R, Pollack S. Electric fields and proliferation in a chronic wound model. *Bioelectromagnetics* 1996; 17: 450-457.

116. Cheng K, Goldman RJ. Electric fields and proliferation in a dermal wound model: cell cycle kinetics. *Bioelectromagnetics* 1998; 19:68-74.

117. Cleary SF, Liu LM, Graham R, Diegelmann RF. Modulation of tendon fibroplasia by exogenous electric currents. *Bioelectromagnetics* 1988; 9:183-194.

118. Dunn MG, Doillon CJ, Berg RA, Olson RM, Silver FH. Wound healing using a collagen matrix: effect of DC electrical stimulation. *J Biomed Mater Res* 1988; 22:191-206.

119. Franke A, Reding R, Tessmann D. Electrostimulation of healing abdominal incisional hernias by low frequency, bipolar, symmetrical rectangular pulses. An experimental study. *Acta Chir Scand* 1990; 156:701-705.

120. Lin Y, Nishimura R, Nozaki K, Sasaki N, Kadosawa T, Goto N, Date M, Takeuchi A. Effects of pulsing electromagnetic fields on the ligament healing in rabbits. *J Vet Med Sci* 1992; 54: 1017-1022.

121. George FR, Lukas RJ, Moffett J, Ritz MC. In-vitro mechanisms of cell proliferation induction: A novel bioactive treatment for acceleraing wound healing. *Wounds* 2002; 14:107-115.

122. Gilbert TL, Griffin N, Moffett J, Ritz MC, George FR. The Provant Wound Closure System induces activation of p44/42 MAP kinase in normal cultured human fibroblasts. *Ann N Y Acad Sci* 2002; 961:168-171.

123. Biedebach MC. Accelerated healing of skin ulcers by

electrical stimulation and the intracellular physiological mechanisms involved. *Acupunct Electrother Res* 1989; 14:43-60.

124. Loschinger M, Thumm S, Hammerle H, Rodemann HP. Induction of intracellular calcium oscillations in human skin fibroblast populations by sinusoidal extremely low-frequency magnetic fields (20 Hz, 8 mT) is dependent on the differentiation state of the single cell. *Radiat Res* 1999; 151:195-200.

125. Thumm S, Loschinger M, Glock S, Hammerle H, Rodemann HP. Induction of cAMP-dependent protein kinase A activity in human skin fibroblasts and rat osteoblasts by extremely low-frequency electromagnetic fields. *Radiat Environ Biophys* 1999; 38:195-199.

126. Binhi VN, Goldman RJ. Ion-protein dissociation predicts 'windows' in electric field-induced wound-cell proliferation. *Biochim Biophys Acta* 2000; 1474:147-156.

127. Cho MR, Marler JP, Thatte HS, Golan DE. Control of calcium entry in human fibroblasts by frequencydependent electrical stimulation. *Front Biosci* 2002; 7:a1-a8.

128. Balcavage WX, Alvager T, Swez J, Goff CW, Fox MT, Abdullyava S, King MW. A mechanism for action of extremely low frequency electromagnetic fields on biological systems. *Biochem Biophys Res Commun* 1996; 222:374-378.

129. Panagopoulos DJ, Messini N, Karabarbounis A, Philippetis AL, Margaritis LH. A mechanism for action of oscillating electric fields on cells. *Biochem Biophys Res Commun* 2000; 272:634- 640.

130. Weimann BI, Hermann D. Studies on wound healing: effects of calcium D-pantothenate on the migration, proliferation and protein synthesis of human dermal fibroblasts in culture. *Int J Vitam Nutr Res* 1999; 69: 113-119.

131. Huang JS, Mukherjee JJ, Chung T, Crilly KS, Kiss Z. Extracellular calcium stimulates DNA synthesis in synergism with zinc, insulin and insulin-like growth factor I in fibroblasts. *Eur J Biochem* 1999; 266:943-951.

132. Takasugi N. Calcium-induced vasodilation due to increase in nitric oxide formation in the vascular bed of rabbit ear preparation. *Jpn J Pharmacol* 1993; 61:177-182.

133. Tran QK, Ohashi K, Matanabe H. Calcium signalling in endothelial cells. *Cardiovasc Res* 2000; 48:13-22.
134. Mizuno O, Kobayashi S, Hirano K, Nishimura J, Kubo C, Kanaide H. Stimulus-specific alteration of the relationship between cytosolic Ca(2+) transients and nitric oxide production in endothelial cells ex vivo. *Br J Pharmacol* 2000; 130:1140-1146.
135. Rapp B, de Boisfleury-Chevance A, Gruler H. Galvanotaxis of human granulocytes. Doserresponse curve. *Eur Biophys J* 1988; 16:313-319.
136. Metzler C, Kampfer H, Stallmeyer B, Pfeilschifter J, Frank S. Large and sustained induction of chemokines during impaired wound healing in the genetically diabetic mouse: prolonged persistence of neutrophils and macrophages during the late phase of repair. *J Invest Dermatol* 2000; 115:245-253.
137. Kindzelskii AL, Petty HR. Extremely low frequency pulsed DC electric fields promote neutrophil extension, metabolic resonance and DNA damage when phase-matched with metabolic oscillators. *Biochim Biophys Acta* 2000; 1495:90-111.
138. Kloth LC, McCulloch JM. Promotion of wound healing with electrical stimulation. *Adv Wound Care* 1996; 9: 42-45.
139. Mann A, Breuhahn K, Schirmacher P, Blessing M. Keratinocyte-derived granulocyte-macrophage colony stimulating factor accelerates wound healing: Stimulation of keratinocyte proliferation, granulation tissue formation, and vascularization. *J Invest Dermatol* 2001; 117: 1382-1390.
140. Gruler H, Nuccitelli R. The galvanotaxis response mechanism of keratinocytes can be modeled as a proportional controller. *Cell Biochem Biophys* 2000; 33:33-51.
141. Pullar CE, Isseroff RR, Nuccitelli R. Cyclic AMP-dependent protein kinase A plays a role in the directed migration of human keratinocytes in a DC electric field. *Cell Motil Cytoskeleton* 2001; 50:207-217.
142. Fang K. Directional migration of human keratinocytes in direct current electric fields requires growth factors and calcium and is regulated by epidermal growth factor receptor. *J Am Acad Dermatol* 2000; 43:702-703.

143. Grose R, Hutter C, Bloch W, Thorey I, Watt FM, Fassler R, Brakebusch C, Werner S. A crucial role of beta 1 integrins for keratinocyte migration in vitro and during cutaneous wound repair. *Development* 2002; 129: 2303-2315.
144. Zhao M, Agius-Fernandez A, Forrester JV, McCaig CD. Directed migration of corneal epithelial sheets in physiological electric fields. *Invest Ophthalmol Vis Sci* 1996; 37:2548- 2558.
145. Nishimura KY, Isseroff RR, Nuccitelli R. Human keratinocytes migrate to the negative pole in direct current electric fields comparable to those measured in mammalian wounds. *J Cell Sci* 1996; 109:199-207.
146. Farboud B, Nuccitelli R, Schwab IR, Isseroff RR. DC electric fields induce rapid directional migration in cultured human corneal epithelial cells. *Exp Eye Res* 2000; 70:667-673.
147. Hinsenkamp M, Jercinovic A, de Graef C, Wilaert F, Heenen M. Effects of low frequency pulsed electrical current on keratinocytes in vitro. *Bioelectromagnetics* 1997; 18:250-254.
148. Kaada B, Eielsen O. In search of mediators of skin vasodilation induced by transcutaneous nerve stimulation: I Failure to block the response by antagonists of endogenous vasodilators. *Gen Pharmacol* 1983; 14:623-633.
149. Kaada B, Emru M. Promoted healing of leprosy ulcers by transcutaneous nerve stimulation. *Acupunct Electrother Res* 1988; 13:165-176.
150. Cramp AF, Noble JG, Lowe AS, Walsh DM. Transcutaneous electrical nerve stimulation (TENS): the effect of electrode placement upon cutaneous blood flow and skin temperature. *Acupunct Electrother Res* 2001; 26:25-37.
151. Matsuda T. Changes in human peripheral blood flow obtained by magnetic stimulation. *IEEE SMC 1999 Conference Proceedings, International Conference on Systems, Man and Cybernetics, 1999, Vol. 6.*
152. Ruocco I, Cuello AC, Parent A, Ribeiro-da-Silva A. Skin blood vessels are simultaneously innervated by sensory, sympathetic, and parasympathetic fibers. *J Comp Neurol* 2002; 448:323- 336.
153. Brown M, McDonnell MK, Menton DN. Polarity effects on

wound healing using electric stimulation in rabbits. Arch Phys Med Rehabil 1989; 70:624-627.

154. Van Hoek AH, Sprakel VS, Van Alen TA, Theuvenet AP, Vogels GD, Hackstein JH. Voltage dependent reversal of anodic galvanotaxis in *Nyctotherus ovalis*. J Eukaryot Microbiol 1999; 46:427-433.

155. Mayrovitz HN, Larsen PB. Effects of compression bandaging on leg pulsatile blood flow. Clin Physiol 1997; 17: 105-117.

156. Mayrovitz HN. Compression-induced pulsatile blood flow changes in human legs. Clin Physiol 1998; 18: 117-124.

157. Malanin K, Kolari PJ, Havu VK. The role of low resistance blood flow pathways in the pathogenesis and healing of venous leg ulcers. Acta Derm Venereol 1999; 79:156-160.

158. Sindrup JH, Avnstorp C, Steenfoss HH, Kristensen JK. Transcutaneous PO₂ and laser Doppler blood flow measurements in 40 patients with venous leg ulcers. Acta Derm Venereol 1987; 67:160-163.

159. Junger M, Klyscz T, Hahn M, Rassner G. Disturbed blood flow regulation in venous leg ulcers. Int J Microcirc Clin Exp 1996; 16:259-265.

160. Belcaro G, Laurora G, Cesarone MR, De Sanctis MT, Incandela L. Microcirculation in high perfusion microangiopathy. J Cardiovasc Surg (Torino) 1995; 36:393-398.

161. Chittenden SJ, Shami SK, Cheattle TR, Scurr JH, Coleridge Smith PD. Vasomotion in the leg skin of patients with chronic venous insufficiency. Vasa 1992; 21:138-142.

162. Mayrovitz HN. Assessment of Human Microvascular Function. In: Drzewiecki G, Li J, eds. Analysis of Cardiovascular Function. New York: Springer, 1998:248-273.

163. Xu S, Okano H, Ohkubo C. Subchronic effects of static magnetic fields on cutaneous microcirculation in rabbits. In Vivo 1998; 12:383-389.

164. Galvanovskis J, Sandblom J, Bergqvist B, Galt S, Hamnerius Y. Cytoplasmic Ca²⁺ oscillations in human leukemia T-cells are reduced by 50 Hz magnetic fields. Bioelectromagnetics 1999; 20:269-276.

165. Galvanovskis J, Sandblom J, Bergqvist B, Galt S, Hamnerius Y. The influence of 50-Hz magnetic fields on cytoplasmic Ca²⁺ oscillations in human leukemia T-cells. *Sci Total Environ* 1996; 180:19-33.
166. Galvanovskis J, JS. Periodic forcing of intracellular calcium oscillators: Theoretical studies of the effects of low frequency fields on the magnitude of oscillations. *Bioelectricity and Bioenergetics* 1998; 46:161-174.
167. Dolmetsch RE, Lewis RS, Goodnow CC, Healy JI. Differential activation of transcription factors induced by Ca²⁺ + response amplitude and duration. *Nature* 1997; 386:855-858.
168. De Koninck P, Schulman H. Sensitivity of CaM kinase II to the frequency of Ca²⁺ oscillations. *Science* 1998; 279:227-230.
169. Hunt TK, Rabkin J, von Smitten K. Effects of edema and anemia on wound healing and infection. *Curr Stud Hematol Blood Transfus* 1986; 53:101-113.
170. Hunt TK, Hopf H, Hussain Z. Physiology of wound healing. *Adv Skin Wound Care* 2000; 13:6- 11.
171. Eliska O, Eliskova M. Morphology of lymphatics in human venous crural ulcers with lipodermatosclerosis. *Lymphology* 2001; 34:111-123.
172. Paavonen K, Puolakkainen P, Jussila L, Jahkola T, Alitalo K. Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. *Am J Pathol* 2000; 156:1499-1504.

31 Electric Current Wound Healing

1. Waldorf H, Fewkes J. Wound healing. *Adv Dermatol* 1995; 10:77-97.
2. Dagher JF. *Cutaneous Wounds*. Mount Kisco, NY: Futura Publishing Company, 1985:99-220.
3. Sanders SL. Pressure ulcers, Part 1: Prevention strategies. *J Am Acad Nurse Pract* 1992; 4(2):63- 70.
4. Whiteneck GG, Charlifue SW, Frankel HL, Fraser MH, Gardner BP, Gerhart KA. Mortality, morbidity, and psychosocial outcomes of persons spinal cord injured more than 20 years ago. *Paraplegia* 1992; 30(9):617-630.
5. Richardson RR, Meyer PR. Prevalence and incidence of pressure sores in acute spinal-cord injuries. *Paraplegia* 1981; 19(4):235-247.
6. Mawson AR, Biundo JJ, Neville P, Linares HA, Winchester Y, Lopez A. Risk-factors for early occurring pressure ulcers following spinal-cord injury. *Am J Phys Med Rehabil* 1988; 67(3): 123- 127.
7. Fuhrer MJ, Garber SL, Rintala DH, Clearman R, Hart KA. Pressure ulcers in communityresident persons with spinal-cord injury—prevalence and risk-factors. *Arch Phys Med Rehabil* 1993; 74(11): 1172-1177.
8. Goodman CM, Cohen V, Armenta A, Thornby J, Netscher DT. Evaluation of results and treatment variables for pressure ulcers in veteran spinal cord-injured patients. *Ann Plast Surg* 1999; 42(6):665-672.
9. Kantor J, Margolis DJ. Treatment options for diabetic neuropathic foot ulcers: A costeffectiveness analysis. *Dermatol Surg* 2001; 27(4):347-351.
10. Braddock M, Campbell CJ, Zuder D. Current therapies for wound healing: electrical stimulation, biological therapeutics, and the potential for gene therapy. *Int J Dermatol* 1999; 38(11):808- 817.
11. Martin P, Hopkinson-Woolley J, McCluskey J. Growth factors and cutaneous wound repair. *Prog Growth Factor Res* 1992; 4(1):25-44.
12. Kunimoto BT. Growth factors in wound healing: the next great innovation? *Ostomy Wound Manage* 1999; 45 (8):56-64.

13. Limova M. New therapeutic options for chronic wounds. *Dermatol Clin* 2002; 20(2):357- +.
14. Beele H. Artificial skin: Past, present and future. *Int J Artif Organs* 2002; 25(3): 163-173.
15. Kannon GA, Garrett AB. Moist wound healing with occlusive dressings. A clinical review. *Dermatol Surg* 1995; 21:583-590.
16. Lucas C, Coenen CHM, de Haan RJ. The effect of low level laser therapy (LLLT) on stage III decubitus ulcers (pressure sores); a prospective randomised single blind, multicentre pilot study. *Lasers in Medical Science* 2000; 15(2):94-100.
17. Lagan KM, McKenna T, Witherow A, Johns J, McDonough SM, Baxter GD. Low-intensity laser therapy/ combined phototherapy in the management of chronic venous ulceration: A placebo-controlled study. *J Clin Laser Med Surg* 2002; 20(3): 109-116.
18. Brown M. Ultrasound for wound management. In: Gogia Prem P, ed. *Clinical Wound Manage*. Thorofare: SLACK, 1995:197-206.
19. Nessbaum EL, Biemann I, Mustard B. Comparison of ultrasound/ultraviolet-C and laser for treatment of pressure ulcers in patients with spinal cord injury. *Phys Ther* 1994; 74(9):812-825.
20. Kalani M, Jorneskog G, Naderi N, Lind F, Brismar K. Hyperbaric oxygen (HBO) therapy in treatment of diabetic foot ulcers—Long-term follow-up. *J Diabetes Complications* 2002; 16(2): 153-158.
21. Vodovnik L, Karba R. Treatment of chronic wounds by means of electric and electromagnetic fields, Part 1 Literature review. *Med Biol Eng Comput* 1992; 30:257-266.
22. Markov MS. Electric-current and electromagnetic-field effects on soft-tissue-implications for wound-healing. *Wounds—A Compendium of Clinical Research and Practice* 1995; 7(3):94-110.
23. Markov MS, Colbert AP. Magnetic and electromagnetic field therapy. *J Back Musculoskel Rehabil* 2000; 15(1): 17-29.

24. Sheffet A, Cytryn AS, Louria DB. Applying electric and electromagnetic energy as adjuvant treatment for pressure ulcers: a critical review. *Ostomy Wound Manage* 2000; 46(2):28-33, 36- 40, 42-44.
25. Wolcott LE, Wheeler PC, Hardwicke HM, Rowley BA. Accelerated healing of skin ulcers by electrotherapy: preliminary clinical results. *South Med J* 1969; 62:795-801.
26. Cuddigan J, Frantz RA. Pressure ulcer research: pressure ulcer treatment. A monograph from the National Pressure Ulcer Advisory Panel. *Adv Wound Care* 1998; 11 (6):294-300.
27. Markov MS, Pilla AA. Electromagnetic-field stimulation of soft-tissues-pulsed radio-frequency treatment of postoperative pain and edema. *Wounds—A Compendium of Clinical Research and Practice* 1995; 7(4):143-151.
28. Gardner SE, Frantz RA, Schmidt FL. Effect of electrical stimulation on chronic wound healing: a meta-analysis. *Wound Repair Regen* 1999; 7(6):495-503.
29. Akai M, Hayashi K. Effect of electrical stimulation on musculoskeletal systems; A meta-analysis of controlled clinical trials. *Bioelectromagnetics* 2002; 23(2): 132-143.
30. Kloth LC, Feedar JA. Acceleration of wound-healing with high-voltage, monophasic, pulsed current. *Phys Ther* 1988; 68(4):503-508.
31. Feedar JA, Kloth LC, Gentzkow GD. Chronic dermal ulcer healing enhanced with monophasic pulsed electrical stimulation. *Phys Ther* 1991; 71(9):639-649.
32. Lundeberg TCM, Eriksson SV, Malm M. Electrical nerve stimulation improves healing of diabetic ulcers. *Ann Plast Surg* 1992; 29:328-331.
33. Jerčinović A, Karba R, Vodovnik L, Stefanovska A, Krošelj P, Turk R. Low frequency pulsed current and pressure ulcer healing. *IEEE Trans Rehabil Eng* 1994; 2(4):225-233.
34. Karba R, Šemrov D, Vodovnik L, Benko H, Šavrin R. DC electrical stimulation for chronic wound healing enhancement. Part 1. Clinical study and determination of electrical field distribution in the numerical wound model. *Bioelectrochem Bioenerg* 1997; 43:265-270.

35. Baker LL, Chambers R, DeMuth SK, Villar F. Effects of electrical stimulation on wound healing in patients with diabetic ulcers. *Diabetes Care* 1997; 20(3):405-412.
36. Barker AT, Jaffe LF, Vanable JW, Jr. The glabrous epidermis of cavies contains a powerful battery. *Am J Physiol* 1982; 242(3):358-366.
37. Robinson KR. The responses of cells to electrical fields—a review. *J Cell Biol* 1985; 101(6):2023- 2027.
38. Sheridan DM, Isseroff RR, Nuccitelli R. Imposition of a physiologic DC electric field alters the migratory response of human keratinocytes on extracellular matrix molecules. *J Invest Dermatol* 1996; 106(4):642-646.
39. Nishimura KY, Isseroff RR, Nuccitelli R. Human keratinocytes migrate to the negative pole in direct current electric fields comparable to those measured in mammalian wounds. *J Cell Sci* 1996; 109:199-207.
40. Farboud B, Nuccitelli R, Schwab IR, Isseroff RR. DC electric fields induce rapid directional migration in cultured human corneal epithelial cells. *Exp Eye Res* 2000; 70(5):667-673.
41. Pullar CE, Isseroff RR, Nuccitelli R. Cyclic AMP-dependent protein kinase a plays a role in the directed migration of human keratinocytes in a DC electric field. *Cell Motil Cytoskeleton* 2001; 50(4):207-217.
42. Gault WR, Gatens PF. Use of the low intensity direct current in management of ischemic skin ulcers. *Phys Ther* 1976; 56:265-269.
43. Munih M, Ichie M. Current status and future prospects for upper and lower extremity motor system neuroprostheses. *Neuromodulation* 2001; 4(4): 176-185.
44. Bajd T, Cikajlo I, Šavrin R, Erzin R, Gider F. FES rehabilitative systems for re-education of walking in incomplete spinal cord injured persons. *Neuromodulation* 2000; 3(3): 167-174.
45. Likar B, Poredoš P, Prešern-Štrukelj M, Vodovnik L, Klešnik M. Effects of electric current on partial oxygen tension in skin surrounding wounds. *Wounds-A Compendium of Clinical Research and Practice* 1993; 5(1): 32-36.
46. Feedar JA, Kloth LC. Acceleration of wound healing with

- high-voltage pulsating direct current. *Phys Ther* 1985; 65(5):741.
47. Mawson AR, Siddiqui FH, Connolly BJ, Sharp CJ, Stewart GH, Summer WR, et al. Effect of high-voltage pulsed galvanic stimulation on sacral transcutaneous oxygen-tension levels in the spinal-cord injured. *Paraplegia* 1993; 31(5):311-319.
48. Bassett CAL. Bioelectromagnetics in the service of medicine. *Electromagnetic Fields* 1995; 250:261-275.
49. Bassett CAL. Beneficial-effects of electromagnetic-fields. *J Cell Biochem* 1993; 51(4):387-393.
50. vanRijswijk L. Wound assessment and documentation. *Wounds-A Compendium of Clinical Research and Practice* 1996; 8(2):57-69.
51. Lazarus GS, Cooper DM, Knighton DR, Margolis DJ, Pecoraro RE, Rodeheaver G, et al. Definitions and guidelines for assessment of wounds and evaluation of healing. *Arch Dermatol* 1994; 130:489-493.
52. Maklebust JA. Pressure ulcer assessment. *Clin Geriatr Med* 1997; 13(3):455.
53. Plassmann P, Jones TD. MAVIS: a non-invasive instrument to measure area and volume of wounds. *Med Eng Phys* 1998; 20(5):332-338.
54. Krouskop TA, Baker R, Wilson MS. A noncontact wound measurement system. *J Rehabil Res Dev* 2002; 39(3): 337-345.
55. Richard JL, Daures JP, Parer-Richard C, Vannereau D, Boulot I. Of mice and wounds reproducibility and accuracy of a novel planimetry program for measuring wound area. *WoundsA Compendium of Clinical Research and Practice* 2000; 12(6): 148-154.
56. Patete PV, Bulgrin JP, Shabani MM, Smith DJ. A non-invasive, three-dimensional, diagnostic laser imaging system for accurate wound analysis. *Physiol Meas* 1996; 17(2):71-79.
57. Rajbhandari SM, Harris ND, Sutton M, Lockett C, Eaton S, Gadour M, et al. Digital imaging: an accurate and easy method of measuring foot ulcers. *Diabet Med* 1999; 16(4):339-342.

58. Marjanovic D, Dugdale RE, Vowden P, Vowden KR. Measurement of the volume of a leg ulcer using a laser scanner. *Physiol Meas* 1998; 19(4):535-543.
59. Covington JS, Griffin JW, Mendius RK, Tooms RE, Clifft JK. Measurement of pressure ulcer volumes using dental impression materials: suggestions from the field. *Phys Ther* 1989; 69:690- 694.
60. Helbich TH, Roberts TPL, Rollins MD, Shames DM, Turetschek K, Hopf HW, et al. Non-invasive assessment of wound-healing angiogenesis with contrast-enhanced MRI. *Acad Radiol* 2002; 9:S145-S147.
61. Jones TD, Plassmann P. An active contour model for measuring the area of leg ulcers. *IEEE Trans Med Imaging* 2000; 19(12):1202-1210.
62. Stefanovska A, Vodovnik L, Benko H, Turk R. Treatment of chronic wounds by means of electric and electromagnetic fields. Part 2. Value of FES parameters for pressure sore treatment. *Med Biol Eng Comput* 1993; 31:213-220.
63. Mayrovitz HN. Shape and area measurement considerations in the assessment of diabetic plantar ulcers. *Wounds –A Compendium of Clinical Research and Practice* 1997; 9(1):21-28.
64. Kantor J, Margolis DJ. Efficacy and prognostic value of simple wound measurements. *Arch Dermatol* 1998; 134(12):1571-1574.
65. Shea JD. Pressure sores-classification and management. *Clin Orthop* 1975; 112:89-100.
66. Russell L. Pressure ulcer classification: the systems and the pitfalls. *Br J Nurs* 2002; 11(12):49- 59.
67. Ferrell BA, Artinian BM, Sessing D. The sessing scale for assessment of pressure ulcer healing. *J Am Geriatr Soc* 1995; 43:37-40.
68. Bartolucci AA, Thomas DR. Using principal component analysis to describe wound status. *Adv Wound Care* 1997; 10(5):93-95.
69. Stotts NA, Rodeheaver GT, Thomas DR, Frantz RA, Bartolucci AA, Sussman C, et al. An instrument to measure healing in pressure ulcers: Development and validation of the Pressure Ulcer Scale for Healing (PUSH). *Journals of*

Gerontology Series A-Biological Sciences and Medical Sciences 2001; 56(12):M795-M799.

70. Johnson M, Miller R. Measuring healing in leg ulcers: Practice considerations. *Appl Nurs Res* 1996; 9(4): 204-208.

71. Gilman TH. Parameter for measurement of wound closure. *Wounds* 1990; 3:95-101.

72. Cukjati D, Reberšek S, Karba R, Miklavčič D. Modelling of chronic wound healing dynamics. *Med Biol Eng Comput* 2000; 38(3):339-347.

73. Cukjati D, Reberšek S, Miklavčič D. A reliable method of determining wound healing rate. *Med Biol Eng Comput* 2001; 39(2):263-271.

74. Johnson M. Using cluster analysis to develop a healing typology in vascular ulcers. *J Vasc Nurs* 1997; 15:45-49.

75. Lyman IR, Tenery JH, Basson RP. Corelation between decrease in bacterial load and rate of wound healing. *Surg Gynecol Obstet* 1970; 130(4):616-620.

76. Birke JA, Novick A, Patout CA, Coleman MC. Healing rates of plantar ulcers in leprosy and diabetes. *Leprosy Rev* 1992; 63:365-374.

77. Gorin DR, Cordts PR, LaMorte WW, Menzoian JO. The influence of wound geometry on the measurement of wound healing rates in clinical trials. *J Vasc Surg* 1996; 23:524-528.

78. Cuddigan J. Pressure ulcer classification: What do we have? What do we need? *Adv Wound Care* 1997; 10(5): 13-15.

79. Karba R, Vodovnik L, Prešern-Štrukelj M, Klešnik M. Promoted healing of chronic wounds due to electrical stimulation. *Wounds* 1991; 3(1):16-23.

80. Skene AI, Smith JM, Doré CJ, Charlett A, Lewis JD. Venous leg ulcers: a prognostic index to predict time to healing. *BMJ* 1992; 305:1119-1121.

81. Kantor J, Margolis DJ. A multicentre study of percentage change in venous leg ulcer area as a prognostic index of healing at 24 weeks. *Brit J Dermatol* 2000; 142(5):960-964.

82. Robnik-Šikonja M, Kononenko I. An adaption of Relief

for attribute estimation in regression. In: Dough F, ed. Machine Learning: Proceedings of the Fourteenth International conference on Machine learning. San Mateo, California: Morgan Kaufman Publ., 1997:296-304.

83. Cukjati D, Robnik-Šikonja M, Reberšek S, Kononenko I, Miklavčič D. Prognostic factors in the prediction of chronic wound healing by electrical stimulation. *Med Biol Eng Comput* 2001; 39(5):542-550.

84. Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and regression trees. Belmont, California: Wadsworth International Group, 1984.

85. Herrick SE, Sloan P, Mcgurk M, Freak L, Mccollum CN, Ferguson MWJ. Sequential changes in histologic pattern and extracellular-matrix deposition during the healing of chronic venous ulcers. *Am J Pathol* 1992; 141 (5): 1085-1095.

86. Reger SI, Hyodo A, Negami S, Kambic HE, Sahgal V. Experimental wound healing with electrical stimulation. *Artif Organs* 1999; 23(5):460-462.

87. Yenpatton GPA, Patton WF, Beer DM, Jacobson BS. Endothelial-cell response to pulsed electromagnetic-fieldsstimulation of growth rate and angiogenesis in vitro. *J Cell Physiol* 1988; 134(1):37-46.

32 Pulsed Magnetic Therapy for the Treatment of Incontinence, Disuse Atrophy, Muscle Spasm, and Muscle Reeducation to Increase Mobility

1. Jalinous Reza. A Guide to Magnetic Stimulation. On-line document, Magstim Company, <http://www.magstim.com/Documents.html>, 2002:3.
2. Cadwell J. Optimizing magnetic stimulation design. *Electroencephalog Clin Neurophysiol* 1991; 43(suppl): 238-248.
3. Jalinous R. Technical and practical aspects of magnetic stimulation. *J Clin Neurophy* 1991; 8:10- 25.
4. Chokroverty S, Hening W. Magnetic brain stimulation: safety studies. *Electroencephalogr Clin Neurophys* 1995; 97:36-42.
5. Galloway N, El-Galley S, Appell S, Russell, Carlan. Extracorporeal Magnetic Innervation Therapy for Stress Urinary Incontinence. *Urology* June 1999.
6. Wilson PD, Bo K, Bourcier A, Hay-Smith J, Staskin D, Nygard I, Wyman J. Conservative management in women. In: Abrams P, Khoury S, Wein A, eds. *Incontinence*. Plymbridge Ltd, Plymouth, 1998:579-636.
7. Bo K, Hagen RH, Kvarstein B, Jorgensen B, Laarson S. Pelvic floor muscle exercise for treatment of female stress urinary incontinence: III Effects of two different degrees of pelvic floor muscle exercises. *Neurourol and Urodyn* 1990; 9:489-502.
8. Fall M, Ahlstrom K, Carlsson CA, Ek A, Erlansdson BE. Contelle: pelvic floor stimulator for stress-urge incontinence. A multicenter study. *Urol* 1986; 27:282-287.
9. Galloway NTM, Appell RA. Extracorporeal magnetic stimulation therapy for urinary incontinence. In: Appell RA, Bourcier AP, LaTorre F, eds. *Pelvic Floor Dysfunction: Investigations and Conservative Treatment*. Rome: C.E.S.I., 1999:291-294.
10. Carlan SJ, Bhullar A, Followup of patients who underwent extracorporeal magnetic enervation, therapy for urinary incontinence. American Urological Annual Meeting, Anaheim, CA, June 2-7, 2001.

11. Brodak PP, Bidair M, Joseph A, Szollar S, Saad J. Magnetic stimulation of the sacral roots. *Neurol Urodynamics* 1993; 12:455-462.

Figure 6 Action potential generation with pulsed magnetic stimulation to prevent disuse atrophy or increase range of motion.

12. McFarlane JP, Foley SJ, DeWinter P, Shah JPR, Craggs MD. Acute suppression of detrusor instability by magnetic stimulation of the sacral nerve roots. *Brit J Neurol* 1997; 80:734-741.

13. Struppler A, Jakob C, Muller-Barna P, Schmid M, Lorenzen HW, Paulig M, Proseigal M. A new method for early rehabilitation in extreme palsy of central origin by magnetic stimulation. *EEG-EMG* 1996; 27:151-157. German.

14. Mills KR, Thompson CCB. Human muscle fatigue investigation by transcranial magnetic stimulation. *Neuroreport* 1995; 6:1966-1968.

15. Davey K, Epstein CM. Magnetic stimulation coil and circuit design. *IEEE Trans Biomed Eng* 2000; 47(11): 1493-1499.

16. Epstein CM, Davey KR. Iron core coils for transcranial magnetic stimulation. *J Clin Neurophysiol* 2002; 19(4).

17. Barker AT, Janinous R, Freeston IL. Non-invasive magnetic stimulation of human motor cortex. *Lancet* 1985; 2: 1106.

Figure 7 Cross-sectional view of female anatomy.

Figure 8 The NeoControl Pelvic Floor Therapy System.

Figure 9 Neotone device.

33 Coblation Radio-Frequency Diskal Nucleoplasty: A Novel Approach To The Management of Acute Disk Herniation

1. Brown D. Update on chemonucleolysis. Spine 1996; 21:585-625.
2. Onik G. Percutaneous lumbar diskectomy using a new aspiration probe. Am J Neuroradiol 1985; 6:290-296.
3. Choy DS, et al. Percutaneous laser disk decompression. Spine 1992; 17:949.

Figure 5 Diskograms demonstrating the proximal and distal positions of the Arthrocare Wand as described in Fig. 4. (a)

and (b) AP spot images showing the proximal and distal position of the Arthrocare Wand. (c) and (d) Lateral spot

images showing the proximal and distal position of the Arthrocare Wand.

4. Choy DS. Percutaneous laser disk decompression (PLDD): Twelve years experience with 752 procedures in 518 patients. J Clin Laser Med Surg 1988; 16(6):325-331.
5. Saal, Saal. Management of chronic discogenic low back pain with a thermal intradiscal catheter. SOAR, pp. 382-389) Physiatry Medical Group, 1999:382-389.
6. Sherk HH. Laser diskectomy. Lasers in Orthopedic Surgery. Medical College of Pennsylvania, 1993; 16:5.
7. Yetkinler DN, Nau WH, Brandt LI, Diederich C. Intervertebral Disc Temperature Measurements During Nucleoplasty and IDET Procedures. European Spine J 2002; 11(4):418.

34 Electricity and the Heart: Innovation and the Evolution of Cardiac Pacing

1. Ott K. The sum of its parts: an introduction to modern histories of prosthetics. In: Ott K, Serlin D, Mihm S, eds. *Artificial Parts, Practical Lives: Modern Histories of Prosthetics*. New York: New York University Press, 2002: 1-42.
2. Hidefjäll P. *The Pace of Innovation: Patterns of Innovation in the Cardiac Pacemaker Industry*. Linköping, Sweden: Linköping University, 1997.
3. Rowbottom M, Susskind C. *Electricity and Medicine: History of Their Interaction*. San Francisco: San Francisco Press, 1984.
4. Schechter DC. *Exploring the Origins of Electrical Cardiac Stimulation*. Minneapolis: Medtronic, 1983.
5. Morus IR. Marketing the machine: the construction of electrotherapeutics as viable medicine in early Victorian England. *Med Hist* 1992; 36:34-52.
6. MacWilliam JA. Electrical stimulation of the heart in man. *Brit Med J* 1889; i:348-350.
7. Howell JD. 'Soldier's heart': the redefinition of heart disease and speciality formation in early twentieth-century Great Britain. *Med Hist* 1985; (suppl 5):34-52.
8. Fleming P. *A Short History of Cardiology*. Amsterdam: Editions Rodopi, 1997.
9. Howell JD. Early perceptions of the electrocardiogram: from arrhythmia to infarction. *Bull Hist Med* 1984; 58: 83-98.
10. Fye WB. A history of cardiac arrhythmias. In: Kastor JA, ed. *Arrhythmias*. Philadelphia: W.B. Saunders, 1994: 1-24.
11. Howell JD. Cardiac physiology and clinical medicine? Two case studies. In: Geison GL, ed. *Physiology in the American Context, 1850-1940*. Bethesda: American Physiological Society, 1987:279-292.
12. Mond HG, Sloman JG, Edwards RH. The first pacemaker. *Pacing Clin Electrophysiol* 1982; 5:278-282.

13. Furman S, Jeffrey K, Szarka G. The mysterious fate of Hyman's pacemaker. *Pacing Clin Electrophysiol* 2001; 24: 1126-1137.
14. Jeffrey K. *Machines in Our Hearts: The Cardiac Pacemaker, the Implantable Defibrillator, and American Health Care*. Baltimore: The Johns Hopkins University Press, 2001.
15. Zoll PM. Resuscitation of the heart in ventricular standstill by external electric stimulation. *N Engl J Med* 1952; 247:768-771.
16. Leatham A, Cook P, Davies JG. External electric stimulator for treatment of ventricular standstill. *Lancet* 1956; ii:1185-1189.
17. Braun E, Macdonald S. *Revolution in Miniature: The History and Impact of Semiconductor Electronics*. 2d ed. Cambridge: Cambridge University Press, 1983.
18. Rhees DJ, Jeffrey K. Earl Bakken's little white box: the complex meanings of the first transistorized pacemaker. In: Finn B, Bud R, Trischler H, eds. *Exposing Electronics*. London: Harwood, 2000:75-113.
19. Greatbatch W. *The Making of the Pacemaker: Celebrating a Lifesaving Invention*. Amherst, N.Y.: Prometheus Books, 2000.
20. Chardack WM. A myocardial electrode for long-term pacemaking. *Ann N Y Acad Sci* 1964; 111:893-906.
21. Furman S, Schwedel JB. An intracardiac pacemaker for Stokes-Adams seizures. *N Engl J Med* 1959; 261: 943-948.
22. Furman S. Recollections of the beginnings of transvenous cardiac pacing. *Pacing Clin Electrophysiol* 1994; 17: 1697-1705.
23. Lagergren H, Johansson L. Intracardiac stimulation for complete heart block. *Acta Chir Scan* 1963; 125: 562-566.
24. Siddons H, Davies JG. A new technique for internal cardiac pacing. *Lancet* 1963; ii:1204- 1205.
25. Chardack WM. Cardiac pacemakers and heart block. In: Gibbon JH Jr, Sabiston DC, Spencer FC, eds. *Surgery of the Chest*. 2d ed. Philadelphia: W.B.Saunders, 1969:824-865.

26. Parsonnet V, Bernstein AD. Transvenous pacing: a seminal transition from the research laboratory. *Ann Thorac Surg* 1989; 48:738-740.
27. Furman S, Parker B, Escher DJW. Transtelephone pacemaker clinic. *J Thorac Cardiovasc Surg* 1971; 61: 827-834.
28. Castellanos A Jr, Lemberg L, Jude JR, et al. Repetitive firing occurring during synchronized electrical stimulation of the heart. *J Thorac Cardiovasc Surg* 1966; 51:334-340.
29. Bilitch M, Cosby RS, Cafferky EA. Ventricular fibrillation and competitive pacing. *N Engl J Med* 1967; 276: 598-604.
30. Ferrer MI. The sick sinus syndrome in atrial disease. *J Am Med Assoc* 1968; 206:645-646.
31. Sutton R, Bourgeois I. *The Foundations of Cardiac Pacing, Part I*. Mount Kisco, N.Y.: Futura, 1991.
32. Parsonnet V, Gilbert L, Zucker R, Werres R, Atherley T, Manhardt M, Cort J. A decade of nuclear pacing. *Pacing Clin Electrophysiol* 1984; 7:90-95.
33. Greatbatch W, Lee JH, Mathias W, Eldridge M, Moser JR, Schneider AA. The solid-state lithium battery: a new improved chemical power source for implantable cardiac pacemakers. *IEEE Trans Biomed Eng* 1971; 18: 317-324.
34. Greatbatch W. Pacemaker technology: energy sources. *Cardiovasc Clin* 1983; 14:239-246.
35. Bowers DL. New pacemaker devices from a technical point of view. In: Thalen HJT, Harthorne JW, eds. *To Pace or Not to Pace: Controversial Subjects in Cardiac Pacing*. The Hague: M. Nijhoff, 1978:126-130.
36. Parsonnet V, Cuddy TE, Escher DJW, Furman S, Morse D, Gilbert L, Zucker IR. A permanent pacemaker capable of external non-invasive programming. *Trans Am Soc Artif Intern Org* 1973; 19:224-228.
37. MacGregor DC, Furman S, Dreifus LS. The utility of the programmable pacemaker. *Pacing Clin Electrophysiol* 1978; 1:254-259.
38. Parsonnet V. The proliferation of cardiac pacing: medical, technical, and socioeconomic dilemmas. *Circulation*

1982; 65:841-845.

39. Moran M. Governing the Health Care State: A Comparative Study of the United Kingdom, the United States and Germany. Manchester and New York: Manchester University Press, 1999.

40. Tyers FO, Brownlee RR. A multiparameter telemetry system for cardiac pacemakers. In: Varriale P, Naclerio EA, eds. Cardiac Pacing: A Concise Guide to Clinical Practice. Philadelphia: Lea & Febiger, 1979:349-368.

41. Sholder J, Levine PA, Mann BM, Mace RC. Bidirectional telemetry and interrogation in cardiac pacing. In: Barold SS, Mugica J, eds. The Third Decade of Cardiac Pacing: Advances in Technology and Clinical Applications. Mount Kisco, N.Y.: Futura, 1982:145-166.

42. Sutton R, Perrins J, Citron P. Physiological cardiac pacing. Pacing Clin Electrophysiol 1980; 3:207-219.

43. Asubel K, Furman S. The pacemaker syndrome. Ann Intern Med 1985; 103:420-429.

44. Hartlaub J. Pacemaker of the future: microprocessor based or custom circuit? In: Barold SS, Mugica J, eds. The Third Decade of Cardiac Pacing: Advances in Technology and Clinical Applications. Mount Kisco, NY: Futura, 1983:417-428.

45. Parsonnet V, Bernstein AD. Cardiac pacing in the 1980s: treatment and techniques in transition. J Am Coll Cardiol 1983; 1:339-354.

46. Sykosch HJ. The new generation of pacemakers. Prog Artif Org 1983; 1:317-323.

47. Bernstein AD, Parsonnet V. Survey of cardiac pacing in the United States in 1989. Am J Cardiol 1992; 69: 331-338.

48. Brinker JA. VVI vs. DDD—new twists to the ongoing controversy [editorial]. Intell Reports Cardiac Pacing Electrophysiol 1990; 9:1 (4).

49. Bernstein AD, Parsonnet V. Survey of cardiac pacing and defibrillation in the United States in 1993. Am J Cardiol 1996; 78:187-196.

50. Humen DP, Anderson K, Brumwell D, Huntley S, Klein GJ. A pacemaker which automatically increases its rate with physical activity. In: Steinbach K, ed. Proceedings of the

VIIth World Symposium on Cardiac Pacing, Vienna, May 1st to 5th, 1983. Darmstadt: Steinkopff, 1983:259- 264.

51. Bernstein AD, Parsonnet V. Survey of cardiac pacing and implanted defibrillator practice patterns in the United States in 1997. *Pacing Clin Electrophysiol* 2001; 24:842-855.

52. Ritter P, Cazeau S, Mugica J. Do we really need automatic pacemakers? In: Barold SS, Mugica J, eds. *New Perspectives in Cardiac Pacing*. Mount Kisco, N.Y.: Futura, 1993:337-346.

53. Increasing efficiency in the pacemaker clinic [panel discussion]. *Guidant/CPI Pacing Dynamics* 1998; 1 Q:6-7, 12.

54. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, Packer M, Clavell AL, Hayes DL, Ellestad M, Trupp RJ, Underwood J, Pickering F, Truex C, McAtee P, Messenger J, the MIRACLE Study Group. Cardiac resynchronization in chronic heart failure. *N Engl J Med* 2002; 346:1845-1853.

55. www.medtronic.com/neuro/, visited July 27, 2002.

56. Hedefjäll P. Can pacemaker innovation go on forever? Unpublished ms, 2001.

57. Gibbons M, Limoges C, Nowotny H, Schwartzman S, Scott P, Trow M. *The New Production of Knowledge: The Dynamics of Science and Research in Contemporary Societies*. Thousand Oaks, Calif. and London: SAGE Publications, 1994.

35 The Energetic Heart: Bioelectromagnetic Communication Within and Between People

1. Stroink G. Principles of cardiomagnetism. In: Williamson SJ, Hoke M, Stroink G, Kotani M, eds. *Advances in Biomagnetism*. New York: Plenum Press, 1989:47-57.
2. Prank K, Schofl C, Laer L, Wagner M, von zur Muhlen A, Brabant G, Gabbiani F. Coding of time-varying hormonal signals in intracellular calcium spike trains. *Pac Symp Biocomput* 1998: 633-644.
3. Schofl C, Prank K, Brabant G. Pulsatile hormone secretion for control of target organs. *Wien Med Wochenschr* 1995; 145:431-435.
4. Schofl C, Sanchez-Bueno A, Brabant G, Cobbold PH, Cuthbertson KS. Frequency and amplitude enhancement of calcium transients by cyclic AMP in hepatocytes. *Biochem J* 1991; 273:799-802.
5. Pribram K, Melges F. Psychophysiological basis of emotion. In: Vinken P, Bruyn G, eds. *Handbook of Clinical Neurology*. Vol. 3. Amsterdam: North-Holland Publishing Company, 1969:316- 341.

A Boy and His Dog

(Heart Rhythms)

Figure 11 Heart rhythm patterns of a boy and his dog. These data were obtained using ambulatory ECG (Holter)

recorders fitted on both Josh, a boy, and Mabel, his pet dog. When Josh entered the room where Mabel was waiting and

consciously felt feelings of love and care towards his pet, his heart rhythms became more coherent, and this change

appears to have influenced Mabel heart rhythms, which then also became more coherent. When Josh left the room, Mabel's

heart rhythms became much more chaotic and incoherent, suggesting separation anxiety!

6. Coles M, Gratton G, Fabini M. Event-related brain potentials. In: Cacioppo J, Tassinari L, eds. *Principles of Psychophysiology: Physical, Social and Inferential Elements*. New York: Cambridge University Press, 1990.

7. Schandry R, Montoya P. Event-related brain potentials and the processing of cardiac activity. *Biol Psychol* 1996; 42:75-85.
8. Song L, Schwartz G, Russek L. Heart-focused attention and heart-brain synchronization: energetic and physiological mechanisms. *Altern Ther Health Med* 1998; 4:44-62.
9. Armour J, Ardell J. *Neurocardiology*. New York: Oxford University Press, 1994.
10. Sandman CA, Walker BB, Berka C. Influence of afferent cardiovascular feedback on behavior and the cortical evoked potential. In: Cacioppo JT, Petty RE, eds. *Perspectives in Cardiovascular Psychophysiology*. New York: The Guilford Press, 1982:189-222.
11. Frysinger RC, Harper RM. Cardiac and respiratory correlations with unit discharge in epileptic human temporal lobe. *Epilepsia* 1990; 31:162-171.
12. McCraty R. Heart-brain neurodynamics: The making of emotions. In: Watkins A, Childre D, eds. *Emotional Sovereignty*. Amsterdam: Harwood Academic Publishers. In press.
13. van der Molen M, Somsen R, Orlebeke J. The rhythm of the heart beat in information processing. In: Ackles P, Jennings JR, Coles M, eds. *Advances in Psychophysiology*. Vol. 1. London: JAI Press, 1985:1-88.
14. Tiller W, McCraty R, Atkinson M. Cardiac coherence: a new, noninvasive measure of autonomic nervous system order. *Altern Ther Health Med* 1996; 2:52-65.
15. McCraty R, Singer D. Heart rate variability: A measure of autonomic balance and physiological coherence. In: Watkins A, Childre D, eds. *Emotional Sovereignty*. Amsterdam: Harwood Academic Publishers. In press.
16. McCraty R, Atkinson M, Tiller WA, Rein G, Watkins A. The effects of emotions on short term heart rate variability using power spectrum analysis. *Am J Cardiol* 1995; 76:1089-1093.
17. McCraty R, Barrios-Choplin B, Rozman D, Atkinson M, Watkins A. The impact of a new emotional selfmanagement program on stress, emotions, heart rate variability, DHEA

and cortisol. *Integr Physiol Behav Sci* 1998; 33:151-170.

18. Collet C, Vernet-Maury E, Delhomme G, Dittmar A. Autonomic nervous system response patterns specificity to basic emotions. *J Auton Nerv Sys* 1997; 62:45-57.

19. McCraty R, Atkinson M, Tomasino D, Goelitz J, Mayrovitz H. The impact of an emotional self-management skills course on psychosocial functioning and autonomic recovery to stress in middle school children. *Integr Physiol Behav Sci* 1999; 34:246-268.

20. McCraty R, Atkinson M. Psychophysiological coherence. In: Watkins A, Childre D, eds. *Emotional Sovereignty*. Amsterdam: Harwood Academic Publishers. In press.

21. McCraty R. Influence of cardiac afferent input on heart-brain synchronization and cognitive performance. *Int J Psychophysiol* 2002; 45:72-73.

22. Baselli G, Cerutti S, Badilini F, Biancardi L, Porta A, Pagani M, Lombardi F, Rimoldi O, Furlan R, Malliani A. Model for the assessment of heart period variability interactions of respiration influences. *Med Biol Eng Comput* 1994; 32:143-152.

23. deBoer RW, Karemaker JM, Strackee J. Hemodynamic fluctuations and baroreflex sensitivity in humans: a beat-to-beat model. *Am J Physiol* 1987; 253:H680-H689.

24. Langhorst P, Schulz G, Lambertz M. Oscillating neuronal network of the "common brainstem system." In: Miyakawa K, Koepchen H, Polosa C, eds. *Mechanisms of Blood Pressure Waves*. Tokyo: Japan Scientific Societies Press, 1984:257-275.

25. Siegel G, Ebeling BJ, Hofer HW, Nolte J, Roedel H, Klubendorf D. Vascular smooth muscle rhythmicity. In: Miyakawa K, Koepchen H, Polosa C, eds. *Mechanisms of Blood Pressure Waves*. Tokyo: Japan Scientific Societies Press, 1984:319-338.

26. Danner DD, Snowdon DA, Friesen WV. Positive emotions in early life and longevity: findings from the nun study. *J Pers Soc Psychol* 2001; 80:804-813.

27. Salovey P, Rothman A, Detweiler J, Steward W. Emotional states and physical health. *Am Psychol* 2000; 55: 110-121.

28. Russek LG, Schwartz GE. Feelings of parental caring

predict health status in midlife: a 35-year follow-up of the Harvard Mastery of Stress Study. *J Behav Med* 1997; 20:1-13.

29. Rein G, Atkinson M, McCraty R. The physiological and psychological effects of compassion and anger. *J Adv Med* 1995; 8:87-105.

30. McCraty R, Atkinson M, Rein G, Watkins AD. Music enhances the effect of positive emotional states on salivary IgA. *Stress Med* 1996; 12:167-175.

31. McCraty R, Atkinson M, Tomasino D. *Science of the Heart*. Boulder Creek, CA: HeartMath Research Center, Institute of HeartMath, Publication No. 01-001, 2001.

32. Barrios-Choplin B, McCraty R, Cryer B. An inner quality approach to reducing stress and improving physical and emotional wellbeing at work. *Stress Med* 1997; 13:193-201.

33. McCraty R, Atkinson M, Tomasino D, Watkins A. Impact of a workplace stress reduction program on blood pressure and emotional health in hypertensive employees. In preparation.

34. Luskin F, Reitz M, Newell K, Quinn TG, Haskell W. A controlled pilot study of stress management training of elderly patients with congestive heart failure. *Prev Cardiol*. In press.

35. McCraty R, Atkinson M, Lipsenthal L. Emotional self-regulation program enhances psychological health and quality of life in patients with diabetes. Boulder Creek, CA: HeartMath Research Center, Institute of HeartMath, Publication No. 00-006.

36. Lehrer P, Smetankin A, Potapova T. Respiratory sinus arrhythmia biofeedback therapy for asthma: a report of 20 unmedicated pediatric cases. *Appl Psychophysiol Biofeedback* 2000; 25:193-200.

37. Rozman D, Whitaker R, Beckman T, Jones D. A pilot intervention program which reduces psychological symptomatology in individuals with human immunodeficiency virus. *Complement Ther Med* 1996; 4:226-232.

38. McCraty R, Tomasino D, Atkinson M. Research, clinical perspectives, and case histories. In: Watkins A, Childre D, eds. *Emotional Sovereignty*. Amsterdam: Harwood Academic Publishers. In press.

39. Childre D, Martin H. The HeartMath Solution. San Francisco: Harper San Francisco, 1999.
40. Childre D, Rozman D. Overcoming Emotional Chaos: Eliminate Anxiety, Lift Depression and Create Security in Your Life. San Diego: Jodere Group, 2002.
41. McCraty R. Heart rhythm coherence—An emerging area of biofeedback. *Biofeedback* 2002; 30:17-19.
42. Baule G, McFee R. Detection of the magnetic field of the heart. *Am Heart J* 1963; 55:95-96.
43. Nakaya Y. Magnetocardiography: a comparison with electrocardiography. *J Cardiogr Suppl* 1984; 3:31-40.
44. McCraty R, Atkinson M, Tiller WA. New electrophysiological correlates associated with intentional heart focus. *Subtle Energies* 1993; 4:251-268.
45. Russell P. The Brain Book. New York: Penguin Books USA, 1979.
46. Wirth DP. The effect of non-contact therapeutic touch on the healing rate of full thickness dermal wounds. *Subtle Energies* 1990; 1:1-20.
47. Grad B. Some biological effects of the laying on of hands: review of experiments with animals and plants. *J Am Soc Psychical Res* 1965; 59:95-171.
48. Keller E. Effects of therapeutic touch on tension headache pain. *Nurs Res* 1986; 35:101-105.
49. Redner R, Briner B, Snellman L. Effects of a bioenergy healing technique on chronic pain. *Subtle Energies* 1991; 2:43-68.
50. Krieger D. Healing by the laying on of hands as a facilitator of bioenergetic change: the response of in vivo human hemoglobin. *Psychoenergetic Systems* 1974; 1:121-129.
51. Rein G, McCraty R. Structural changes in water and DNA associated with new physiologically measurable states. *J Sci Explor* 1994; 8:438-439.
52. Rein G, McCraty R. Modulation of DNA by coherent heart frequencies. Proceedings of the Third Annual Conference of the International Society for the Study of Subtle Energy and Energy Medicine, Monterey, CA, June 25-29, 1993:58-62.

53. Quinn J. Therapeutic touch as an energy exchange: Testing the theory. *ANS Adv Nurs Sci* 1984; 6:42-49.
54. Hatfield E. Emotional Contagion. New York: Cambridge University Press, 1994.
55. Levenson RW, Ruef AM. Physiological aspects of emotional knowledge and rapport. In: Ickes W, ed. *Empathic Accuracy*. New York: Guilford Press, 1997.
56. Levenson R, Gottman J. Physiology and affective predictors of change in relationship satisfaction. *J Pers Soc Psychol* 1985; 49:85-94.
57. Robinson J, Herman A, Kaplan B. Autonomic responses correlate with counselor-client empathy. *J Couns Psychol* 1982; 29:195-198.
58. Reidbord SP, Redington DJ. Nonlinear analysis of autonomic responses in a therapist during psychotherapy. *J Nerv Ment Dis* 1993; 181:428-435.
59. Marci CD. Psychophysiology and psychotherapy: The neurobiology of human relatedness. *Practical Reviews of Psychiatry-Audio Tape* 2002; 25(3).
60. McCraty R, Atkinson M, Tomasino D, Tiller W. The electricity of touch: Detection and measurement of cardiac energy exchange between people. In: Pribram K, ed. *Brain and Values: Is a Biological Science of Values Possible*. Mahwah, NJ: Lawrence Erlbaum Associates, 1998: 359-379.
61. Russek L, Schwartz G. Interpersonal heart-brain registration and the perception of parental love: a 42 year followup of the Harvard Mastery of Stress Study. *Subtle Energies* 1994, 5:195- 208.
62. Russek L, Schwartz G. Energy Cardiology: a dynamical energy systems approach for integrating conventional and alternative medicine. *Advances* 1996; 124-24.
63. Childre D, Cryer B. *From Chaos to Coherence: The Power to Change Performance*. Boulder Creek, CA: Planetary, 2000.
64. Litovitz TA, Krause D, Mullins JM. Effect of coherence time of the applied magnetic field on ornithine decarboxylase activity. *Biochem Biophys Res Commun* 1991; 178:862-865.

65. Wiesenfeld K, Moss F. Stochastic resonance and the benefits of noise: From ice ages to crayfish and SQUIDS. Nature 1995; 373:33-36.

36 Static Magnetic Fields and Microcirculation

1. Kim KS, Lee YJ. The effect of magnetic application for primary dysmenorrhea. *Kanhohak Tangu* 1994; 3: 148-179.
2. Takeshige C, Sato M. Comparisons of pain relief mechanisms between needling to the muscle, static magnetic field, external qigong and needling to the acupuncture point. *Acupunct Electrother Res* 1996; 21:119-131.
3. Vallbona C, Hazlewood CF, Jurida G. Response of pain to static magnetic fields in postpolio patients: a doubleblind pilot study. *Arch Phys Med Rehabil* 1997; 78:1200-1203.
4. Holcomb RR, Worthington WB, McCullough BA, McLean MJ. Static magnetic field therapy for pain in the abdomen and genitals. *Pediatr Neurol* 2000; 23:261-264.
5. Segal NA, Toda Y, Huston J, Saeki Y, Shimizu M, Fuchs H, Shimaoka Y, Holcomb R, McLean MJ. Two configurations of static magnetic fields for treating rheumatoid arthritis of the knee: a double-blind clinical trial. *Arch Phys Med Rehabil* 2001; 82:1453-1460.
6. Hinman MR, Ford J, Heyl H. Effects of static magnets on chronic knee pain and physical function: a doubleblind study. *Altern Ther Health Med* 2002; 8:50-55.
7. Lud GV, Demeckiy AM. Use of permanent magnetic field in reconstructive surgery of the main arteries (experimental study). *Acta Chir Plast* 1990; 32:28-34.
8. Weinberger A, Nyska A, Giler S. Treatment of experimental inflammatory synovitis with continuous magnetic field. *Isr J Med Sci* 1996; 32:1197-1201.
9. Alfano AP, Taylor AG, Foresman PA, Dunkl PR, McConnell GG, Conaway MR, Gillies GT. Static magnetic fields for treatment of fibromyalgia: a randomized controlled trial. *J Altern Complement Med* 2001; 7:53-64.
10. Tkach EV, Abilova AN, Gazalieva ShM. Characteristics of the effect of a constant electromagnetic field on reparative processes in spinal cord injuries. *Zh Nevropatol Psikhiatr Im S S Korsakova* 1989; 89:41-44.
11. Man D, Man B, Plosker H. The influence of permanent magnetic field therapy on wound healing in suction lipectomy patients: a double-blind study. *Plast Reconstr*

Surg 1999; 104:2261- 2268.

12. Bruce GK, Howlett CR, Huckstep RL. Effect of a static magnetic field on fracture healing in a rabbit radius. Preliminary results. Clin Orthop 1987; 222:300-306.

13. Darendeliler MA, Darendeliler A, Sinclair PM. Effects of static magnetic and pulsed electromagnetic fields on bone healing. Int J Adult Orthodon Orthognath Surg 1997; 12:43-53.

14. Yan QC, Tomita N, Ikada Y. Effects of static magnetic field on bone formation of rat femurs. Med Eng Phys 1998; 20:397-402.

15. Xu S, Tomita N, Ohata R, Yan Q, Ikada Y. Static magnetic field effects on bone formation of rats with an ischemic bone model. Biomed Mater Eng 2001; 11:257-263.

16. Ivanov SG, Smirnov W, Solov'eva FV, Liashevskaja SP, Selezneva LI. The magnetotherapy of hypertension patients. Ter Arkh 1990; 62:71-74.

17. Ivanov SG. The comparative efficacy of nondrug and drug methods of treating hypertension. Ter Arkh 1993; 65: 44-49.

18. Mellander S, Johansson B. Control of resistance, exchange, and capacitance functions in the peripheral circulation. Pharmacol Rev 1968; 20:117-196.

19. Burnstock G, Griffith SG. Innervation of microvascular smooth muscle. In: Messemer K, Hammersen F, eds. Progress in Applied Microcirculation. Vol. 3. Basel: Karger, 1983:19-39.

20. Osborne NN. Coexistence of neurotransmitter substances in a specifically defined invertebrate neurone. In: Cuello AC, ed. Co-Transmission. London: Macmillan, 1982:207-222.

21. Vizi ES. Presynaptic modulation of neurochemical transmission. Prog Neurobiol 1979; 12:181- 290.

22. Furness JB, Marshall JM. Correlation of the directly observed responses of mesenteric vessels of the rat to nerve stimulation and noradrenaline with the distribution of adrenergic nerves. J Physiol 1974; 239:75-88.

23. Siegel G, Malmsten M, Klussendorf D, Hofer HW. Vascular smooth muscle, a multiply feedback-coupled system of high versatility, modulation and cell-signaling variability. Int

J Microcirc Clin Exp 1997; 17:360-373.

24. Mulvany MJ. Functional characteristics of vascular smooth muscle. In: Messemer K, Hammersen F, eds. Progress in applied microcirculation. Vol. 3. Basel: Karger, 1983:4-18.

25. Ignarro LJ. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. *Circ Res* 1989; 65:1-21.

26. Funk W, Intaglietta M. Spontaneous arteriolar vasomotion. In: Messemer K, Hammersen F, eds. Progress in applied microcirculation. Vol. 3. Basel: Karger, 1983:66-82.

27. Zweifach BW. Microcirculation in health and disease. In: Manabe H, Zweifach BW, Messmer K, eds. Microcirculation in circulatory disorders. Springer-Verlag: Tokyo, 1988:3-9.

28. Asano M, Yoshida K, Tatai K. Microphotoelectric plethysmography using a rabbit ear chamber. *J Appl Physiol* 1965; 20:1056-1062.

29. Greenough CG. The effects of pulsed electromagnetic fields on blood vessel growth in the rabbit ear chamber. *J Orthop Res* 1992; 10:256-262.

30. Ohkubo C, Xu S. Acute effects of static magnetic fields on cutaneous microcirculation in rabbits. *In Vivo* 1997; 11:221-225.

31. Xu S, Okano H, Ohkubo C. Subchronic effects of static magnetic fields on cutaneous microcirculation in rabbits. *In Vivo* 1998; 12:383-389.

32. Okano H, Gmitrov J, Ohkubo C. Biphasic effects of static magnetic fields on cutaneous microcirculation in rabbits. *Bioelectromagnetics* 1999; 20:161-171.

33. Gmitrov J, Ohkubo C, Okano H. Effect of 0.25 T static magnetic field on microcirculation in rabbits. *Bioelectromagnetics* 2002; 23:224-229.

34. Yamada S, Mayadas TN, Yuan F, Wagner DD, Hynes RO, Melder RJ, Jain RK. Rolling in P-selectin-deficient mice is reduced but not eliminated in the dorsal skin. *Blood* 1995; 86:3487- 3492.

35. Pluen A, Boucher Y, Ramanujan S, McKee TD, Gohongi T,

di Tomaso E, Brown EB, Izumi Y, Campbell RB, Berk DA, Jain RK. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. *Proc Natl Acad Sci USA* 2001; 98:4628- 4633.

36. Yuan F, Salehi HA, Boucher Y, Vasthare US, Tuma RF, Jain RK. Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. *Cancer Res* 1994; 54: 4564-4568.

37. Gohongi T, Fukumura D, Boucher Y, Yun CO, Soff GA, Compton C, Todoroki T, Jain RK. Tumor-host interactions in the gallbladder suppress distal angiogenesis and tumor growth: involvement of transforming growth factor beta1. *Nat Med* 1999; 5:1203-1208.

38. Fukumura D, Gohongi T, Kadambi A, Izumi Y, Ang J, Yun CO, Buerk DG, Huang PL, Jain RK. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. *Proc Natl Acad Sci USA* 2001; 98:2604-2609.

39. Jain RK. The Eugene M. Landis Award Lecture 1996. Delivery of molecular and cellular medicine to solid tumors. *Microcirculation* 1997; 4:1-23.

40. Okano H, Ohkubo C. Modulatory effects of static magnetic fields on blood pressure in rabbits. *Bioelectromagnetics* 2001; 22:408-418.

41. Okano H, Ohkubo C. Anti-pressor effects of whole-body exposure to static magnetic field on pharmacologically induced hypertension in conscious rabbits. *Bioelectromagnetics*. In press.

42. Asano M, Brånemark PI. Microphotoelectric plethysmography using a titanium chamber in man. In: Harders H, ed. *Advances in Microcirculation*. Vol. 4. Basel: S.Karger, 1972:131-160.

43. Xu S, Okano H, Ohkubo C. Acute effects of whole-body exposure to static magnetic fields and 50-Hz electromagnetic fields on muscle microcirculation in anesthetized mice. *Bioelectrochemistry* 2000; 53:127-135.

44. Okano H, Ohkubo C. Effects of static magnetic fields on plasma levels of angiotensin II and aldosterone associated with arterial blood pressure in genetically hypertensive rats. *Bioelectromagnetics*. In press.

45. Owen MP, Walmsley JG, Mason MF, Bevan RD, Bevan JA. Adrenergic control in three artery segments of diminishing diameter in rabbit ear. *Am J Physiol* 1983; 245:H320-H326.
46. Edwards RM. Response of isolated renal arterioles to acetylcholine, dopamine, and bradykinin. *Am J Physiol* 1985; 248:F183-F189.
47. Matsukawa S, Suzuki H, Itaya Y, Kumagai H, Saruta T. Effects of nicardipine on the systemic and renal hemodynamics in acutely elevated blood pressure induced by vasoactive agents in conscious rabbits. *Japan Heart J* 1987; 28:435-443.
48. Persson MG, Gustafsson LE, Wiklund NP, Moncada S, Hedqvist P. Endogenous nitric oxide as a probable modulator of pulmonary circulation and hypoxic pressor response in vivo. *Acta Physiol Scand* 1990; 140: 449-457.
49. Kanai S, Okano H, Orita M, Abe H. Clinical study of neck and shoulder pain for therapeutic effectiveness with application of static magnetic field. *J Japan Soc Pain Clinicians* 1996; 3:11- 17.
50. Kanai S, Okano H, Susuki R, Abe H. Therapeutic effectiveness of static magnetic fields for low back pain monitored with thermography and deep body thermometry. *J Japan Soc Pain Clinicians* 1998; 5:5-10.
51. Kanai S, Taniguchi N, Susuki R. Therapeutic effectiveness of static magnetic fields for osteoarthopathy. *J Japan Soc Pain Clinicians* 1999; 6:361-366.
52. Gmitrov J, Ivanco I, Gmitrova A. Magnetic field effect on blood pressure regulation. *Physiol Bohemoslov* 1990; 39:327-334.
53. Gmitrov J, Gmitrova A. Geomagnetic field and artificial 0.2 T static magnetic field combined effect on blood pressure. *Electro Magnetobiol* 1994; 13:117-122.
54. Gmitrov J, Ohkubo C, Yamada S, Gmitrova A, Xu S. Static magnetic field effects on sinocarotid baroreceptors in rabbits exposed under conscious conditions. *Electro Magnetobiol* 1995; 14:217-228.
55. Gmitrov J. Static magnetic field effect on sinocarotid baroreceptors in humans. *Electro Magnetobiol* 1996; 15: 183-189.

56. Gmitrov J, Ohkubo C. Static-magnetic-field effect on baroreflex sensitivity in rabbits. *Electro Magnetobiol* 1998; 17:217-228.
57. Gmitrov J, Ohkubo C. Artificial static and geomagnetic field interrelated impact on cardiovascular regulation. *Bioelectromagnetics* 2002a; 23:329-338.
58. Gmitrov J, Ohkubo C. Verapamil protective effect on natural and artificial magnetic field cardiovascular impact. *Bioelectromagnetics* 2002b; 23:531-541.
59. Bogosav L, Neda PN. Heart rate in rats exposed to constant magnetic fields. *Electro Magnetobiol* 1993; 12: 117-123.
60. Skorik VI, Zhernovoi AI, Sharshina LM, Kulikova NA, Rudakova ZV, Chirukhin VA. Changes in the blood flow oxygen capacity under the action of a permanent magnetic field. *Biull Eksp Biol Med* 1993; 116:386-388.
61. Jankovic BD, Maric D, Ranin J, Veljic J. Magnetic fields, brain and immunity: effect on humoral and cellmediated immune responses. *Int J Neurosci* 1991; 59:25-43.
62. Jankovic BD, Jovanova-Nesic K, Nikolic V. Locus ceruleus and immunity. III. Compromised immune function (antibody production, hypersensitivity skin reactions and experimental allergic encephalomyelitis) in rats with lesioned locus ceruleus is restored by magnetic fields applied to the brain. *Int J Neurosci* 1993; 69:251-269.
63. Jankovic BD, Jovanova-Nesic K, Nikolic V, Nikolic P. Brain-applied magnetic fields and immune response: role of the pineal gland. *Int J Neurosci* 1993; 70:127-134.
64. Azanza MJ. Steady magnetic fields mimic the effect of caffeine on neurons. *Brain Res* 1989; 489:195-198.
65. Eichwald C, Kaiser F. Model for external influences on cellular signal transduction pathways including cytosolic calcium oscillations. *Bioelectromagnetics* 1995; 16:75-85.
66. Muehsam DJ, Pilla AA. The sensitivity of cells and tissues to exogenous fields: effects of target system initial state. *Bioelectrochem Bioenerg* 1999; 48:35-42.
67. Rosen AD. Magnetic field influence on acetylcholine

release at the neuromuscular junction. *Am J Physiol* 1992; 262:C1418-C1422.

68. Rosen AD, Lubowsky J. Modification of spontaneous unit discharge in the lateral geniculate body by a magnetic field. *Exp Neurol* 1990; 108:261-265.

69. Cavopoli AV, Wamil AW, Holcomb RR, McLean MJ. Measurement and analysis of static magnetic fields that block action potentials in cultured neurons. *Bioelectromagnetics* 1995; 16:197-206.

70. McLean MJ, Holcomb RR, Wamil AW, Pickett JD, Cavopoli AV. Blockade of sensory neuron action potentials by a static magnetic field in the 10 mT range. *Bioelectromagnetics* 1995; 16:20-32.

71. Trabulsi R, Pawlowski B, Wieraszko A. The influence of steady magnetic fields on the mouse hippocampal evoked potentials in vitro. *Brain Res* 1996; 728:135-139.

72. Wieraszko A. Dantrolene modulates the influence of steady magnetic fields on hippocampal evoked potentials in vitro. *Bioelectromagnetics* 2000; 21:175-182.

73. Rosen AD. Threshold and limits of magnetic field action at the presynaptic membrane. *Biochim Biophys Acta* 1994; 1193:62-66.

74. Rosen AD. Membrane response to static magnetic fields: effect of exposure duration. *Biochim Biophys Acta* 1993; 1148:317-320.

75. Balaban PM, Bravarenko NI, Kuznetsov AN. Influence of a stationary magnetic field on bioelectric properties of snail neurons. *Bioelectromagnetics* 1990; 11:13-25.

76. Ayrapetyan SN, Grigorian KV, Avanesian AS, Stamboltsian KV. Magnetic fields alter electrical properties of solutions and their physiological effects. *Bioelectromagnetics* 1994; 15:133-142.

77. Rosen AD. Inhibition of calcium channel activation in GH3 cells by static magnetic fields. *Biochim Biophys Acta* 1996; 1282:149-155.

78. Rosen AD, Lubowsky J. Magnetic field influence on central nervous system function. *Exp Neurol* 1987; 95: 679-687.

79. Hong CZ, Harmon D, Yu J. Static magnetic field influence on rat tail nerve function. Arch Phys Med Rehabil 1986; 67:746-749.
80. Hong CZ. Static magnetic field influence on human nerve function. Arch Phys Med Rehabil 1987; 68:162-164.
81. Bell GB, Marino AA, Chesson AL. Alterations in brain electrical activity caused by magnetic fields: detecting the detection process. Electroencephalogr Clin Neurophysiol 1992; 83:389-397.
82. Fuller M, Dobson J, Wieser HG, Moser S. On the sensitivity of the human brain to magnetic fields: evocation of epileptiform activity. Brain Res Bull 1995; 36:155-159.
83. Dobson J, St Pierre T, Wieser HG, Fuller M. Changes in paroxysmal brainwave patterns of epileptics by weakfield magnetic stimulation. Bioelectromagnetics 2000; 21:94-99.
84. Hirai T, Nakamichi N, Yoneda Y. Activator protein-1 complex expressed by magnetism in cultured rat hippocampal neurons. Biochem Biophys Res Commun 2002; 292:200-207.
85. Kyuhou S, Okada YC. Detection of magnetic evoked fields associated with synchronous population activities in the transverse CA1 slice of the guinea pig. J Neurophysiol 1993; 70: 2665-2668.
86. Okada YC, Wu J, Kyuhou S. Genesis of MEG signals in a mammalian CNS structure. Electroencephalogr Clin Neurophysiol 1997; 103:474-485.
87. Kirschvink JL, Gould JL. Biogenic magnetite as a basis for magnetic field detection in animals. BioSystems 1981; 13:181-201.
88. Weaver JC, Vaughan TE, Astumian RD. Biological sensing of small field differences by magnetically sensitive chemical reactions. Nature 2000; 405:707-709.
89. Lohmann KJ, Johnsen S. The neurobiology of magnetoreception in vertebrate animals. Trends Neurosci 2000; 23: 153-159.
90. Kirschvink JL, Walker MM, Diebel CE. Magnetite-based magnetoreception. Curr Opin Neurobiol 2001; 11: 462-467.
91. Ritz T, Dommer DH, Phillips JB. Shedding light on

vertebrate magnetoreception. *Neuron* 2002; 34:503-506.

92. Semm P, Schneider T, Vollrath L. Effects of an earth-strength magnetic field on electrical activity of pineal cells. *Nature* 1980; 288:607-608.

93. Semm P, Demaine C. Neurophysiological properties of magnetic cells in the pigeon's visual system. *J Comp Physiol [A]* 1986; 159:619-625.

94. Němec P, Altmann J, Marhold S, Burda H, Oelschlager HH. Neuroanatomy of magnetoreception: the superior colliculus involved in magnetic orientation in a mammal. *Science* 2001; 294:366-368.

95. Semm P, Nohr D, Demaine C, Wiltschko W. Neural basis of the magnetic compass: Interactions of visual, magnetic and vestibular inputs in the pigeon's brain. *J Comp Physiol [A]* 1984; 155:283-288.

96. Walker MM, Diebel CE, Haugh CV, Pankhurst PM, Montgomery JC, Green CR. Structure and function of the vertebrate magnetic sense. *Nature* 1997; 390:371-376.

37 Magneto-Metabolic Therapy for Advanced Malignancy and Cardiomyopathy†

1. Eliot RS. Stress and the Major Cardiovascular Disorders. Mount Kisco: Futura Publishing, 1979:51-52.
2. Rosch PJ. Can stress cause coronary heart disease? Stress Medicine 1994; 10:207-210.
3. Selye H. The pluricausal cardiopathies. Ann N Y Acad Sci 1969; 156(1):195-206.
4. Sodi Pallares D, Medrano G, Bisteni A, Ponce de León JJ. Deductive and Polyparametric Electrocardiography. Mexico D.F.: Inst. Nacional de Cardiol, 1970.
5. Einstein A, Infeld L. The Evolution of Physics. New York: Simon and Schuster, 1961.
6. Sodi-Pallares D, Fishleder B, Cisneros F, Vizcaíno. A low sodium, high water and high potassium regimen in the successful management of some cardiovascular diseases. Can Med Assoc J 1960; 83:243.
7. Laborit H. Stress and Cellular Function. Philadelphia: JB Lippincott, 1959.
8. Sodi Pallares D, Testelli MR, Fishleder BL, Bisteni A. Effect of an intravenous solution of potassium-glucoseinsulin solution on the electrocardiographic signs of myocardial infarction. Am J Cardiol 1962; 9:166.
9. Sodi Pallares D, Bisteni A, Medrano GA, Testelli MR, De Micheli A. The polarizing treatment of acute myocardial infarction: possibility of its use in other cardiovascular conditions. Dis Chest 1963; 43:424.
10. Maroko PR, Libby P, Sobel BE, Bloor CM, Sybers HD, Shell WE, Covell JW, Braunwald E. Effect of glucoseinsulin-potassium infusion on myocardial infarction following experimental coronary artery occlusion. Circulation 1972; 45(6):1160-1175.
11. Maroko PR, Braunwald E. Effects of metabolic and pharmacologic interventions on myocardial infarct size following coronary occlusion. Circulation 1976; 53(3 suppl):I162-I168.
12. Prasad K, Callaghan JC. Electrophysiologic basis of use

of a polarizing solution in the treatment of myocardial infarction. *Clin Pharmacol Ther* 1971; 12(4):666-675.

13. Thys JP, Cornil A, Smets P, Degaute JP, Rudi N, Bernard R, Denolin H. Significance of the "polarizing" treatment of myocardial infarction. *Acta Cardiol* 1974; 29(1):19-29.

14. Zukowski SJ. Polarizing solutions in treatment of arrhythmias. *J Am Osteopath Assoc* 1973; 131-138.

Figure 12 Seventy-two-year-old male with adenocarcinoma of the prostate and metastases to the ribs and pelvis

showing destruction of the pubis. (a) Treatment was started on July 7, 1997 with dramatic improvement in general well

being as well as osteolytic lesions in the pelvis after only 4 days. (b) On July 25 the reduction in metastases was even

more impressive. (c) The patient had to return to the United States where he intended to find a physician to continue the

treatment, but contact was lost because he was apparently unable to accomplish this. Reduction in metastases was even

more impressive.

15. Bekheit S, Isber N, Jani H, Butrous G, Boutjdir M, el-Sherif N. Reduction of ischemia-induced electrophysiologic abnormalities by glucose-insulin infusion. *J Am Coll Cardiol* 1993; 22 (4): 1214-1222.

16. Lazar HL, Zhang X, Rivers S, Bernard S, Shemin R. Limiting ischemic myocardial damage using glucoseinsulin-potassium solutions. *Ann Thorac Surg* 1995; 60(2):411-416.

17. Jonassen AK, Aasum E, Riemersma RA, Mjos OD, Larsen TS. Glucose-insulin-potassium reduces infarct size when administered during reperfusion. *Cardiovasc Drugs Ther* 2000; 14(6): 615-623.

Figure 13 Seventy-five-year-old female seen on March 29, 1998 complaining of progressively severe abdominal pain,

weight loss, and fatigue for a month. Tomography revealed a malignancy of the body and head of the pancreas with

invasion of regional lymph nodes (a and b). She was started on diet, received polarizing solution twice weekly along

with daily application of 150 G to the affected area. She improved rapidly with respect to relief of pain, return of energy,

and weight gain, and her general condition was excellent 24 months later, (c) She continued to do well and tomograms

at 36 months showed no increase in the tumor size and necrotic areas could be seen (d and e). She was seen by an

oncologist who told her that the original diagnosis must have been an error since nobody with this type of pancreatic

cancer lives for 3 years, and she could eat as much salt as she wanted and discontinue the treatment. The patient was

pleased with this opinion and took his advice but died shortly thereafter.

Figure 14 (a) Before treatment, (b) after 2 months, (c) after 6 months, and (d) after 7 months.

18. Kobayashi A, Kamiya J, Yamashita T, Ishizaka K, Hayashi H, Kamikawa T, Yamazaki N. Effects of glucoseinsulin-potassium solution on free fatty acid metabolism in ischemic myocardium. *Jpn Circ J* 1984; 48(6): 591-595.

19. Hess ML, Okabe E, Poland J, Warner M, Sewart JR, Greenfield LJ. Glucose, insulin, potassium protection during the course of hypothermic global ischemia and reperfusion: a new proposed mechanism by the scavenging of free radicals. *J Cardiovasc Pharmacol* 1983; 5(1):35-43.

20. Hoekenga DE, Brainard JR, Hutson JY. Rates of glycolysis and glycogenolysis during ischemia in glucoseinsulin-potassium-treated perfused hearts: A ¹³C, ³¹P nuclear magnetic resonance study. *Circ Res* 1988; 62(6): 1065-1074.

21. Quinones-Galvan A, Ferrannini E. Metabolic effects of glucose-insulin infusions: myocardium and whole body. *Curr Opin Clin Nutr Metab Care* 2001; 4(2):157-163.

22. Cottin Y, Lhuillier I, Gilson L, Zeller M, Bonnet C, Toulouse C, Louis P, Rochette L, Girard C, Wolf JE. Glucose

insulin potassium infusion improves systolic function in patients with chronic ischemic cardiomyopathy. *Eur J Heart Fail* 2002; 4(2):181-184.

23. Alegria Ezquerro E, Maceria Gonzalez A. Therapy with glucose-insulin-potassium reduces the complications in the acute phase of myocardial infarct. Arguments in favor. *Rev Esp Cardiol* 1998; 1(9):720-726.

24. Smith A, Grattan A, Harper M, Royston D, Riedel BJ. Coronary revascularization: a procedure in transition from on-pump to off-pump? The role of glucose-insulin-potassium revisited in a randomized, placebo-controlled study. *J Cardiothorac Vasc Anesth* Aug 2002; 16(4):413- 420.

25. Pissarek M, Goos H, Nohring J, Kensicki C, Jonas B, Liebetrueth J, Lindenau KF, Krause EG. Beneficial effect of combined glucose-insulin-potassium and mechanical support in acute myocardial ischaemia. *Biomed Biochim Acta* 1986; 45(5):629-636.

26. Haider W, Hiesmayr M. Glucose-insulin-potassium (GIK) in prevention and therapy of myocardial ischemia. *Wien Klin Wochenschr* 2000; 112(7):310-321.

27. Apstein CS, Taegtmeyer H. Glucose-insulin-potassium in acute myocardial infarction: the time has come for a large, prospective trial. *Circulation* 1997; 96(4):1074-1077.

28. Apstein CS. Glucose-insulin-potassium for acute myocardial infarction: Remarkable results form a new prospective, randomized trial. *Circulation*, 1998, 2223-2226.

29. Diaz R, Paolasso A, Piegas S, Tajer CD, et al. Metabolic modulation of acute myocardial infarction. *Circulation*. 1998; 2227-2346.

30. Opie LH. Proof that glucose-insulin-potassium provides metabolic protection of ischaemic myocardium? *Lancet* 1999; 353:768-769.

31. Ling GN. A new model for the living cell: a summary of the theory and recent experimental evidence in its support. *Int Rev Cytol* 1969; 26:1-61.

32. Ling GN, Ochsenfeld MM. Na + and K + levels in living cells: do they depend on the rate of outward transport of Na + ? *Physiol Chem Phys* 1976; 8(5):389-395.

33. Ling GN. A theoretical foundation provided by the Association-induction Hypothesis for possible beneficial effects of a low Na high K diet and other similar regimens in the treatment of patients suffering from debilitating illnesses. *Agressologie* 1983; 24(7):293-302.
34. Cope FW. Pathology of structured water and associated cations in cells (ther tissue damage syndrome) and its medical treatment. *Physiol Chem Phys* 1977; 9(6):547-553.
35. Cope FW. A medical application of the Ling Association-Hypothesis: The high potassium, low sodium diet of the Gerson cancer therapy. *Physiol Chem Physics*, 1978.
36. Trump BF, Berezesky IK, Chang SH, Pendergrass RE, Mergner WJ. The role of ion shifts in cell injury. *Scan Electron Microsc* 1979; (3):1-13.
37. Trump BF, Berezesky IK, Phelps PC. Sodium and calcium regulation and the role of the cytoskeleton in the pathogenesis of disease: a review and hypothesis. *Scan Electron Microsc* 1981; (Pt 2):434-454.
38. Cone CD. Unified theory on the basis of mechanism of normal mitotic control and oncogenesis. *J Theor Biol* 1971; 30:151-181.
39. Skou JC. Enzymatic basis for active transport of of Na⁺ and K⁺ across the cell membrane. *Physiol Rev* 1965; 45: 596-608.
40. Skou JC, Esmann M. The Na, K-ATPase. *Journal of Bioenergetics and Biomembranes* 1992; 24:249-261. Trump BF, Berezesky IK, Phelps PC. Sodium and calcium regulation and the role of the cytoskeleton in the pathogenesis of disease: a review and hypothesis. *Scan Electron Microsc* 1981; (Pt 2):434-454
41. Damadian R, Cope FW. NMR in cancer. V. Electronic diagnosis of cancer by potassium (39K) nuclear magnetic resonance: spin signatures and T1 beat patterns. *Physiol Chem Phys* 1974; 6(4):309-322.
42. Sodi Pallares D. Lo Que He Descubierta En El Tejido Canceroso. [What I Have Discovered About Cancer Tissue.] Mexico City: D Sodi Pallares, 1998.

38 Electromagnetic Fields as an Adjuvant Therapy to Antineoplastic Chemotherapy

1. Nordenstrom BEW. Biologically Closed Electric Circuits. Stockholm: Nordic Medical Publications, 1983.
2. Nordenstrom BEW. Electrochemical treatment of cancer. I: Variable response to anodic and cathodic fields. *Am J Clin Onc* 1989; 12:530-536.
3. Xin Y, Xue F, Ge B, Zhao F, Shi B, Zhang W. Electrochemical treatment of lung cancer. *BEMS* 1997; 18:8-13.
4. Mir L, Orlowski S, Belehradec J, Paoletti C. Electrochemotherapy potentiation of antitumor effect of Bleomycin by local electric pulses. *Eur J Can* 1991; 27:68-72.
5. Szent-Gyorgi A. Chemical and biological effects of ultra-sonic radiation. *Nature* 1933; 131:278.
6. Payne-Scott R, Love WH. Tissue cultures exposed to the influence of a magnetic field. *Nature* 1936; 134:277.
7. Lenzi M. A report of a few recent experiments on the biologic effects of magnetic fields. *Radiology* 1940; 35: 307-314.
8. Levengood W. Cytogenetic variations induced with a magnetic probe. *Nature* 1966; 209:1009- 1013.
9. Weber T, Cerilli J. Inhibition of tumor growth by the use of non-homogeneous magnetic fields. *Cancer* 1971; 28: 340-343.
10. Alexiou C, Arnold W, Klein R, Parak F, Hulin P, Bergemann C, Erhardt W, Wagenpfeil S, Lubbe A. Locoregional cancer treatment with magnetic drug targeting. *Can Res* 2000; 60:6641- 6648.
11. Babincova M, Altanerova V, Lampert M, Altaner C, Machova E, Sramka M, Babinec P. Sitespecific in vivo targeting of magnetoliposomes using externally applied magnetic field. *Z Naturforsch* 2000; 55c:278-281.
12. Kubo T, Sugita T, Shimose S, Nitta Y, Ikuta Y, Murakami T. Targeted systemic chemotherapy using magnetic liposomes with incorporated adriamycin for osteosarcoma in hamsters. *Int J Onc* 2001; 18:121-125.

13. Petrini M, Matii L, Sabbatini A, Carulli G, Grassi B, Cadossi R, Ronca G, Conte A. Multidrug resistance and electromagnetic fields. *J Bioelectric* 1990; 9:209-212.
14. Williams C, Markov M. Therapeutic electromagnetic field effects on angiogenesis during tumor growth: A pilot study in mice. *Electro Magnetobiol* 2001; 20:323-329.
15. Williams C, Markov M, Hardman W, Cameron I. Therapeutic electromagnetic field effects on angiogenesis and tumor growth. *Antican Res* 2001; 21:3887-3892.
16. Sabo J, Mirossay L, Horovcak L, Sarissky M, Mirossay A, Mojzis J. Effects of static magnetic field on human leukemic cell line HL-60. *Bioelectrochemistry* 2002; 56:227-231.
17. Ruiz Gomez M, Vega J, de la Pena L, Gil Carmona L, Morillo M. Growth modification of human colon adenocarcinoma cells exposed to a low-frequency electromagnetic field. *J Physiol Biochem* 1999; 55:79-84.
18. Tuffet S, deSeze R, Moreau J, Veyret B. Effects of a strong pulsed magnetic field on the proliferation of tumour cells in vitro. *Bioelectrochem Bioenerget* 1993; 30:151-160.
19. Johann S, Lederer, Mikorey S, Kraus W, Blumel G. Influence of electromagnetic fields on morphology and mitochondrial activity of breast cancer cell line MCF-7. *Bioelectrochem Bioenerget* 1993; 30:127-132.
20. de Mattei M, Caruso A, Traina G, Pezzetti F, Baroni T, Sollazzo V. Correlation between pulsed electromagnetic fields exposure time and cell proliferation increase in human osteosarcoma cell lines and human normal osteoblast cells in vitro. *BEMS* 1999; 20:177-182.
21. Raylman R, Clavo A, Wahl R. Exposure to strong magnetic field slows the growth of human cancer cells in vitro. *BEMS* 1996; 17:358-363.
22. Watson J, Parrish E, Rinehart C. Selective potentiation of gynecologic cancer cell growth in vitro by electromagnetic fields. *Gyn Oncol* 1998; 71:64-71.
23. Salvatore J, Blackinton D, Polk C, Mehta S. Non-ionizing electromagnetic radiation: a study of carcinogenic and cancer treatment potential. *Reviews on Env Health* 1994; 10:197-207.

24. Hannan C, Liang Y, Allison J, Searle J. In Vitro cytotoxicity against human cancer cell lines during pulsed magnetic field exposure. *Anticancer Res* 1994; 14:1517-1520.
25. Hirata M, Kusuzaki K, Takeshita H, Hashiguchi S, Hirasawa Y, Ashihara T. Drug resistance modification using pulsing electromagnetic field stimulation for multidrug resistant mouse osteosarcoma cell line. *Anticancer Res* 2001; 21:317-320.
26. Liang Y, Hannan C, Chang B, Schoenlein P. Enhanced potency of Daunorubicin against multidrug resistant subline KB-ChR-8-5-11 by a pulsed magnetic field. *Anticancer Res* 1997; 17:2083-2088.
27. Miyagi N, Sato K, Rong Y, Yamamura S, Katagiri H, Kobayashi K, Iwata H. Effects of PEMF on a murine osteosarcoma cell line: Drug resistant (P-Glycoprotein-positive) and nonresistant cells. *BEMS* 2000; 21: 112-121.
28. Fanelli C, Coppola S, Barone R, Colussi C, Gualandi G, Volpe P, Ghibelli L. Magnetic fields increase cell survival by inhibiting apoptosis via modulation of Ca²⁺ influx. *FASEB J* 1999; 13:95-102.
29. Morris J, Sasser L, Miller D, Dagle G, Rafferty C, Ebi K, Anderson L. Clinical progression of transplanted large granular lymphocytic leukemia in Fischer 344 rats exposed to 60 Hz magnetic fields. *BEMS* 1999; 20:48-56.
30. Bellossi A. Effect of static magnetic field on survival of leukemia-prone AKR mice. *Rad Env Biophys* 1986; 25: 75-80.
31. Bellossi A, Desplaces A, Morin R. Effect of a pulsed magnetic field on tumoral C3H/Bi female mice. *Can Biochem Biophys* 1988; 10:59-66.
32. de Seze R, Tuffet S, Moreau J, Veyret B. Effects of 100 mT time varying magnetic fields on the growth of tumors in mice. *BEMS* 2000; 21:107-111.
33. Tofani S, Barone D, Cintorino M, de Santi M, Ferrara A, Orlassino R, Ossola P, Peroglio F, Rolfo K, Ronchetto F. Static and ELF magnetic fields induce tumor growth inhibition and apoptosis. *BEMS* 2001; 22:419-428.
34. Zucchini P, Cadossi R, Emilia G, Torelli G, Santantonio

M, Mandolini G. Effect of pemf on mice injected with cyclophosphamide. In: Brighton C, Pollack S, eds. Electromagnetics in Biology and Medicine. San Francisco: SF Press, 1991:207-209.

35. Cadossi R, Zucchini P, Emilia G, Franceschi C, Cossarizza A, Santantonio M, Mandolini G, Torelli G. Effect of low frequency low energy pulsing electromagnetic fields on mice injected with Cyclophosphamide. *Exp Hem* 1991; 19:196-201.

36. Gray J, Frith C, Parker J. In vivo enhancement of chemotherapy with static electric or magnetic fields. *BEMS* 2000; 21:575-583.

37. Hannan C, Liang Y, Allison J, Pantazis C, Searle J. Chemotherapy of human carcinoma xenografts during pulsed magnetic field exposure. *Antican Res* 1994; 14:1521-1522.

38. Omote Y, Hosokawa M, Komatsumoto M, Namieno T, Nakajima S, Kubo Y, Kobayashi H. Treatment of experimental tumors with a combination of a pulsing magnetic field and an antitumor drug. *Japan J Can Res* 1990; 81:956-961.

39. Moroz P, Jones SK, Gray BN. The effect of tumor size on ferromagnetic embolization hyperthermia in a rabbit liver tumor model. *Int J Hyperthermia* 2002; 18:129-140.

40. Salvatore JR. Static magnetic fields in the treatment of human malignancy. Abstract #10-2. Bioelectromagnetics Society Annual Meeting. June 23-27, 2002. Quebec, Canada.

41. Salvatore JR, Harrington J, Kummert T. Phase I clinical study of a static magnetic field combined with antineoplastic chemotherapy in the treatment of human malignancy: initial safety and toxicity data. *BEMS* 2003; 24: 524-527.

39 Can Magnetic Fields Inhibit Angiogenesis and Tumor Growth?

1. Leek RD. The prognostic role of angiogenesis in breast cancer. *Anticancer Res* 2001; 21:4325- 4332.
2. Mc Namara DA, Harney JH, Walsh TN, Redmond HP, Bouchier HD. Significance of angiogenesis in cancer therapy. *Brit J Surg* 1998; 85(8): 1044-1055.
3. Folkman J, Shing Y. Angiogenesis. *J Biol Chem* 1992; 267(16): 10931-10934.
4. Murata J, Ishibashi T, Khalil A, Hata Y, Yoshikawa H, Inomata H. Vascular endothelial growth factor play a role in hyperpermeability of diabetic retinal vessels. *Ophthalmic Res* 1995; 27:48-52.
5. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. *Nature Med* 1995; 1(1):27-31.
6. Mc Laren J, Prentice A, Charnockjones DS, Millican SA, Muller KH, Sharkley AM. Vascular endothelial growth factor is produced by peritoneal-fluid microphages in endometriosis and is regulated by ovarian-steroids. *J Clin Invest* 1996; 482-489.
7. Sokmen S, Sarioglu S, Fuzun M, Terzi C, Kupelloglu A, Aslan B. Prognostic significance of angiogenesis in rectal cancer. *Anticancer Res* 2001; 21:4341-4348.
8. Saito H, Tsujitani S. Angiogenesis, angiogenic factor expression and prognosis of gastric carcinoma. *Anticancer Res* 2001; 21:4365-4372.
9. Vemeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella F, Vilae G, Veidner N, Harris AL, Dirix LY. Quantification of angiogenesis in solid tumors: an international consensus on the methodology and criteria of evaluation. *Eur J Cancer* 1996; 14:2474-2484.
10. Folkman J. Tumor angiogenesis: therapeutic implications. *N Engl J Med* 1971; 285:1182- 1186.
11. Ribatti D, Vacca A, De Falco G, Roccaro A, Roncali L, Dammacco F. Angiogenesis, angiogenic factors expression and hematological malignances. *Anticancer Research* 2001; 21:4333-4340.
12. Ausprunk DH, Folkman J. Migration and proliferation of

endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. *Microvasc Res* 1977; 14:53-65.

13. Sheibani N, Frazier WA. Thrombospondin-1, PECAM-1 and regulation of angiogenesis. *Histopathol* 1999; 14: 285-294.

14. Tannock IF. The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumor. *Brit J Cancer* 1968; 22:258-273.

15. Vartanian RK, Weidner N. Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma. *Am J Pathol* 1994; 144:1188-1194.

16. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. *Cell* 1996; 86:353-364.

17. Coede V, Fleckenstein G, Dietrich M, Osmer RGM, Kuhn W, Augustin HG. Prognostic value of angiogenesis in mammary tumors. *Anticancer Res* 1998; 18:2199-2202.

18. Folkman J. Angiogenesis and its inhibitors. In: DeVita VT, Helman S, Rosenberg S, eds. *Important Advances in Oncology*. Philadelphia: JB Lippincott C, 1985:42-62.

19. Hori A, Sasada R, Matsutani E, Naito K, Sakura Y, Fujita T, Kozai Y. Suppression of solid tumor growth by immuno-neutralizing monoclonal antibody against human basic fibroblast growth factor. *Cancer Res* 1991; 51: 6180-6184.

20. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. *Nature* 1993; 362:841-844.

21. Corbett TH, Griswood DP Jr, Roberts BJ, Peckham JC, Schabel FM Jr. Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy. *Cancer Treatment Rep* 1978; 62:1471-1488.

22. Teicher BA, ed. *Anticancer Drug Development Guide*. Totowa, NJ: Humana Press, 1997.

23. Vanzulli S, Cazzaniga S, Braidot MF, Vecchi A, Montovani A, Weinstok de, Calmanovici R. Detection of endothelial cells by MEC 13.3 monoclonal antibody in mice

mammary tumors. *Biocell* 1997; 21:39-46.

24. Williams CD, Markov MS. Therapeutic electromagnetic field effects of angiogenesis during tumor growth: a pilot study in mice. *Electro Magnetobiol* 2001; 20:323-329.

25. Williams CD, Markov MS, Hardman WE, Cameron IL. Therapeutic electromagnetic field effects on angiogenesis and tumor growth. *Anticancer Res* 2001; 21:3887-3892.

26. De Seze R, Tuffet S, Moreau JM, Veyret B. Effect of 100-mT time-varying magnetic fields on the growth of tumors in mice. *Bioelectromagnetics* 2000; 21:107-111.

27. Ruifrok AC. Quantification of immunohistochemical staining by color translation and automated thresholding. *Analyt Quant Cytol Histol* 1997; 19:107-113.

28. De Lisser HM, Christofidou-Solomidou M, Strieter RM, Burdick MD, Robinson CS, Wexler RS, Kerr JS, Garlanda C, Merwin JR, Madri JA, Albelda SM. Involvement of endothelial PECAM-1/CD31 in angiogenesis. *Am J Pathol* 1997; 151:671-677.

29. Charpin C, Garcia S, Bouvier C, Andras L, Bonnier P, Lavaut M-N, Allasia C. CD31/PECAM Automated and quantitative immunochemical assay in breast carcinomas. *Am J Clin Pathol* 1997; 107:534-554.

30. Hauser IA, Riess R, Hausknecht B, Thuringer H, Sterzel RB. Expression of cell adhesion molecules in primary renal disease and renal allograft rejection. *Nephrol Dial Transplant* 1997; 12:1122-1131.

31. Jain RK. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. *J Natl Cancer Inst* 1989; 81(8):570-576.

32. Markov MS. Influence of radiation on biological systems. In: Allen MJ, ed. *Charge and Field Effects in Biosystems II*. New York: Plenum Press, 1990:241-250.

33. Folkman J, Hahmfeldt P, Hlatky L. Cancer: looking outside the genome. *Nature Reviews. Molecular Cellular Biol* 2001; 1:76-79.

34. Hannan CJ, Liang Y, Allison JD, Searle JR. In vitro cytotoxicity against human cancer cell lines during pulsed magnetic field exposure. *Anticancer Res* 1994; 14(4A):1517-1520.

35. Liang Y, Hannan CJ, Chang BK, Schoenlein PV. Enhanced potency of daunorubicin against multidrug resistant subline KB-ChR-8-5-11 by a pulsed magnetic field. *Anticancer Res* 1997; 17(3C):2083-2088.

36. Salvatore JR, Blackinton D, Polk C, Mehta S. Nonionizing electromagnetic radiation: a study of carcinogenic and cancer treatment potential. *Rev Environmental Health* 1994; 10(3-4): 197- 207.

37. Salvatore JR. Nonionizing electromagnetic fields and cancer: a review. *Oncology* 1996; 10 (4): 563-570.

40 Electroporation for Electrochemotherapy and Gene Therapy

1. Mir LM. Therapeutic perspectives of in vivo cell electroporabilization. *Bioelectrochemistry* 2001; 53:1-10.
2. Kotnik T, Bobanovič F, Miklavčič D. Sensitivity of transmembrane voltage induced by applied electric fields—a theoretical analysis. *Bioelectrochem Bioenerg* 1997; 43:285-291.
3. Kotnik T, Miklavčič D. Analytical description of transmembrane voltage induced by electric fields on spheroidal cells. *Biophys J* 2000; 79:670-679.
4. Gimsa J, Wachner D. Analytical description of the transmembrane voltage induced on arbitrarily oriented ellipsoidal and cylindrical cells. *Biophys J* 2001; 81:1888-1896.
5. Susil R, Šemrov D, Miklavčič D. Electric field induced transmembrane potential depends on cell density and organization. *Electro Magnetobiol* 1998; 17:391-399.
6. Pavlin M, Pavšelj N, Miklavčič D. Dependence of induced transmembrane potential on cell density, arrangement, and cell position inside a cell system. *IEEE Trans Biomed Eng* 2002; 49:605-612.
7. Miklavčič D, Beravs K, Šemrov D, Čemažar M, Demšar F, Serša G. The importance of electric field distribution for effective in vivo electroporation of tissues. *Biophys J* 1998; 74:2152-2158.
8. Tekle E, Astumian RD, Chock PB. Selective and asymmetric molecular transport across electroporated cell membranes. *Proc Natl Acad Sci USA* 1994; 91:11512-11516.
9. Neumann E, Toensing K, Kakorin S, Budde P, Frey J. Mechanism of electroporative dye uptake by mouse B cells. *Biophys J* 1998; 74:98-108.
10. Gabriel B, Teissié J. Time courses of mammalian cell electroporabilization observed by millisecond imaging of membrane property changes during the pulse. *Biophys J* 1999; 76:2158- 2165.
11. Rols MP, Teissié J. Electroporabilization of mammalian cells to macromolecules: control by pulse duration. *Biophys J* 1998; 75:1415-1423.

12. Satkauskas S, Bureau MF, Puc M, Mahfoudi A, Scherman D, Miklavčič D, Mir LM. Mechanisms of in vivo DNA electrotransfer: respective contributions of cell electropermeabilization and DNA electrophoresis. *Mol Ther* 2002; 5:133-140.
13. Rols MP, Delteil C, Golzio M, Dumond P, Cros S, Teissie J. In vivo electrically mediated protein and gene transfer in murine melanoma. *Nature Biotechnol* 1998; 16:168-171.
14. Sukharev SI, Klenchin VA, Serov SM, Chernomordik LV, Chizmadzhev YA. Electroporation and electrophoretic DNA transfer into cells. *Biophys J* 1992; 63:1320-1327.
15. Weaver JC, Chizmadzhev YA. Theory of electroporation: a review. *Bioelectrochem Bioenerg* 1996; 41:135-160.
16. Kakorin S, Stoylov SP, Neumann E. Electrooptics of membrane electroporation in diphenylhexatriene-doped lipid bilayer vesicles. *Biophys Chem* 1996; 58:109-116.
17. Marinkk SJ, Lindahl E, Edholm O, Mark AE. Simulation of the spontaneous aggregation of phospholipids into bilayers. *J Am Chem Soc* 2001; 123:8638-8639.
18. Kandušer M, Fošnarič M, Šentjurc M, Kralj-Iglič V, Hägerstrand H, Iglič A, Miklavčič D. Effect of surfactant polyoxyethylene glycol (C12E8) on electroporation of cell line DC3F. *Colloid Surf A* 2003; 214:205-217.
19. Sale AJH, Hamilton WA. Effects of high electric fields on microorganisms: I. Killing of bacteria and yeasts. *Biochim Biophys Acta* 1967; 148:781-788.
20. Hamilton WA, Sale AJH. Effects of high electric fields on microorganisms: II. Mechanism and action of the lethal effect. *Biochim Biophys Acta* 1967; 148:789-800.
21. Vernhes MC, Benichou A, Pernin P, Cabanes PA, Teissie J. Elimination of free-living amoebae in fresh water with pulsed electric fields. *Water Res* 2002; 36:3429-3438.
22. Mouneimne Y, Tosi PF, Barhoumi R, Nicolau C. Electroinsertion of full length recombinant CD4 into red blood cell membrane. *Biochim Biophys Acta* 1990; 1027:53-58.
23. Raffy S, Teissie J. Electroinsertion of glycoporphin A in interdigitated-fusion giant unilamellar lipid vesicles. *J Biol Chem* 1997; 272:25524-25530.

24. Abidor IG, Sowers AE. Kinetics and mechanism of cell membrane electrofusion. *Biophys J* 1992; 61: 1557-1569.
25. Sowers AE. Membrane electrofusion: a paradigm for study of membrane fusion mechanisms. *Methods Enzymol* 1993; 220:196-211.
26. Heller R. Spectrofluorometric assay for cell-tissue electrofusion. *Methods Mol Biol* 1995; 48:341-353.
27. Mekid H, Mir LM. In vivo cell electrofusion. *Biochim Biophys Acta* 2000; 1524:118-130.
28. Scott-Taylor TH, Pettengell R, Clarke I, Stuhler G, La Barthe MC, Walden P, Dalgleish AG. Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines. *Biochim Biophys Acta* 2000; 1500:265-267.
29. Orentas RJ, Schauer D, Bin Q, Johnson BD. Electrofusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine. *Cell Immunol* 2001; 213:4-13.
30. Schmidt E, Leinfelder U, Gessner P, Zillikens D, Bröcker EB, Zimmermann U. CD19+ B lymphocytes are the major source of human antibody-secreting hybridomas generated by electrofusion. *J Immunol Methods* 2001; 255:93-102.
31. Prausnitz MR, Bose VG, Langer R, Weaver JC. Electroporation of mammalian skin: A mechanism to enhance transdermal drug delivery. *Proc Natl Acad Sci USA* 1993; 90:10504- 10508.
32. Vanbever R, Lecouturier N, Preat V. Transdermal delivery of metoprolol by electroporation. *Pharmacol Res* 1994; 11:1657-1662.
33. Zewert TE, Pliquett U, Langer R, Weaver JC. Transport of DNA antisense oligonucleotides across human skin by electroporation. *Biochim Biophys Res Commun* 1995; 212:286-292.
34. Mir LM, Orłowski S, Belehradek J, Paoletti C. Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses. *Eur J Cancer* 1991; 27:68-72.
35. Mir LM, Orłowski S, Belehradek J Jr, Teissie J, Rols MP, Sersa G, Miklavčič D, Gilbert R, Heller R. Biomedical

applications of electric pulses with special emphasis on antitumor electrochemotherapy. *Bioelectrochem Bioenerg* 1995; 38:203-207.

36. Serša G, Čemažar M, Miklavčič D. Antitumor effectiveness of electrochemotherapy with cisdiamminedichloroplatinum(II) in mice. *Cancer Res* 1995; 55:3450-3455.

37. Mir LM, Glass LF, Serša G, Teissié J, Domenge C, Miklavčič D, Jaroszeski MJ, Orlowski S, Reintgen DS, Rudolf Z, Belehradek M, Gilbert R, Rols MP, Belehradek J Jr, Bachaud JM, DeConti R, Štabuc B, Čemažar M, Coninx P, Heller R. Effective treatment of cutaneous and subcutaneous malignant tumors by electrochemotherapy. *Brit J Cancer* 1998; 77:2336-2342.

38. Serša G, Štabuc B, Čemažar M, Miklavčič D, Rudolf Z. Electrochemotherapy with cisplatin: clinical experience in malignant melanoma patients. *Clin Cancer Res* 2000; 6:863-867.

39. Čemažar M, Serša G, Miklavčič D. Electrochemotherapy with cisplatin in the treatment of tumour cells resistant to cisplatin. *Anticancer Res* 1998; 18:4463-466.

40. Serša G, Čemažar M, Miklavčič D, Chaplin DJ. Tumor blood flow modifying effect of electrochemotherapy with bleomycin. *Anticancer Res* 1999; 19:4017-4022.

41. Serša G, Čemažar M, Parkins CS, Chaplin DJ. Tumour blood flow changes induced by application of electric pulses. *Eur J Cancer* 1999; 35:672-677.

42. Gehl J, Skovsgaard T, Mir LM. Vascular reactions to in vivo electroporation: characterization and consequences for drug and gene delivery. *Biochim Biophys Acta* 2002; 1569:51-58.

43. Serša G, Kranjc S, Čemažar M. Improvement of combined modality therapy with cisplatin and radiation using electroporation of tumors. *Int J Radiat Oncol Biol Phys* 2000; 46:1037-1041.

44. Aihara H, Miyazaki J. Gene transfer into muscle by electroporation in vivo. *Nat Biotechnol* 1998; 16:867-870.

45. Mir LM, Bureau MF, Gehl J, Rangara R, Rouy D, Caillaud JM, Delaere P, Branellec D, Schwartz B, Scherman D. High efficiency gene transfer into skeletal muscle mediated by

electric pulses. Proc Natl Acad Sci USA 1999; 96:4262-4267.

46. Durieux AC, Bonnefoy R, Manissolle C, Freyssenet D. High-efficiency gene electrotransfer into skeletal muscle: description and physiological applicability of a new pulse generator. Biochem Biophys Res Commun 2002; 296: 443-450.

47. Rizzuto G, Cappelletti M, Maione D, Savino R, Lazzaro D, Costa P, Mathiesen I, Cortese R, Ciliberto G, Laufer R, La Monica N, Fattori E. Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation. Proc Natl Acad Sci USA 1999; 96:6417-6422.

48. Bettan M, Emmanuel F, Darteil R, Caillaud JM, Soubrier F, Delaere P, Branelec D, Mahfoudi A, Duverger N, Scherman D. High-level protein secretion into blood circulation after electric pulse-mediated gene transfer into skeletal muscle. Mol Ther 2000; 2:204-210.

49. Rols MP, Teissié J. Electroporation of mammalian cells: quantitative analysis of the phenomenon. Biophys J 1990; 58:1089-1098.

50. Wolf H, Rols MP, Boldt E, Neumann E, Teissié J. Control by pulse parameters of electric field-mediated gene transfer in mammalian cells. Biophys J 1994; 66:524-531.

51. Maček-Lebar A, Kopitar NA, Ihan A, Serša G, Miklavčič D. Significance of treatment energy in cell electroporation. Electro Magnetobiol 1998; 17:253-260.

52. Čemažar M, Jarm T, Miklavčič D, Maček-Lebar A, Ihan A, Kopitar NA, Serša G. Effect of electric-field intensity on electroporation and electrosensitivity of various tumor-cell lines in vitro. Electro Magnetobiol 1998; 17:261-270.

53. Tomov TC. Quantitative dependence of electroporation on the pulse parameters. Bioelectrochem Bioenerg 1995; 37:101-107.

54. Chang DC. Cell poration and cell fusion using an oscillating electric field. Biophys J 1989; 56:641-652.

55. Chang DC, Gao PQ, Maxwell BL. High efficiency gene transfection by electroporation using a radiofrequency electric field. Biochim Biophys Acta 1991; 1092:153-160.

56. Tekle E, Astumian RD, Chock PB. Electroporation by

using bipolar oscillating electric field: An improved method for DNA transfection of NIH 3T3 cells. *Proc Natl Acad Sci USA* 1991; 88:4230-4234.

57. Schoenbach KH, Peterkin FE, Alden RW, Beebe SJ. The effects of pulsed electric fields on biological cells: experiments and applications. *IEEE Trans Plasma Sci* 1997; 25:284-292.

58. Kotnik T, Mir LM, Flisar K, Puc M, Miklavčič D. Cell membrane electropermeabilization by symmetrical bipolar rectangular pulses. Part I. Increased efficiency of permeabilization. *Bioelectrochemistry* 2001; 54:83-90.

59. Kotnik T, Miklavčič D, Mir LM. Cell membrane electropermeabilization by symmetrical bipolar rectangular pulses. Part II. Reduced electrolytic contamination. *Bioelectrochemistry* 2001; 54:91-95.

60. Pucihar G, Mir LM, Miklavčič D. The effect of pulse repetition frequency on the uptake into electropermeabilized cells in vitro with possible applications in electrochemotherapy. *Bioelectrochemistry* 2002; 57:167-172.

61. Rols MP, Teissié J. Ionic-strength modulation of electrically induced permeabilization and associated fusion of mammalian cells. *Eur J Biochem* 1989; 179:109-115.

62. Djuzenova CS, Zimmermann U, Frank H, Sukhorukov VL, Richter E, Fuhr G. Effect of medium conductivity and composition on the uptake of propidium iodide into electropermeabilized myeloma cells. *Biochim Biophys Acta* 1996; 1284:143-152.

63. Pucihar G, Kotnik T, Kanduser M, Miklavčič D. The influence of medium conductivity on electropermeabilization and survival of cells in vitro. *Bioelectrochemistry* 2001; 54:107-115.

64. Rols MP, Teissié J. Modulation of electrically induced permeabilization and fusion of Chinese hamster ovary cells by osmotic pressure. *Biochemistry* 1990; 29:4561-4567.

65. Golzio M, Mora MP, Raynaud C, Delteil C, Teissié J, Rols MP. Control by osmotic pressure of voltage-induced permeabilization and gene transfer in mammalian cells. *Biophys J* 1998; 74:3015-3022.

66. Rols MP, Delteil C, Serin G, Teissié J. Temperature

effects on electrotransfection of mammalian cells. *Nucleic Acids Res* 1994; 22:540.

67. Miklavčič D, Šemrov D, Mekid H, Mir LM. A validated model of in vivo electric field distribution in tissues for electrochemotherapy and for DNA electrotransfer for gene therapy. *Biochim Biophys Acta* 2000; 1523:73-83.

68. Pliquett U, Gift EA, Weaver JC. Determination of the electric field and anomalous heating caused by exponential pulses with aluminum electrodes in electroporation experiments. *Bioelectrochem Bioenerg* 1996; 39:39-53.

69. Loste F, Eynard N, Teissié J. Direct monitoring of the field strength during electropulsation. *Bioelectrochem Bioenerg* 1998; 47:119-127.

70. Loomis-Husselbee JW, Cullen PJ, Irvine RF, Dawson AP. Electroporation can cause artefacts due to solubilization of cations from the electrode plates. *Biochem J* 1991; 277:883-885.

71. Gilbert RA, Jaroszeski MJ, Heller R. Novel electrode designs for electrochemotherapy. *Biochim Biophys Acta* 1997; 1334:9-14.

72. Ramirez LH, Orłowski S, An D, Bindoula G, Dzodic R, Ardouin P, Bognel C, Belehradec J, Munck JN, Mir LM. Electrochemotherapy on liver tumours in rabbits. *Brit J Cancer* 1998; 12:2104-2111.

73. Puc M, Reberšek S, Miklavčič D. Requirements for a clinical electrochemotherapy device- electroporator. *Radiol Oncol* 1997; 31:368-373.

41 Electroporation Therapy: Treatment of Cancer and Other Therapeutic Applications

1. Rose WC, Lee FY, Golik J, Kadow J. Preclinical oral antitumor activity of BMS-185660, a paclitaxel derivative. *Cancer Chemother Pharmacol* 2000; 46:246-250.
2. Walker RD, Smith EW. The role of percutaneous penetration enhancers. *Adv Drug Del Rev* 1996; 18:295-301.
3. Inoue N, Kobayashi D, Kimura M, Toyama M, Sugawara I, Itoyama S, Ogiwara M, Sugibayashi K, Morimoto Y. Fundamental investigation of a novel drug delivery system, a transdermal delivery system with jet injection. *Int J Pharma* 1996; 137:75-84.
4. Muddle AG, Longridge DJ, Sweeney PA, Burkoth TL, Bellhouse BJ. Transdermal delivery of testosterone to conscious rabbits using powderject—a supersonic powder delivery system. *Proc Int Symp Control Tel Bioact Mater, Controlled Release Society, Inc.* 1997; 24:713-714.
5. Hofmann GA, Dev SB, Nanda GS, Rabussay D. Electroporation therapy of solid tumors. *Crit Rev Therapeutic Drug Carrier Systems* 1999; 16:523-569.
6. Heller R, Gilbert R, Jaroszeski MJ. Clinical applications of electrochemotherapy. *Adv Drug Deliv Rev* 1999; 4 (35): 119-129.
7. Dev SB, Rabussay D, Widera G, Hofmann GA. Medical applications of electroporation. *IEEE Trans Plasma Sci* 2000; 28:206-223.
8. Mir LM. Therapeutic perspectives of in vivo cell electropermeabilization. *Bioelectrochemistry* 2000; 53:1-10.
9. Smith LC, Nordstrom JL. Advances in plasmid gene delivery and expression in skeletal muscle. *Curr Opin Mol Ther* 2000; 2:150-154.
10. Sale AJH, Hamilton WA. Effects of high electric fields on microorganisms. I. Killing bacteria and yeasts. *Biochim Biophys Acta* 1967; 148:781-788.
11. Neumann E, Rosenheck K. Permeability changes induced by electric impulses in vesicular membranes. *J Membr Biol* 1972; 10:279-290.
12. Neumann E, Schaefer-Ridder M, Wang Y, Hofschneider PH.

Gene transfer into mouse lymphoma cells by electroporation in high electric fields. *EMBO J* 1982; 1:841-845.

13. Nikoloff FA. *Methods in Molecular Biology*. Vol. 47, 48. Totowa, NJ: Humana Press, 1995.

14. Muramatsu T, Nakamura A, Park HM. In vivo electroporation: a powerful and convenient means of nonviral gene transfer to tissues of living animals (Review). *Int J Mol Med*; 1998; 1:55-62.

15. Weaver JC. Electroporation: a general phenomenon for manipulating cells and tissues. *J Cell Biochem* 1993; 51: 235-426.

16. Weaver JC, Chizmadzhev YA. Theory of electroporation: a review. *Bioelectrochemistry and Bioenergetics* 1996; 41:135-160.

17. Weaver JC. Electroporation of cells and tissues. *IEEE Trans Plasma Sci* 2000; 28:24-33.

18. Neumann E, Kakorin S, Toensing K. Principles of membrane electroporation and transport of macromolecules. In: Jaroszeski MJ, Heller R, Gilbert R, eds. *Methods in Molecular Medicine. Electrically Mediated Delivery of Molecules to Cells*. Vol. 37. Totowa, NJ: Humana Press, 2000:1-35.

19. Mir LM, Glass LF, Serša G, Teissié J, Domenge C, Miklavčič D, Jaroszeski MJ, Orlowski S, Reintgen DS, Rudolf Z, Belehradek M, Gilbert R, Rols M-P, Belehradek J Jr, Bachaud J-M, De Conti R, Štabuc B, Čemažar M, Cininx P, Heller R. Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. *Br J Cancer* 1998; 77:2336-2342.

20. Schoenbach KH, Beebe SJ, Buescher ES. Intracellular effect of ultrashort electrical pulses. *Bioelectromagnetics* 2001; 22:440-448.

21. Muller KJ, Sukhorukov VL, Zimmermann U. Reversible electroporation of mammalian cells by high-intensity, ultra-short pulses of submicrosecond duration. *J Membr Biol* 2001; 184:161-170.

22. Kuriyama S, Tsujinoue H, Toyokawa Y, Mitoro A, Nakatani T, Yoshiji H, Tsujimoto T, Fukui H. A potential approach for electrochemotherapy against colorectal carcinoma using a clinically available alternating current system with

bipolar snare in a mouse model. *Scand J Gastroenterol* 2001; 36:297-302.

23. Nanda GS, Sun FX, Hofmann GA, Hoffman RM, Dev SB. Electroporation therapy of human larynx tumors HEp-2 implanted in nude mice. *Anticancer Res* 1998; 18:999-1004.

24. Okino M, Mohri H. Effects of a high-voltage electrical impulse and an anticancer drug on in vivo growing tumors. *Jpn J Cancer Res* 1987; 78:1319-1321.

25. Mir LM, Belehradek M, Domenge C, Orlowski S, Poddevin B, Belehradek J Jr, Schwaab G, Luboinski B, Paoletti C. L'électrochimiothérapie, un nouveau traitement antitumoral: premier essai clinique. *C R Acad Sci Paris* 1991; 313:613-618.

25b. Nordenström B. Survey of mechanisms in electrochemical treatment of cancer. *Eur J Surg* 1994; 574(suppl.): 93-109.

26. Keating A, Nolan E, Filshie R, Dev SB. Ex vivo stromal cell electroporation of factor IX cDNA for treatment of hemophilia B. In: Jaroszeski MJ, Heller R, Gilbert R, eds. *Methods in Molecular Medicine. Electrically Mediated Delivery of Molecules to Cells*. Vol. 37. Totowa, NJ: Humana Press, 2000:359-368.

27. Heller R, Gilbert R, Jaroszeski MJ. Clinical trials for solid tumors using electrochemotherapy. Jaroszeski MJ, Heller R, Gilbert R, eds. *Methods in Molecular Medicine. Electrically Mediated Delivery of Molecules to Cells* 2000; Vol. 37. Totowa, NJ: Humana Press, 2000:137-156.

28. In: Jaroszeski MJ, Heller R, Gilbert R, eds. *Methods in Molecular Medicine. Electrically Mediated Delivery of Molecules to Cells*. Vol. 37. Totowa, NJ: Humana Press, 2000.

29. Orlowski S, Belehradek J Jr, Paoletti C, Mir LM. Transient electroporation of cells in culture. Increase of the cytotoxicity of anticancer drugs. *Biochem Pharmacol* 1988; 37:4727- 4733.

30. Poddevin B, Orlowski S, Belehradek J Jr, Mir LM. Very high cytotoxicity of bleomycin introduced into the cytosol of cells in culture. *Biochem Pharmacol* 1991; 42(suppl):S67-S75.

31. Mir LM, Tounekti O, Orlowski S. Bleomycin: revival of an old drug. *Gen Pharmacol* 1996; 27:745-748.

32. Jaroszeski MJ, Dang V, Pottinger C, Hickey J, Gilbert R, Heller R. Toxicity of anticancer agents mediated by electroporation in vitro. *Anticancer Drugs* 2000; 11:201-208.
33. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. *Cancer* 1981; 47: 207-214.
34. Tounekti O, Pron G, Belehradek J Jr, Mir LM. Bleomycin, an apoptosis-mimetic drug that induces two types of cell death depending on the number of molecules internalized. *Cancer Res* 1993; 53(22):5462-5469.
35. Hofmann GA, Dev SB, Dimmer S, Nanda GS. Electroporation therapy: a new approach for the treatment of head and neck cancer. *IEEE Trans Biomed Eng* 1999; 46:752-759.
36. Dev SB, Nanda GS, Austin M, Bleecher S, Hofmann GA. Electroporation-mediated drug delivery is highly effective for treatment of solid tumors. *Proc Am Assoc Cancer Res* 1999; 40:582.
37. Nanda GS, Bleecher S, Dev SB, Rabussay D. Electroporation therapy of head and neck tumors. *Oral Oncology* 2001; 7:318-322.
38. Ono K, Kinashi Y, Masunaga S, Suzuki M, Takagaki M. Effect of electroporation on cell killing by boron neutron capture therapy using borocaptate sodium (¹⁰B-BSH). *Jpn J Cancer Res* 1998; 89:1352-1357.
39. Ono K, Kinashi Y, Masunaga S, Suzuki M, Takagaki M. Electroporation increases the effect of borocaptate (¹⁰BBSH) in neutron capture therapy. *Int J Radiat Oncol Biol Phys* 1998; 42:823-826.
40. Omura S, Tsuyuki Y, Ohta S, Li X, Bukawa H, Fujita K. Rapid tumor necrosis induced by electrochemotherapy with intratumoral injection of bleomycin in a hamster tongue model. *Int J Oral Maxillofac Surg* 2000; 29: 119-125.
41. Omura S, Tsuyuki Y, Ohta S, Bukawa H, Fujita K. In vivo antitumor effects of electrochemotherapy in a tongue cancer model. *Int J Oral Maxillofac Surg* 1999; 57:965-972.
42. Hasegawa H, Kano M, Hoshi N, Watanabe K, Satoh E, Nakayama B, Suzuki T. An electrochemotherapy model for rat tongue carcinoma. *J Oral Pathol Med* 1998; 27:249-254.

43. Jaroszeski MJ, Gilbert R, Perrott R, Heller R. Enhanced effects of multiple treatment electrochemotherapy. *Melanoma Res* Dec. 1996; 6:427-433.
44. Heller R, Jaroszeski M, Perrott R, Messina J, Gilbert R. Effective treatment of B16 melanoma by direct delivery of bleomycin using electrochemotherapy. *Melanoma Res* 1997; 7:10-18.
45. Serša G, Čemažar M, Miklavčič D. Antitumor effectiveness of electrochemotherapy with cisdiamminedichloroplatinum(II) in mice. *Cancer Res* 1995; 55:3450-3455.
46. Mashiba H, Ozaki Y, Ikuno S, Matsunaga K. Augmentation of antiproliferative and antitumor effect on human cancer cells in combined use of electroporation with a plant toxin, saporin. *Cancer Biother Radiopharm* 2001; 16: 495-499.
47. Dev SB, Nanda GS, An Z, Wang X, Hoffman RM, Hofmann GA. Effective electroporation therapy of human pancreatic tumors implanted in nude mice. *Drug Deliv* 1997; 4:293- 299.
48. Nanda GS, Sun FX, Hofmann GA, Hoffman RM, Dev SB. Electroporation enhances therapeutic efficacy of anticancer drugs: treatment of human pancreatic tumor in animal model. *Anticancer Res* 1998; 18:1361-1366.
49. Jaroszeski MJ, Coppola D, Nesmith G, Heller L, Gilbert R, Pottinger C, Dang V, Hickey J, Heller R. Electrically mediated delivery of bleomycin for the treatment of rat hepatomas and hamster pancreatic adenocarcinoma. *Proc Am Assoc Cancer Res* 1999; 40:582.
50. Okino M, Esato K. The effects of a single high voltage electrical stimulation with an anticancer drug on in vivo growing malignant tumors. *Jpn J Surg* 1990; 20:197-204.
51. Okino M, Tomie H, Kanesada H, Marumoto M, Esato K, Suzuki H. Optimal electric conditions in electrical impulse chemotherapy. *Jpn J Cancer Res* 1992; 83:1095-1101.
52. Ramirez LH, Orłowski S, An D, Bindoula G, Dzodic R, Ardouin R, Bognel Cr, Belehradec J Jr, Munck J, Mir LM. Electrochemotherapy on liver tumors in rabbits. *Br J Cancer* 1998; 77:2104-2111.
53. Jaroszeski MJ, Gilbert RA, Heller R. In vivo antitumor

effects of electrochemotherapy in a hepatoma model. *Biochim Biophys Acta* 1997; 1334:15-18.

54. Jaroszeski MJ, Coppola D, Pottinger C, Benson K, Gilbert RA, Heller R. Treatment of hepatocellular carcinoma in a rat model using electrochemotherapy. *Eur J Cancer* 2001; 37:422-430.

55. Baba M, Iishi H, Tatsuta M. In vivo electroporetic transfer of bcl-2 antisense oligonucleotide inhibits the development of hepatocellular carcinoma in rats. *Int J Cancer* 2000; 85:260-266.

56. Chazal M, Benchinol D, Baque P, Pierrefite V, Milano G, Bourgeon A. Treatment of hepatic metastases of colorectal cancer by electrochemotherapy: an experimental study in the rat. *Surgery* 1998; 124:536-540.

57. Nanda GS, Merlock RA, Hofmann GA, Dev SB. A novel and effective therapy for prostate cancer. *Proc Am Assoc Cancer Res* 1998; 39:472.

58. Horikoshi T, Naganuma H, Ohashi Y, Ueno T, Nukui H. Enhancing effect of electric stimulation on cytotoxicity of anticancer agents against rat and human glioma cells. *Brain Res Bull* 2000; 51:371-378.

59. Salford LG, Persson BR, Brun A, Ceberg CP, Kongstad PC, Mir LM. A new brain tumour therapy combining bleomycin with in vivo electropermeabilization. *Biochem Biophys Res Commun* Jul 1993; 194(30):938-943.

60. Nanda GS, Merlock RA, Hofmann GA, Dev SB. Membrane permeabilization of MCF-7 cells by electrical pulses enhances cytotoxicity of anticancer drugs. *Proc Am Assoc Cancer Res* 1997; 38:260.

61. Belehradec JJ, Orłowski S, Poddevin B, Paoletti C, Mir LM. Electrochemotherapy of spontaneous mammary tumors in mice. *Eur J Cancer* 1991; 27:73-76.

62. Kambe M, Arita D, Kikuchi H, Funato T, Tezuka F, Gamo M, Murakawa Y, Kanamaru R. Enhancing the effect of anticancer drugs against the colorectal cancer cell line with electroporation. *Tohoku J Exp Med* 1990; 180: 161.

63. Kuriyama S, Kikukawa M, Mitoro A, Tsujinoue H, Nakatani T, Yamazaki M, Yoshiji H, Toyokawa Y, Yoshikawa M, Fukui H. Antitumor effect of electrochemotherapy on colorectal carcinoma in an orthotopic mouse model. *Int J Oncol* 1999;

14:321-326.

64. Kuriyama S, Matsumoto M, Mitoro A, Tsujinoue H, Nakatani T, Fukui H, Tsujii T. Electrochemotherapy for colorectal cancer with commonly used chemotherapeutic agents in a mouse model. *Dig Dis Sci* 2000; 45: 1568-1577.

65. Tada T, Matsumoto K, Suzuki H. Electrochemotherapy significantly inhibits the growth of colon 26 tumors in mice. *Surg Today* 1997; 27:506-510.

66. Kuriyama S, Matsumoto M, Mitoro A, Tsujinoue H, Toyokawa Y, Nakatani T, Yamazaki M, Okamoto S, Fukui H. Electrochemotherapy against colorectal carcinoma: comparison of in vitro cytotoxicity of 5-fluorouracil, cisplatin and bleomycin. *Int J Oncol* 1999; 15:89- 94.

67. Kuriyama S, Mitoro A, Tsujinoue H, Toyokawa Y, Nakatani T, Yoshiji H, Tsujimoto T, Okuda H, Nagao S, Fukui H. Electrochemotherapy can eradicate established colorectal carcinoma and leaves a systemic protective memory in mice. *Int J Oncol* 2000; 16:979-985.

68. Ogihara M, Yamaguchi O. Potentiation of effects of anticancer agents by local electric pulses in murine bladder cancer. *Urol Res* 2000; 28:391-397.

69. Yamaguchi O, Irisawa C, Baba K, Ogihara M, Yokota T, Shiraiwa Y. Potentiation of antitumor effect of bleomycin by local electric pulses in mouse bladder tumor. *Tohoku J Exp Med* 1994; 172:291-293.

70. Gehl J, Skovsgaard T, Mir LM. Enhancement of cytotoxicity by electropermeabilization: an improved method for screening drugs. *Anticancer Drugs* 1998; 9:319-325.

71. Hofmann GA, Dev SB, Nanda GS. Electrochemotherapy: transition from laboratory to the clinic. *IEEE Eng Med Biol* 1996; 15:124-132.

72. Orłowski S, An D, Belehradec J Jr, Mir LM. Antimetastatic effects of electrochemotherapy and of histoincompatible interleukin-2-secreting cells in the murine Lewis lung tumor. *Anticancer Drugs* 1998; 9: 551-556.

73. Kanesada H. Anticancer effect of high voltage pulses combined with concentration dependent anticancer drugs on Lewis lung carcinoma, in vivo. *J Jpn Cancer Ther* 1990; 25:2640-2648.

74. Yabushita H, Yoshikawa K, Hirata M, Furuya H, Hojyoh T, Fukatsu H, Noguchi M, Nakanishi M. Effects of electrochemotherapy on CaSki cells derived from a cervical squamous cell carcinoma. *Gynecol Oncol* 1997; 65: 297-303.
75. Horiuchi A, Nikaido T, Mitsushita J, Toki T, Konishi I, Fujii S. Enhancement of antitumor effect of bleomycin by low-voltage in vivo electroporation: a study of human uterine leiomyosarcomas in nude mice. *Int J Cancer* 2000; 88:640-644.
76. Hyacinthe M, Jaroszeski MJ, Dang WV, Coppola D, Karl RC, Gilbert RA, Heller R. Electrically enhanced drug delivery for the treatment of soft tissue sarcoma. *Cancer* 1999; 85:409-417.
77. Engstrom PE, Ivarsson K, Tranberg KG, Stenram U, Salford LG, Persson BR. Electrically mediated drug delivery for treatment of an adenocarcinoma transplanted into rat liver. *Anticancer Res* 2001; 21:1817-1822.
78. Čemažar M, Parkins CS, Holder AL, Kranjc S, Chaplin DJ, Serša G. Cytotoxicity of bioreductive drug tirapazamine is increased by application of electric pulses in SA-1 tumours in mice. *Anticancer Res* 2001; 21: 1151-1156.
79. Crooke ST, Bradner WT. Bleomycin, a review. *J Med* 1976; 7:333-428.
80. Twentyman PR. Bleomycin-mode of action with particular reference to the cell cycle. *Pharmacol Ther* 1983; 23: 417-441.
81. Povirk LF, Austin MJ. Genotoxicity of bleomycin. *Mutat Res* 1991; 257:127-143.
82. Tounekti O, Kenani A, Foray N, Orłowski S, Mir LM. The ratio of single- to double-strand DNA breaks and their absolute values determine cell death pathway. *Br J Cancer* 2001; 84:1272-1279.
83. Chang X, Wang J, Shan C. Pingyangmycin (bleomycin A5)-mediated electrochemotherapy for human prostate cancer cell line PC-3M in athymic mice. *Chinese J Exp Surgery* 1999; 16:510.
84. Jain RK. Barriers to drug delivery in solid tumors. *Sci Am* 1994; 271:58-65.
85. Heller R, Jaroszeski MJ, Glass LF, Messina JL, Rapaport

DP, DeConti RC, Fenske NA, Gilbert RA, Mir LM, Reintgen DS. Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy. *Cancer* 1996; 77:964-971.

86. Glass LF, Pepine ML, Fenske NA, Jaroszeski M, Reintgen DS, Heller R. Bleomycin-mediated electrochemotherapy of metastatic melanoma. *Arch Dermatol* 1996; 132:1353-1357.

87. Heller R, Jaroszeski MJ, Reintgen DS, Puleo CA, DeConti RC, Gilbert RA, Glass LF. Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. *Cancer* 1998; 83:148-157.

88. Reintgen DS, Jaroszeski MJ, Heller R. Electrochemotherapy, a novel approach to cancer. *Skin Cancer Found J* 1996; 14:17-19.

89. Serša G, Štabuc B, Čemažar M, Miklavčič D, Rudolf Z. Electrochemotherapy with cisplatin: clinical experience in malignant melanoma patients. *Clin Cancer Res* 2000; 6:863-867.

90. Yu NY, Orenberg EK, Luck EE, Brown DM. Antitumor effect of intratumoral administration of fluorouracil/ epinephrine injectable gel in C3H mice. *Cancer Chemother Pharmacol* 1995; 36:27-34.

91. Rabussay DP, Nanda GS, Goldfarb PM. Enhancing the effectiveness of drug-based cancer therapy by electroporation (electropermeabilization). *Tech Cancer Res Treat* 2002; 1:71-81.

92. Rols M-P, Bachaud J-M, Giraud P, Chevreau C, Roché H, Teissié J. Electrochemotherapy of cutaneous metastases in malignant melanoma. *Melanoma Res* 2000; 10:468-474.

93. sikić BI. Bleomycin. In: Droz JP, Cvitkovic E, Armand JP, Khoury S, eds. *Handbook of Chemotherapy in Clinical Oncology*, 1998:143-146.

94. Panje WR, Hier MP, Garman GR, Harrell E, Goldman A, Bloch I. Electroporation therapy of head and neck cancer. *Ann Otol Rhinol Laryngol* 1998; 779-785.

95. Frölich M, Henke E, Gens J, Seela W, Franke WG. Evaluation of intratumoral bleomycin application in a tumor model and in a clinical pilot study. *Deutsche Zeitschrift für Mund, Kiefer und Gesicht-chirurgie* 1990; 14: 456-462.

96. Ceberg CP, Brun A, Mir LM, Persson BRR, Salford LG. Enhanced boron uptake in RG 2 rat gliomas by electroporation in vivo—a new possibility in boron neutron capture therapy. *Anticancer Drugs* 1994; 5: 463-466.
97. Čemažar M, Skrk J, Mitrovic B, Serša G. Changed delivery of boron to tumours using electroporation for boron neutron capture therapy with BSH. *Br J Radiol* 2000; 73:195-200.
98. Engstrom PE, Jonsson AC, Persson BRR, Strand S, Salford LG. Enhanced cellular uptake of radiopharmaceuticals with electroporation. Application with ¹¹¹In-oxine. *Tumor Target* 1996; 2:251-258.
99. Belehradek M, Orlowski S, Ramirez LH, Pron G, Poddevin B, Mir LM. Electroporation of cells in tissues assessed by the qualitative and quantitative electroloading of bleomycin. *Biochim Biophys Acta* 1994; 1190:155-163.
100. Rabussay D, Dev ND, Fewell J, Smith LC, Widera G, Zhang L. Enhancement of therapeutic drug and DNA delivery into cells by electroporation. *J Phys D* 2003; 36:348-363.
101. Čemažar M, Miklavčič D, Mir LM, Belehradek J Jr, Bonnay M, Fourcault D, Serša G. Electrochemotherapy of tumours resistant to cisplatin: a study in a murine tumour model. *Eur J Cancer* 2001; 37:1166-1172.
102. Belehradek M, Domenge C, Luboinski B, Orlowski S, Belehradek J Jr, Mir LM. Electrochemotherapy, a new antitumor treatment. *Cancer* 1993; 72:3694-3700.
103. Serša G, Čemažar M, Semrov D, Miklavčič D. Changing electrode orientation improves the efficacy of electrochemotherapy of solid tumors in mice. *Bioelectrochem Bioenerget* 1996; 39:61-66.
104. Gilbert RA, Jaroszeski MJ, Heller R. Novel electrode designs for electrochemotherapy. *Biochim Biophys Acta* 1997; 1334:9-14.
105. Gehl J, Skovsgaard T, Nielsen SL, Mir LM. Electroporation of muscle tissue in vivo in mice: sensitivity investigated by uptake of ⁵¹Cr-EDTA. *Proc Am Assoc Cancer Res* 1997; 38:260.
106. Glass LF, Fenske NA, Jaroszeski M, Perrott R, Harvey DT, Reintgen DS, Heller R. Bleomycin-mediated electrochemotherapy of basal cell carcinoma. *J Am Acad*

Dermatol 1996; 34:82-86.

107. Rodríguez-Cuevas S, Barroscó-Bravo S, Almanza-Estrada J, Cristobal-Martínez L, Gonzalez-Rodríguez E.

Electrochemotherapy in primary and metastatic skin tumors: phase II trial using intralesional bleomycin. Arch Med Res 2001; 32:273-276.

108. Panje WR, Sadeghi N. Endoscopic and electroporation therapy of paranasal sinus tumors. Am J Rhinol 2000; 14: 187-191.

109. Allegretti JP, Panje WR. Electroporation therapy for head and neck cancer including carotid artery involvement. Laryngoscope 2001; 111:52-56.

110. Goldfarb P, Biel M, Hanna E, Houck J, Klotch D, Nathan CO, Panje W, Robbins T, Shaw G, El-Sayed S, Hier M, Jones V, Nasser J, Rice. A phase II study using electroporation (EPT) and intratumoral bleomycin in patient with recurrent head and neck cancer: a safe and active treatment approach. Proceedings of ASCO 1999; 18:39a.

111. Goldfarb P, Biel M, El-Sayed S, Hanna E, Hier M, Houck J, Klotch D, Nathan CO, Panje W, Robbins T, Shaw G, Jones V, Nasser J, Rice D, Vieira F. Treatment of recurrent head and neck cancer utilizing electroporation with intralesional bleomycin: long term results. Proceedings of ASCO 2002; 21:183b.

112. Burian M, Formanek M, Regele H Acta Otolaryngol 2003; 123:264-268.

113. Glass LF, Jaroszeski M, Gilbert R, Reintgen DS, Heller R. Intralesional bleomycin-mediated electrochemotherapy in 20 patients with basal cell carcinoma. J Am Acad Dermatol 1997; 37:596-599.

114. Gehl J, Geertsen PF. Efficient palliation of haemorrhaging malignant melanoma skin metastases by electrochemotherapy. Melanoma Res 2000; 10:585-589.

115. Kubuota Y, Mir LM, Nakada T, Sasagawa I, Suzuki H, Aoyama N. Successful treatment of metastatic skin lesions with electrochemotherapy. J Urol 1998; 160:1426.

116. Domenge C, Orłowski S, Luboinski B, De Baere T, Schwaab G, Belehradek J Jr, Mir LM. Antitumor Electrochemotherapy. Cancer 1996; 77:956-963.

117. Rudolf Z, Štabuc B, Čemažar M, Miklavčič D, Vodovnik L, Serša G. Electrochemotherapy with bleomycin. The first clinical experience in malignant melanoma patients. *Radiat Oncol* 1995; 29:229-235.
118. Giraud P, Bachaud J-M, Teissié J, Rols M-P. Effects of electrochemotherapy on cutaneous metastases of human malignant melanoma (correspondence). *Int J Radiation Oncology Biol Phys* 1996; 36:1285.
119. Serša G, Čufer T, Čemažar M, Reberšek M, Rudolf Z. Electrochemotherapy with bleomycin in the treatment of hypernephroma metastasis: case report and literature review. *Tumori* 2000; 86:163-165.
120. Serša G, Štabuc B, Čemažar M, , , Rudolf Z. Electrochemotherapy with cisplatin: potentiation of local cisplatin antitumour effectiveness by application of electric pulses in cancer patients. *Eur J Cancer* 1998; 34:1213-1218.
121. Serša G, Štabuc B, Čemažar M, Miklavčič D, Rudolf Z. Electrochemotherapy with cisplatin: the systemic antitumour effectiveness of cisplatin can be potentiated locally by the application of electric pulses in the treatment of malignant melanoma skin metastases. *Melanoma Res* 2000; 10:381-385.
122. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. *N Engl J Med* 2001; 345:1890-1900.
123. Serša G. Electro-chemotherapy. Animal model work review. *Methods Mol Med* 2000; 37:119- 136.
124. Nanda GS, Rabussay D. Safety of head and neck tumor treatment by electroporation therapy: effect on healthy tissues. In: Varma AK, Roodenburg JLN, eds. *Oral Oncology*. Delhi: Macmillan India Ltd, 2001:326-331.
125. Tounekti O, Belehradek J Jr, Mir LM. Relationships between DNA fragmentation, chromatin condensation, and changes in flow cytometry profiles detected during apoptosis. *Exp Cell Res* 1995; 217:506-516.
126. Serša G, Čemažar M, Miklavčič D, Chaplin DJ. Tumor blood flow modifying effect of electrochemotherapy with bleomycin. *Anticancer Res* 1999; 19:4017-4022.
127. Serša G, Čemažar M, Parkins CS, Chaplin DJ. Tumour blood flow changes induced by application of electric

pulses. *Eur J Cancer* 1999; 35:672-677.

128. Gehl J, Skovsgaard T, Mir LM. Vascular reactions to in vivo electroporation: characterization and consequences for drug and gene delivery. *Biochim Biophys Acta* 2002; 1569:51-58.

129. Čemažar M, Parkins CS, Holder AL, Chaplin DJ, Tozer GM, Serša G. Electroporation of human microvascular endothelial cells: evidence for an anti-vascular mechanism of electrochemotherapy. *Br J Cancer* 2001; 84: 565-570.

130. Engstrom PE, Persson BR, Brun A, Salford LG. A new antitumour treatment combining radiation and electric pulses. *Anticancer Res* 2001; 21:1809-1815.

131. Voznesenskii AI, Galanova YV, Archakov AI. Covalent binding of bleomycin to concanavalin A and immunoglobulin G enhances the ability of the bleomycin-Fe(II) complex to destroy the erythrocyte membrane. *Biomed Sci* 1991; 2:147-150.

132. Sauer H, Putz V, Fischer K, Hescheler J, Wartenberg M. Increased doxorubicin uptake and toxicity in multicellular tumour spheroids treated with DC electrical fields. *Br J Cancer* 1999; 80:1204-1213.

133. Ortiz LA, Lasky J, Hamilton RF Jr, Holian A, Hoyle GW, Banks W, Peschon JJ, Brody AR, Lungarella G, Friedman M. Expression of TNF and the necessity of TNF receptors in bleomycin-induced lung injury in mice. *Exp Lung Res* 1998; 24:721-743.

134. Micallef M. Immunoregulatory cytokine production by tumor-bearing rat spleen cells and its modulation by bleomycin. *Anticancer Drugs* 1993; 4:213-222.

135. Nelson WG, Kastan MB. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. *Mol Cell Biol* 1994; 14:1815-1823.

136. Mendiratta SK, Thai G, Eslahi NK, Thull NM, Matar M, Bronte V, Pericle F. Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2. *Cancer Res* 2001; 61:859-863.

137. Nanda GS, Dev SB, Bleecher S, Rabussay D. A novel treatment modality for head and neck tumors. 8th International Conference on Differentiation Therapy, Montreal, Canada, October 1999, p. 61, Abstract No. 75.

138. Jaroszeski MJ, Coppola D, Nesmith G, Pottinger C, Hyacinthe M, Benson K, Gilbert R, Heller R. Effects of electrochemotherapy with bleomycin on normal liver tissue in a rat model. *Eur J Cancer* 2001; 37:414-421.
139. Mir LM, Roth C, Orlowski S, Quintin-Colonna F, Fradelizi D, Belehradec J Jr, Kourilsky P. Systemic antitumor effects of electrochemotherapy combined with histoincompatible cells secreting interleukin-2. *J Immunother Emphasis Tumor Immunol* 1995; 17:30-38.
140. Serša G, Čemažar M, Menart V, Gaberc-Porekar V, Miklavčič D. Anti-tumor effectiveness of electrochemotherapy with bleomycin is increased by TNF- α on SA-1 tumors in mice. *Cancer Lett* 1997; 116: 85-92.
141. Serša G, Kranjc, Čemažar M. Improvement of combined modality therapy with cisplatin and radiation using electroporation of tumors. *Int J Radiat Oncol Biol Phys* 2000; 46:1037-1041.
142. Mouneimne Y, Tose PF, Barhouni R, Nicolau C. Electroinsertion of full length recombinant CD4 into red blood cell membrane. *Biochim Biophys Acta* 1990; 272:53-58.
143. Zeira M, Tose PF, Mouneimne Y, Lazarte J, Sneed L, Volsky DJ, Nicolau C. Full-length CD4 electroinserted in the erythrocyte membrane as a long-lived inhibitor of infection by human immunodeficiency virus. *Proc Natl Acad Sci USA* 1991; 88:4409-4413.
144. Hollinger FB, Mouneimne Y, Lahart C, Tose PF, Dimitrov D, Nicolau C. Life span of circulating membrane CD4 inserted into the plasma membranes of autologous red blood cells of HIV-infected subjects. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 1995; 9:126-132.
145. Raffy S, Teissie J. Surface charge control of electroporation and glycoprotein electroinsertion with 1,2diacyl-sn-glycero-3-phosphocholine (lecithin) liposomes. *Eur J Biochem* 1997; 250:315-319.
146. Raffy S, Teissie J. Electroinsertion of glycoprotein A in interdigitation fusion giant unicellular lipid vesicles. *J Biol Chem* 1997; 272:25524-25530.
147. El Ougari K, Teissie J, Benoist H. Glycoprotein A protects K562 cells from natural killer cell attack. *Role*

of angiogenesis. *J Biol Chem* 1995; 270:26970-26975.

148. Mounneimne Y, Barhoumi R, Myers T, Slogoff S, Nicolau C. Stable rightward shifts of the oxyhemoglobin dissociation curve induced by encapsulation of inositol hexaphosphate in red blood cells using electroporation. *FEBS Lett* 1990; 275:117-120.

149. Ogata Y, Goto H, Sakaguchi K, Suzuki M, Ohsaki K, Suzuki K, Saniabadi AR, Kamitani T, Takahashi A. Characteristics of neo red cells, their function and safety: in vivo studies. *Artif Cells Blood Substit Immobil Biotechnol* 1994; 22:875-881.

150. Crawford N, Chronos N. Electro-encapsulating drugs within blood platelets: local delivery to injured carotid arteries during angioplasty. *Semin Interv Cardiol* 1996; 1:91-102.

151. Banning A, Brewer L, Wendt M, Groves PH, Cheadle H, Penny WJ, Crawford N. Local delivery of platelets with encapsulated iloprost to balloon injured pig carotid arteries: effect on platelet deposition and neointima formation. *Thromb Haemost* 1997; 7:190-196.

152. Sakamoto T, Oshima Y, Sakamoto M, Kawano YI, Ishibashi T, Inomata HH, Ohnishi Y. Electroporation and bleomycin in glaucoma-filtering surgery. *Invest Ophthalmol Vis Sci* 1997; 38:2864-2868.

153. Oshima Y, Sakamoto T, Nakamura T, Tahara Y, Goto Y, Ishibashi T, Inomata H. The comparative benefits of glaucoma filtering surgery with an electric-pulse targeted drug delivery system demonstrated in an animal model. *Ophthalmol* 1999; 106:1140-1146.

154. Oshima Y, Sakamoto T, Hisatomi T, Tsutsumi C, Sassa Y, Ishibashi T, Inomata H. Targeted gene transfer to corneal stroma in vivo by electric pulses. *Exp Eye Res* 2002; 74:191-198.

155. Blair-Parks K, Weston BC, Dean DA. High-level gene transfer to the cornea using electroporation. *J Gene Med* 2002; 4:92-100.

156. Oshima Y, Sakamoto T, Yamanaka I, Nishi T, Ishibashi T, Inomata H. Targeted gene transfer to corneal endothelium in vivo by electric pulse. *Gene Ther* 1998; 5:1347-1354.

157. Yokoyama A, Oshitari T, Negishi H, Dezawa M, Mizota A,

Adachi-Usami E. Protection of retinal ganglion cells from ischemia-reperfusion injury by electrically applied Hsp27. *Invest Ophthalmol Vis Sci* 2001; 42:3283-3286.

158. Dezawa M, Takano M, Negishi H, Mo X, Oshitari T, Sawada H. Gene transfer into retinal ganglion cells by in vivo electroporation: a new approach. *Micron* 2002; 33:1-6.

159. Dev SB, Rabussay D, Widera G, Hofmann GA. Medical applications of electroporation. *IEEE* 2000; 28: 206-223.

160. Dev NB, Preminger TJ, Hofmann GA, Dev SB. Sustained local delivery of heparin to the rabbit arterial wall with an electroporation catheter. *Cathet Cardiovasc Diagn* 1998; 45:337-345.

161. Dev NB, Hofmann GA, Dev SB, Rabussay D. Intravascular electroporation markedly attenuates neointima formation after balloon injury of the carotid artery in the rat. *J Intervent Cardiol* 2000; 13:331-338.

162. Dev SB, Giordano FJ, Brown DL. In vivo delivery of gene to rabbit carotid artery by electroporation. *Proceedings of the US Third and Japan Symposium on Drug Delivery Systems, Maui, Hawaii, Dec 17-22, 1995.*

163. Martin JB, Young JL, Benoit JN, Dean DA. Gene transfer to intact mesenteric arteries by electroporation. *J Vasc Res* 2000; 37:372-380.

164. Kupfer JM, Ruan XM, Liu G, Matloff J, Forrester J, Chaux A. High-efficiency gene transfer to autologous rabbit jugular vein grafts using adenovirus-transferrin/polylysine-DNA complexes. *Hum Gene Ther* 1994; 5: 1437-1443.

165. Wang Y, Bai Y, Price C, Boros P, Qin L, Bielinska AU, Kukowska-Latallo JF, Baker JR Jr, Bromberg JS. Combination of electroporation and DNA/dendrimer complexes enhances gene transfer into murine cardiac transplants. *Am J Transplant* 2001; 1:334-338.

166. Oshima K, Sen L, Cui G, Tung T, Sacks BM, Arellano-Kruse A, Laks H. Localized interleukin-10 gene transfer induces apoptosis of alloreactive T cells via FAS/FASL pathway, improves function, and prolongs survival of cardiac allograft. *Transplantation* 2002; 73:1019- 1026.

167. Mozes G, Mohacsi T, Gloviczki P, Menawat S, Kullo I, Spector D, Taylor J, Crotty TB, O'Brien T.

Adenovirus-mediated gene transfer of macrophage colony stimulating factor to the arterial wall in vivo. *Arterioscler Thromb Vasc Biol* 1998; 18:1157-1163.

168. Prausnitz MR, Bose VG, Langer R, Weaver JC. Electroporation of mammalian skin: a mechanism to enhance transdermal drug delivery. *Proc Natl Acad Sci USA* 1993; 15:10504- 10508.

169. Banga AK. Electrically assisted transdermal and topical drug delivery. Bristol, PA and London, UK: Taylor & Francis, 1998.

170. Bose S, Ravis WR, Lin YJ, Zhang L, Hofmann GA, Banga AK. Electrically-assisted transdermal delivery of buprenorphine. *J Control Release* 2001; 73:197-203.

171. Zhang L, Lerner S, Rustrum WV, Hofmann GA. Electroporation-mediated topical delivery of vitamin C for cosmetic applications. *Bioelectrochem Bioenerg* 1999; 48:453-461.

172. Sen A, Zhao Y, Zhang L, Hui SW. Enhanced transdermal transport by electroporation using anionic lipids. *J Control Release* 2002; 82:399-405.

173. Wallace MS, Ridgeway B, Jun E, Schulteis G, Rabussay D, Zhang L. Topical delivery of lidocaine in healthy volunteers by electroporation, electroincorporation, or iontophoresis: an evaluation of skin anesthesia. *Reg Anesth Pain Med* 2001; 26:229-238.

174. Chang SL, Hofmann GA, Zhang L, Deftos LJ, Banga AK. The effect of electroporation on iontophoretic transdermal delivery of calcium regulating hormones. *J Control Release* 2000; 66:127-133.

175. Zhang L, Nolan E, Kreitschitz S, Rabussay DP. Enhanced delivery of naked DNA to the skin by non-invasive in vivo electroporation. *Biochim Biophys Acta* 2002; 1572:1-9.

176. McKinlay JB. The worldwide prevalence and epidemiology of erectile dysfunction. *Int J Impot Res* 2000; 12:S6-S11.

177. Zhang L, Azadzoi K, Chang SL, Banga AK, Hofmann GA, Rabussay DP, Goldstein I. Potential noninvasive approach to ameliorate male erectile dysfunction by electroporation: a feasibility evaluation in vitro, in rabbit, in human subjects [abstr], *Int J Impot Res* 2000; 13(suppl 1):S17.

178. Zhang L, Rabussay DP. Clinical evaluation of safety and human tolerance of electrical sensation induced by electric fields with noninvasive electrodes. *Bioelectrochem* 2002; 56:233-236.
179. Magee TR, Ferrini M, Garban HJ, Vernet D, Mitani K, Rajfer J, Gonzales-Cadavid NF. Gene therapy of erectile dysfunction in the rat with penile neuronal nitric oxide synthase. *Biol Reprod* 2002; 67:20-28.
180. Sokol DL, Gewirtz AM. Gene therapy: basic concepts and recent advances. *Crit Rev Eukaryot Gene Expr* 1996; 6:29-57.
181. Gottschalk U, Chan S. Somatic gene therapy. Present situation and future perspective. *Arzneimittelforschung* 1998; 48(11):1111-1120.
182. Knoell DL, Yim IM. Human gene therapy for hereditary diseases: a review of trials. *Am J Health Syst Pharm* 1998; 55:899-904.
183. DeMatteo RP, Yeh H, Friscia M, Caparrelli D, Burke C, Desai N, Chu G, Markmann JF, Raper SE, Barker CF. Cellular immunity delimits adenoviral gene therapy strategies for the treatment of neoplastic diseases. *Ann Surg Oncol* 1999; 6:88-94.
184. Muruve DA, Barnes MJ, Stillman IE, Libermann TA. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. *Hum Gene Ther* 1999; 10:965-976.
185. Muramatsu T, Nakamura A, Park HM. In vivo electroporation: a powerful and convenient means of non viral gene transfer to tissues of living animals. *Intl J Mol Med* 1998; 1:55-62.
186. Ahira H, Miyazaki J. Gene transfer into muscle by electroporation. *Nat Biotechnol* 1998; 16:867-870.
187. Mathiesen I. Electroporation of skeletal muscle enhances gene transfer in vivo. *Gene Ther* 1999; 6: 508-514.
188. Mir LM, Bureau MF, Gehl J, Rangara R, Rouy D, Caillaud JM, Delaere P, Branellec D, Schwartz B, Scherman D. High efficiency gene transfer into skeletal muscle by electric pulses. *PNAS (USA)* 1999; 96:4262-4267.
189. Srivastava I, Kam E, Sun Y, Stamatatos L, Montefiori

S, Otten G, O'Hagen D, Sing M, Donnelly JJ, Ulmer J, Barnett S. Enhanced neutralizing antibody responses induced in rhesus macaques by 0-gp 140DV2 SF162 in a prime-boost regimen. Abstract 306-W presented at The Ninth Conference on Retroviruses and Opportunistic Infections. Seattle, WA, 2002.

190. Babiuk S, Baca-Estrada ME, Foldvari M, Storms M, Rabussay D, Widera G, Babiuk LA. Electroporation improves the efficacy of DNA vaccines in large animals. *Vaccine* 2002; 20: 3399-3408.

191. Keating A, Nolan E, Filshie R, Dev SB. In: Jaroszeski MJ, Heller R, Gilbert R, eds. *Methods in Molecular Medicine*. Totowa, N.J.: Humana, 2000:359-368.

192. Keating A, Berkahn L, Filshie R. A phase I study of the transplantation of genetically marked autologous bone marrow stromal cells. *Hum Gene Ther* 1998; 9:591-600.

193. Roth DA, Tawa NE Jr, O'Brien JM, Treco DA, Selden RF. Factor VIII transkaryotic therapy study group. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe A hemophilia. *N Engl J Med* 2001; 344:1735-1742.

194. Black KL, Fahkrai H. A phase I study of the safety of injecting malignant glioma patients with irradiated TGF-beta-2 antisense gene modified autologous tumor cells. 1995; 138.

195. Fahkrai H, Gutheil JC. A phase II study of antisense TGF-beta +/- IL-2 gene transfected allogeneic tumor cells as a vaccine in patients with stage IIIIB and IV non-small cell lung cancer. 1999:331.

196. Fahkrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, Royston I, Sobol RE. Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. *Proc Natl Acad Sci USA* 1996; 93:2909-2914.

197. Liao LM, Fahkrai H, Black KL. Prolonged survival of rats with intracranial C6 gliomas by treatment with TGFbeta antisense gene. *Neurol Res* 1998; 20:742-747.

198. Tang DC, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. *Nature* 1992; 356:152-154.

199. Widera G, Austin M, Rabussay D, Goldbeck C, Barnett SW, Chen M, Leung L, Ottern GR, Thudium K, Selby M, Ulmer JB. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. *J Immunol* 2000; 164:4635-4640.

200. Tollefsen S, Tjelle T, Schneider J, Harboe M, Wiker H, Hewinson G, Huygen K, Mathiesen I. Improved cellular and humoral immune responses against *Mycobacterium tuberculosis* antigens after intramuscular DNA immunisation combined with muscle electroporation. *Vaccine* 2002; 20:3370-3378.

201. Drabick JJ, Glasspool-Malone J, King A, Malone RW. Cutaneous transfection and immune responses to intradermal nucleic acid vaccination are significantly enhanced by in vivo electroporation. *Mol Ther* 2001; 3:249-255.

42 The Paradigm of Biologically Closed Electric Circuits and Its Clinical Applications

1. Curé J. On the identity of Einstein's cosmic ether. Proceeding of the International Congress celebrated in Perugia University, Italy, September 1989.
2. Einstein A. The Meaning of Relativity. Princeton University Press, 1955:82.
3. Erohkin NS. Electromagnetic field as part of matter in problems of charge neutralization. Cambridge: Proceedings PIERS, Mass, 1991:475.
4. Nordenström BEW, Ipavec S, Alfas S. Interferences between electromagnetic field and biological matter—the concept of BCEC. *Int J Environ Stud* 1992; 42:157-167.
5. Nordenström BEW. Biologically closed electric circuits: clinical, experimental and theoretical evidence for an additional circulatory system. Stockholm: Nordic Medical Publications, 1983.
6. Nordenström BEW. An additional circulatory system: vascular-interstitial closed electric circuits. *J Biol Phys* 1987; 15:43-55.
7. Nordenström BEW. Link between electromagnetic field and biological matter. *Int J Environ Stud* 1992; 41: 233-250.
8. Nordenström BEW. Hand movements above the unshielded tail of a shielded rat induce differences of voltage inside the animal. *Am J Acupuncture* 1992; 20:159-163.
9. Nordenström BEW. Fleischner lecture. Biokinetic impact on structure and imaging of the lung: the concept of biologically closed electric circuits. *AJR* 1985; 145:447-467.
10. Nordenström BEW. Vesicles, basement membranes and the endothelial fibrin film as possible products of biological electrode reactions. In: Eckert GH, Gutmann F, Keyzer H, eds. *Electropharmacology*. Boca Raton, Boston: CRC Press, 1990:189-203.
11. Nordenström BEW, Kinn A-C, Elbarouni J. Electric modification of kidney function. The excretion of radiographic contrast media and Adriamycin. *Invest Radiol* 1991; 26:157-161.

12. Nordenström BEW. I. Neurovascular activation requires conduction through vessels. *Physiol Chem Phys Med NMR* 1989; 21:249-256.
13. Nordenström BEW, Larsson H. II. Slow and rapid electrical pulses in the caval vein at painevoked leg contraction in the rat. *Physiol Chem Phys Med NMR* 1989; 21:257-264.
14. Nordenström BEW. III. The action potential: an effect of fuel cell reactions in the synapse. *Physiol Chem Phys Med NMR* 1989; 21:265-278.
15. Nordenström BEW. Vascular-interstitial-neurovascular activation: differences in femoral and sciatic nerves in the rat. *J Bioelectr* 1989; 8:109-117.
16. Nordenström BEW. IV. Electrical pulses appear in the inferior vena cava and abdominal aorta at contraction of leg muscles. *Physiol Chem and Phys Med NMR* 1992; 24:147-152.
17. Nordenström BEW. V. Potential differences in the inferior vena cava and between cava and extravascular electrode at leg contraction in man. *Physiol Chem Phys Med NMR* 1992; 24:153- 158.
18. Nordenström BEW. VI. Synaptic fuel cell reactions in vascular-interstitial-neuromuscular activation. *ElectroMagnetobiol* 1992; 11:99-115.
19. Bockris JO'M, Drazic DM. *Electro-chemical Science*. New York: Barnes and Noble Books, 1972.
20. Weiss L. Studies on cellular adhesion in tissue culture. *Exp Cell Res* 1968; 53:608.
21. Fidler IJ. Incorporation of immunomodulators in liposomes for systemic activation of macrophages and therapy of cancer metastases. *CRS Press* 1993; 2:45-63.
22. Skou JC. The relationship of a (Mn²⁺ +Na⁺)-activated K⁺ stimulated enzyme or enzyme system to the active linked transport of Na⁺ and K⁺ across the cell membrane. In: Kleinzeller A, Kotyk A, eds. *Membrane Transport and Metabolism*. New York: Academic Press, 1961.
23. Nordenström B. The paradigm of biologically closed electric circuits (BCEC) and the formation of an

international association (IABC) for BCEC systems. Eur J Surg 1994; 574(suppl):7-23.

24. Nordenström B. Survey of mechanisms in electrochemical treatment (ECT) of cancer. Eur J Surg 1994; 574(suppl): 93-109.

25. Nordenström B. Electrostatic field interference with cellular and tissue function, leading to dissolution of metastases that enhances the effect of chemotherapy. Eur J Surg 1994; 574(suppl):121-135.

43 Electrochemical Therapy of Tumors

1. Reis A, Henninger T. Experimental study on biological response of ECT in animals. *Klin Wochenschrift* 1953; 1: 39-42.
2. Nordenström B. *Biologically Closed Electric Circuits*. Stockholm, Sweden: Nordic Medical Publications, 1983.
3. Fu Y. The experimental research of malignant tumors treated by direct current. *Mie Med Univ* 1985; 19:9.
4. Manabe T. The direct current therapy and experimental research of malignant tumors. *J Japan Cancer* 1988; 23 (3):696-699.
5. Nisiguchi I. The direct current therapy of malignant tumors. *J Japan Radiol Assoc* 1987; 47(4):621-628.
6. Ito H. The suppression effect of tumor proliferation by direct current. *J Japan Cancer Ther* 1988; 23:696-702.

Figure 2 8 weeks later, after EChT, the wound healed.

7. Nakayama T. The clinical evaluation of radioactive ray sectioning irradiation combined with direct current therapy. *J Japan Radiol Assoc* 1988; 48:1269-1273.
8. Nordenstrom BEW. Biokinetic impact on structure and imaging of the lung: The concept of biologically closed electric circuits.
9. Nordenstrom BEW. Clinical trials of electrophoretic ionization in the treatment of malignant tumors. *IRCS Med Su* 1987; 6:537.

Figure 3 In low electric quantity group (45 C for 1.0 cm diameter), survived tumor cells were found.

Figure 4 In large electric quantity group (100 C for 1.0 cm diameter), tumor cells were killed completely.

10. Nordenstrom BEW. Impact of biologically closed electric circuits (BCEC) on structure and function. *Integrative physiological and behavioral science*. 1992; 27:285-303.
11. Nordenstrom BEW. Electrochemical treatment of cancer. I. Variable response to anodic and cathodic fields. *Am J Clin Oncol (CCT)* 1989; 12:530-536; Fu Yu. The experimental research of malignant tumors treated by direct current. *Mie*

Med Univ 1985; 19:9.

12. Manabe T. The direct current therapy and experimental research of malignant tumors. J Japan Cancer 1988; 23(3):696-699.

13. Nisiguchi I. The direct current therapy of malignant tumors. J Japan Radiol Assoc 1987; 47(4):621-628.

14. Ito H. The suppression effect of tumor proliferation by direct current. J Japan Cancer 1988; 23(3):671-696.

15. Nakayama G. The clinical evaluation of radioactive ray sectioning irradiation combined with direct current therapy. J Japan Radiol Assoc 1988; 48(10): 1269-1273.

16. Xin Yuling, et al. Experimental Research of Electrochemical Therapy Mechanism. People's Health Publication, 1995.

17. Yokoyama Mi. Local tumor therapy by direct current. J Japan Cancer 1988; 23(9):2040.

18. Xin Yuling. The advancement of electrochemical therapy of tumors in China. Chinese Oncol 1993; 2(11):20-22.

19. Xin Yuling. 334 cases of malignant tumors treated with electrochemical therapy. J Cancer 1995; 10(4):258-261.

20. Xin Yuling. The clinical application of electrochemical therapy of malignant tumors. Gen Clin J 1990; 6(5): 25-28.

21. Yuling Xin. Hepatoma therapy with direct current guided by ultrasound. J of China-Japan Friendship Hospital 1989; 3(4):247-251.

22. Xin Yuling. The clinical application of electrochemical therapy of malignant tumors. J Med Theoret Exper Study 1993; 6(3):14-20.

23. Xin Yuling. The clinical effect of lung cancer by electrochemical therapy. J Cancer 1993; 12(4):318-321.

Figure 5 Coagulatory necrosis around anode.

24. Xin Yuling. Advances in the treatment of malignant tumors by electrochemical therapy. Eur J Surg 1994; 574 (suppl):31-33.

25. Xin Yuling. The analysis of the clinical effect in 211

cases in middle and later stages lung cancer treated by ECT. Chinese J Integr Trad West Med 1991; 13(3):135-139.

26. Xin Yuling. Electrostatic therapy of lung cancer and pulmonary metastasis. Eur J Surg 1994; 574(suppl):35-37.

27. Xin Yuling. Effects of radiotherapy combined with traditional Chinese medicines of large mass liver cancer. Chinese J Oncol 1992; 14(1):57-61.

28. Xin Yuling. Modern Diagnosis and Treatment of Lung Cancer. People's Health Pub, 1993.

29. Xin Yuling. Verschiedene Tumoren, die mit elektrochemischen methoden in letzten 12, Jahren therapiert wurden. Die Biologische und die Medizinische Tragodie 2002; 239-260.

Figure 6 Liquid necrosis around cathode area.

Figure 7 Experiment of ECHT on human lung cancer showed presence of tumor necrosis and much gas.

Figure 8 Experiment of ECHT on resected lung cancer to observe different biological effects of anode and cathode. It

showed that the killing effect of a cathode is stronger than an anode.

Figure 9 BK 2000 instrument of ECHT. Four outputs controlled by computer. AC 200-240 V, 50- 60 Hz, 150 W,

voltage: 0-25V±0.1V, electric current: 0-200mA±2mA, electric quantity: 0-9999 C. (The instrument is made by Prof.

Hongbin Pang.)

Figure 10 Electrodes made of platinum.

44 Cranial Electrotherapy Stimulation for Anxiety, Depression, Insomnia, Cognitive Dysfunction, and Pain

1. Appel CP. Effect of electrosleep: review of research. *Goteborg Psychol Rep* 1972; 2:1-24.
2. Brown CC. Electroanesthesia and Electrosleep. *Am Psychol* 1975; 30:402-425.
3. Taaks H, Kugler J. Electrosleep and brain function. *Electroenceph Clin Neurophysiology* 1968; 24:62-94.
4. Ryan JJ, Souheaver GT. The role of sleep in electrosleep therapy for anxiety. *Dis Nerv Syst* 1977; 38:515-517.
5. Gibson TH, O'Hair DE. Cranial application of low level transcranial electrotherapy vs. relaxation instruction in anxious patients. *Am J Electormed* 1987; 418-21.
6. England RR. Treatment of migraine headache utilizing cerebral electrostimulation. MS thesis, North Texas State University, Denton, Texas, 1976
7. Kirsch DL. *The Science Behind Cranial Electrotherapy Stimulation*. 2d ed. Edmonton, Alberta: Medical Scope Publishing, 2002.
8. Smith RB. Cranial electrotherapy stimulation. In: Myklebust JB, Cusick JF, Sances A Jr, Larson SF, eds. *Neural Stimulation*. Vol II. Boca Raton: CRC Press, 1985:130.
9. Jarzembski WB, Laarson SJ, Sances A Jr. Evaluation of specific cerebral impedance and cerebral current density. *Annals of the New York Academy of Sciences* 1970; 170:476-490.
10. Ferdjallah M, Bostick FX Jr, Barr RE. Potential and current density distributions of cranial electrotherapy stimulation (CES) in a four-concentric-spheres model. *IEEE Transactions on Biomedical Engineering* 1996; 43(9): 939-943.
11. Smith RB. Cranial electrotherapy stimulation in the treatment of stress related cognitive dysfunction, with an eighteen month follow up. *Journal of Cognitive Rehabilitation* 1999; 17:14-18.
12. Rosenthal SH, Wulfson NL. Electrosleep: a clinical

trial. *American Journal of Psychiatry* 1970; 127:175-176.

13. Smith RB, O'Neill L. Electrosleep in the management of alcoholism. *Biological Psychiatry* 1975; 10:675-680.

14. Bianco F Jr. The efficacy of cranial electrotherapy stimulation (CES) for the relief of anxiety and depression among polysubstance abusers in chemical dependency treatment. Ph.D dissertation, The University of Tulsa, Oklahoma, 1994.

15. Tomosovic M, Edwards RV. Cerebral electrotherapy for tension-related symptoms in alcoholics. *Quarterly J Studies Alcohol* 1973; 34:1352-1355.

16. Matteson MT, Ivancevich JM. An exploratory investigation of CES as an employee stress management technique. *J Health Human Res Admin* 1986; 9:93-109.

17. Wolf FM. *Meta-analysis; quantitative methods for research synthesis*. Newbury Park: Sage Publications, 1986: 51.

18. Heffernan M. The effect of a single cranial electrotherapy stimulation on multiple stress measures. *The Townsend Letter for Doctors and Patients* 1995; 147:60-64.

19. Voris MD. An investigation of the effectiveness of cranial electrotherapy stimulation in the treatment of anxiety disorders among outpatient psychiatric patients, impulse control parolees and pedophiles. Delos Mind/Body Institute, Dallas and Corpus Cristi, Texas, 1995.

20. Winick R. Cranial electrotherapy stimulation (CES): a safe and effective low cost means of anxiety control in a dental practice. *General Dentistry* 1999; 47(1):50-55.

21. O'Connor ME, Bianco F, Nicholson R. Meta-analysis of cranial electrostimulation in relation to the primary and secondary symptoms of substance withdrawal. 12th Annual Meeting of the Bioelectromagnetics Society, June 14, 1991.

22. Klawansky S, Yeung A, Berkey C, Shah N, Chalmers TC. Meta-analysis of randomized controlled trials of cranial electrotherapy stimulation: efficacy in treating selected psychological and physiological conditions. *Journal of Nervous and Mental Diseases* 1995; 183(7):478-485.

23. Gomez E, Mikhail AR. Treatment of methadone withdrawal with cerebral electrotherapy (electrosleep). *Brit J*

Psychiatry 1978; 134:111-113.

24. Schmitt R, Capo T, Frazier H, Boren D. Cranial electrotherapy stimulation treatment of cognitive brain dysfunction in chemical dependence. J Clin Psychiatry 1984; 45:60-63.

25. Gold M, Pottash ALC, Sternbach H, Barbaban J, Annitto W. Anti-withdrawal effects of alpha methyl dopa and cranial electrotherapy. 12th Annual Meeting of the Society for Neuroscience, 1982.

26. National Research Council, Division of Medical Sciences. An evaluation of electroanesthesia and electrosleep. FDA Contract 70-22, Task Order No. 20 (NTIS PB 241305), 1974; 1-54.

27. Rosenthal SH. Electrosleep therapy. Current Psychiatric Therapies 1972; 12:104-107.

28. Kratzenstein CG. Schreiben von dem Nutzen der Electricitaet in der Arzneiwissenschaft. Halle, 1745

29. Wageneder FM, Iwanovsky A, Dodge CH. Electrosleep (cerebral electrotherapy) and electroanesthesia—the international effort at evaluation. Foreign Science Bulletin 1969; 5(4): 1-104.

30. Forster S, Bernard S, Bendon JG. Preliminary observations on electrosleep. Arch Phys Med Rehabil 1963; 44: 481-489.

31. Straus B, Elkind A, Bodian CA. Electrical induction of sleep. Am J Med Sci 1964; 248:514-520.

32. Magora F, Beller A, Assael MI, Askenazi A. Some aspects of electrical sleep and its therapeutic value. In: Wageneder FM, St. Schuy, eds. Electrotherapeutic Sleep and Electroanaesthesia. Excerpta Medica Foundation, International Congress Series No. 136. Amsterdam, 1967:129-1354.

33. Moore JA, Mellor CS, Standage KF, Strong H. A double-blind study of electrosleep for anxiety and insomnia. Biol Psychiatry 1975; 10(1):59-63.

34. Lichtbroun AS, Raicer MC, Smith RB. The treatment of fibromyalgia with cranial electrotherapy stimulation. J Clin Rheumatol 2001; 7:72-78.

35. McKenzie RE, Rosenthal SH, Driessner JS. Some psychophysiological effects of electrical transcranial stimulation (electrosleep). In: Wulfsohn NL, Sances A, eds. *The Nervous System and Electric Currents*. New York: Plenum, 1976:163-167.
36. Itil T, Gannon P, Akpınar S, Hsu W. Quantitative EEG analysis of electrosleep using frequency analyzer and digital computer methods. *Electroencephalogr Clin Neurophysiol* 1971; 31:294.
37. Weiss MF. The treatment of insomnia through use of electrosleep: an EEG study. *J Nervous Mental Dis* 1973; 157:108-120.
38. Cartwright RD, Weiss MF. The effects of electrosleep on insomnia revisited. *J Nerv Ment Dis* 1975; 161(2): 134-137.
39. Smith RB. Is microcurrent stimulation effective in pain management? An additional perspective. *Am J Pain Management* 2001; 11 (2):64-68.
40. Schmitt R, Capo T, Boyd E. Cranial electrotherapy stimulation as a treatment for anxiety in chemically dependent persons. *Alcoholism: Clin Experiment Res* 1986; 10:158-160.
41. Patterson MA, Firth J, Gardiner R. Treatment of drug, alcohol and nicotine addiction by neuroelectric therapy: analysis of results over 7 years. *J Bioelectricity* 1984; 3(1, 2): 193-221.
42. Mellow NK, Mendelson JH. Alterations in states of consciousness associated with chronic ingestion of alcohol. In: Zubin J, Shagass C, eds. *Neurobiological aspects of psychopathology*. 58th Annual Meeting of the American Psychopathological Association, 1969.
43. Clarke JG. Some aspects of intellectual deficit and depression in heavy drinkers. *J Irish Med Assoc* 1976; 69: 29-32.
44. Ornstein P. Cognitive deficits in chronic alcoholics. *Psychol Rep* 1977; 40:719-724.
45. Kapur N, Butters N. Visuoperceptive deficits in long-term alcoholics and alcoholics with Korsakoff's psychosis. *J Studies Alcohol* 1977; 38:2025-2035.
46. Sivan AB. Benton visual retention test. 5th ed. San

Antonio, Texas: Psychological Corporation, 1991.

47. Wechsler D. Statistical properties of the scale. Manual for the Wechsler Adult Intelligence Scale-Revised. New York: Psychological Corporation, 1981.

48. Kellogg CE, Morton NM. Revised beta examination, second edition (beta-II). San Antonio, Texas: The Psychological Corporation, 1978.

49. Smith RB. Confirming evidence of an effective treatment for brain dysfunction in alcoholic patients. *J Nervous Mental Dis* 1982; 170:275-278.

50. Sharp JR, Rosenbaum G, Goldman MS, Whitman RD. Recoverability of psychological functioning following alcohol abuse; acquisition of meaningful synonyms. *J Consult Clin Psychol* 1977; 45:1023-1028.

51. O'Leary MR, Radford LM, Chaney EF, Schau EJ. Assessment of cognitive recovery in alcoholics by use of the Trail Making Test. *J Clin Psychol* 1977; 33:579-582.

52. Smith RB, Day E. The effects of cerebral electrotherapy on short-term memory impairment in alcoholic patients. *Int J Addictions* 1977; 12:575-582.

53. McNair DM, Lorr M, Droppleman LF. Edits manual for the profile of mood states. San Diego, California: Educational and Industrial Testing Service, 1992.

54. Smith RB, Tiberi A, Marshall J. The use of cranial electrotherapy stimulation in the treatment of closed-headinjured patients. *Brain Injury* 1994; 8:357-361.

55. Childs A, Crismon ML. The use of cranial electrotherapy stimulation in post-traumatic amnesia: a report of two cases. *Brain Injury* 1988; 2:243-247.

56. Bennett RM, Cook DM, Clark SR, et al. Hypothalamic-pituitary-insulin-like growth factor-1 axis dysfunction in patients with fibromyalgia. *Journal of Rheumatology* 1997; 24:384-389.

57. Tyres S, Smith RB. Treatment of fibromyalgia with cranial electrotherapy stimulation. *Original Internist* 2001; 8 (3): 15-17.

58. Tyers S, Smith RB. A comparison of cranial electrotherapy stimulation alone or with chiropractic

therapies in the treatment of fibromyalgia. *The American Chiropractor* 2001; 23(2):39- 41.

59. Lichtbroun AS, Raicer MC, Smith RB. The use of Alpha-Stim cranial electrotherapy stimulation in the treatment of fibromyalgia. 15th Annual International Symposium on Acupuncture and Electro-Therapeutics, Columbia University, New York City, October 21-24, 1999.

60. Cork RC. Alpha-Stim CES for fibromyalgia. Study in progress: Louisiana State University Medical Center, Shreveport, 2002.

61. Tan G. Alpha-Stim CES for spinal cord injury pain. Study in progress: Veterans Affairs Hospital, Houston, 2002.

62. Pozos RS, Strack LE, White RK, Richardson AW. Electro-sleep versus electroconvulsive therapy. In: Reynolds DV, Sjoberg AE, eds. *Neuroelectric Research*. Vol. 23. Springfield: Charles Thomas, 1971:221-225.

63. Braverman E, Smith RB, Smayda R, Blum K. Modification of P300 amplitude and other electrophysiological parameters of drug abuse by cranial electrical stimulation. *Current Therapeutic Res* 1990; 48:586-596.

64. Siegesmund KA, Sances A Jr., Larson SJ. The effects of electrical currents on synaptic vesicles in monkey cortex. In: Wageneder FM, St. Schuy, eds. *Electrotherapeutic Sleep and Electroanaesthesia*. Internation Congress series No. 136. Amsterdam: Excerpta Medica Foundation, 1967:31-33.

65. Alpher EJ, Kirsch DL. A patient with traumatic brain injury and full body reflex sympathetic dystrophy treated with cranial electrotherapy stimulation. *Am J Pain Management* 1998; 8:124- 128.

66. Champagne C, Papiemik E, Thierry JP, Noviant Y. Transcutaneous cerebral electric stimulation by Limoge current during labor. *Ann Fr Anesth Reanim* 1984; 3:405-413.

67. Childs A. Droperidol and CES in Organic Agitation. *Clinical Newsletter of the Austin Rehabilitation Hospital*, 1995.

68. Naveau S, Barritault L, Zourabichvili O, Champagne C, Prieur G, Limoge A, Poynard T, Chaput JC. Analgesic effect of transcutaneous cranial electrostimulation in patients treated by Nd:YAG laser for cancer of the rectum. A

double-blind randomized trial. *Gastroenterol Clin Biol* 1992; 16:8-11.

69. Stanley TH, Cazalaa JA, Atinault A, Coeytaux R, Limoge A, Louville Y. Transcutaneous cranial electrical stimulation decreases narcotic requirements during neurolept anesthesia and operation in man. *Anesthesia Analgesia* 1982; 61(10):863-866.

70. Stanley TH, Cazalaa JA, Limoge A, Louville Y. Transcutaneous cranial electrical stimulation increases the potency of nitrous oxide in humans. *Anesthesiology* 1982; 57:293-297.

71. Mantz J, Azerad J, Limoge A, Desmots JM. Transcranial electrical stimulation with Limoge's currents decreases halothane requirements in rats. Evidence for the involvement of endogenous opioids. *Anesthesiology* 1992; 76:253-260.

72. Stinus L, Auriacombe M, Tignol J, Limoge A, Le Moal M. Transcranial electrical stimulation with high frequency intermittent current (Limoge's) potentiates opiate-induced analgesia: blind studies. *Pain* 1990; 42(3): 351-363.

73. Warner R, Hudson-Howard L, Hojnsen C, Skolnick M. Serotonin involvement in analgesia induced by transcranial electrostimulation. *Life Sciences* 1990; 46:1131-1138.

45 Low-Intensity Millimeter Waves in Biology and Medicine

1. Golant MB, Vilenskaya RL, Zyulina EA. Lot of wideband low-power oscillators in the millimeter and submillimeter bands. PTE 1965; 4:136-139. In Russian.
2. Devyatkov ND, ed. Backward-Wave Tubes of the Millimeter and Submillimeter Bands. Moscow: Radio i Svyaz', 1985. In Russian.
3. Betskii OV, Kislov VV, Devyatkov ND. Low-intensity MM waves in medicine and biology. Biomed Eng 2000; 28-1, 2:247-268.
4. Betskii OV, Devyatkov ND. MM-wave therapy conceptual design. Biomeditsinskaya Radioelektronika 2000; 8: 53-63. In Russian.
5. Sevast'yanova LA, Potapov SL, Adamenko VG. Combined influence of x-ray and super-highfrequency radiation on the bone marrow. Nauch Dokl Vyssh Shkoly, Ser Biofizika, Biol Nauki 1969; 6:46. In Russian.
6. Sevast'yanova LA. Biological effects of MM radio waves on normal tissues and malignant tumors. In: Devyatkov ND ed. Effects of Nonthermal MM-Wave Influence on Biological Objects. Moscow: IRE AN SSSR, 1983:48-62. In Russian.
7. Sevast'yanova LA, Golant MB, Adamenko VG. Effect of microwave radiation on marrowbone count variations caused by antineoplastic chemotherapeutic compounds. Proceedings of The Second Congress of Oncologists. Omsk 1980:136. In Russian.
8. Sevast'yanova LA, Golant MB, Zubenkova ES. Effect of MM radio waves on normal tissues and malignant tumors. In: Devyatkov ND, ed. Application of Low-Intensity MM-Wave Radiation in Biology and Medicine. Moscow: IRE AN SSSR, 1985:37-49. In Russian.
9. Adey WR. Frequency and power window in tissue interactions with weak electromagnetic fields. Proc of IEEE 1980; 68-1:119.
10. Soboleva EI, Ignasheva LP. Survival rate of animals exposed to a lethal dose during transplantation of a cryogenically preserved bone marrow subjected to EHF irradiation. International Symposium on Millimeter Waves of Nonthermal Intensity in Medicine, Moscow Oct. 3-6, 1991;

2:354-452.

11. Govallo VI, Barer FS, Volchek IA. Electromagnetic-radiation-induced human lymphocyte and fibroblast production of a cell proliferation activation factor. International Symposium on Millimeter Waves of Nonthermal Intensity in Medicine, Moscow Oct. 3-6, 1991; 2:340-344.
12. Kamenev YuF, Shaposhnikov YuG, Mussa M, Akimov GV. Physical factors in the complex surgical treatment of a missile limb wound. Aktual'nye Voprosy Voennoi Meditsiny Kabul, 1988; 78-80. In Russian.
13. Ryzhkova LB, Starik AM, Volgarev AP, Gal'chenko SV, Sazonov AYU. Protective effect of low-intensity MMwave radiation at a lethal influenzal infection. International Symposium on Millimeter Waves of Nonthermal Intensity in Medicine, Moscow Oct. 3-6, 1991; 2:373- 377.
14. Poslavskii MV. Physical EHF therapy in ulcer treatment and prevention. International Symposium on Millimeter Waves of Nonthermal Intensity in Medicine, Moscow Oct. 3-6, 1991; 2:142-146.
15. Adaskevich VG. Application efficiency of MM-wave radiation in the complex treatment of patients with atopic dermatitis. Millimetrovye Volny v Biologii i Meditsine 1994; 3:78-81. In Russian.
16. Adaskevich VG. Clinical efficiency and immunoregulatory and neurohumoral effects of MM therapy in patients with atopic dermatitis. Biomed Eng 2000; 28-3:80-88.
17. Gedymin LE, Erokhin VV, Bugrova KM. Electromagnetic waves of the MM-wave band in therapy of sarcoidosis of lungs and intrathoracic lymph nodes. Millimetrovye Volny v Biologii i Meditsine 1994; 4:10-16. In Russian.
18. Pulyaeva EL, Vetokhina SV. Application of EHF therapy in treatment of genital herpes. Millimetrovye Volny v Biologii i Meditsine 1997; 9-10:55-56. In Russian.
19. Elbakidze IL, Ordynskii VF, Sudakova EV. EHF therapy in treatment of inflammatory sexually transmitted diseases. Millimetrovye Volny v Biologii i Meditsine 1998; 1, 11:39-41. In Russian.
20. Donetskaya SV, Zaitseva SYu, Viktorov AM. Effect of EHF therapy on skin microbiocenosis in vulgaris acne patients.

Millimetrovye Volny v Biologii i Meditsine 1996; 7:57-59.

21. Kholodov YUA, Lebedeva NN. Responses of the Human Nervous System on Electromagnetic Fields. Moscow: Nauka, 1992. In Russian.

22. Lebedeva NN, Sulimov AV. Sensory indication of electromagnetic fields of the millimeter-wave band. Millimeter Waves in Medicine and Biology. Moscow: IRE RAN, 1989:176-182. In Russian.

23. Lebedeva NN, Kotrovskaya TI. Electromagnetic perception and individual features of human being. Crit Rev Biomed Eng 2001; 29-3:440-449.

24. Kotrovskaya TI. Human being's sensory responses to a weak electromagnetic stimulus. Millimetrovye Volny v Meditsine i Biologii 1994; 3:32-38. In Russian.

25. Lebedeva NN. Sensory and subsensory responses of a healthy human being to a peripheral influence of lowintensity MM waves. Millimetrovye Volny v Biologii i Meditsine 1993; 2:5-23. In Russian.

26. Lebedeva NN. CNS responses to electromagnetic fields with different biotropic parameters. Biomeditsinskaya Radioelektronika 1998; 1:24-36. In Russian.

27. Khromova SV. Millimeter-Wave-Induced Modification of Behavioral Reactions in Rats. Thesis Summary of Doctor of Philosophy in Biological Sciences. Moscow: Institute for Higher Nerve Activity of the Russian Academy of Sciences, 1990. In Russian.

28. Arzumanov YuL, Kolotygina RF, Khonicheva NM. Investigation of the stress-protective effect of EHF electromagnetic waves on animals. Millimetrovye Volny v Meditsine i Biologii 1994; 3:5-10. In Russian.

29. Kolotygina RF, Khonicheva NM, Arzumanov YuL. MM-wave radiation and alcohol narcosis duration in animals with different types of behavior. Technical Twentieth Russian Symposium with Foreign Participants on Millimeter Waves in Medicine and Biology, Moscow, Apr 24-26, 1997. In Russian.

30. Temur'yants NA, Chuyan EN, Tumanyants EN, Tishkina OO, Viktorov NV. Dependence of the antistress effect of electromagnetic waves of the MM-wave band on exposure location in rats with different typologic features. Millimetrovye Volny v Biologii i Meditsine 1993; 2:51-58.

In Russian.

31. Temur'yants NA, Chuyan EN. Effect of microwaves of nonthermal intensity on the development of hypokinetic stress in rats with different individual features. *Millimetrovye Volny v Biologii i Meditsine* 1992; 1:22-32. In Russian.

32. Lebedeva NN, Sulimova OP. Modifying effect of MM waves on the human CNS functional state under stress simulation. *Millimetrovye Volny v Biologii i Meditsine* 1994; 3:16-21. In Russian.

33. Temur'yants NA, Khomyakova OV, Tumanyants EN, Derpak MN. Dynamics of some psychophysiological indices during microwave therapy. Eleventh Russian Symposium with Foreign Participants on Millimeter Waves in Medicine and Biology, Moscow, Apr 24-26, 1997. In Russian.

34. Krainov VE, Sulimova OP, Larionov IYu. Application of EHF influence in the combined method of psychoemotional rehabilitation. Eleventh Russian Symposium with Foreign Participants on Millimetrovye Volny v Meditsine i Biologii, Moscow, Apr 24-26, 1997. In Russian.

35. Tsaritsinskii VI, Taranskaya AD, Derkach VN. Application of electromagnetic waves of the MM-wave band in treatment of depressive states. International Symposium on Millimeter Waves of Nonthermal Intensity in Medicine, Moscow, Oct 24-26, 1997.

36. Lebedeva NN. Physiological mechanisms of biological effects of low-intensity electromagnetic waves of the MMwave band. The Eleventh Russian Symposium with Foreign Participants on Millimeter Waves in Medicine and Biology, Moscow Apr 24-26, 1997. In Russian.

37. Garkavi LKh, Kvakina EB, Kuz'menko TS. Antistress Reactions and Activation Therapy. Moscow: Imedis, 1998. In Russian.

38. Lyusov VA, Lebedeva AYu, Shchelkunova IG. MM-wave correction for hemorheologic disorders in patients with unstable stenocardia. *Millimetrovye Volny v Biologii i Meditsine* 1995; 5:46-49. In Russian.

39. Lyusov VA, Volov NA, Lebedeva AYu. Some mechanisms of MM-wave radiation effect on unstable stenocardia pathogenesis. Tenth Russian Symposium on Millimeter Waves in Biology and Medicine, Moscow, Apr 24-26, 1997. In

Russian.

40. Lyusov VA, Lebedeva AYU, Fedulaev YUN. Application of combined infrared laser and MMwave therapies in outpatients with exertion stenocardia of the second functional class. Tenth All-Russia Congress of Cardiologists, Chelyabinsk, 1996. In Russian.

41. Lebedeva AYU. The use of millimeter wavelength electromagnetic waves in cardiology. Biomedical Engineering 2000; 28-1(2):339-350.

42. Lebedeva AYU. Application of electromagnetic radiation of the MM-wave band in the combined treatment of cardiovascular diseases. Biomeditsinskaya Radioelektronika 1998; 2:49-54. In Russian.

43. Pletnev SD. The use of millimeter band electromagnetic waves in clinical oncology. Biomedical Engineering 2000; 29-2:573-588.

44. Kamenev YuF, Sarkisyan AG, Govallo VI. To the optimization problem of low-intensity MMwave treatment of limb injuries complicated by wound infections. Seventh All-Union Workshop on Application of Low-intensity MM-wave Radiation in Biology and Medicine, Moscow, 1989. In Russian.

45. Kamenev YuF, Devyatkov ND, Toporov YuA. Activation MM-wave therapy of limb injuries complicated by wound infections. Meditsinskaya Radiologiya 1992; 7-8:43-45. In Russian.

46. Kamenev YuF, Berglezov MA, Nadgeriev VM. EHF therapy of trophic ulcers of amputation limb stumps. Rehabilitation Treatment of Limb Injuries and Diseases, Moscow, 1993:96-97. In Russian.

47. Kamenev YuF, Shitikov VA, Batpenov ND. Requirements for long-term and stable remission of various types of deforming osteoarthritis. Vestnik Travmatologii i Ortopedii im. N.N. Pirogova 1997; 4:9-13. In Russian.

46 The Use of Electrical Stimulation to Treat Morbid Obesity

1. Mason EE. Gastric surgery for morbid obesity. *Surg Clin N Am* 1992; 72:501-513.
2. Gastrointestinal surgery for severe obesity. NIH Consensus Dev Conf Consensus Statement 1991. *Am J Clin Nutr* 1992; 55:615S-619S.
3. Gonzalez MF, Deutsch JA. Vagotomy abolishes cues of satiety produced by gastric distention. *Science* 1981; 212:1283-1284.
4. Smith GP, Jerome C, Cushin BJ, Eterno R, Simansky KJ. Abdominal vagotomy blocks the satiety effect of cholecystokinin in the rat. *Science* 1981; 213:1036-1037.
5. Ritter RC, Ritter S, Ewart WR, Wingate DL. Capsaicin attenuates hindbrain neuron responses to circulating cholecystokinin. *Am J Physiol* 1989; 257:R1162-R1168.
6. Bray GA. Afferent signals regulating food intake. *Proc Nutr Soc* 2000; 59:373-384.
7. Houpt TR, Houpt KA, Swan AA. Duodenal osmoconcentration and food intake in pigs after ingestion of hypertonic nutrients. *Am J Physiol* 1983; 245:R181-R189.
8. Cigaina V, Saggioro A, Rigo V. Long-term effects of gastric pacing to reduce feed intake in swine. *Obes Surg* 1996; 6:250-253.
9. Cigaina V, Saggioro A. Pacing the stomach: five years experience with an obese patient population [abstr P8]. *Obes Surg* 2001; 11:171.
10. George MS, Nahas Z, Bohning DE. Vagus Nerve Stimulation therapy: A research update. *Neurology* 2002; 59 (Suppl 4):S56-S561.

47 Biocurrent Therapy for Macular Degeneration

1. Tielsch JA. Vision problems in the United States: a report on blindness and vision impairment in adults age 40 and older. Prevent Blindness America. Schaumburg, IL: Prevent Blindness America, 1994.
2. Evans J, Wormald R. Is the incidence of registrable age-related macular degeneration Increasing? Br J Ophthalmol 1996; 80:9-14.
3. Fine SL, Berger JW, Maguire MG, Ho AC. Age related macular degeneration. N Engl J Med 2000; 342: 483-492.
4. Vingerling JR, Klaver CC, Hofman A, de Jong PT. Epidemiology of age-related Maculopathy. Epidemiol Rev 1995; 17:347-360.
5. Scilley K, Jackson GR, Cideciyan AV, Maguire MG, Jacobson SG, Owsley C. Early Age related maculopathy and self-reported visual difficulty in daily life. Am Acad Ophthalmol 2002; 109:1235-1242.
6. Neftel WB. Galvano-Therapeutics. New York: D.Appleton & Company, 1871.
7. Erb W. Handbook of Electro-Therapeutics. New York: William Wood & Co, 1883.
8. Allen MJ, Jarding JB, Zehner R. Macular degeneration treatment with nutrients and micro current electricity. J Orthomol Med 1998; 13:211-214.
9. Hardy RA. Retina. In: Vaughan D, ed. General Ophthalmology. 15th ed. Stamford, CT: Appleton and Lange, 1999.
10. Holz FG, Wolfensberger TJ, Piguet B. Bilateral macular drusen in age-related macular degeneration: prognosis and risk factors. Ophthalmology 1994; 101:1522-1528.
11. Fine AM, Elman MJ, Ebert JE, Prestia PA, Starr JS, Fine SL. Earliest symptoms caused by neovascular membranes in the macula. Arch Ophthalmol 1986; 104:513-514.
12. Rakoczy PE, Mann K, Cavaney PM, Robertson T, Papadimitreou J, Constable J. Detection and possible functions of a cysteine protease involved in digestion of rod outer segments by retinal pigment epithelial cells.

Invest Ophthalmol Vis Sci 1994; 35:4100-4108.

13. Klein ML, Mauldin WM, Stoumbos VD. Heredity and age-related macular degeneration: observations in monozygotic twins. Arch Ophthalmol 1994; 112:932-937.

14. Green WR, Enger C. Age related macular degeneration histopathologic study. Ophthalmology 1993; 100: 1519-1535.

15. Allikmets R, Shroyer NF, Singh N, Seddon JM, Lewis RA, Bernstein PS, Peiffer A, Zabriskie NA, Li Y, Hutchinson A, Dean M, Lupski JR, Leppert M. Mutation of the Stargart disease gene (ABCR) in age-related macular degeneration. Science 1997; 277:1805-1807.

16. Hung S, Seddon JM. The relationship between nutritional factors and age-related macular degeneration. In: Bendich A, Deckelbaum RJ, eds. Preventive Nutrition: The Comprehensive Guide for Health Professionals. Totowa, NJ: Humana Press, 1997.

17. Seddon JM, Willett WC, Speizer FE, Hankinson SE. A prospective study of cigarette smoking and age-related macular degeneration in women. JAMA 1996; 276:1141-1146.

18. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 1991; 109:1220-1231.

19. Editor. Eying protons. Scientific American 1999; 275:22.

20. TAP Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in agerelated macular degeneration with vertiporfin: two year results of 2 randomized clinical trials. Arch Ophthalmol 1999; 117: 1329-1345.

21. Newsome DA, Swartz M, Leone NC, Elston RC, Miller E. Oral zinc in macular degeneration. Arch Ophthalmol 1988; 106:192-198.

22. Gunn RM. On continuous electrical current as a therapeutic agent in atrophy of the optic nerve and in retinitis pigmentosa. Royal London Ophthalmic Hospital Reports 1882; 10:161-192.

23. Derby H. On the possible retardation of retinitis pigmentosa. Am Ophthalmol Soc Trans 1886- 1887; 4:217-227.

24. Massey GB. Practical Electrotherapeutics and Diathermy. New York: the Macmillan Company, 1924.
25. Du Bois-Reymond E. Untersuchungen Über Thierische Elektricitat. Berlin: Reimer, 1860.
26. Barnes TC. Healing rate of human skin determined by the measurement of the electrical potential of experimental abrasions. Am J of Surg 1942; 69:82-88.
27. Nordenström BEW. Biokinetic impacts on structure and imaging of the lung: the concept of biologically closed electric circuits. Am J Roentg 1985; 145:447-467.
28. Becker RD. A method for producing cellular dedifferentiation by means of very small electric currents. Trans NY Acad Sci 1967; 29:606-615.
29. Cheng N, Van Hoof H, Bockn E, Hoogmartens MJ, Mulier J, De Ducker F, Sansen WM, De Loecker W. The effects of electric currents on ATP generation, protein synthesis and membrane transport in rat skin. Clin Ortho and Rel Res 1982; 171:264-271.
30. Huang R, Peng L, Hertz L. Effects of a low-voltage static electric field on energy metabolism in astrocytes. Bioelectromagnetics 1997; 18:77-80.
31. Holian O, Astumian RD, Lee RC, Reyes HM, Attar BM, Walter RJ. Protein Kinase C activity is altered in HL60 cells exposed to 60 Hz AC electric fields. Bioelectromagnetics 1996; 17:504- 509.
32. O'Clock GD, Leonard T. In vitro response of retinoblastoma, lymphoma and non-malignant cells to direct current: therapeutic implications. German J Oncol 2001; 33:85-90.

48 Clinical Trials Involving Static Magnetic Field Applications

1. Cohen D, Yoram P, Cuffin BN, Schmid SJ, eds. Magnetic Fields Produced by Steady Currents in the Body. Proc Nat Acad Sci USA 1970; 77:1447-1451.
2. Reite M, Zimmerman JE, Edrich J, Zimmerman J. The human magnetoencephalogram: some EEG and related correlations. Electroencephalogr Clin Neurophysiol 1976; 40:59-66.
3. Saarinen M, Siltanen P, Karp PJ, Katila TE. The normal magnetocardiogram: I Morphology. Ann Clin Res 1978; 10(suppl 21): 1-43.
4. Armstrong RA, Janday B. A brief review of magnetic fields from the human visual system. Ophthalmic Physiol Opt 1989; 9:299-301.
5. Alfano AP, Taylor AG, Foresman PA, Dunkl PR, McConnell GG, Conaway MR, Gillies GT. Static magnetic fields for treatment of fibromyalgia: a randomized controlled trial. J Complementary and Alternative Med 2001; 7:53-64.
6. Borsa PA, Liggett MS. Flexible magnets are not effective in decreasing pain perception and recovery time after muscle microinjury. J Athletic Training 1998; 33:150-155.
7. Brown CS, Parker N, Ling F, Wan J. Effects of magnets on chronic pelvic pain. Obstet Gynecol 2000; 95(suppl 1):S29.
8. Caselli MA, Clark N, Lazarus S, Velez Z, Venegas L. Evaluation of magnetic foil and PPT insoles in the treatment of heel pain. J Am Podiatric Med Assoc 1997; 87:11-16.
9. Carter R, Aspy CB, Mold J. The effectiveness of magnet therapy for treatment of wrist pain attributed to carpal tunnel syndrome. J Fam Pract 2002; 51:38-40.
10. Chaloupka EC, Kang J, Mastrangelo MA. The effect of flexible magnets on hand muscle strength: a randomized, double-blind study. J Strength Cond Res 2002; 16:33-37.
11. Colbert AP, Markov MS, Banerji M, Pilla AA. J Back Musculoskeletal Rehabil 1999; 13:19- 31.
12. Colbert AP. Magnets on Sishencong and GV 20 to treat depression: Clinical observations in 10 patients. Medical Acupuncture spring/Summer 2000; 12:20-24.

13. Collacott EA, Zimmerman JT, White DW, Rindone JP. Bipolar permanent magnets for the treatment of chronic low back pain: a pilot study. *JAMA* 2000; 283:1322-1324.
14. Hinman MR, Ford J, Heyl H. Effects of static magnets on chronic knee pain and physical function: a doubleblind study. *Alternative Therapies* 2002; 8:50-55.
15. Holcomb RR, Parker RA, Harrison MS. Biomagnetics in the treatment of human pain-past, present, future. *Envir Med* 1991; 8:24-60.
16. Holcomb RR, Worthington WB, McCullough BA, McLean MJ. Static magnetic field therapy for pain in the abdomen and genitals. *Pediatric Neurol* 2000; 23:261-264.
17. Hong CZ, Lin JC, Bender LF, Schaeffer JN, Meltzer RJ, Causin P. Magnetic necklace: its therapeutic effectiveness on neck and shoulder pain. *Arch Phys Med Rehabil* 1982; 63:462-466.
18. Man D, Man B, Plosker H. The influence of permanent magnetic field therapy on wound healing in suction lipectomy patients: a double-blind study. *Plast Reconstr Surg* 1999; 104:2261-2266.
19. Segal N, Huston J, Fuchs H, Holcomb R, McLean MJ. Efficacy of a static magnetic device against knee pain associated with inflammatory arthritis. *J Clin Rheumatol* 1999; 5:302-305.
20. Segal NA, Toda Y, Huston, Saeki Y, Shimizu M, Fuchs H, Shimaoka Y, Holcomb R, McLean MJ. Two configurations of static magnetic fields for treating rheumatoid arthritis of the knee: a double-blind clinical trial. *Arch Phys Med Rehabil* 2001; 82:1453-1460.
21. Liu S, Chen Z, Hou J, Wang J, Wang J, Zhang X. Magnetic disk applied on Neiguan point for prevention and treatment of cisplatin-induced nausea and vomiting. *J Trad Chin Med* 1991; 11:81-183.
22. Suen LKP, Wong TKS, Leung AWN. Auricular therapy using magnetic pearls on sleep: a standardized protocol for the elderly with insomnia. *Clin Acup Oriental Med* 2002; 3:39-50.
23. Vallbona C, Hazlewood CF, Jurida G. Response of pain to static magnetic fields in postpolio patients: a double

- blind pilot study. Arch Phys Med Rehabil 1997; 78:1200-1203.
24. Weintraub MI. Chronic submaximal magnetic stimulation in peripheral neuropathy: Is there a beneficial therapeutic relationship? Am J Pain Manag 1998; 8:12-16.
25. Weintraub MI. Magnetic bio-stimulation in painful diabetic peripheral neuropathy: a novel intervention-a randomized, double-placebo crossover study. Am J Pain Manag 1999; 9:8-17.
26. Weintraub MI, Cole SP. Neuromagnetic treatment of pain in refractory carpal tunnel syndrome: an electrophysiological and placebo analysis. J Back Musculoskel Rehabil 2002; 15:77-82.
27. Markov MS, Colbert AP. Magnetic and electromagnetic field therapy. J Back Musculoskel Rehabil 2001; 15: 17-29.
28. Santwani MT. Magnetotherapy for Common Diseases. Delhi: Hind Pocket Books, 1992.
29. Birla GS, Hemlin C. Magnet Therapy: The Gentle & Effective Way to Balance Body. Rochester, VT: Healing Arts Press, 1999.
30. Schiegl H. Healing Magnetism. London: Century, 1987.
31. Matsumoto K, Birch S. Hara Diagnosis: Reflections on the Sea. Brookline: Paradigm Press, 1988.
32. MA, Manaka Y, Itaya K, Birch S. Chasing the Dragon's Tail. Brookline: Paradigm Press, 1995.
33. Nakagawa K. Magnetic field-deficient syndrome and magnetic treatment. Japan Med J 1976; 2745:24-32.
34. Blechman AM, Oz M, Nair V, Ting W. Discrepancy between claimed field flux density of some commercially available magnets and actual gaussmeter measurements. Alternative Therapies 2001; 7:92-95.
35. Markov MS. Electric Current and Electromagnetic field effects on soft tissue: Implications for wound healing. WOUNDS 1995; 7:94-110.
36. Rose P. The Practical Guide to Magnet Therapy. New York: Sterling, 2001.

37. Travell JG, Simons DG. Myofascial Pain and Dysfunction The Trigger Point Manual Vols 1 & 2. Baltimore: Williams and Wilkins, 1983.
38. Baldry PE. Acupuncture, Trigger Points and Musculoskeletal Pain. 2d ed. Edinburgh: Churchill Livingstone, 1993.
39. Markov MS.
40. Kaptchuk TJ. The placebo effect in alternative medicine: can the performance of a healing ritual have clinical significance? *Ann Intern Med* 2004; 136:817-825.
41. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. *JAMA* 1998; 279:1200-1205.

49 Pain-Free and Mobility-Free Magnetic Force in Orthodontic Therapy

1. Bassett CAL, Pilla AA, Pawluk RJ. A nonsurgical salvage of surgically resistant pseudoarthroses and nonunions by pulsing electromagnetic fields. *Clin Orthop* 1977; 124:117-128.
2. Stark TM, Sinclair PM. Effect of pulsed electromagnetic fields on orthodontic tooth movement. *Am J Orthod Dentofacial Orthop* 1987; 91:91-104.
3. Darendeliler MA, Sinclair PM, Kusey RP. The effects of samarium cobalt magnets and pulsed electromagnetic fields on tooth movement. *Am J Orthod Dentofacial Orthop* 1995; 107:578- 588.
4. Gromak GB, Leis GA. Evaluation of the efficient use of constant magnetic fields in traumatologic patients. Electromagnetic therapy in traumas and diseases of the support motor apparatus. Riga: RMI, 1987:88-95. in Russian.
5. Detlar IE, Blaus AP, Naudinja IJ, Tarauska AV. Magnetic therapy in the treatment of long tubular bone fractures and lengthening of extremities. Electromagnetic therapy in traumas and diseases of the support motor apparatus. Riga: RMA, 1987:110-123. in Russian.
6. Golyakhovsky V. Local and continuous exposure to a permanent magnetic field as a means of boosting reparative osteogenesis. Proceedings of the Kuybyshev Regional Conference on Magnetic Fields in the Clinic, June 1976. Translated from Russian.
7. Golyakhovsky V. Magnetotherapy as part of the treatment strategy for diaphyseal fractures of tubular bones. Proceeding of the Kuybyshev Regional Conference on Magnetic Fields in the Clinic, June 1976. Translated from Russian.
8. Holcomb RR, Parker RA, Harrison MS. Biomagnetics in the treatment of human pain: past, present, future. *Environ Med* 1991a; 8:24-30.
9. McLean MJ, Holcomb RR, Wamil AW, Pickett JD, Cavapol AV. Blockade of sensory neuron action potentials by a static magnetic field in the 10mT range. *Bioelectromagnetics* 1995; 16: 20-32.
10. Cavapol AV, Wamil AW, Holcomb RR, McLean MJ. Measurement and analysis of static magnetic fields that

block action potentials in cultured neurons.
Bioelectromagnetics 1995; 16:197-206.

11. Blechman AM, Oz M, Nair V, Ting W. Discrepancy between claimed field flux density of some commercially available magnets and actual gaussmeter measurements. Alternative Therapies 5 Sept/Oct 2001; 7.

12. Blechman AM, Smiley H. Magnetic force in orthodontics. Am J Orthod 1978; 74:435-443.

13. Blechman AM, Alexander C. New miniaturized magnets for molar distalization. Clinical Impressions, Ormco Corp 1995;4(4):14-19.

14. Rare-earth permanent magnets. Vacodym, Vacomax. Edition 2000. Vacuumschmelze GMBH, Hanau, Germany.

15. Jones DB, Ryaby JT. Low energy time-varying electromagnetic field interactions with cellular control mechanisms. In: Blank M, Findl E, eds. Mechanistic approaches to interactions of electric and electromagnetic fields with living systems. London: Plenum Press, 1987:389-397.

16. DeMarco LA. Comparative histologic response of osteogenic capacity of the cranial sagittal suture of SpragueDawley rats to tensile orthopedic force applied in a local magnetic field of varying orientations. A research report submitted in partial fulfillment for the requirement for clinical certification. Dept of Orthodontics, University of Maryland Dental School, Baltimore, MD, June 1988.

17. Kawata T, Hirota K, Sumitomi K, Umehara K, Yano K, Topping HJ. A new orthodontic force system of magnetic brackets. Am J Orthod Dentofacial Orthop 1987; 92:241-248.

18. Graber TM. Magnets and impacted canines. Northcroft Memorial Lecture. British Society for the Study of Orthodontics. Manchester, UK, September 4, 1989.

19. Vardimon AD, Graber TM, Drescher D, Bourauel C. Rare-earth magnets and impaction. Am J Orthod Dentofacial Orthop 1991; 100:494-512.

20. Itoh T, Tokuda T, Kiyosue S, Hirose T, Matsumoto M, Chaconas SJ. Molar distalization with repelling magnets. J Clin Orthod 1991; 25:611-617.

21. Blechman AM, Steger ER. A possible mechanism of action of repelling molar distalizing magnets. Part I. *Am J Orthod Dentofacial Orthop* 1995; 108:428-431.
22. Haraszthy VI, Zambon JJ, Trevisan M, Zeid M, Genco RJ. Identification of periodontal pathogens in atheromatous plaques. *J Periodontol* 2000; 71(10):1554-1560.
23. Chiu B. Multiple infections in carotid atherosclerotic plaques. *Am Heart J* 1999; 138(5):s534-s536.
24. Li L, Messas E, Batista EL Jr, Levine RA, Amar A. Porphyromonas gingivalis infection accelerates the progression of atherosclerosis in a heterozygous apolipoprotein E-deficient murine model. *Circulation* 2002; 105(7):861-867.
25. Ervedi N, Kadir T, Ozkan H, Acar A. Investigation of bacteremia after orthodontic banding. *Am J Orthod Dentofacial Orthop* 1999; 116(6):687-690.
26. Erverdi N, Biren S, Kadir T, Acar A. Investigation of bacteremias following debanding. *Angle Orthod* 2000; 70(1):11-14. Discussion 15.
27. McLaughlin JD, Coulter WA, Coffey A, Burden DJ. The incidence of bacteremia after orthodontic banding. *Am J Orthod Dentofacial Orthop* 1996; 109(6):639-644.
28. Roberts GJ, Lucas VS, Omar J. Bacterial endocarditis and orthodontics. *J R Coll Surg Edinb* 2000; 45(3): 141-145.
29. Glurich I, Grossi S, Albini B, Ho A, Shah R, Zeid M, Baumann H, Genco RJ, De Nardin E. Systemic inflammation in cardiovascular and periodontal disease: comparative study. *Clin Diagn Lab Immunol* 2002; 9(2): 425-432.
30. Noack B, Genco RJ, Trevisan M, Grossi S, Zambon JJ, De Nardin E. Periodontal infections contribute to elevated systemic C-reactive protein level. *J Periodontol* 2001; 72(9): 1221-1227.
31. Slade GD, Offenbacher S, Beck JD, Heiss G, Pankow JS. Acute-phase inflammatory response to periodontal disease in the U.S. population. *J Dent Res* 2000; 79(1):49-57.